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Bacillus anthracis, the causative agent of anthrax, has to be able to adapt to
different physical conditions encountered during the beginning and establishment of the
infection process inside the host. One of these conditions is the availability of nutrients
like iron.

B. anthracis secretes siderophores capable of competing with the iron

transport/storage proteins of the host.

Previous studies have been dedicated to the

analysis of these systems. However, the impact of iron availability on B. anthracis
metabolism from a global perspective remains as unclear. In this dissertation, I combined
an in silico genome-scale metabolic analysis with experimental studies for B. anthracis
grown under different iron conditions in order to study the impact of iron availability on
the metabolism of the bacterium.

To develop the first genome-scale metabolic model for B. anthracis, I designed
and implemented a new methodology for the curation of genome scale metabolic models
that combined a genetic algorithm and flux balance analysis (GAFBA). GAFBA finds
metabolites whose mass balance constraints cannot be satisfied, because the metabolite is
participating in additional reactions that were not taken into account during the
reconstruction process. This resulted in an unfeasible solution to the optimization

Eddy Johana Bautista Bautista, University of Connecticut, 2014
problem. GAFBA facilitates the curation of genome-scale metabolic networks, and aids
in fundamental studies in metabolism.

During the experimental studies of the growth of B. anthracis under ironpoor/rich conditions, the carbon metabolism increased under iron-poor conditions,
although this did not directly support growth. Thus, the B. anthracis model was used to
characterize the metabolic response of the bacteria under iron-poor/rich conditions.
Under iron-poor conditions, a down regulation in the TCA cycle reactions resulted in the
reduced uptake of some amino acids. Also, the production of siderophores increased. A
higher glucose uptake rate was found to fulfill amino acids requirements for siderophore
biosynthesis and growth. For the first time, I found a correlation between the biosynthesis
of autoinducer-2, a quorum sensing signal molecule, and the growth of B. anthracis under
iron-poor conditions.
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1. INTRODUCTION
1.1. Overview

The development of high-throughput experimental technologies, computational
biology, and bioinformatics has allowed the study of cells as a system, as opposed to
the traditional reductionist approach that studies complex systems as individual
elements working in isolation. This field of scientific research, which takes a global
approach, is known as systems biology. Here, theoretical, experimental, and
computational approaches are integrated in order to establish connections between
genes, proteins, metabolites, and other cellular/subcellular entities. This global
approach aids in the explanation and prediction of the complex cellular behaviors of
biological systems.

Systems biology has been extensively used for the elucidation of metabolic
models [1,2], because it allows the collection and integration of various data types in a
form suitable for mathematical analysis, as is schematically represented in Figure 1.
The establishment of a quantitative model allows for the compact and integrated
analysis of complex metabolic networks, and their associated and often non-intuitive
behavior. These models can be used to analyze phenotypes, guide strain design, and
investigate fundamental metabolic questions.
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Figure 1. Schematic representation of the integration of various data types for the
reconstruction of metabolic models. Figure taken from Reaves et al. [1]

The research reported herein applies systems biology to the reconstruction and
analysis of the metabolic networks of Mycoplasma gallisepticum, and Bacillus
anthracis. It takes advantage of the use of genome-scale metabolic models to
investigate fundamental metabolic questions, and combines experimental and
computational work. Through experiments, a microorganism’s behavior can be
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characterized. Nonetheless, metabolic interactions can be difficult to understand
through experimentation alone.. On the other hand, metabolic models give a complete
description of cellular functions. Therefore, this thesis will bring together these two
tools, and demonstrate how the reconstruction and analysis of metabolic models help
to explain the impact of iron availability on the Bacillus anthracis metabolism.

The reconstruction of genome-scale metabolic modeling is a time consuming
process. Thiele et al. [3] have mentioned that the reconstruction could take anywhere
from six months to two years depending on the knowledge of the organism, genome
size, and the complexity of the metabolism. I hypothesized that the reconstruction time
could be reduced through the use of a new methodology that combines a genetic
algorithm (GA), and flux balance analysis (FBA), named GAFBA. I developed and
tested GAFBA with the reconstruction of the genome-scale metabolic model of M.
gallisepticum

and B. anthracis. The reconstruction time using GAFBA ranged

between 1-4 months. Moreover, it provided additional help throughout the curation
process. It is a powerful tool for fundamental advances in biology. For instance,
during the curation process of the M. gallisepticum genome-scale metabolic model,
many logical hypotheses arose that have yet to be experimentally confirmed, such as
the presence of formate dehydrogenase, NAD+ synthethase, and Na-ATPase enzymes.

Based on the transcriptional profiles [6-8] of Bacilus anthracis under iron
deprivation conditions, I hypothesized that the following changes would be likely to
occur under iron-poor conditions: an increase in the flux of reactions involved in the
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biosynthesis, secretion and re-uptake of siderophores, a decrease in some amino acid
uptake, and a reduced growth rate under iron-poor conditions. All these conditions
were observed during the experiments and in the results of the model when the iron
concentration of the media was reduced.
1.2.Motivation

The overall motivation behind the research presented here was to understand
the cellular behavior of M. gallisepticum and B. anthracis from a metabolic
perspective. This was achieved by combining an in silico genome scale metabolic
analysis with experimental studies. Through the GAFBA methodology, two models
were created: M. gallisepticum and B. anthracis.

A model of M. gallisepticum was reconstructed and curated in order to prove
the principle of the GAFBA v1.0 methodology. Genome-scale metabolic models are
generally under-determined. To solve these models, optimization theory is used where
an objective function for the cell is postulated in order to determine the optimal
distribution of metabolic resources. However, genome-scale metabolic models often
result in an unfeasible solution when the model is constrained to experimental
information. It was hypothesized that this was because some metabolites’ mass
balance constraints could not be satisfied due to missing/incorrect reactions, incorrect
directionality of reactions, and missing/incorrect metabolites. This was the result of an
incomplete or erroneous genomic annotation. Identifying the metabolites that violate
the mass balance constraints is a non-trivial problem. GAFBA v1.0 determines these
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problematic metabolites.

To resolve the problematic metabolites, it is generally

necessary to add some reactions, or to adjust their metabolic networks in a way that
will solve the optimization problem. Furthermore, GAFBA v1.0 helped to identify
minimal media growth components, which is the main issue during the growth of
fastidious microorganisms such as M. gallisepticum.

The motivation behind the B. anthracis was to gain a better understanding of
its metabolism. This information could ultimately lead to the development of
strategies that will better protect people from anthrax. There are many studies on B.
anthracis that have focused on virulence factors, elucidating and understanding the
biosynthetic pathway, and the secretion and uptake of siderophores as individual
elements. Very few studies however, have looked at the global metabolism of B.
anthracis under conditions similar to the ones found in the alveolar macrophage (iron
starvation and oxidative stress), a primary infection target for B. anthracis. These
studies are based on transcriptomic and proteomic analysis [4-6], but based on the
literature review, no metabolomic studies have been carried out.
1.3.

Research significance and novelty

This research helped me develop and test GAFBA, the new methodology for
the curation process. GAFBA was used in the reconstruction of a small, and a large
genome-scale metabolic network. M. gallispeticum has a small genome (~1 MB)
compared to that of B. anthracis Sterne (~5.2 MB). GAFBA reduces the time required
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for the reconstruction process, and is a powerful tool for fundamental biological
studies.

GAFBA compiled all previously generated metabolic data into the M.
gallisepticum genome-scale metabolic model, which is the first model for this
pathogenic microorganism. Through the curation process, many logical hypotheses
arose that have yet to be experimentally confirmed. The study of M. gallisepticum’s
metabolism improves the understanding of its inner workings.

The genome-scale metabolic network analysis of the global metabolism of B.
anthracis’ vegetative cells elucidates of how B. anthracis survives within the alveolar
macrophage, and establishes a productive infection. This is an initial approximation of
how the host and B. anthracis interact during the infection process. Ultimately, it can
help in the development of improved treatment options and vaccines.

The host/pathogen interaction was ranked as number seven out of the top ten
biotechnologies for improving health in developing countries [7]. As a consequence,
some have started to use models in order to study these interactions, such as the model
developed using an MS2-infected Escherichia coli [8], and the model for the human
alveolar macrophage and Mycoplasma tuberculosis [9]. The known host-pathogen
interactions for B. anthracis have been partially determined by experimental
observation of the bacteria. But, there is no mechanistic model that provides a deeper
insight of the infection process. Therefore, this research attempts to start this process
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of reconstruction of the interaction between the human alveolar macrophage (HM) and
Bacillus anthracis, by generating a metabolic model for the bacteria.

This B. anthracis model is the first one for the bacterium. Additionally, it is the
first one to include the siderophore biosynthetic, secretion, and uptake pathways in
gram-positive bacteria. The existing metabolic models for gram-positive bacteria do
not take into account the siderophore sub-pathway. Therefore, this B. anthracis model
is expected to can be used as a guide for other gram-positive bacteria models, and it is
anticipated that some of the knowledge discovered in this work can be applied to
related species.

The analysis of the genome-scale model of B. anthracis under different iron
conditions allows one to identify a down-regulation in the TCA cycle reactions from
2-oxoglutarate to oxaloacetate, which resulted in the reduced uptake of some amino
acids under iron-poor conditions. This situation produced an increase in the glycolysis
pathway to synthesize some of the amino acids required for siderophore production
and for growth. Finally, I found a possible correlation of the growth between B.
anthracis’ metabolism under iron-poor conditions and the production of autoinducer2, a quorum sensing signal molecule. This correlation has not been experimentally
reported yet, however I was able to find it by using the genome-scale metabolic
modeling of the bacterium. This outcome highlights the importance of studying
bacterial metabolism from a global perspective, rather than as individual elements
working in isolation.
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1.4. Dissertation organization

The dissertation is divided into nine chapters. The background is presented in
Chapter 2. Meanwhile, Chapter 3 introduces a genetic algorithm/flux balance analysis
(GAFBA v1.0) methodology for reconstructing genome scale metabolic models. In
this chapter, GAFBA v1.0 is developed and validated by reconstructing a genomescale metabolic network of Mycoplasma gallisepticum. Chapter 4 is dedicated to
enhancing GAFBA v1.0. A user-friendly interface is presented, as well as additional
algorithms to speed up the curation process. This chapter is pure computational work.
On the contrary, Chapter 5 explains the in vivo experiments of B. anthracis growing
under two different iron conditions: a media treated with a resin to decrease the iron
concentration (iron-poor media), and a media supplemented with ferrous sulfate
solution (iron-rich media). Next, Chapter 6 introduces the first genome-scale
metabolic network for B. anthracis. In this chapter, the experimentally measured
fluxes reported in Chapter 5 are applied as constraints to the model. Thus, in silico
analysis gives insight into the metabolic adaptation of the bacterium under different
iron conditions (poor/rich). Then, Chapter 7 inquires about the possible connection
between the secretion of a quorum sensing signal molecule and the growth of B.
anthracis under iron reduced conditions. Finally, Chapters 8 and 9 conclude this work
and present possible future work.
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2. LITERATURE REVIEW
Below is a summary of the background for the research presented in the
following chapters.
2.1. Genome-scale metabolic models (GEMs)

A GEM is a fully mechanistic model that represents the relationship between
the genotype and phenotype of an organism’s metabolism. These models have been
used in biomedical and biological research such as the contextualization of highthrough data [10], guidance of metabolic engineering [11], directing hypothesis-drive
discovery[12], representation of multi species relationships [13], and network property
discovery[14], as was summarized by Oberhardt et al. [15].

GEMs compile the available genomic, biochemical, and physiological
information on an organism, creating a draft reconstruction. It then goes through a
curation process to fill the gaps, and remove any possible errors by examining the
literature, experimental data, and databases. Finally, the reconstruction is converted
into a mathematical model. The mathematical models can be quantitative, analyzed
using a dynamic modeling approach, or a constraint-based modeling approach [15,16].
The dynamic modeling of metabolic networks consisting of thousands of reactions is
often difficult, because of the necessity for a large number of experimentally
determined parameters and the computational complexity. To overcome these issues,
the constraint-based modeling approach was used [17].
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2.1.1. CONSTRAINT-BASED MODELING

In constraint-based modeling, the solution space of all possible metabolic
phenotypes is narrowed by imposing mass balance constraints and cellular limitations
to the reconstructed metabolic network, as is shown in Figure 2. Constraints such as
cellular limitations are based on enzyme capacity, reaction stoichiometry,
directionality of the reaction, gene regulatory constraints, and environmental factors.
The allowable solution space contains all the possible flux distributions that a
metabolic network could have [18]. Then, linear programming (LP) is used to
calculate an optimal flux distribution that satisfies a relevant objective function. Flux
Balance Analysis (FBA) was used to calculate the optimal states in this research.

Figure 2. The conceptual basis of constraint-based modeling. This figure is an
adaptation of Figure 1 from Orth, et al. [19], and Box 1 from Papp, et al. [20]. Mass
balance constraints and capacity constraints are imposed to a reconstructed metabolic
network leading to a allowable solution space. The network can have any flux
distribution within this space. Linear programming can be applied to optimize a
defined objective function.
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2.1.1.1. Flux balance analysis (FBA)

FBA starts with a mathematical representation of the reaction network
stoichiometries, and describes how substrates are converted to metabolite products and
biomass constituents [21]. Thus, a dynamic mass balance for each of the metabolites
presented in the network is written:

dx!
=
dt

S!" v! − µμx!

Eq. (2.1)

!

where x! is the concentration (moles/ cell mass) of metabolite i, S!" is the
stoichiometric coefficient of metabolite i in reaction j, v! is the flux (moles/cell
mass/time) of reaction j, and µμ is the cellular growth rate (time-1).

It is generally accepted that metabolism operates on a much faster time scale
than changes in cellular phenotype, for instance cell division [16,21,22]. Therefore,
the transient mass balance can be simplified to only consider the steady state. As a
result, there is no accumulation of metabolites, or:

0=

S!" v! − µμx!

Eq. (2.2)

!

In Equation 2.2, the first term on the right-hand side represents the net
synthesis rate of metabolite i over all the reactions. The second term is the dilution of
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the metabolite i pool due to biomass growth. The dilution term can be neglected,
because the effect of this term on the metabolite concentration is generally small
compared to the fluxes for each reaction in which the metabolite participates
[21,23,24]. Thus, the Equation 2.2 is reduced to a simpler linear mass balance:

S   ∙ v = 0

Eq. (2.3)

where 𝑆 represents the matrix of stoichiometric coefficients, and 𝑣 is the vector of
fluxes through all the reactions. Each row from the matrix 𝑆 corresponds to a unique
metabolite in the network. Some of them are intracellular, and some are extracellular.
Each column from the matrix represents one reaction. The fluxes can be classified as
intracellular reactions, transport fluxes, and exchange fluxes. The last one represents
the flow of nutrients/products into, or out of the biochemical system. Transport
reactions define the flow of metabolites occurring across cell and subcellular
compartment membranes.

Additional constraints are added to the system in order to reduce the space of
the allowable flux distribution. The set of constraints are represented as:

α!    ≤ v!    ≤    β!

Eq. (2.4)

where α! and β! are the lower and upper bound respectively of the j fluxes.
The constraints can the physicochemical kind, based on the reversibility/irreversibility
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of the reaction. For irreversible reactions, the lower boundary α! is set to zero. On the
contrary, for reversible reactions, the lower boundary is defined as negatively infinite.
The upper boundary for reversible and irreversible reactions is set to infinity.
Furthermore, any experimental information can be added into the model by assigning
values to α! and β! , such as experimentally measured uptake/secretion rates. It is also
possible to add regulatory constraints by using Equation 2.4. For instance, setting aj
and Bj to zero can represent the repression of certain enzymes under specific
environmental conditions.

Typically, in genome-scale metabolic networks, the number of metabolites is
less than the number of fluxes. This results in an under-determined system, for which
there exists a range of possible solutions to the network fluxes [22]. Each solution
represents a specific metabolic phenotype under particular conditions. Because the
objective function and constraints are linear in nature, FBA employs linear
programming (LP) to choose the flux distribution that is most optimal for a given
objective [23]. It should be noted that the flux distribution is not necessarily unique,
and there can be more than one flux distribution that reaches the optimal value of the
objective function [16].

In LP, the constraints and the objective function are all linear with respect to
the fluxes. The LP problem is formulated as;
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Minimize/Maximize Z
where Z   =   

c! ∙ v! = 𝐜 ∙ 𝐯

Eq. (2.5)

Where Z is the objective function to be maximized. This is represented as linear
combination of fluxes v! . The term c! is a biologically determined coefficient that
exhibits the contribution of v! to the objective function Z.

Different objective functions can be applied, such as the maximization of
biomass, maximization/minimization of ATP production, and the minimization of
redox potential [23,25,26].

In the past, the FBA approach combined with the

maximization of biomass formation as an objective function has successfully predicted
the growth rate [16]. Moreover, it has been argued that the growth of microorganisms
over a long period of time in laboratory conditions confers an optimal growth
phenotype on commonly used substrates in growth media [27]. For that reason, the
objective function used for this research is the maximization of biomass formation.
2.2. Genetic algorithm (GA)

Genetic algorithms (GAs) were invented by John Holland in the 1960s at the
University of Michigan [28]. GAs are adaptive heuristic search algorithms based on
the evolutionary theories of natural selection and genetic. GAs identify solutions to
optimization problems by searching a set of candidate solutions referred to as the
population. The candidate solutions are encoded on simple data structures referred to
as chromosomes. Each of the encoded parameters in a chromosome is referred to as a
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gene. The genes are either single bits or small blocks of neighboring bits. They
usually have a value of 0 or 1.

The GA process starts with the random generation of an initial population.
Then the chromosomes in the current population are evaluated and assigned a fitness
value that depends on how well that chromosome solves the problem. The next step is
the formation of a new population to be used in the following iteration, or generation
of the algorithm. The new population is formed using a specific selection strategy,
operations such as crossover and/or mutation resulting in the generation of new
solutions to the problem being solved [29].

2.2.1. SELECTION STRATEGY

There are many ways to accomplish selection, including roulette wheel
selection, tournament selection, elite selection, and linear-rank selection [28]. Elite
selection guarantees that the fittest members of each generation are selected.
Specifically, a limited number of chromosomes with the best fitness values are copied
to the next generation, avoiding the crossover and mutation operators.

2.2.2. CROSSOVER OPERATION

Crossover operation is the primary genetic operator. It exchanges the
information between two parent chromosomes. First, random segments of the parent
chromosomes are selected. Then, those segments are exchanged to form two new
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chromosomes with the same length as the parents. A schematic representation is
shown in Figure 3.

Figure 3. One point crossover operation. A crossover operation is performed in
two parental chromosomes if a random number is lower that the probability of
crossover (Pc).

2.2.3. MUTATION OPERATION

Mutation operation replaces a randomly chosen gene on a chromosome with its
opposite value. For instance, if the value of the gene were zero, it would be changed to
one. Randomly sampling new points within the search space helps prevent premature
convergence.. Mutation occurs randomly and very rarely with a probability (Pm).
Typically, this mutation rate is less than ten percent [30]. Figure 4 has an example of
mutation operation.
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Figure 4. Mutation operation. Pm is the probability of mutation.

The process of going from the evaluation of fitness to the formation of a new
population constitutes one generation in the execution of a genetic algorithm. Genetic
algorithms cannot guarantee convergence. Therefore, termination is commonly
triggered when either a maximum number of generations has been reached, or a
satisfactory fitness level has been achieved [30].
2.3. Pathogenic microorganisms

This sub-section presents a general review of the pathogenesis and
microbiological characteristics of the two microorganisms studied in this dissertation.

2.3.1. MYCOPLASMA GALLISEPTICUM

M. gallisepticum is an avian pathogen that results in chronic respiratory disease
(CRD) in poultry. It lacks a cell wall, has a flask-shaped appearance, and can survive
from a few days to months depending on the environmental conditions.
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Conventionally, Mycoplasma have a small genome. Therefore, they have been
considered model systems for defining the minimal set of genes required for survival.
M. gallisepticum’s genome size is 996,422 bp long, with a G+C content of 31% [31].

M. gallisepticum infections are the source of significant economic losses in
poultry production annually. Worldwide, the yearly losses have been estimated to
exceed $780 million, and in the United States the annual losses in egg production have
been estimated to be about $150 million. As a consequence, the National Poultry
Improvement Plan has requested regular surveillance and the development of
strategies to control and prevent the M. gallisepticum infection [32].

In the United States, a great deal of attention has been given to the eradication
of this organism from most commercial chickens and turkey breeding flocks.
However, it remains present in other poultry operations, mainly because the M.
gallisepticum infection is difficult to diagnose. Current techniques are laborious,
depend upon special expertise, and typically have false results [32]. Furthermore, the
infection is easily spread via by aerosol exposure and egg transmission. Outbreaks are
hard to control with antimicrobial therapy. Antibiotics can alleviate clinical signs, but
they cannot eliminate the infection. In the U.S., there are three live vaccines available
for use during the growing phase (F strain, ts-11, and 6/85), but they can be used only
with permission of the state veterinarian. Some virulence is retained in the F strain,
and ts-11 and 6/85 are less virulent than the F strain, but they are also less effective
[33].

37

The infection starts when the bacteria colonize the mucosal surface of the
respiratory tract. Figure 5 compares normal and infected tracheal tissue in birds. One
important step in the colonization process is the cytadherence of the tip-like structures
of M. gallisepticum to the tracheal lumen epithelial cells. Once the bacterium is
attached to the epithelial cell, the fusion of the cell membrane with M. gallisepticum
can occur. This can happen within 5 minutes after infection, and the number of
intracellular mycoplasmas increase in 24 hours. Then, the disease may progress
through systemic infection [34,35].

Figure 5. Comparison of normal (A) and infected (B) tracheal tissue. This figure
was taken from Figure 2 from Vitula, et al [36]. Figure 2A: Normal mucosa lined
with a pseudo-stratified columnar epithelium with knocilia(1), and a
fibrocartilaginious layer (2]) Figure 2B: Trachea of a bird infected with M.
gallisepticum. The inflammatory exudate is adhered to the epithelium (1). The trachea
is moderately infiltrated by lymphocytes and plasma cells (2) and (3).
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2.3.2. BACILLUS ANTHRACIS
2.3.2.1. History

In 1850, Pierre Rayer and Casimir-Joseph Davaine observed rod-like
organisms present in the blood of anthrax-infected animals and humans. Davaine
suggested that those microorganisms were probably causing the disease. In 1876,
Robert Koch studied the complete life cycle of the bacteria, and stated that anthrax
could only be transmitted from one host to another by transfer of the Bacilli [37].
Louis Pasteur created the first vaccine against anthrax containing live attenuated
organisms in 1881. During the last century, anthrax infections decreased significantly..
However, during World War I and World War II, countries such as Germany,
England, France, Russia, and Japan developed programs in order to produce B.
anthracis for biological warfare. In 1979, an accidental anthrax outbreak occurred near
Moscow. This case is known as the Sverdlovsk Epidemic. Many individuals suffered
gastrointestinal, cutaneous, and inhalation anthrax. After many investigations, the
incident was linked to a secret biological weapons program at a nearby military
compound. In 2001, anthrax attacks occurred in the U.S with spores in powder form.
The spores were sent to several news media offices and two U.S. Senators. Five
people died, including one in Connecticut, and 17 others were infected [38]. Taking
these events and the potential harm anthrax may cause into consideration, it is
necessary to develop better strategies to protect people from anthrax infections.
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2.3.2.2. Microbiology and pathogenesis

B. anthracis is a facultative anaerobic, gram-positive, non-motile, large rod
and spore forming bacteria. Bacilli will form spores when local nutrients in the
environment are exhausted, as happens after host death and exposure to air. The spores
are highly resistant and can survive for decades.

B. anthracis has two plasmids, pXO1 and pXO2, that encode the major
virulence factors. The pXO1 plasmid codes for three toxins: the lethal factor, the
edema factor, and the protective antigen. These proteins are individually nontoxic, but
in binary combinations, they result in hemorrhages, edema, and necrosis. The pXO2
plasmid encodes the genes involved in the synthesis of the polyglutamyl capsule that
inhibits host phagocytosis of the vegetative form of B. anthracis. Both plasmids are
necessary for full virulence; the loss of either results in an attenuated strain, such as
the Sterne strain, which only has the pXO1 plasmid. Therefore, B.anthracis Sterne can
synthesize exotoxins, but not the capsule [39]. It is known that the capsule does not
have an important role in the first stages of the infection process, but it facilitates the
systemic spread of the Bacilli through the bloodstream, and its escape from the lungs
[40].

Anthrax can be manifested in three forms: cutaneous, inhalation or
gastrointestinal. A picture of cutaneous and inhalation anthrax is shown in Figure 6.
Inhalation and gastrointestinal anthrax result in higher incidences of fatality. The
infection process begins when spores enter the body through the skin or mucosa. Then,
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local macrophages phagocytose the spores and transport them to the regional lymph
nodes. The spores germinate inside the macrophage during the intracellular step of the
life cycle of B. anthracis. It is believed that spore germination may be triggered by
signals such as elevated temperature (≥ 37 ºC), elevated CO2 concentrations (≥ 5%),
and serum components, which are typical conditions inside the host. After the
vegetative cells are released from the macrophage, they continue to multiply and enter
the lymphatic system and bloodstream, where they spread to the body and produce
septicemia [41].

Figure 6. Forms of anthrax, a picture of cutaneous anthrax is on the left, and a
picture of inhalation anthrax is on the right panel [42], The dark space at the upper
right and upper left of the colored chest x-ray are the lungs, and the red region
represents the B. anthracis infection. [43]
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3. A GENETIC ALGORITHM/FLUX BALANCE ANALYSIS (GAFBA)
METHODOLOGY FOR CURATION OF GENOME-SCALE METABOLIC
MODELS

This chapter is a modified version of the paper: “Semi-automated curation of
metabolic models via flux balance analysis: a case study with Mycoplasma
gallisepticum,” by Eddy J. Bautista, Joseph Zinski, Steven M. Szczepanek, Erik L.
Johnson, Edan R. Tulman, Wei-Mei Ching, Steven J. Geary, Ranjan Srivastava. The
author’s contribution to this research included model development, curation, and all of
the computational work.
3.1. Chapter Synopsis

Genome-scale metabolic modeling, a technique primarily used for metabolic
engineering and synthetic biology, shows tremendous potential as a tool for
fundamental research, and the curation of metabolism. Through a novel integration of
flux balance analysis and genetic algorithms, a strategy to curate metabolic networks
and facilitate the identification of metabolic pathways that may not be directly
inferable solely from genome annotation was developed. Specifically, metabolites
involved in unknown reactions can be determined, and potentially erroneous pathways
can be identified. The procedure developed allows for a new fundamental insight into
metabolism, as well as acting as a semi-automated curation methodology for genomescale metabolic modeling. To validate the methodology, a genome-scale metabolic
model for the bacterium Mycoplasma gallisepticum was created. Several reactions not
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predicted by genome annotation were postulated by the curator and validated via the
literature. The model predicted an average growth rate of 0.358 ± 0.12 h−1 , closely
matching the experimentally determined growth rate of M. gallisepticum, which is
0.244 ± 0.03 h−1 . This work presents a powerful algorithm for facilitating the
identification and curation of previously known and new metabolic pathways, as well
as presenting the first genome-scale reconstruction of M. gallisepticum.
3.2. Introduction

Metabolic network modeling is an iterative process that starts with the
generation of a genome-scale reconstruction of metabolism, utilizing all current
annotations and literature information. Next, an expert manually curates the draft
reconstruction, and the computational model is generated. Finally, a comparison of the
in silico results relative to the experimental information is assessed. The iterative
process stops when the results from the model are nearly the same as the experimental
results. In the future, as more information becomes available, the model can be
updated in order to fill all possible gaps and achieve better results [3,44,45].

Most

genome annotations are carried out using automated techniques, many of which rely
on pairwise similarity scoring of the predicted proteins to those in databases [45-48].
Such a process is imperfect, as the ability to reliably annotate a given protein with a
specific function can be greatly impacted by sequence divergence, lack of reliable
functional knowledge, or annotation for sequence matches. This currently results in
genome annotations that may not accurately or completely reflect the organism’s
metabolic functions. The use of metabolic network modeling provides an additional
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and powerful methodology to help compensate for these gaps in knowledge, leading to
a more accurate reconstruction of an organism’s metabolism.

The model curation process improves the draft reconstruction by identifying
and filling the gaps present in the network, removing reactions that are not likely
present in the organism, and enforcing overall consistency across the network. Some
automatic computational strategies for identifying missing reactions and filling the
gaps have been developed previously, such as GapFind [47], GapFill [47], the
Pathway Tools Hole Filler [49], the “metabolic expression placement” [50,51],
MetaFlux [52], and Model SEED [53]. GapFind is an optimization-based procedure to
identify missing reactions in the network. Gaps can be filled with GapFill by adjusting
the existing metabolic network through reversing the directionality of existing
reactions; adding transport reactions between compartments; adding exchange fluxes;
or by adding a minimum number of reactions from a reference database [54].
MetaFlux is part of the Pathway Tools software for generating FBA models. It uses a
multiple gap filling approach based on mixed integer linear programming (MILP),
which suggests reactions to be added from the MetaCyc database, identifies biomass
metabolites which are required but can not be produced, and chooses nutrient and
secretion fluxes to be added to the model from a “try set” defined by the user. Model
SEED is a web-based resource for the creation of new metabolic models. After a
preliminary reconstruction model is created in Model SEED, an auto-completion step
is performed by using an MILP algorithm that identifies the minimal set of reactions
from the SEED reaction database needed to fill the gaps present in the network.
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However, all these approaches are dependent upon an existing reference database of
information to resolve these curation issues. Here, a new algorithm for facilitating the
curation of models is presented. The approach integrates a genetic algorithm (GA)
with flux balance analysis.

The novelty and strength of this GA/Flux Balance

Analysis (GAFBA v1.0) strategy lies in its ability to both aid in fundamental studies
of metabolism, and to facilitate the curation of genome-scale metabolic networks,
rather than functioning solely as a predictive tool. Furthermore, the strategy is
independent of a reference database, allowing the researcher to investigate other
avenues of curation. However, this approach does not preclude the use of existing
databases as one of those sources of information.

Rather it provides increased

flexibility in evaluating the system of interest.

The premise of the GAFBA v1.0 method is based upon the observation that the
optimization of an initial genome-scale metabolic model often results in no feasible
solution when experimental information is incorporated.

This result indicates that

some of the constraints cannot be satisfied, because they are mutually contradictory.
The GAFBA v1.0 method identifies the mass balanced constraints that may be relaxed
to solve the FBA optimization problem. If relaxing a selected constraint allows the
problem to be solved, it is likely that the associated metabolite was participating in a
metabolic reaction that, due to lack of information during the reconstruction process,
was not taken into account in the model. As a result, the metabolite and the potential
reactions in which it may participate should be reviewed. The approach developed
here employs a genetic algorithm to identify the minimum number of constraints that
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could be relaxed in order to achieve a feasible solution to the FBA optimization
problem.

To develop and evaluate this strategy, Mycoplasma gallisepticum was chosen
as the model organism. The choice of M. gallisepticum for the validation of the
GAFBA v1.0 methodology was driven by our expertise on the organism, and the
organism’s importance to the poultry industry.

M. gallisepticum causes chronic

respiratory disease in chickens and infectious sinusitis in turkeys [55]. The disease can
be easily propagated by direct or indirect means. M. gallisepticum has been a concern
to the poultry industry because of the resultant increase in chick and poultry mortality,
reduced egg production, and increased costs related to medication, prevention and
control programs. For example, in 1994, the layer industry alone lost between $118
and $150 million in the United States [56] due to M. gallisepticum infections. A better
understanding of M. gallisepticum biology, including virulence, genomics, and
metabolic processes has the potential to allow for the development and improvement
of the vaccines and control strategies for this disease.

In this work, the metabolic network of M. gallisepticum was developed by
using the organism’s annotated genome sequence, compiling existing enzymatic data,
employing genome-scale bioinformatics-driven homology searches, referencing the
metabolism of other closely related Mycoplasma strains, generating a comprehensive
biomass equation, and finally analyzing how all the metabolites in the system
interacted with each other using the GAFBA v1.0 algorithm.
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3.3. Material and Methods
3.3.1. GENETIC ALGORITHM PARAMETERS

The genetic algorithm (GA) maintained a population of chromosomes where each one
of them represented a potential metabolic model for M. gallisepticum. The
chromosomes were encoded in such a way that each gene symbolized a mass balance
constraint. If the mass balance constraint for a metabolite was relaxed, the gene was
assigned a value of zero. If it was enforced, the gene was assigned a value of one. The
population was evolved using the genetic operations of reproduction, crossover, and
mutation. In the reproduction operation (elite selection), the best chromosomes were
copied unchanged into the new population. Meanwhile, the crossover operation
swapped information between two parent chromosomes.

Finally, the mutation

operation randomly selected one or more mass balance constraints to alter the gene
value from its initial value. For instance, if the initial gene value was one, it was
changed to zero and vice versa.
GA was implemented using an elite selection strategy [28]. The population
consisted of 30 chromosomes.

The crossover probability was set to 70%. The

mutation probability was set to 1%. The GAFBA v1.0 algorithm was run for 2,000
generations per simulation. The choice of 2,000 generations as the termination criteria
was based on empirical observation. It was found that by 2,000 generations, the
system generally reached a plateau, and no further changes in biomass and constraints
were observed. Each simulation took around seven hours on a 3.33 GHz Intel Core 2
Duo CPU/ 4 GB workstation. Thus, the total time for the 40 simulations was
approximately 12 days.

47

3.3.2.

FLUX BALANCE ANALYSIS

The theory behind the development of FBA was discussed in chapter 2.
However, in this subsection the constraints applied to the specific case of
M.gallisepticum are defined. Since the media was undefined, the exchange fluxes had
to be determined from literature information on relative species [57-59]. The
boundaries for the exchange fluxes were defined for metabolites in the media as
−∞ ≤ v j ≤ ∞ ,

implemented:

and for secretion of metabolites the following constraint was
0≤vj ≤∞

[58]. The list of nutrients and secretions are provided in

appendix A3.4. The lower boundary of the non-growth associate maintenance
−1 −1
(NGAM) value was set to 8.4 mmol gDW h , based on the value for the M.

genitalium iPS189 model [58]. The NGAM value represents the energy consumed for
processes such as turnover of macromolecules, maintenance of concentration
gradients, and electrical potential gradients when the cells do not grow [60]. The upper
and lower boundaries of the glucose uptake rate and lactate secretion rate were set to
−1 −1
the experimentally determined values, which were -16.53 mmol gDW h for glucose,

−1 −1
and 10.29 mmol gDW h for lactate. The lower boundary value of the oxygen

−1 −1
uptake rate was constrained to -43 mmol gDW h to avoid reaction-looping behavior

[3,52]. The objective function to be maximized was the biomass equation for M.
gallisepticum.
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3.3.3. EXPERIMENTAL PROTOCOLS

All the relevant information on the experimental methodology can be found in
appendix 2.
3.4. Results
3.4.1. HYBRID GENETIC ALGORITHM/FLUX BALANCE ANALYSIS (GAFBA)

The hybrid Genetic Algorithm/Flux Balance Analysis Algorithm (GAFBA
v1.0) algorithm embeds the Flux Balance Analysis (FBA) optimization problem
within a genetic algorithm to identify problematic metabolic constraints, and is
schematically depicted in Figure 7. The optimization problem was resolved through a
hierarchical approach, with the minimization of the number of relaxed constraints
being given primary importance. The pool of models that had the same number of
constraints relaxed were then further discriminated against by determining which
individual models had the highest growth rate values, a frequently used objective
function for FBA [61-64]. After each simulation, a list of problematic metabolites,
whose mass balance constraints were forced to be relaxed, was generated to elucidate
potential errors or missing information. Based on these data, it was possible to decide
the best manner by which to fill in the missing information if possible. A revised
version of the mechanisms for solving gaps previously presented by Maranas’ group
was manually applied [47]. The options were: 1) change the directionality of a
reaction, 2) add an exchange flux for the metabolite, 3) add a transport or intracellular
reaction, 4) remove a reaction or metabolite from the model, or 5) no change.
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Examples for each case are presented in the appendix 1. The option chosen was based
on experimental data, literature data or information from related organisms.

Figure 7. Flowchart for the GAFBA v1.0 algorithm. A schematic depiction of the
GAFBA v1.0 algorithm used to determine the genome-scale metabolic model for M.
galliscepticum. The steps in purple are operations performed by the user.

The initial genome-scale metabolic model was based upon an updated
annotation of the M. gallisepticum genome [65]. Using the Pathway tools software
platform [66], a Pathway Genome Database was constructed that accounted for all
metabolic pathways, as determined from the genome annotation.
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The GA started with the random generation of an initial population of data
structures referred to as “chromosomes”, per the GA parlance [28,67]. Each
chromosome represented a potential metabolic model of the microorganism. The
chromosomes were binary encoded where each of the genes represented a mass
balance constraint. If the mass balance constraint for a metabolite was relaxed, the
gene was assigned a value of zero. If it was enforced, the gene was assigned a value
of one. The number of mass balance constraints that were relaxed in the initial
population was determined randomly. Examples of the mass balance constraints
enforced and relaxed are shown in Figure 8. A feasible solution to the optimization
problem is found when the mass balance constraints of metabolite E and A are
allowed to be relaxed. By relaxing the mass balance constraint of metabolite A, the
flux through V1 can be different than zero, allowing the production of metabolite D
required to fulfill the experimentally observed secretion of metabolite H. Something
similar happens when the mass balance constraint of metabolite E is relaxed. V5 can
be carried out with a flux different than zero, allowing the experimentally observed
uptake of metabolite C.
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Figure 8. An example of relaxed and enforced mass balance constraints for a
metabolite.

The population was then allowed to evolve using the genetic operations of
reproduction, crossover, and mutation in order to achieve a fitter population, and
ultimately an accurate metabolic model. The objective function for GAFBA v1.0 was
to minimize the number of mass balance constraints relaxed. The problem is
formulated as follows,

!

g !   

Minimize F   = l −   

Eq. (3.1)

!!!

where F is the number of mass balance constraints relaxed, l is the length of the
chromosome or total number of mass balance constraints, i is the number of genes,
and 𝑔 is the gene value (0 or 1).
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The objective function of GAFBA was subject to the requirement that the FBA model
return a feasible solution. If the FBA optimization of a chromosome resulted in an
unfeasible solution, a negative one (-1) was assigned to its F value. Moreover, if two
chromosomes had the same number of mass balance constraints relaxed (F value), the
best one was the chromosome with the higher growth rate.
The FBA problem is presented in the set of Equations 3.2,

Maximize Z =

c! ∙ v!   

Subject  to    S! ∙    v! = 0  

Eq. (3.2)

and    S! ∙    v! ≠ 0  
  and  α!    ≤ v!    ≤    β!   

where Z is the growth rate, the subscript E refers to the mass balance constraints
enforced, and the subscript R indicates the mass balance constraints relaxed. All the
other variables have been defined in the previous chapter.
A list of the problematic metabolites was generated upon completion of the
run. Problematic metabolites were defined as those that were unable to fulfill the mass
balance under the given conditions; manual review of each of the metabolites, as well
as some of the upstream and/or downstream metabolites in the associated pathway was
required. The analysis of the metabolites upstream and/or downstream in the pathway
helped to determine if the problem could be corrected by adjusting the mass balance of
a closely connected metabolite instead of the problematic metabolite directly. For
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example in Figure 8, the problematic metabolite could be C because one of the
downstream reactions (V5) responsible for consuming the metabolite (C) is blocked,
since it is producing a dead end metabolite (E). Thus, it is necessary to adjust the mass
balance of the dead end metabolite (E) and not the mass balance of the so-called
problematic metabolite (C). An example of an upstream issue in Figure 8 could be the
problematic metabolite D. V1 is the reaction responsible for producing metabolite D,
however it has no flux due to the lack of a reactant (A). Under such conditions, the
mass balance for the reactant (A) has to be adjusted rather than the mass balance of the
initially identified “problematic” metabolite (D).

After updating the model, a new simulation was started. If a metabolite was
added or removed, a new initial population was generated randomly and evolution was
allowed to proceed. If no metabolite was added or removed, GAFBA v1.0 could either
be continued from where it left off using the final population from the previous run as
the seed population, or an entirely new population could be generated. The
evolutionary process was then re-started. The ultimate termination criterion was when
none of the mass balances constraints needed to be relaxed.
3.4.2. INITIAL RECONSTRUCTION OF THE M. GALLISEPTICUM METABOLIC MODEL

The first step in the reconstruction of a genome-scale metabolic model of M.
gallisepticum, was to analyze the published annotation of Strain R Clone 2 [65] using
the Pathway Tools Pathologic automated metabolic network generation platform [68].
Pathway Tools Pathologic compiled reactions associated with Enzyme Commission
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(EC) numbers and enzymes listed in the annotation [66]. Next, an in-depth literature
review focusing on previously elucidated enzymatic activity was performed. Reactions
shown to be active in M. gallisepticum were subsequently added. Reactions shown to
be inactive were removed. A total of 23 reactions were added due to supporting
experimental data and are listed in Table 1. Five total reactions, shown in Table 2,
were added based on BLASTP homology results. Two reactions catalyzed by
annotated enzymes that were found in previous studies were not present in M.
gallisepticum. These reactions were subsequently removed and are listed in Table 3.

Once the pool of published enzymatic data had been exhausted, the Pathway
Tools Hole Filler was used to generate a list of gene candidates to potentially fill gaps
in various metabolic pathways. Any candidate reaction from Pathway Hole Filler with
a probability assignment over 0.9 was selected for further evaluation in order to
eliminate false positives, and about two thirds of the candidates were accepted.
Supporting evidence for the additional function of the genes selected by the Pathway
Hole Filler, along with the reactions catalyzed are shown in Table 4. In total, 12 high
confidence enzymes were assigned due to the results of the Pathway Hole Filler
analysis. Taking these modifications into account, the initial model consisted of 446
metabolites involved in 380 reactions.
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Table 1. Summary of reactions added to the metabolic model based on
experimental data in the literature. Enzyme names normally catalyzing reactions
described in the literature and corresponding E.C. assignments are listed. All EC
numbers were determined via Pathway Tools v14. M. gallisepticum genes potentially
associated with these activities are noted, and enzymes/activities lacking gene
associations of confidence are indicated with question marks.
Enzyme Name
HMG-CoA Synthase
CoA transphorase
Membrane DNAases and
RNaases
Succinyl CoA:
Acetoacetate CoAtransferase
HMG-CoA Reductase
Malate synthase
Pyruvate Carboxylase
AMP phosphatase
GMP phosphatase
dAMP
Adenylosuccinate
synthetase
Adenylosuccinate lyase
Deoxyadenosine kinase
(ATP-dependent)
Deoxyguanosine kinase
(ATP-dependent)
Deoxycytidine deaminase
Uridine phosphorylase
Deoxyuridine
phosphorylase
Uracil phosphorylase
Malate dehydrogenase
Ribose-5-phosphate
isomerase
Asparate aminotransferase
Serine
hydroxymethyltransferase
Phospholipase A1

EC #
2.3.3.10
2.8.3.8

Associated Gene
?
?

Citation
[69]
[69]

None

?

[70]

2.8.3.5

?

[69]

1.1.1.34
2.3.3.9
6.4.1.1
3.1.3.5
3.1.3.5
3.1.3.5

?
?
?
?
?
?

[69]
[71]
[71]
[72,73]
[72-74]
[75]

6.3.4.4

?

[76]

4.3.2.2

[76]

3.5.4.14
2.4.2.3

?
MGA_0174,
MGA_0175
MGA_0174,
MGA_0175
MGA_0361
?

[49,77]
[49,73,77]

2.4.2.23

?

[73]

None
1.1.1.37

MGA_0362
MGA_0746

[49,73]
[71,78,79]

5.3.1.6

MGA_0886

[74,80]

2.6.1.1

?

[81]

None

MGA_1146

[82]

3.1.1.32

?

[83]

2.7.1.76
2.7.1.133

[74]
[74]
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Table 2. Summary of reactions added based on BLASTP analysis. Listed here are
M. gallisepticum genes found by forward and reverse BLASTP [84,85] searches to be
significantly similar to genes in related mycoplasmas that catalyze the corresponding
listed reactions. These reactions were added to the model. All EC numbers were
determined via Pathway Tools v14.
Enzyme name

1,2
diacylglycerol
3-Bgalactosyltrans
ferase
Galactolipid
galactosyltrans
ferase
Phosphoglycer
ate kinase
(dGTP)
Phosphoglycer
ate kinase
(GTP)
Phosphopento
mutase

Organism

Locus

Forward
E value

Revers
CitaeE
tion
Value

MGA_000
1

M.
pneumonaie

mpn
483

3.E-15

7E-13

[86,8
7]

2.4.1.18
4

MGA_000
1

M.
pneumonaie

mpn
483

3.E-15

7.E-13

[86,8
7]

2.7.2.3

MGA_118
7

M.
pneumonaie

mpn
429

1.E-128

1.E-128

[88,8
9]

2.7.2.10

MGA_118
7

M.
pneumonaie

mpn
429

1.E-128

1.E-128

[88,8
9]

5.4.2.7

MGA_035
8

M.
pneumonaie

mpn
066

6.E-120

7.E-120

[89]

EC #

M. gal
Locus

2.4.1.46

Table 3. Reactions removed based on experimental studies. Here, the reactions
and associated enzymes that were shown to be absent in M. gallisepticum based on
previous experimental studies, and were therefore not incorporated into the model are
listed.

Enzyme name
Deoxyribose-5phosphate aldolase
dUTPase

Removed due to experimental evidence
Associated
EC #
gene

Citation

4.1.2.4

MGA_0363

[80]

3.6.1.23

MGA_0994

[75,90]
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Table 4. Enzymes added based on Pathway Tools analysis. This table shows the
genes, previously annotated functions, newly annotated functions, reaction EC
numbers, and HF probability, along with the rationale for why they were added. All
EC numbers were determined via Pathway Tools v14. It should be noted that the
functionalities listed here are in addition to the original functionality of the given gene.
Gene

Annotated
Gene
Function

New HF Gene
Function

Hole
EC#

Ptools HF
Probability

MGA_0008

Putative
Glycerol-3phosphate
acyltransferase

Glycerol-3phosphate Oacyltransferase

2.3.1.15

0.98

Glycine
Decarboxylase

None

1.00

Folate
interconversion

NAD(P)(+)
Transhydrogen
ase (Bspecific)

1.6.1.1

0.99

Needed for
NADP charging

0.99

Needed to
provide an acyl
carrier protein for
lipid metabolism

MGA_0161

MGA_0161

MGA_0181

MGA_0291

MGA_0364

MGA_0594

MGA_0594

Dihydrolipoa
mide
dehydrogenase
(E3)
component of
PDH complex
Dihydrolipoa
mide
dehydrogenase
(E3)
component of
PDH complex
Fatty acid
/phospholipid
synthesis
protein Plsx
Inorganic
polyphosphate
/ATP-NAD
kinase
Purine
nucleoside
phosphorylase
deoD-type
GlutamyltRNA
synthetase
(Glutamate—
tRNA ligase)
(GluRS)
GlutamyltRNA
synthetase
(Glutamate—
tRNA ligase)
(GluRS)

AcylPhosphate
Synthase

None

Additional
Citation/
Rationale
Needed for
glycerol
incorporation for
phospholipid
biosynthesis

NADH Kinase

2.7.1.86

0.96

Needed for
NADH
metabolism

Deoxyinosine
phosphatase

None

0.99

[73]

Glutamine
tRNA ligase

6.1.1.18

1.00

Necessary tRNA
charging pathway

Glutamine
tRNA ligase

None

0.92

Necessary to the
glutaminyl-tRNA
charging pathway
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Gene

Annotated
Gene
Function

MGA_0596

Bifunctional
protein folD

MGA_0833

MGA_0950

MGA_1065

Acetyl-CoA
hydrolase
Guanosine
polyphosphate
pyrophosphoh
ydrolases/
synthetase
AsparaginyltRNA
synthetase

New HF Gene
Function

Additional
Citation/
Rationale
Homology to
E.Coli’s FolD
which catalyzes
this reaction

Hole
EC#

Ptools HF
Probability

1.5.1.15

1.00

2.8.3.8

0.98

[69]

GTPpyrophosphoki
nase

2.7.6.5

1.00

Needed for
ppGpp
Biosynthesis

Asparate
tRNA ligase

6.1.1.-

1.00

Needed for Lasparginyl tRNA
charging pathway

Methylenetetra
hydrofolate
dehydrogenase
(NAD+)
Acetate CoA
transferase

3.4.3. REFINEMENT OF THE INITIAL RECONSTRUCTION

FBA of the initial M. gallisepticum model resulted in no feasible solution.
Thus, the model was analyzed using GAFBA v1.0 to identify reaction holes,
unproduced but necessary biomass components, and metabolites with no membrane
transporter or degradation pathway. The biomass equation was meticulously
investigated. A large number of citations were accumulated for many metabolites that
were known to be biosynthesized by M. gallispeticum, but were not accounted for
based on the genome annotation. For example, phosphatidylcholine, cardiolipin, and
sphingomylin are all phospholipids known to have working biosynthesis pathways in
M. gallispeticum based on previously conducted fatty acid radioactive labeling assays
[91]. Nevertheless, there are a number of reactions necessary to biosynthesize these
components that are absent in M. gallispeticum. Therefore, logical reactions were
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assigned to complete these biosynthesis pathways, usually by referencing similar
pathways in other Mycoplasma genomes. A total of 16 reactions were added. A list of
all of these added reactions, along with a brief description of the rationale for the
additions and all relevant citations are shown in Table 5. However, it is critical to note
that the rationale for including these pathways was to complete the model. It does not
constitute as proof of the existence of these pathway. That being said, the requirement
of such pathways for the model does open up interesting experimental questions and
new hypotheses.

Despite the application of the changes shown in Table 5, some mass balances
remained inconsistent. Using GAFBA v1.0, additional changes were needed in order
to fulfill the mass balance and additional runs continued to require refinement of the
model.

The remaining modifications are presented in Table 6 with the details

described below.

Through the use of GAFBA v1.0, it was found that the mass balance on the
charged tRNA’s and uncharged tRNA’s could not be enforced under the given
metabolic description. The discrepancy was due to uncharged tRNA’s being converted
to charged tRNA’s by tRNA ligase reactions without participating in other reactions.
This ultimately resulted in the depletion of uncharged tRNA’s if the mass balance was
enforced without modifications. To rectify this imbalance, another reaction was added
representing a recycling process to convert the charged tRNA’s to uncharged tRNA’s,
thereby completing the cycle. These reactions were added to the biomass equation.
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This was similar to the approach taken for M. genitalium model iPS189 [58], which
also includes charged and uncharged tRNA molecules in the biomass equation.
Table 5. Initial model modifications. The first set of changes made to the
preliminary model based on GAFBA v1.0 results is provided. Rationale and relevant
citations are listed for each.
Enzyme
Name

EC #

Needed Product/
Un-degraded
Metabolite

Pyruvate
kinase

2.7.4.6

DNA

Phosphatidat
e
phosphatase

3.1.3.4

A phosphotidylcholine

Phosphatidyl
glycerophos
phatase

3.1.3.27

Cardiolipin

Unnamed

2.7.8.-

Cardiolipin

2.7.7.15

A phosphotidylcholine

2.7.8.2

A phophotidylcholine

Chlorinepho
sphate
cytidylytrans
ferase
Diacylglycer
ol
chlorinephos
photransfera
se
Sphingomyel
in Synthase

2.7.8.27

A sphingomyelin

PNPase

3.1.3.7

Adenosine 3’,5’biphosphate

Fatty acid
acyl group
creator

6.2.1.20

Acyl-fatty acid

Rationale

Needed for DNA
synthesis. 7 reactions
total of this EC#
added.
Needed to synthesize a
lipid experimentally
proven to be
biosynthesized
Needed to synthesize a
lipid experimentally
proven to be
biosynthesized
Needed to synthesize a
lipid experimentally
proven to be
biosynthesized
Needed to synthesize a
lipid experimentally
proven to be
biosynthesized
Needed to synthesize a
lipid experimentally
proven to be
biosynthesized
Needed to synthesize a
lipid experimentally
proven to be
biosynthesized
Biphosphate, the
byproduct of the acyl
carrier protein charging
reaction necessary for
fatty acid utilization
Needed for fatty acid
assimilation

Citation

[88]

[91]

[91]

[91]

[91]

[91]

[83,91]

[91-93]

[91-93]
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EC #

Needed Product/
Un-degraded
Metabolite

Rationale

Citation

2.4.1.8

B-D-glucose-6phosphate

Needed for maltose
degradation

[94]

None

5-methyltetrahydrofolate

Tetrahydrofolate

[82]

2.7.1.35

Pyridozyl 5’phosphate

Needed for vitamin B6
production

[89]

2.7.1.89

Fructose-1,6biphosphate

Fructose degradation
essential

[94]

2.7.1.89

Thiamine
diphosphate

From thiamine

[89]

2.7.4.16

Thiamine
diphosphate

3.3.1.1

S-adenosyl-Lhomocysteine

Enzyme
Name
Maltose
phosphorylas
e
Serine
hydromethyl
tranferase
Pyridoxamin
e kinase
Fructose-1phosphate
kinase
Thiamine
kinase
Thiaminemonophosph
ate kinase
Adenosylho
mocysteinas
e

Needed to complete
vitamin b1 biosynthesis
from thiamine
Needed to degrade the
S-adenosyl-Lhomocysteine formed
from tRNA
methylation

[89]

none

Table 6. Remaining changes made to model. The cumulative changes from the
second and succeeding rounds of analysis done with the GAFBA v1.0 algorithm are
presented.
Metabolite

compartment

Charged tRNA's

cytosol

Uncharged tRNA’s

cytosol

Oxygen
Cytidine
Hydrogen peroxide
Carbon dioxide
Chloride
L-alpha-alanine
L-cysteine
L-threonine
L-glutamine
L-aspartate

cytosol
cytosol
cytosol
cytosol
cytosol
cytosol
cytosol
Cytosol
Cytosol
Cytosol

change

reference

added recycling rxn to
[51]
biomass
added recycling rxn to
[51]
biomass
added exchange flux Experimental conditions
added exchange flux
[57]
added exchange flux
added exchange flux
added exchange flux
[57]
added exchange flux
[57]
added exchange flux
[57]
added exchange flux
[57]
added exchange flux
[95]
added exchange flux
[57]
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Metabolite

compartment

change

reference

Glycine
all the rest of amino
acids
Ceramides

Cytosol

added exchange flux

[57]

Extracellular

added exchange flux

[57]

Extracellular

Biomass

Cytosol

Ribose-5-phosphate

Cytosol

Ribose-5-phosphate

Cytosol

Thymidine

Cytosol

Sodium ion
Formate
a protein Lmethionine
Choline

Extracellular
Cytosol

dCTP

Cytosol

added exchange flux
GAM was calculated
and added to biomass
equation
changed the
directionality of E.C.
5.3.1.6
changed the
directionality of E.C.
5.1.3.1
changed the
directionality of E.C.
2.4.2.4
added exchange flux
added E.C. 1.2.1.2 rxn
remove general rxn
RXN-8668
added E.C. 3.6.3.7
Changed the direction
of E.C. 1.8.1.9

NAD+

Cytosol

cytosol
Cytosol

Added E.C. 6.3.5.1

[3]
KEGG [96]
KEGG [96]
KEGG [96]
[57,97]
[89]

[98]
KEGG [96]
[57,58]

Because the growth medium used experimentally was undefined, many of the
necessary exchange fluxes for the model could not be explicitly resolved.

The

decision to add an exchange flux to the model was based on experimental information
and on the composition of defined media for relative species, such as M. genitalium
[58] and M. laidlawii [57]. All added exchange fluxes are listed in Table 6.

The experimental data was insufficient to directly calculate the velu of growth
associated maintenance (GAM) and non-growth associated maintenance (NGAM) for
M. gallisepticum. Thus, the GAM of M. pneumonia [89] was added to the biomass
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equation, and the value for NGAM was taken from the M. genitalium iPS189 model
[58].

GAFBA v1.0 selected formate as a problematic metabolite, since formate was
produced by the peptide deformylase enzyme (E.C. 3.5.1.88) and the biomass reaction,
as is shown in Figure S3. However, no reaction consuming formate was present.
Therefore, the reaction catalyzed by the enzyme formate dehydrogenase (E.C. 1.2.1.2)
was added to the model in order to complete the mass balance of formate. This
reaction is present in other Mycoplasmas [89], and based on the GAFBA v1.0 results.
It was hypothesized that this reaction was also part of M. gallisepticum’s metabolic
network.

Another problematic metabolite identified by GAFBA v1.0 that was hindering
the successful simulation of the metabolic network, was choline.

The M.

gallisepticum model required choline for the production of phosphatidyl choline,
which was ultimately necessary for biomass.

Although the reaction for the

consumption of choline was present, no choline was predicted to enter the cell. Based
on the reconstruction, the transport reaction for choline, represented by flux V21 in
Figure 9, was coupled with sodium ion transport. When choline was transported from
the extracellular space to the cytosol, it co-transported a sodium ion. The problem was
that the sodium ion in the cytosol was not used in any other reaction. To avoid the
accumulation of unused sodium in the cell, the model predicted that the flux through
the transport reaction (V21) was zero. A possible solution for this problem was to add
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a reaction that used sodium ions. In reviewing the literature, it was found that sodium
is used for volume regulation in Mycoplasma [98-103] via translocation from the
cytosol to the extracellular environment by Na-ATPase (E.C. 3.6.3.7). Searching the
M. gallisepticum proteome for Na-ATPase using BLASTP [84,85], and the
Aspergillus fumigatus Af293 sodium P-type ATPase (GenBank Accession no.
XP_751881.1) as a probe, the best match (82% percentage coverage, score of 306, and
E-producing value of 5.E-91) was identified at locus NP_853020.2, the previously
annotated cation that transported ATPase MGA_1061.

Figure 9. Choline Subnetwork. The purple circle shows the unconstrained
metabolite. The thin blue arrows are the standard fluxes, while the thick blue arrows
are the exchange fluxes. The orange arrow represents the proposed solution. The solid
blue line is the plasma membrane and the dashed blue line is the system boundary.
The red circle is an abstraction of the biomass pool.

65

The mass balance for dCTP was also required to be unconstrained, based on
GAFBA v1.0 results. This was because more dCTP was produced from dCDP than
was consumed by the biomass reaction. The dCDP was produced from CDP coupled
with reduced thioredoxin, and oxidized NrdH glutaredoxin-like protein. When the
metabolic networks of these metabolites were checked, the thioredoxin reductase
reaction (E.C. 1.8.1.9) was found to be reversed [96].

Correcting E.C. 1.8.1.9

directionality resolved the dCTP problem.

The last two metabolites for which the mass balance constraints were relaxed
were 2-phospho-4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol, and nicotinamide
adenine dinucleotide (NAD+).

2-phospho-4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol is a metabolite
in the methylerythitol phosphate pathway (MEP). It is used for the production of
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), the two
precursors of isoprenoid. For many years, it was assumed that all organisms produced
IPP from acetyl-CoA through the mevalonic acid pathway (MVA), and that IPP was
isomerized to DMAPP [104-106]. However, an alternative pathway was reported for
the production of the building blocks of isoprenoid in bacteria and plants [107-110].
Although this has been studied in a variety of mycoplasmas, results regarding the
presence or even partial presence of the MEP pathway have yet to be resolved. Some
labs have reported not finding any of the genes encoding for the MEP pathway [111113], while other labs found that mycoplasmas have portions of the MEP pathway
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[106], including M. penetrans [114] and M. gallisepticum [115]. The MEP pathway in
the M. gallisepticum model ended in the production of (E)-4-hydroxy-3-methyl-but-2enyl pyrophosphate (HMB-PP), a dead-end metabolite in the model. No gene was
associated with the HMB-PP reductase reaction (E.C. 1.17.1.2) responsible for
converting HMB-PP to IPP. Two things that remain unclear are whether or not M.
gallisepticum has a complete MEP pathway, and the purpose of the HMB-PP
metabolite.

The second constraint that required relaxing was that of the NAD+ mass
balance. NAD+ is recovered by passing the electrons from NADH to oxygen and
lactate, but these mechanisms did not provide enough NAD+ in the model. Thus, a
reaction to synthesize NAD+ was required. M. gallispeticum had a partial NAD+
salvage pathway. The partial pathway starts with the conversion of nicotinate to
nicotinate

mononucleotide,

catalyzed

by

the

enzyme

nicotinate

phosphoribosyltransferase (E.C. 2.4.2.11). Then, nicotinate mononucleotide is
converted to nicotinate adenine dinucleotide through the reaction catalyzed by
nicotinate-nucleotide adenyltransferase (E.C. 2.7.7.18). Next, nicotinate adenine
dinucleotide is converted to NAD+ by NAD+ synthethase (E.C. 6.3.5.1), but no gene
was found for this enzyme in M. gallisepticum. Interestingly, M. pneumonia uses
NAD+ synthetase reaction to synthesize NAD+, but blasting this gene against M.
gallisepticum shows no close homology. One more possibility was that NAD+ was
taken from the media, but no literature evidence was found concerning the
requirements of NAD+ [116]. Instead, the media composition of M. genitalium [58]
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and M. laidlawii [57] had nicotinate, the starting component of the partial NAD
salvage pathway. Based on the observation that M. gallisepticum had two reactions of
the partial pathway and the requirement of the starting component in other relatives, it
was hypothesized that the NAD+ synthetase reaction was present in M. gallisepticum.
However, more experimental and computational work is clearly required to validate
this theory.

Interestingly, when the NAD+ synthetase reaction was added to the model, it
was possible to enforce all the mass balance constraints. The mass balance of 2phospho-4-{cytidine 5'-diphospho}-2-C-methyl-D-erythritol was consistent after
adding NAD+ synthethase, because the MEP pathway no longer had any flux going
through it.
3.4.4. FINAL

MODEL

The final model was obtained after 40 runs of GAFBA v1.0, with each run
consisting of 2,000 generations.

Figure 10 shows the results for each of the

simulations and the corresponding growth rate values, and Figure 11 shows the
number of mass balance constraints that were relaxed. The best model, represented by
simulation 40, was able to close all the mass balance constraints and had a growth rate
value of 0.358

± 0.12 h-1, compared to the experimental value of 0.244 ± 0.03 h-1.

The final M. gallisepticum model accounted for 441 metabolites and 395 reactions.
The model had 234 intracellular reactions; 86 transport reactions for the transfer of
metabolites between the extracellular space and the cytosolic compartment; and 73
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exchange reactions that allowed the uptake or secretion of metabolites either to or
from the system boundary. A complete description of the model is provided in
appendix 3.

Figure 10. Predicted growth rate over the course of model evolution. 40
simulations were carried out for 2,000 generations each. The columns represent the
growth rate values. Result 41 is the average value of the experimentally measured M.
gallisepticum growth rate. The dashed line running the length of the graph also
indicates the average experimentally measured growth rate, and is shown as a
reference to facilitate comparison with the simulation results.
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Figure 11. Metabolic constraints relaxed over the course of model evolution. 40
simulations were carried out for 2,000 generations each. The columns represent the
number of mass balances for which the constraints were relaxed.

3.4.5. COMPARISON OF M. GALLISEPTICUM MODEL AND M. GENITALIUM IPS189
MODEL

To provide a better context for the M.gallisepticum model, it is compared to
the iPS189 of M.genitalium [58]. A summary of the comparison is provided in Table
7.
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The M. gallisepticum model was larger than the M. genitalium model, as was
expected since the genome size of M.genitalium is 0.58 Mb compared to 1.01 Mb for
M.gallisepticum. The genome of M. gallisepticum had 817 genes that encoded for 763
proteins [31]; in contrast, M.genitalium had 524 genes that codified for 475 proteins
[117]. The G+C content of M.gallisepticum is 31.5%, while the G+C content of M.
genitalium is 32% [31].
Table 7. Comparison of the Mycoplasma gentialium model (iPS189) [58] and the
model presented in this paper for Mycoplasma gallisepticum.

Metabolites
Cytoplasmic
Extracellular
Reactions
Intracellular Rxn
Transport Rxn
Exchange Flux

Mycoplasma genitalium
(iPS189)
276
261
85
349
178
84
87

Mycoplasma gallisepticum
362
359
82
395
234
86
73

The M.genitalium model had 46 fewer reactions than the M.gallisepticum
model. However, it turns out that the iPS189 model had more exchange fluxes. The
additional exchange fluxes in the M. genitalium model were required to account for
the exchange of amino acids as a combination of dipeptides. M.gallisepticum, only
had fluxes for the amino acid exchange as monopeptides. The exchange of dipeptides
in the M. gallisepticum model was represented as a general reaction (trans-rxn7tv3945), due to a lack of information about the specificity of this transporter.
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Additionally, the M.gallisepticum model had 86 more metabolites than the
iPS189 model. These metabolites were mainly located in the cytosol space and
included lipids. The iPS189 model did not have fully specified lipids in the biomass
reaction, or the associated lipid reactions. The M. gallisepticum model included
cardiolipin, sphingomyelin, phosphatidylcholine, cholesterol, etc; and a set of
reactions related to lipid metabolism, such as phosphatidate phosphatase
(E.C.3.1.3.40);

phosphatidylglycerophosphatase

(E.C.3.1.3.27);

diacylglycerol

chlorinephosphotransferase (E.C. 2.7.8.2); sphingomyelin synthase (E.C. 2.78.27); etc.
3.4.6. M. GALLISEPTICUM MODEL CREATED WITH MODEL SEED

The RAST annotation server [118] was used to develop an annotated genome
for SEED. Then, Model SEED [53] was used to generate a preliminary reconstruction
or the M. gallisepticum

model via the web-based resource (http://iris.kbase.us).

During this process, Model SEED created a biomass reaction. The media chosen was
a defined media already present in Model SEED. After running the auto-completion
tool in Model SEED, a growth rate of 2.02

h−1

was predicted. The model had 358

reactions and 389 metabolites. When the M. gallisepticum model from SEED was
constrained to the experimentally measured glucose uptake rate and lactate production
rate,

the model predicted no growth.

It was not possible to use the model

optimization tools of Model SEED, as they were not available on the website at that
time. As a result, a better fitting model incorporating the experimental growth data
could not be created. Instead, GAFBA v1.0 was used to perform a 2,000 generation
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run, resulting in a growth rate value of

2.5 h-1.

However, the mass balances

constraints of acetaldehyde, and dCMP had to be relaxed.

One more trial was done using the M.gallisepticum model from Model SEED,
and adding the biomass reaction and media composition defined in this work without
adding any of the lipid metabolites and tRNA charged/uncharged, since the
M.gallisepticum model from Model SEED did not have them. The model generated
had 354 reactions and 391 metabolites. The glucose uptake rate and lactate production
rate were constrained to the experimental values, and again; no growth was predicted.
GAFBA v1.0 was used to evaluate the potential gaps of Model SEED. A 2,000
generation run was performed, resulting in a growth rate of 1.32 h-1 with 12 mass
balance constraints being relaxed. These results indicate that GAFBA v1.0 may be
used with Model SEED to identify problematic metabolites.
3.5. Discussion

The goal of this work was to develop an approach that could be used to curate
metabolic networks, facilitating a fundamental understanding and the discovery of
metabolism. To test this idea, a strategy was applied to the reconstruction of a
genome-scale metabolic network for M. gallisepticum. By using GAFBA v1.0, it was
possible to find gaps and inconsistencies present in the network that went beyond
genome annotation. It was generally possible to fill these gaps based on the described
heuristics, and/or searching through the literature. Even when the process was not
automated, time spent at the curation level was minimized because problematic
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metabolites were identified, allowing one to focus only on the significant issues
remaining.

An argument could be made for using optimization strategies other than a
genetic algorithm, such as a mixed integer linear programming (MILP) approach, like
MetaFlux, Model SEED, and GapFill. Although the MILP approach is a powerful one,
the GA method provides certain advantages such as scaling more effectively for the
study of large networks, and generating a population of solutions that, as a whole,
provide further insight into the problem domain.

A factor in favor of MILP, is that it could potentially be faster than using GA.
This is especially true for smaller models. However, even when the GA running time
is greater than MILP, the computational time is not the rate-limiting step in the overall
curation process. Rather the manual portion of the curation, such as the literature
review and the assembly of the preliminary model, are the most time consuming..

In general, a GA based method may be seen as unnecessary for a small model
such as the one developed in this work. However, it is anticipated that in the future,
systems to be analyzed will grow significantly. Such growth may be due to organism
complexity, or dealing with microbial consortia. Under such circumstances, it is
expected that GAFBA v1.0 will be comparable or faster than MILP based methods,
since the computational complexity of GA falls within a range of O(n^1.5) to O(n^2),
where n is the number of metabolites in the model [119].

In contrast, MILP
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computational complexity grows exponentially with system size [120,121]. It should
be further pointed out that GA’s fall into the class of algorithms known as
“embarrassingly parallel.” Although the approach presented does not currently take
advantage of this feature, work is currently underway to parallelize the algorithm.
With the advent of massively multi-core systems and especially GPU based
computing, it is anticipated that significant gains in speed may be realized.

Additionally, the GAFBA v1.0 approach provides some important advantages
over existing curation strategies. The most significant advantage is the possibility to
identify problems without relying on a database for reference. For example, MetaFlux
requires MetaCyc, Model SEED requires the SEED reaction database, and GapFill
requires a customized multi-organism database. GAFBA v1.0 provides flexibility by
allowing the identification and potential resolution of metabolic inconsistencies
without requiring access to any type of database. It is important to realize, however,
that GAFBA v1.0 may be used in conjunction with the other approaches described, as
was illustrated earlier with Model SEED. Thus, the information from these databases
is not lost. Rather, GAFBA v1.0 may be used to complement existing approaches, or
it may be used on its own.

MetaFlux requests that the user set the values for the weights of the objective
function in the MILP objective function. This step necessitates the proper
understanding of the meaning of each weight. The weights can be selected to create
models for different scenarios. The GAFBA v1.0 methodology does not need the user
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to define any weights. Thus, the set of metabolites to be studied will not depend on
values defined by the user. In addition, MetaFlux does not have the ability to add
reactions between compartments (e.g. transport reaction), resulting in an additional
level of complexity for curation purposes. GAFBA v1.0, however, does permit the
addition of reactions between compartments. Interestingly, MetaFlux does not give
information about the metabolites that may be problematic; instead it provides a set of
reactions to add in order to resolve metabolic inconsistencies. Conversely, GAFBA
v1.0 does not provide a list of reactions to add, but rather points out problematic
metabolites that may be used to direct further research.

These complementary

approaches suggest that some synergy may be possible.

When comparing Model SEED with GAFBA v1.0, Model SEED provides a
significant advantage in that it generates a biomass reaction and defined media for an
organism. However, when the M. gallisepticum model created by Model SEED was
used with the experimentally determined glucose and lactate constraints, the model
predicted no growth, suggesting that more curation was needed. By applying GAFBA
v1.0 to the Model SEED generated model incorporating the experimental data, it was
possible to identify the two problematic metabolic constraints inhibiting the viability
of the model. This result serves to highlight GAFBA v1.0’s role as a curation tool and
its ability to complementarity the existing model development software.

In general, GAFBA v1.0 provides an alternative and complementary curation
and modeling strategies to existing approaches. GAFBA v1.0 could help improve the
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quality of existing metabolic networks, and generate new and more complete
networks.

Furthermore, because the approach used by GAFBA v1.0 is

complementary to existing approaches, it can be used after a model is created with
Model SEED or MetaFlux.

With respect to M. gallisepticum specifically, the new genome-scale model
generated using GAFBA v1.0 replicated the experimentally observed data well. It is
likely that the predicted growth rate was higher than the experimental value observed,
because the NGAM value and the GAM used in the model were based on the M.
genitalium iPS189 model [58] and M. pneumoniae [89].

Further experiments are

required to determine the appropriate NGAM value and GAM value for M.
gallispeticum.

The results of GAFBA v1.0 have highlighted a number of pursuable
experimental avenues. For example, while GAFBA v1.0 predicts the presence of
formate dehydrogenase, NAD+ synthethase, and Na-ATPase enzymes for M.
gallisepticum, their presence still needs to be experimentally verified. The elucidation
of the MEP pathway’s role in M. gallispecticum metabolism may ultimately provide a
fundamental understanding of the organim’s metabolism. It is also important to
determine if the MEP pathway is essential to the survival of M. gallisepticum, since it
could elucidate possible drug targets, as was recently illustrated in research for control
of the Mycobacterium tuberculosis [122,123], Haemophilus influenzae [124], and in
the treatment against malaria [125,126].
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4. GAFBA v1.0 IMPROVEMENT

This chapter introduces three important tools developed to build a more robust,
user-friendly, and faster curation tool. The chapter is divided into three subsections.
The first one introduces the frequency analysis tool, which identifies unique
problematic metabolites across the population of the chromosomes. This subsection is a
modified version of the proceedings paper published as “Leveraging ensemble
information of evolving populations in genetic algorithms to identify incomplete
metabolic pathways,” [127] by Eddy J Bautista and Ranjan Srivastava. In Proceeding of
the fifteenth annual conference companion on Genetic and evolutionary computation.
Amsterdam, The Netherlands: ACM; 2013. p. 39-40.
In subsection two, the consistency checker tool (MassChecker) is developed.
MassChecker finds metabolites that are taken as “problematic” ones as a result of the
random generation of the initial population in the first step of GAFBA v1.1, but are
already fulfilling their mass balance constraint.
The last subsection describes the graphic user-friendly interface for GAFBA v1.1.
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4.1. Leveraging Ensemble Information of Evolving Populations in Genetic
Algorithms to Identify Incomplete Metabolic Pathways
4.1.1. INTRODUCTION

The genome-scale metabolic model is a powerful tool for modeling metabolism.
The constraint-based approach known as flux balance analysis (FBA) has been
particularly fruitful [128]. FBA has been successfully used for fundamental research
[129], recombinant protein and metabolite production [130], and for biomedical
development [131], with applications in drug target identification [132], understanding
host/pathogen interactions [8], and the investigation of human metabolic diseases. FBA
models are constructed through an iterative process where reactions are assigned to the
annotated genes in a genome sequence; the biomass composition and energy
requirements are determined; and additional constraints such as mass balance,
thermodynamic, environmental and other physico-chemicals are specified. Gaps in the
metabolic network are identified and filled using literature information and databases,
resulting in a quantitative stoichiometric model of the system. Because the model is
underdetermined, an objective function is postulated, such as the maximization of the
biomass reaction, to determine the optimal distribution of metabolic resources or fluxes.

The most time-consuming part of the reconstruction process is identifying and
resolving the gaps in the metabolic network.

In Chapter 3, GAFBA v1.0, which

integrates a genetic algorithm (GA) with FBA, was introduced to identify and resolve illformed mass balance constraints resulting in erroneous models. In the process, it is
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possible to take advantage of the ensemble of information inherent to the evolving
population. Specifically, it is possible to identify and focus on the analysis of metabolites
with relaxed mass balance constraints, which appear in most of the chromosomes across a
population. Here, an algorithm is presented to help identify these metabolites. The
algorithm should be used after a considerable number of simulations has been
accumulated, or when the number of mass balance constraints relaxed is overwhelming.
Thus, an additional criteria or tool is necessary to identify the most problematic
metabolites. It was applied during the development of a genome-scale metabolic model
for Mycoplasma gallisepticum using GAFBA v1.0. The methodology and results were
discussed in chapter 3.
4.1.2. METHODS
4.1.2.1.Frequency analysis of relaxed metabolic constraints

When minimizing the number of relaxed constraints, the GA generates a
population of models represented by chromosomes from which one can determine the
metabolic restraints that need to be relaxed.. It is possible to determine the frequency
with which a metabolic constraint is relaxed across the population of the chromosomes.
The metabolic constraints that have the highest frequency of relaxation are likely to be
the most problematic to the generation of a feasible metabolic model. As the populations
evolved, frequencies were tracked across generations This provided additional
information regarding the importance of a particular metabolic constraint to the viability
of the model. The specific details regarding the implementation of the frequency analysis
for the relaxed metabolic constraints are depicted in Figure 12.
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Figure 12. Frequency Analysis of Relaxed Metabolic Constraints. The frequency of
relaxed metabolic constraints across chromosomes in a population, as well as across
simulations, provides insight into which metabolites are truly critical to the development
of a viable genome-scale metabolic model.
Each simulation consisted of 30
chromosomes that were evolved for 2,000 generations. The frequency of relaxed
metabolic constraints across the top 20 chromosomes and across different simulations
was monitored. The most frequently relaxed constraints were targeted for curation to
resolve the inconsistencies in the model. The step in blue is an operation performed by
the user.

The process started by selecting the final populations of two different GAFBA
simulations for comparison, as is shown in Figure 12. For instance, simulation n and
simulation n+∆x, where n is any number of simulations and ∆x is an incremental interval
defined by the user. Each simulation consisted of evolving model populations for 2,000
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generations. Then in each simulation, the metabolites with relaxed mass balance
constraints that appeared in all the top 20 chromosomes of the population were selected.
These metabolites formed the set of shared problematic metabolites at simulation n, and
simulation n+∆x respectively. Finally, the sets of shared problematic metabolites from
simulation n and n+∆x were compared, and the metabolites that arose in both sets formed
the group of the most problematic metabolites. Therefore, the most problematic
metabolites were studied first, and then the rest of problematic metabolites were
analyzed.
4.1.3. RESULTS

The initial model of M. gallisepticum consisted of 446 metabolites and 380
reactions. Implementing the model resulted in no feasible solution to the optimization
problem due to inconsistent constraints. The model was then analyzed using GAFBA
v1.0 to identify problematic metabolites. Randomly selected simulations were used for
carrying out frequency analysis. The analysis was done at simulations 3, 5, 17, 27, 36,
and the results are presented in Table 8. At simulation number three, 23 metabolites were
shared among the pool of the best 20 chromosomes. The best model only had one more
metabolite dropped.
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Table 8. Result of the analysis of relaxed mass balance constraints for select
simulations.

Simulation
number

Number of shared
relaxed metabolic
constraints in the best 20
chromosomes

Number of relaxed
metabolic
constraints in the
best individual

Number of shared
relaxed metabolic
constraints already
present in a previous
simulation

3

23

24

NA

5

16

24

9

17
27
36

9
5
1

12
5
1

6
4
1

At simulation number five, 16 metabolites with relaxed mass balance constraints
were common in the pool of the best 20 chromosomes. While reviewing the list of
metabolites, it was observed that nine metabolites were already dropped in simulation
number 3, and four of them were charged/uncharged tRNAs. Thus, a recycling reaction
for the charged/uncharged metabolites was added to the biomass equation [58].

Nine common metabolites were found at simulation number 17 among the best 20
chromosomes. Six of them already appeared in either simulation number 3 or 5. One of
them was ribose-5-phosphate. By checking the metabolic pathway around this metabolite,
the directionality of two reactions, Ribulp3epim-Rxn (E.C. 5.1.3.1) and Rib5pisom-Rxn,
were changed to reversible (E.C. 5.3.1.6).

At simulation number 27, five metabolites were found to be common in all the
best 20 chromosomes. Four of them appeared in previous simulations. At this point,
sodium ion and L-phosphatidate were selected for analysis. It was observed that by
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solving the mass balance of sodium ion, the mass balance of L-phosphatidate could be
closed, since the metabolites were connected through the choline pathway. The problem
with the sodium ion was that its transport was coupled with the transport of choline.
Choline was one of the precursors of phosphatidyl choline, which is a component of the
biomass of M. gallisepticum. Thus, the transportation of choline was required, but it was
set to zero to avoid the accumulation of sodium ions in the cytosol. The solution was to
add a reaction that used sodium ions in the cytosol. A Na-ATPase transport reaction that
regulates volume in Mycoplasma was added [103].

NAD+ was the only problematic metabolite in the best chromosome at simulation
number 36. It was present in all the top 20 chromosomes, and it had already appeared in a
previous simulation. The model had a partial biosynthesis pathway for NAD+. It was
hypothesized that NAD+ synthase reaction was present in M. gallisepticum, based on the
observation of two reactions of the partial pathway, and the requirement of the starting
component in other relatives [57,58],

At simulation 40, the best and final model was obtained. This model was able to
close all the mass balance constraints, and had a growth rate value of 0.3258 ± 0.12 h-1,
compared to the experimental value of 0.244 ± 0.03 h-1. The final M. gallisepticum
model accounted for 441 metabolites and 395 reactions.
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4.1.4. IMPACT

The importance of the development, curation, and implementation of high quality
genome-scale metabolic models will continue to grow in the biotechnological and
biomedical arenas. As a result, the development of strategies to facilitate this process
will be of extraordinary value. Of particular interest will be strategies that reduce the
amount of experimental work required, as experiments are costly, time consuming, and
often tedious. The use of GAs for optimization purposes is well established. In this case,
the ensemble of information on the population being evolved turns out to be biologically
relevant.
A significant advantage to GAFBA v1.0, is its ability to carry out a population
frequency analysis in order to determine the most problematic metabolites. By observing
the most frequently occurring relaxed constraints in that population, it was possible to
identify candidate metabolites that were most likely to be problematic. These results are
extraordinarily valuable, as they provide the researcher with a starting point regarding
which metabolites are most likely causing the model to fail. It allows the researcher to
focus on the most critical metabolites whose resolution will likely give the greatest return
on the investment of time, effort, and money.
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4.2. MassChecker, a mass balance constraint consistency checker tool for GAFBA.

The composition of the initial population in GAs has been reported to affect their
convergence, performance, and their ability to find the best possible solution [133-136].
If the initial population is good, the possibility of finding good solutions increases.
Random generation of the initial population is useful, because it increases the diversity of
the population and can represent any region within the search space [136].
In GAFBA v1.0, during the generation of the initial population of solutions for
use with the GA, whether a mass balance constraint is enforced or relaxed is determined
randomly. As a result, some metabolites with an already closed mass balance are
inaccurately labeled as “problematic”. These metabolites will be referred to as “false
positives.” As new solutions evolve over the course of generations, the number of false
positives decreases. However, these situations slow down the evolution of the model
through the curation process. Moreover, the number of “false positives” at the end of a
simulation increases with the size of the model. Therefore, a mass balance constraint
consistency checker tool, MassChecker, is introduced. MassChecker was developed to
find these false positives and adjust the chromosomes to keep them in the model as
enforced mass balance constraints. MassChecker enhances the performance of GAFBA
v1.0, while reducing the number of simulations required during the curation process, as
well as the total running time.

MassChecker was implemented in GAFBA v1.1, and tested during the
development of the genome-scale metabolic model for Bacillus anthracis. Here, a
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comparison of the evolution of the model using GAFBA v1.0 and GAFBA v1.1, which
includes the MassChecker tool, is presented.
4.2.1 METHODS
4.2.1.1 Genetic algorithm parameters

The genetic algorithm parameters used were:

a population size of 30

chromosomes, crossover probability of 30%, and mutation probability of 1%. Elite
selection was chosen as a selection strategy, with an elite fraction of 20%. Two-point
crossover was performed, and bottom re-seed was not allowed. The GAFBA v1.1
algorithm was run for 2,000 generations per simulation, and 10 simulations in total were
carried out. All simulations were implemented on a 2.7 GHz Intel Core i5 computer. For
the GAFBA v1.0 algorithm, each simulation (2,000 generations) took approximately 4
hours. Meanwhile, the running time for one simulation with GAFBA v1.1 was 3 hours.
Thus, the total time for the 10 simulations was 40 hours with GAFBA v1.0, and 30 hours
with GAFBA v1.1.

GAFBA v1.1 is a new version of the GAFBA algorithm that includes a
MassChecker tool, and the bottom re-seed operation. The bottom re-seed operation
replaces the chromosomes of the bottom part of the population with new randomly
generated chromosomes.
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4.2.1.2 Flux Balance analysis parameters

The Pathway Tools v16.0 software platform [68] was used to generate the initial
model for B. anthracis from an existing pathway genome database (bant260899
version15.5), which accounted for all metabolic pathways as determined from the
genome annotation.

The model had 1,104 reactions and 1,094 metabolites. More

information on the B. anthracis model is presented in Chapter 6.

The bounds for the reversible reactions were −∞ ≤ v j ≤ ∞ , whereas for the
irreversible reactions, they were 0 ≤ v j ≤ ∞ . The boundaries for the exchange fluxes were
defined for metabolites in the media as −∞ ≤ v j ≤ ∞ , and for the secretion of metabolites
the following constraint was implemented: 0 ≤ v j ≤ ∞ . The media composition used was
the one from the iron reduced media (IRDM) [137] shown in Table 9. The lower
−1 −1
boundary of the NGAM value was set to 6.75 mmol gDW h , based on the

experimentally measured value for Bacillus subtilis [138].

The upper and lower

boundaries of the experimentally measured fluxes are presented in Table 10.

The

objective function chosen for the optimization problem was the maximization of the
biomass equation for B. anthracis, which is provided in appendix A8.7.
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Table 9. Iron reduced media (IRDM) media composition.
IRDM media composition
glucose

aspartate

Fe3+

arginine

proline

K+

leucine

serine

Mg2+

methionine

thiamine

Mn2+

cysteine

threonine

Na+

phenylalanine

tryptophan

sulfate

histidine

glutamate

phosphate

isoleucine

Ca2+

water

valine

Cl-

proton

Table 10. Experimentally measured fluxes used as constraints for the FBA model.
Rate
Glucose uptake rate
Carbon dioxide production rate
Oxygen uptake rate
Lactate uptake rate
Glutamic acid uptake rate
Iron uptake rate
Bacillibactin production rate
Petrobactin production rate
Protocatechuate production rate

Upper/Lower boundary
(mmol gDW-1 h-1)
-13.157
6.29
-6.737
-0.973
-0.266
-0.00075
0.0023
0.0163
0.0241

4.2.1.3 Mass balance constraint consistency checker (MassChecker)

The GAFBA v1.1 algorithm is presented in Figure 13. After the initial population
was randomly generated, an optimal flux distribution was determined by FBA for each of
the chromosomes in the population.. The fitness of each chromosome was scored based
on the minimum number of mass balance constraints relaxed, and the value of the
biomass reaction. Next, the elite pool was selected based on the predetermined elite
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fraction, and MassChecker was applied to each of the chromosomes in the elite pool.
MassChecker inspected each of the mass balances of the metabolites with relaxed
constraints in the chromosome. It took the flux distribution from FBA, and calculated the
summation of the fluxes through the reactions in which the metabolite participated. If the
summation was equal to zero, by definition the mass balance constraint was fulfilled.
Thus, the gene on the corresponding chromosome was changed to one that enforced the
mass balance constraints.
Subsequently, MassChecker analyzed all the chromosomes from the elite pool.
They were then copied to the new population. Applying the genetic operations of
crossover and mutation, the remainder of the population was bred. Next, if the bottom reseed operation was allowed, and the generation number was equal to the desired bottom
re-seed frequency, then the bottom part of the population determined by the bottom reseed fraction was replaced with randomly generated chromosomes. This prevents
premature convergence of the population, and also increases the searching space. This
process kept running until the number of generations was equal to 2,000, at which point
GAFBA v1.1 stopped and the list of problematic metabolites was generated. After the
changes were made in the model, GAFBA v1.1 could be initialized from the random
generation of the initial population, or by using the last population from the previous
simulation. This process was continued until the number of mass balance constraints
relaxed was equal to zero and the growth rate was near the experimental one.
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Figure 13. GAFBA v1.1. This new version of the GAFBA algorithm includes a
MassChecker tool and the bottom re-seed operation. BRF refers to the bottom reseed
frequency. The steps in purple are operations performed by the user.
4.2.2

RESULTS

The evolution of the number of mass balance constraints relaxed is presented in
Figure 14 for the GAFBA v1.0 algorithm without MassChecker. Three trials were run
with the same initial conditions, and with the random generation of the initial population.
The number of mass balance constraints relaxed at generation zero was 323 for the first
run, 314 for the second run, and 263 for the third run. The relaxed constraints were
slowly decreased to a final value of around 60 for the first run, 63 for the second run, and
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69 for the third run. After 20,000 generations, the number of mass balance constraints
relaxed had not stabilized for any of the runs. This means that more generations are
needed for it to reach a stable value.

Figure 14. Comparison of the evolution of mass balance constraints on GAFBA v1.0
and GAFBA v1.1. For each algorithm three runs were made. The magenta (run 1), blue
(run 2), and light green (run 3) lines are the runs for GAFBA v1.0. The black (run 1),
light blue (run 2), and red (run 3) lines are the results for GAFBA v1.1.

Figure 14 shows the evolution of the mass balance constraints relaxed for
GAFBA v1.1, which includes the MassChecker tool. The same conditions were used as
the ones for the GAFBA v1.0 trials. The number of mass balance constraints relaxed at
simulation zero were 94 for the first run, 205 for the second run, and 130 for the third
run. It is evident that MassChecker sped up the minimization of the number of
problematic mass balances. After only 2,000 generations, it had fallen below 50 for all
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three trials. Moreover, the stabilization of the number of mass balance constraints
dropped was reached around 9,000 generations for the first and third runs. The second
run was stable for some generations, until generation 16,000 when the number of mass
balance constraints relaxed decreased from 39 to 34. Thus, only nine simulations were
needed to start the analysis of the problematic metabolites. More importantly, only 24
(run 1), 34 (run 2), and 18 (run 3) metabolites needed to be analyzed with GAFBA v1.1,
compared to the 60 (run 1), 61 (run 2), and 69 (run 3) metabolites from GAFBA v1.0
without MassChecker.

The number of false positives found in the chromosomes from the elite pool is
established in Figure 15. The values are only for the first run of GAFBA v1.0 with
MassChecker. Since the elite fraction was set to 20%, six chromosomes formed the elite
pool. At generation zero, MassChecker found 212 false positives for chromosome one,
284 for chromosome two, 332 for chromosome three, 459 for chromosome four, 487 for
chromosome five, and zero false positives for chromosome six. As the number of
generations increased, the number of false positives decreased substantially. This result
was mainly because the effects of the random population generation had dissipated.
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Figure 15. Evolution of the number of false positives in the elite pool for the first run
using GAFBA v1.1. The embedded chart presents the number of false positives found
in the top elite chromosomes at generation number zero.

4.2.3.

IMPACT

The random generation of the initial population for the GA part of the GAFBA
v1.0 methodology caused some metabolites with an already closed mass balance to be
considered problematic. MassChecker was developed to find these false positives, and
adjust the chromosomes to keep them in the model as enforced mass balance constraints.

MassChecker was developed as a consequence of the overwhelming number of
false positives that appeared in the first runs of GAFBA v1.0. The main concern was the
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curation of large models, where the number of mass balance constraints dropped from the
beginning of the reconstruction could confuse the curator. Furthermore, toward the end
of the reconstruction process, the number of mass balance constraints relaxed in GAFBA
v1.0 could hit a plateau before reaching the ideal scenario of all mass balance constraints
being enforceable. As a result, the curator might think that something was wrong with the
model when there really was no problem at all.

MassChecker was merged with GAFBA v1.0 in GAFBA v1.1. It randomly
generates an initial population while simultaneously removing the debilitating effects of
false positives.. GAFBA v1.1 is faster and more efficient than the old version. The
MassChecker tool speeds up the curation process by decreasing the number of
simulations needed to achieve stability. Most importantly, the number of mass balance
constraints relaxed was reduced by 60%, which permits one to focus only on the
metabolites that really have problems.

4.3.GAFBA v1.1 Software: a tool for the semi-automated curation of genome scale
metabolic reconstruction.

4.3.1. INTRODUCTION

The capability of emulating the experimental behavior of a microorganism in
silico depends on the quality of the genome-scale metabolic network [3,139]. For that
reason, an outstanding curation process during the reconstruction of the network is
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required. The curation process helps to solve issues such as erroneous metabolite names
or reaction names, localization of metabolites within the cell, directionality of the
reaction to proceed and filling the gaps present in the network [47]. Several tools have
been developed such as the Pathway tools hole filler [49]. Here, a Bayesian classifier is
used to determine the probability that a candidate protein will be able to fill the hole.
With metabolic expression placement (MEP), the algorithm searches for possible
enzymes to fill the gaps using gene expression data, and the local structure of the partially
reconstructed metabolic network [51]. Satish Kumar et al. [47] developed an optimization
based procedure (GapFind) to find the gaps present in the network, which can then be
filled with an optimization based procedure (GapFill) using four specific mechanisms
[47]. MetaFlux [52] uses a multiple gap filling approach based on mixed integer linear
programming (MILP), which suggests reactions to be added from the MetaCyc database.
Model SEED [53] identifies the minimum set of reactions from the SEED reaction
database that must be added in order to fill the gaps present in the network.

GAFBA v1.1 [127] is complementary to previously developed software
platforms.

It uses a genetic algorithm (GA) to help the user identify metabolites

preventing the optimization problem from being solved.
4.3.2. METHODS

The process of curating the metabolic network involves four stages illustrated in
Figure 16. The first stage involves collecting the requisite information. In the second
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stage, the GA is run. Results are evaluated during the third stage. In the fourth stage, the
final model is generated.

The first stage requires an SBML file of the metabolic information as input. The
SBML file may be generated from the Pathway Tools bioinformatics suite [66].
Additionally, the specific biomass reaction, the exchange fluxes, and the environmental
conditions, such as measured fluxes and medium composition need to be specified.
Finally, an objective function must be chosen. It can be the maximization or
minimization of biomass, a specific reaction present in the data, or users can create their
own objective functions. At this stage, the parameters for the GA should be specified,
such as crossover probability, number of points for the crossover operation, the mutation
rate, the elite fraction, the bottom re-seed fraction, the frequency of bottom re-seed, the
population size of the potential solutions, the number of generations, and the number of
simulations.. If the user is unfamiliar with these parameters, reasonable default values
are provided. It is recommended that the population size be smaller (<50), and that multipoint crossover (> 2) and lower elite fractions (< 0.2) should be used. If the user observes
that the population is becoming uniform too quickly, the bottom re-seed fraction and the
frequency of the bottom re-seed should be defined. Typically, values are 0.2 for the
bottom re-seed fraction, while the suggested frequency for carrying out bottom re-seed is
once every 100 generations.
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Figure 16. Four stages of the curation process. The parallelograms indicate the first
stage. Also shown is the corresponding GUI window for this stage. The second stage is
represented by the hexagon and the rectangle. The third stage is the trapezoid, and two
of the files generated are shown, The fourth stage is indicated by the oval. The steps in
blue are operations performed by the user.

For the second stage, all of the information is integrated to generate an initial
population of solutions for GAFBA v1.1. Then GAFBA v1.1 evolves the initial
population into a new population by applying all the genetic operations, including
reproduction, crossover, mutation, and bottom re-seed, as well as the MassChecker tool.
When the program reaches the number of desired generations, five files are generated.
The first one has the model of the best chromosome from the GA population, which is the
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one with the minimum number of mass balance constraints relaxed. It is the input file for
running the linear programming solver, glpsol. This file has all the variables associated
with each of the reactions, the constraints and the objective functions. The second file has
the flux distribution of this model. The lists of the problematic metabolites, whose mass
balances were left open, are generated in another file. The fourth file has the best
chromosome identified every 100 generations throughout the entire simulation. The final
file has the last population of the current simulation.

The third stage involves identifying the potential missing reactions in the network,
whether through literature review, experiments, or re-evaluation of the metabolic network
for potential errors in the preliminary model. Additionally, the user should review the
problematic metabolites and determine whether the mass balance constraints may be kept
by either removing or adding exchange fluxes or intracellular reactions, changing the
directionality of reactions, and/or removing metabolites. To help the user, GAFBA v1.1
has a tool that analyzes the frequency of relaxed metabolic constraints. This tool finds the
metabolites with the highest frequency of relaxation throughout the population. These
metabolites are the most likely to be pathological to the generation of a feasible metabolic
model, since they must consistently be relaxed in most models to generate a feasible
solution [127].

The first three stages are repeated until the in silico results closely match the
experimental ones, or until all the mass balance constraints are kept. At this point, the
fourth stage has been reached and the result is the final model.
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4.3.3.

IMPLEMENTATION

The software platform was developed in Common Lisp, and compiled using the
LispWorks 6.0.1 Professional Edition compiler. The software is available under the BSD
Open Source License. The software package carries out linear programming by calling
the GNU Linear Programming Kit (http://www.gnu.org/software/glpk/). The software is
available for Windows, OS X, and Linux. More information can be found in the
comprehensive manual, which is provided in appendix 4.
4.3.4.

IMPACT

A software platform capable of facilitating the curation and implementation of a
genome-scale metabolic model for flux balance analysis has been developed. Using a
genetic algorithm, it is capable of finding metabolites that may be participating in
unspecified reactions. With this software platform, it is anticipated that novel reactions
or pathways may be identified, and curation may be simplified and streamlined.
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5

IMPACT OF IRON AVAILABILITY ON BACILLUS ANTHRACIS
METABOLISM

This chapter has been submitted with minor modification as “Impact of iron
availability on Bacillus anthracis metabolism.” Eddy J. Bautista, Andrea M. DiVenere,
and Ranjan Srivastava. 2013, Journal of Bacteriology.
5.1 Chapter Synopsis

To establish a successful infection, Bacillus anthracis must be able to adapt to a
variety of different physico-chemical conditions encountered when infecting a host,
including the presence or scarcity of nutrients. One such critical nutrient is iron, which is
generally sequestered by a variety of iron transport/storage protein systems. For B.
anthracis to effectively compete with these host systems for iron, it secretes high-affinity
metal chelators. Previous studies have been dedicated to the analysis of these systems.
However, it is still unclear how the availability of iron impacts bacterial metabolism.. In
this work, the results of fermentation studies on the Sterne strain of B. anthracis grown
under iron-poor/rich conditions are reported, and a comparative metabolic analysis is
presented. During the exponential phase, the growth rate and six production/uptake rates
were measured: glucose uptake rate, lactate production rate, siderophore production rate,
iron uptake rate, carbon dioxide production rate, and oxygen uptake rate. It was observed
that in iron-poor conditions the glucose uptake rate, oxygen uptake rate, and carbon
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dioxide production rate were higher than in iron-rich conditions. Furthermore, it was
noted that in both cases, a metabolic shift was observed.

The first phase was

characterized by lactate secretion (Phase I); during the second phase (Phase II), lactate
was consumed. Other observations when going from Phase I to Phase II in both iron-rich
and iron-poor conditions included a marked decrease in growth rate, and a decreased iron
uptake rate. Also, no siderophore production was detected in Phase I.
5.2 Introduction

During the bacterial pathogen infection process, bacteria go through a series of
metabolic adaptations in order to germinate and grow within a host. The bacteria have to
be able to adjust to different physical conditions, such as pH, oxygen availability,
osmotic pressure, and the availability of nutrients like iron. In fact, host-imposed iron
availability is one of the initial barriers to infection [140].

Iron is an essential nutrient for almost all microorganisms. However, free iron
damages biological macromolecules as a result of the oxidative stress caused by the
metal-catalyzed generation of superoxides, hydrogen peroxide, hydroxyl radicals, ferryl
and perferryl radicals [141]. As a result, practically no iron exists in serum that is not
bound to heme, sequestered in iron-storage and iron-transport proteins (ferritin,
transferrin, lactoferrin), or incorporated as cofactors for various enzymes [142].
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Bacillus anthracis, a gram-positive bacterium, is the causative agent of anthrax. In
order to survive and grow, it has to be able to capture iron from its host. To fulfill this
goal, the bacteria produce compounds referred to as siderophores and hemophores.
Hemophores scavenge heme from various hemoproteins. Siderophores are high affinity
metal chelators that are able to compete with the iron-transport proteins and iron-storage
proteins. It has been reported in an in vitro study that B. anthracis can acquire iron from
hemoglobin and transferrin, but not from lactoferrin [143]. Siderophores are produced
when B. anthracis is inside the alveolar macrophage, where the environment allows the
germination of spores and the rapid out-growth of vegetative cells during the intracellular
phase of the anthrax lifecycle. This stage is very important in establishing the infection.
B. anthracis produces two known catechol siderophores: bacillibactin and petrobactin.

Recently, attention has been given to the study of iron acquisition systems in
gram-positive bacteria [144,145]. B. anthracis contains more iron acquisition systems
than non-pathogenic members of the genus Bacillus [140]. It has been argued that the
number and efficiency of these systems in B. anthracis are linked to bacterial
pathogenicity [146-148].

Many studies have focused on elucidating and understanding the biosynthetic
pathway, as well as the secretion and uptake of siderophores in B. anthracis [142,148152]. However, there have not been any studies to date investigating the metabolism of
the bacterium by studying key metabolites of the exo-metabolome under conditions
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similar to the ones found in the alveolar macrophage (iron starvation and oxidative
stress).

The metabolic response of B. anthracis to different iron conditions is reported
here. The experiments were carried out under two conditions. The first was an iron-rich
condition with concentrations of iron at 20 µM, while the second condition, referred to as
an iron-poor condition, involved treating media with a chelating agent to reduce the iron
concentration to 2.24 µM.

During the course of the experiment, a shift from lactate production to lactate
consumption was observed under both iron conditions. Based on this shift, two phases
were defined. The period in which lactate was produced was referred to as Phase I, while
the period in which lactate was consumed was referred to as Phase II. The growth rate
and concentrations of eight key metabolites were measured in both phases. The uptake
rates were calculated for glucose, iron, glutamic acid, lactate, and oxygen. The secretion
rates were determined for carbon dioxide, lactate and the siderophores. A clear increase
in the carbon metabolism of B. anthracis during iron-poor conditions was observed when
compared to iron-rich conditions in both phases.

104

5.3 Materials and Methods

Pre-treatment of glassware, fermentor vessel, and tubing. All glassware used in the
experiments was washed with 9 M nitric acid solution for three hours and rinsed with
copious amounts of distilled water [148]. The tubing, the carbon dioxide probe, and the
oxygen probe from the fermentor vessel were treated with 1% sodium carbonate and 1
mM ethylenediaminetetra-acetic acid (EDTA), following the procedure described
previously [153]. The fermentor vessel was cleaned with a 15% potassium hydroxideethanol saturated solution for 24 hours. Then, the potassium hydroxide-ethanol solution
was removed, and a 0.5 M phosphoric acid solution was added to the vessel for one more
hour. Finally, the vessel was washed with an abundant amount of distilled water. The
vessel was assembled; the tubing was put in place and covered with aluminum foil, along
with any open port. The entire apparatus was then autoclaved.

Media preparation. Two types of media were used for the experiments. The first was
reduced iron media (IRDM), representing an iron-poor environment. The second media
used was replete iron media (IRM), representing an iron-rich environment. IRDM was
based on a previously described formulation [137]. Stock solutions of defined medium,
salts, 10% casamino acids (Fisher), and 20% dextrose were made with distilled-deionized
water (MilliQ), and they were treated separately with CHELEX 100 resin following the
manufacture’s batch chelatin method (BioRad). The resin was removed by filtration. The
defined medium composition (g/l) was as follows: 0.53 serine, 1.5 threonine, 1.5 valine,
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3.28 leucine, 1.66 aspartic acid, 4.05 glutamic acid, 2.18 arginine hydrochloride, 1.94
histidine monohydrochloride monohydrate, 0.22 cystine, 0.75 methionine, 0.72 proline,
1.65 phenylalanine, 1.28 tryptophan, 0.03 thiamine hydrochloride, and 2% hydrochloric
acid. Salts included (g/l): 0.25 MgSO4*7H2O, 0.025 MnSO4*H2O, 17 KH2PO4, 21.8
K2HPO4, and 2% hydrochloric acid. Since the CHELEX resin has a moderate affinity for
Mg+ ions, MgSO4*7H2O was added to the salts after the resin treatment [148]. The
defined medium, salt stock solution, and glucose stock solutions were sterilized by
filtration. The casamino acids stock solution was autoclaved for 20 min. IRDM was
composed of 4% of the defined medium and salts, 12% of casamino acids, 1% of
dextrose solution, and 0.3% PIPES buffer. 10 N NaOH solution was added to adjust the
pH to 7.5. The iron concentration of IRDM was determined by ion-coupled plasma mass
spectrometry, and was found to be 2.24 µM. The formulation of IRM was the same as
IRMD, except that IRMD was supplemented with a freshly prepared ferrous sulfate
solution to a final concentration of 20 µM.

Bacterial strains and growth conditions. Bacillus anthracis Sterne 34F2 (pXO1+
pXO2-) was used in all the work described here. B. anthracis stock cultures were
prepared from vegetative cells grown to late exponential phase in IRDM at 37 °C and
shaken at 300 rpm in an incubator-shaker (New Brunswick Scientific, Edison, NJ, Classic
Series C24 incubator shaker). The stock cultures were prepared by mixing 0.5 ml of
bacterial cultures with 0.5 ml of 30% glycerol. These stocks were stored at -70 °C. For
the IRDM experiments, fresh media were inoculated to 1.5% (v/v) stock cultures, and
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grown overnight (17 h) in IRDM at 37 °C at 300 rpm. The bacteria were then diluted in
IRDM media to a ratio of 1:3, and allowed to recover for 1.5 hours. Cells were collected
by centrifugation, and washed three times with phosphate-buffered saline and a final
wash in IRDM [150]. The pellet was re-suspended in 10 ml of IRDM. Then, the bacteria
were diluted to an OD600 of 0.05 in 1.4 L of IRDM in the fermentor vessel. For the IRM
experiments, the protocol was the same as the IRDM experiments, except that the media
used was IRM for the final wash prior to inoculation of the fermentation vessel.

Fermentation conditions. The fermentation experiments were done using a New
Brunswick Bio-Flo 3000 Bioreactor with a 3.0 L working volume vessel. 1.4 L of IRDM
media were added to the sterilized vessel. For the IRDM experiments, the media was
supplemented with ferrous sulfate 30 minutes prior to inoculum addition. For each
condition, triplicate experiments were carried out on different days. The OxyProbe
dissolved oxygen sensor (Broadley James) and the InPro 5000i carbon dioxide sensor
(Mettler-toledo) were sterilized with 70% ethanol solution and UV light. The probes were
inserted into the vessel, wich were connected to the fermentor unit. The OxyProbe was
calibrated following the two point calibration method as described in the Bio-Flo 3000
fermentor manual, and the InPro 5000i carbon dioxide sensor was calibrated using a one
point calibration methodology as described in the Mettler-Toledo M400 transmitter
manual. The temperature was measured with a resistance temperature detector submerged
into the thermowell of the vessel. The temperature set point was fixed at 37 °C, and was
controlled by the BioFlo 3000 microprocessor-based built-in controller. Agitation was set
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to 400 rpm. Air was allowed to enter the system through a 0.2 µm PTFE filter, and
aeration was adjusted to 2.0 SLPM. The dissolved oxygen (dO2) was not allowed to
decrease below 75% of saturation. Oxygen control was accomplished by increasing
agitation from the initial 400 rpm to 500 rpm using an agitation/dO2 cascade control
system as described in the Bio-Flo 3000 fermentor manual. The pH was measured
offline using an Accumet pH/temperature electrode (Fisher Scientific). It was adjusted to
approximately 7.5 before the addition of the inoculum with 10N NaOH solution and/or
10 N HCl.

Then, the inoculum was added to the fermentor vessel through the addition port of
the headplate. The initial carbon dioxide concentration and dO2 were recorded. A sample
from the fermentation liquor was taken to measure the initial OD600, pH, glucose
concentration,

lactate

concentration,

glutamic

acid

concentration,

siderophore

concentration, and iron concentration. Cells were allowed to enter the exponential phase,
and three samples were taken during this time.

Analytical techniques. Cell density was measured at 600 nm using a BioMate™ 3
spectrophotometer (Thermo Spectronic, USA). Samples were first filtered through a
0.2 µm syringe filter. Glucose concentration, lactate concentration, and glutamic acid
concentration were measured using a YSI 2700 Biochemistry Analyzer. The Arnow
Assay was used to measure the levels of extracellular catechol siderophores as described
elsewhere [137,152,154]. A standard curve was established using 2,3-dihydroxybenzoate
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(2,3-dhb). Iron concentration was measured using a Perkin Elmer Optima 7300DV
Inductively Coupled Plasma Optical Emission Spectrometer (ICP/OES).

The dry weight correlation for the bacteria in each media was determined by
taking 100 ml of fermentation broth three times during the exponential phase. The cells
were collected by centrifugation at 4000 rpm at 4 °C for ten minutes. Then, the pellet was
washed twice with PBS, re-centrifuged, and transferred to dry pre-weighed 2 ml
centrifuge tubes. The pellets were dried at 75 °C for 7 days, or to a constant volume [23].

Metabolite uptake and secretion rate calculation. For all the metabolites, the solution
for the dynamic equation of the mass balance was fit to the experimental data using
nonlinear fitting algorithms [8,23,155] from Matlab (MathWorks, USA). Appendix five
describes the calculations in detail.

Western blot analysis. Samples for western blot were taken from the fermentor broth at
an OD600 of 0.8. Cells were collected by centrifugation, and washed three times with PBS
buffer [156]. The pellets were stored at -70 °C. To analyze samples via western blotting,
48 µL of pellet were solubilized by boiling in 32 µL of 5X sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 95 °C for 10 minutes.
Blanks were prepared in the same way with IRMD and IRM without bacteria. An equal
amount of samples,and blanks were loaded into 4-15% Mini-PROTEAN TGX Precast
Gels (Biorad). They were blotted to a nitrocellulose membrane. Protein blots were
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blocked in 5% nonfat milk in TBS-T buffer for one hour at room temperature under
gentle agitation. Next, the membranes were exposed to 1 µg/ml of B. anthracis mouse
anti-PA monoclonal serum (Thermo scientific) in TBS-T with 5% nonfat milk for two
hours at room temperature under gentle agitation. The membranes were washed three
times with TBS-T for 5 minutes. The membranes were incubated with anti-mouse IgGalkaline phosphatase (Sigma) dilute 1:15,000 in TBS-T with 5% nonfat milk for one hour
at room temperature with gentle agitation. Next, the membrane was washed three times
with TBS-T for 5 minutes, and rinsed with TBS. Finally, the blot was developed using
SIGMAFAST BCIP/NBT (Sigma) tablets. All western blot experiments were run in
duplicate using samples from two different cultures [157,158].
5.4 Results

Two metabolic states observed during growth under iron-poor/rich conditions. B.
anthracis Sterne was grown aerobically under iron-poor and iron-rich conditions. During
the experiments, two phases were observed. The first phase was characterized by the
production of L-lactate, and is referred to as Phase I. It was then observed that L-lactate
was re-assimilated in the second phase, which is referred to as Phase II. This behavior
was observed independently of the iron concentration, as is shown in Figures 17a and
18a. It was further noted that the consumption of L-lactate occurred before glucose
exhaustion, and started when the dissolved oxygen concentration reached 75% of
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saturation. At this point, the agitation/dO2 cascade control system of the fermentor
oscillated the agitation speed between 400 rpm to 500 rpm to maintain control of the dO2.

Figure 17. Levels of extracellular metabolites and growth rate under iron-poor
conditions. A. L-lactate (green triangles), glucose (red squares), and biomass (Blue
diamonds). B. Oxygen (blue stars), and carbon dioxide (red dots). The dotted vertical line
represents the point of transition between Phase I and Phase II. The black arrow in the B
panel indicates the point that oxygen concentration reached 75%, and the control of the
dissolved oxygen concentration started by changing the speed of the agitator. The data
corresponds to one of the experiments carried out in triplicate. The data points for the
other experiments are provided in Appendix 6.
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Figure 18. Levels of extracellular metabolites and growth rate under iron-rich
conditions. A. L-lactate (green triangles), glucose (red squares), and biomass (blue
diamonds). B. Oxygen (blue stars), and carbon dioxide (red dots). The dotted line
represents the point of transition between Phase I and Phase II. The black arrow in the B
panel indicates the point that oxygen concentration reached 75% and the control of the
dissolved oxygen concentration started by changing the speed of the agitator. The data
corresponds to one of the triplicated experiments. The data points for the other
experiments are provided in Appendix 6.
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During the lactate production stage, B. anthracis produced lactic acid via the
lactate dehydrogenase enzyme (ldh). The production of lactate under aerobic conditions
was likely an indication of overflow metabolism, as has been reported for Bacillus
subtilis when growing in a medium containing an excess of glucose [159-161]. Under
such conditions, lactate production eliminates excess carbon from the cell. Meanwhile,
the lactate dehydrogenase reaction helped the electron transfer chain keep the redox
balance by regenerating NAD+, which is required in the earlier steps of glycolysis [162].
In the second stage observed, B. anthracis started to consume the lactate that was
accumulated in the media. Lactate likely provided additional energy for siderophore
biosynthesis, since siderophore production started at nearly the same time as lactate
consumption (data not shown). Also, lactate could contribute to carbon structure through
phosphoenolpyruvate, which is needed for siderophore biosynthesis.

Two reactions could be responsible for the consumption of lactate in Phase II;
they are lactate dehydrogenases, or lactate oxidoreductase. In Lactobacillus plantarum,
lactate utilization has been reported to be carried out through NAD+-dependent lactate
dehydrogenases [163]. However, in B. subtilis [164,165] and Staphylococcus aureus
[166], lactate consumption is achieved with the enzyme lactate oxidoreductase encoded
by the lutABC operon. Chai et al. [164] found homologs of B. subtilis lutABC in different
bacteria, including B. anthracis, by doing chromosomal alignment. Moreover, Pohl et al.
[5] reported the induction of BA1315 (LutA protein), BA1316 (LutB protein), BA1317
(LutC protein), and BA1314 (LutR protein) genes in B. anthracis when hydrogen
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peroxide was added to the media to cause oxidative stress to the bacterium. LutR is a
GntR-like repressor, which mediates the induction of lutABC when lactate is present in
the media. Therefore, it was hypothesized that the lactate consumption in B. anthracis
was carried out through the lactate oxidoreductase reaction rather than using the lactate
dehydrogenase enzyme.

Growth rate decreased under iron-poor conditions. The effect of iron on the growth
rate was quantified during fermentation runs under iron-poor/rich conditions. The growth
was monitored spectrophotometrically. The results are shown in Figure 19 for Phases I
and II. The growth rate was lower in iron-poor conditions compared to iron-rich
conditions in both phases. However, the effect of iron depletion in the media was more
detrimental to the growth rate in Phase II. The growth rate decreased by 30% in Phase II
under iron-poor conditions relative to iron-rich conditions, as compared to a reduced
growth rate of only 8% during Phase I. These results are in agreement with previously
described behavior for B. anthracis under iron-poor conditions [6,137,167]. Carlos et al.
[6] reported a noticeable decrease in growth rate during the middle of the exponential
phase, and an early on-set of stationary phase under iron-poor conditions.
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Figure 19. Growth rate for both phases. Blue columns indicate iron-poor conditions,
and orange columns are the iron-rich conditions. The columns denote the mean of the
independently triplicated experiments, and the error bars are the standard error of the
mean.

Lactate secretion/uptake rates. During Phase I, no significant difference in lactate
secretion was observed under the iron-poor versus iron-rich conditions, as indicated in
Figure 20A. In Phase II however, a more than two-fold increase in the lactate uptake rate
under iron-poor conditions was seen, as indicated in Figure 20B.
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Figure 20. (A) Lactate secretion rate during Phase I and (B) lactate uptake rate
during Phase II. Blue columns indicate iron-poor conditions, and orange columns are
the iron-rich conditions. The columns denote the mean of the independently triplicated
experiments, and the error bars are the standard error of the mean.

Interestingly, the shift to lactate consumption in Phase II was different than what
has been reported in other studies. For instance, Staphylococus aureus increases the
production of lactate in order to decrease the local pH, which facilitates the release of
host iron-sequestering proteins under iron deprivation conditions [168].

Also, B.
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anthracis transcriptomic analysis shows an up-regulation of lactate dehydrogenase and
lactate permease under iron depletion conditions [6]. Furthermore, B. subtilis studies of
the iron-sparing response identify a repression in the synthesis of the LutABC lactate
oxidoreductase enzyme [165,169], which is responsible for lactate utilization under iron
deprivation conditions.

In the current study, no large reduction in the pH value under iron-poor conditions
was observed relative to iron-rich conditions. This result is contrary to the pH behavior
reported for S. aureus growing under iron-poor conditions.

Indeed, the pH in B.

anthracis under iron-poor and iron-rich condition showed similar behavior, and they
finished near the same values. In iron-poor conditions, the pH started at 7.50 and dropped
to 7.02 by the end of Phase I. By the end of Phase II, the pH was approximately 6.53. In
iron-rich conditions, the pH started at 7.55 and finished at 6. 92 by the end of Phase I. It
decreased slightly to 6.45 by the end of Phase II.

The difference between the lactate secretion results reported here and elsewhere
[6,165,168,169] could be caused by differences in the experimental conditions.
Specifically, none of the other studies controlled the dO2. Additionally, in S. aureus
experiments iron was depleted by either adding an iron chelator (2,2’-dipyridyl) to the
media, or by mutating the fur gene, which is a ferric uptake global transcriptional
repressor.

These two approaches could result in a more severe reduction in iron

concentration than in the experiments described here.
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As a part of the iron sparing response of B. subtilis, Smaldone et al. reported that
under limited iron conditions, sRNAs regulated by the fur gene repressed the translation
of the LutABC proteins [165,169]. However, the consumption of lactate during Phase II
suggests that the genes encoding for lactate oxidoreductase were not repressed under the
current experimental conditions. These contradictory results could be caused by the
severe iron reduction imposed by the mutation of the fur gene in the B. subtilis study, as
compared to the current study. Another possibility is that, under the experimental
conditions studied, the LutABC proteins in anthracis are not translationally regulated by
the fur gene.

Reduction in iron concentration increases the carbon dioxide secretion rate. The
carbon dioxide secretion rate was found to be higher under iron-poor conditions than in
iron-rich conditions for both phases.

These results are depicted in Figure 21. The

secretion rate was found to be 27% lower in iron-rich conditions than in iron-poor
conditions during Phase I. During Phase II, the secretion rate was 21% lower in iron-rich
conditions. Similar ratios between iron-poor/rich values were kept for both phases.
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Figure 21. Carbon dioxide secretion rate during Phases I and II. The blue columns
indicate iron-poor conditions, and the orange columns are the iron-rich conditions. The
columns denote the mean of the independently triplicated experiments, and the error bars
are the standard error of the mean.

Glutamic acid uptake rate. No statistically significant difference was found between
the iron-poor and iron-rich conditions for the glutamic acid uptake rate during Phase I, as
is shown in Figure 22. During Phase II, the consumption of glutamic acid was five-fold
lower during growth in iron-poor conditions. This reduction in the glutamic acid uptake
rate under iron-poor conditions could be caused by a down-regulation of the
proton/glutamic acid transport gene, as was reported by analyzing the data from the
transcriptional profiling of B. anthracis during iron starvation [6].
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Figure 22. Glutamic acid uptake in Phases I and II. The blue columns indicate ironpoor conditions, and the orange columns are the iron-rich conditions. The columns denote
the mean of the independently triplicated experiments, and the error bars are the standard
error of the mean.

Glucose uptake rate was higher under iron-poor conditions. It was found that B.
anthracis consumed less glucose during iron-rich conditions than in iron-poor conditions
in both phases, as is shown in Figure 23. During Phase I, the glucose uptake rate in ironrich conditions was 20% lower than in iron-poor cultures. During Phase II, the glucose
uptake rate under iron-rich conditions was 35% lower as compared to the iron-poor
cultures. A slight incremental increase in the glucose uptake rate under lower iron
concentrations was observed at Phase II compared to Phase I.
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Figure 23. Glucose uptake rate at Phase I and Phase II. The blue columns indicate
iron-poor conditions, and the orange columns are the iron-rich conditions. The columns
denote the mean of the independently triplicated experiments, and the error bars are the
standard error of the mean.

Oxygen uptake rate decreased as iron concentration increased. The oxygen uptake
rate (OUR) was found to be higher in iron-poor conditions than in iron-rich conditions
during Phase I and Phase II, as is shown in Figure 24. During Phase I, OUR was 21%
higher in iron-poor conditions than in iron-rich conditions. However in Phase II, OUR
was 44% higher in iron-poor conditions than in iron-rich conditions.
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Figure 24. Oxygen uptake rate during Phases I and II. The blue columns indicate
iron-poor conditions, and the orange columns are the iron-rich conditions. The columns
denote the mean of the independently triplicated experiments, and the error bars are the
standard error of the mean.

Siderophores were produced only during Phase II. Siderophores were not detected in
either iron-rich or iron-poor cultures during Phase I. These results are in agreement with
previously reported findings, stating that the production of siderophores begins in the
middle of exponential phase, and peaks in the stationary phase [149,167].

Siderophores were secreted 3.3 times faster in iron-poor conditions than in ironrich conditions, as is shown in Figure 25. This is not surprising, since studies have shown
that iron deprivation up-regulates the biosynthesis pathway and secretion of siderophores,
as well as other iron transport mechanisms [6,170]. B. anthracis secretes two known
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siderophores: bacillibactin and petrobactin. Both have higher affinity for iron (𝐾!!"# =
10!".! and 𝐾!!"# = 10!" ) as compared to transferrin 𝐾! = 10!" [142]. This property
allows the bacteria to compete more efficiently for iron during the infection process.

Figure 25. Siderophore secretion rate for Phase II. No siderophores were detected in
Phase I. The blue columns indicate iron-poor conditions, and the orange columns are the
iron-rich conditions. The columns denote the mean of the independently triplicated
experiments, and the error bars are the standard error of the mean.

Supplementation of the media with iron did not abolish siderophore secretion. The
secretion of siderophores at high iron concentrations has been reported in previous
experiments [149,171]. Lee et al. [171] suggest that the bac locus encoding the
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biosynthesis of

bacillibactin is highly regulated at the transcriptional level by iron

concentration. However, under iron rich conditions, small amounts of bacillibactin could
be produced [148]. Meanwhile, the transcriptional regulation of the petrabactin
biosynthesis pathwaty at the asb locus is less effective under iron rich conditions. In
addition to the iron regulation of the siderophore biosynthetic pathway, it has been found
that temperature [143,148,149], aeration rates [171], and CO2/bicarbonate levels
[148,149] also have an impact on petrobactin and bacillibactin production. Nonetheless,
under any combination of these conditions, petrobactin has always been detected,
suggesting constitutive production.

In this study, petrobactin and bacillibactin

concentrations were not measured directly; rather the total siderophore concentration was
measured. However, based on the previous evidence, it was hypothesized that the main
siderophore detected under iron rich condition was likely to be petrobactin.

Iron was primarily consumed during Phase I. The iron uptake rate was 1.72-fold
higher in Phase I under iron-rich conditions than in iron-poor conditions. In Phase II, the
iron uptake-rate was 3.8 times faster in iron-rich conditions than in iron-poor conditions,
although absolute uptake rates in both conditions were slower than observed for Phase I.
The results are illustrated in Figure 26. It is likely that during Phase I, the iron
concentration in the iron-poor cultures was adequate to facilitate the passive/active
transport of iron into the bacteria. As a consequence, the relative difference in the iron
uptake rate between the iron-rich and iron-poor conditions was not as high as seen in
Phase II.
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Figure 26. Iron uptake rate during Phases I and II. The blue columns indicate ironpoor conditions, and the orange columns are the iron-rich conditions. The columns denote
the mean of the independently triplicated experiments, and the error bars are the standard
error of the mean.

During Phase II, the iron in the IRDM media was nearly depleted. As a result, the
uptake of iron was lower under these conditions. Even with the production of
siderophores, the bacteria were unable to collect significant levels of iron due to the lack
of iron in the environment.

Carbon metabolism was more active under iron-poor conditions. As was shown,
more glucose and oxygen were consumed under iron-poor conditions in both phases.
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Additionally, more carbon dioxide was produced during iron-poor conditions in both
phases. Nonetheless, this increased carbon metabolism did not reflect in higher growth
rates under iron-poor conditions. On the contrary, the growth rates were slower in ironpoor cultures than in iron-rich cultures in both phases. These results suggest that an
increased carbon metabolism does not necessarily support growth.

Impact of iron concentration on protective antigen production. To determine the
effect of iron on the production of toxins, the presence of the protective antigen (PA)
protein was monitored via western blot. Additionally, it was hypothesized that if toxins
were detected in the cell, they could to explain the increased carbon metabolism observed
under iron-poor conditions. Samples were taken at the end of the exponential growth
phase, since accumulations of toxins are highest at this time [172].

Figure 27 shows the western blot results for PA detection in IRDM, representing
iron-poor conditions, and IRM, representing iron-rich conditions. The results were
compared to cells growing under IRDM/IRM with bicarbonate. It is known that
bicarbonate induces the production of toxins [173]; thus it was used to establish a positive
control. Experiments showed that unless bicarbonate was in the media, PA was not
produced, which was expected and consistent with previous reports [173]. These results
suggest that the observed increase in carbon metabolism under iron-poor conditions is not
caused by toxin production.
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Figure 27. Western blot analysis of Protective Antigen protein. Western blot results
for the four conditions and their blanks. “Blanks” were media before the inoculation of
bacteria. IRDM is iron-reduced media, IRM is iron-replete media, IRDMB is iron
reduced media with bicarbonate, and IRMB is iron replete media with bicarbonate. The
black-dashed line shows the approximate position of the protective antigen at 83 kDa.

5.5 Discussion

For years, the importance of iron to the growth and development of pathogenic
bacteria has been recognized. As a mechanism of defense, the host organisms sequester
their iron in iron storage/transport proteins. Meanwhile, B. anthracis secretes two
siderophores, bacillibactin and petrobactin in order to battle for iron under iron deplete
conditions. Bacillibactin is deactivated by siderocalin, a protein that is part of the host’s
immune response. Petrobactin, however, is able to evade siderocalin, and it has been
shown that a mutation in its biosynthesis pathway attenuates B. anthracis pathogenesis in
mice [137]. In B. anthracis, siderophore metabolism has been well studied [142,148127

152]. Despite these studies, the impact of iron availability on the metabolism of B.
anthracis remains unclear. Over the course of the current studies, an increase in the
production of siderophores under iron-poor condition in Phase II was observed, as has
been reported in the previous studies [149,150]. During Phase I, the concentration of iron
in iron-poor conditions was initially enough to support almost normal bacteria growth.
However, as the number of cells increased, the continuing depletion of iron in the ironpoor environment during Phase II activated components of the iron-sparing response,
such as the biosynthesis of siderophores [169,170].

During Phase II, the energy requirements for growth and siderophore production
were fulfilled by an increase in glucose uptake and by the consumption of lactate
accumulated in the media during Phase I. B. anthracis not only needs energy for
siderophore biosynthesis, but also for recapturing the ferric-siderophore complexes
secreted into the media [142,150,152,174-176]. Additionally, the bacteria require
sufficient reducing power to free the iron from the ferric-siderophore complexes, which
also increases the energy demand [174,177].

It was surprising to observe an increase in the glucose uptake rate, carbon dioxide
secretion rate, and oxygen uptake rate during iron-poor conditions, especially in
conditions where the growth rates decreased. There are two potential explanations for this
phenomenon.

The first possibility is that B. anthracis may have an up-regulated

glycolysis pathway during iron-poor conditions to produce fermentation by-products for
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energy, and to regenerate NAD+. A similar behavior has been observed in S. aureus,
albeit for a different purpose. In S. aureus, the glycolysis pathway is up-regulated to
produce lactate for media acidification purposes [168]. The second possibility is that the
biosynthesis of amino acids may be up-regulated for the production of siderophores
during Phase II, as has been seen in B. subtilis. Here, it can be argued that under the
media condition used, amino acid biosynthesis is not required, since casamino acids
should provide them. However, the transcriptional profiling of B. anthracis under iron
starvation conditions reported a downregulation of amino acid permease family proteins
and oligopeptide ABC transporters [6]. This is in agreement with the reduction of the
glutamic acid uptake rate observed in these studies during the iron-poor conditions in
Phase II. Thus, in response to the reduction of amino acids uptake, the bacteria may
increase the biosynthesis of some amino acids, and many of the precursors to the amino
acids’ biosynthesis pathways come from the glycolysis pathway.

The higher glucose uptake rate and oxygen uptake rate did not result in a higher
growth rate in B.anthracis under iron-poor conditions. Thus, it is hypothesized that B.
anthracis conserves energy less efficiently under iron-poor conditions, which is similar to
what has been reported for Escherichia coli growing in succinate under iron-deficient
conditions [178]. It is possible that there are other energy consuming process occurring in
the bacteria not related to biomass production. These could include processes such as
maintenance, energy loss due to leaks, and/or production of signaling molecules,
regulatory proteins, or small RNAs. Small RNAs such as RyhB, have been reported to
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mediate the repression of iron-containing proteins under iron starvation conditions in B.
subtilis [169] and other bacteria [179,180].
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6. GENOME-SCALE METABOLIC RECONSTRUCTION FOR BACILLUS
ANTHRACIS STERNE AND ANALYSIS OF ITS METABOLIC
ADAPTATION TO DIFFERENT IRON CONDITIONS.

6.1.Chapter Synopsis
The infection process for Bacillus anthracis, the causative agent of anthrax,
begins when spores enter the body through the skin or mucosa. Then, local macrophages
phagocytose the spores, where they germinate. After the vegetative cells are released
from the macrophage, they enter the lymphatic system and bloodstream where they
spread through the body and produce septicemia, shock, and finally death. When B.
anthracis are living inside macrophages, the bacteria have to compete for iron with host
iron transport/storage proteins. To effectively compete, the bacteria secrete siderophores,
which are powerful iron chelators. The biology of siderophores has been well studied.
However, the impact of iron availability to B. anthracis metabolism from a global
perspective remains unknown. Genome-scale metabolic models allow for the compact
and integrated analysis of complex metabolic networks and their associated, often nonintuitive, behavior. In this work, the metabolic model of B. anthracis was developed
using GAFBA v1.1 which compiled all the available information for the bacteria and
other closely related Bacillus strains to generate a comprehensive biomass equation, and
analyzed how all of the metabolites in the system interacted with each other. Then the B.
anthracis model was used to analyze the metabolic response to iron-poor/rich conditions.
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During iron deprivation, a down regulation of some of the reactions of the TCA cycle,
and a reduction on the uptake of amino acids were observed. For the first time, a
correlation between the biosynthesis of autoinducer-2, a quorum sensing signal molecule,
and the growth of B. anthracis under iron-poor conditions was reported.
6.2. Introduction

B. anthracis is a gram positive, spore forming, and facultative anaerobe
bacterium.

Bacilli will form spores when local nutrients in the environment are

exhausted, which happens after host death and exposure to air. The spores are highly
resistant and can survive in soil for decades. B. anthracis has been recognized as a
bioterrorism agent because of its ability to produce anthrax. The Center for Disease
Control and Prevention has created three levels of classification for biological agents
using three categories, A, B, and C, depending upon threat level. B. anthracis is part of
category A, the highest priority agents. Considering that anthrax can be easily transmitted
from person to person, an anthrax attack could result in a high mortality rate [181,182].

During the 20th century, anthrax was part of military programs for developing of
biological agents for warfare in countries such as Germany, England, France, Russia and
Japan. In 1979, an accidental anthrax occurred outbreak near Moscow. This case is
known as the Sverdlovsk epidemic. Many individuals suffered gastrointestinal,
cutaneous, and inhalation anthrax. After many investigations, the incident was linked to a
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secret biological weapons program at a nearby military compound. In 2001, anthrax
attacks occurred in the U.S with spores in powder form. Five people were killed, and 17
others were infected [38,183].

Anthrax can be treated with antibiotics, if it is diagnosed early enough in the
infection process. However, the diagnosis is very difficult to make [184]. Furthermore,
the existing vaccines are not completely efferctive.. Therefore, a better understanding of
the bacteria’s metabolism during the infection process, and its interaction with the host
will provide an exceptional insight into the anthrax disease.

During the different stages of infection, B. anthracis has to be able to adapt to the
availability of nutrients such as iron. Iron is important for numerous cellular processes.
Nevertheless, it is highly toxic because it is insoluble at physiological pH. As a
consequence, host molecules with very high binding affinities such as transferrin, ferritin
and hemoglobin sequester iron. This mechanism protects the host from from bacterial
infection, since the iron concentration is kept below the level required to support bacterial
growth and virulence.

B. anthracis secretes siderophores and hemophores in order to compete with the
host’s iron transport and iron storage proteins for iron. Hemophores are useful after the
escape from the macrophage, since they extract heme groups from hemoglobin. On the
contrary, siderophores are important during the intracellular life cycle of B. anthracis
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inside the macrophage. There are two known biosynthesis systems for siderophores
encoded within the genome of B. anthracis: petrobactin and bacillibactin. Petrobactin
confers an important advantage to the bacteria, because petrobactin can escape from the
action of host-produced siderocalin. Siderocalin binds to bacterial siderophores,
preventing iron delivery to the bacteria [140].

The influence of B. anthracis’s iron acquisition systems on its pathogenicity has
been previously studied. For instance, when the genome of B. anthracis was compared
with the genome of non-pathogenic members of the genus Bacillus, it was found that B.
anthracis contains more iron acquisition systems [140]. In another study, a mutation in
the petrobactin biosynthesis pathway of B. anthracis (ΔasbA) reduced the growth in irondepleted media and in macrophages. Moreover, the B. anthracis virulence in mice was
attenuated with this mutation. However, the mutation (ΔbacCEBF) in the bacillibactin
biosynthesis pathway did not show any impact on the growth of iron-depleted media or in
macrophages. Additionally, no effect on the virulence in mice was observed [137].

The biosynthesis pathway, secretion, and uptake of siderophores in B. anthracis
have been well studied [142,148-152]. However, there are few studies [5,6,185,186]
about the global metabolism of B. anthracis during conditions similar to the ones found
in the alveolar macrophage (iron starvation and oxidative stress). Existing studies are
based on transcriptomic and proteomic analysis. Based upon a survey of the literature, no
metabolomic studies have been carried out. For that reason, the goal of this study is to
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understand the cellular behavior of the bacteria as a whole from a metabolic perspective.
An in silico genome scale metabolic model was used to simulate the growth of the
bacteria under different iron conditions.

This chapter presents the analyses of the metabolic adaptation of B. anthracis to
different iron conditions. As a part of the study, the first genome-scale reconstruction of
the metabolic network of B. anthracis Sterne 34F2 was developed. It contains fully
functional biosynthesis, secretion and uptake pathways for siderophores. The model was
validated against experimental data for the growth of B. anthracis. The bacteria were
grown in iron-poor media that had an iron concentration of 2.24 µM, and in iron-rich
media with a concentration of 20 µM. During the experiments on both iron conditions,
two metabolic states or phases were observed. The first phase, Phase I, was characterized
by lactate production. In the second phase, referred to as Phase II, lactate was consumed.
Thus, in total four models were analyzed: two models for Phase I under iron-poor/rich
conditions, and two more for Phase II in iron-poor/rich cultures.

6.3.Methods

6.3.1. GENETIC ALGORITHM/FLUX BALANCE ANALYSIS APPROACH (GAFBA V1.1)

GAFBA v1.1 methodology has been explained in detailed in Chapter 3 and
Chapter 4. However, in this subsection, the parameters for the genetic algorithm are
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defined. The population size used was 30 chromosomes. The crossover probability was
set to 70%, and the mutation probability was 1%. Elite selection was chosen as the
selection strategy, with an elite fraction of 20%. Seven-point crossover was performed,
and bottom re-seed was allowed, with a bottom re-seed frequency of every 100
generations. The GAFBA v1.1.algorithm was run for 2,000 generations per simulation,
and 169 simulations in total were carried out. All simulations were implemented on a 2.7
GHz Intel Core i5 computer. Each simulation (2,000 generations) took about three hours.
Thus, the total time for the 169 simulations was 28 days.
6.3.2 FLUX BALANCE ANALYSIS

Flux Balance analysis was introduced in Chapter 2. However, in this subsection,
the constraints applied to the specific case of B. anthracis are described. The media
composition used was the one from the iron-poor/iron-reduced media (IRDM), or ironrich/iron-replete media (IRM) [137]. The nutrient and secretion fluxes are defined in
appendix A8.4. The upper and lower boundaries of the experimentally measured fluxes
are presented in Table 11 for each of the four conditions. For the siderophores’
experimental constraints, the Arnow Assay only allows for the measurement of total
catechol siderophore. To get the specific values for petrobactin, bacillibactin, and
protocatechuate, a ratio was calculated using experimental information [149,171].
Additional constraints to the model were defined based on the available experimental
information. The upper boundaries for transport of the ferric-siderophore complexes were
calculated using the maximum transport velocity based on the kinetic experiments for B.
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cereus [187]. Furthermore, some regulatory constraints were applied to the model based
on the experimental conditions and information from the literature. These constraints are
defined in Appendix A8.9, along with a brief description of the rationale for the
regulation, and all relevant citations. In all four models, 17 reactions were downregulated base on media composition. The reaction responsible for iron transport was
only down-regulated under iron-poor conditions in Phase II. It was hypothesized that
under low iron concentrations, the iron was only taken up through the ferric-siderophore
complex. The objective function chosen for the optimization problem was the
maximization of the biomass reaction for B. anthracis. The biomass equations for each
case are defined in Appendix A8.5-A8.8.
6.3.3. FLUX VARIABILITY ANALYSIS (FVA)

FVA is a method that helps to investigate the metabolic network flexibility and
redundancy [188]. FVA determines the range of values where the fluxes can change
without affecting the value of the objective function [189].

The process starts by

calculating the value of the objective function for the base type FBA problem. Then,
FVA applies a series of optimization problems to maximize and minimize each of the
fluxes of the metabolic network while keeping the value of the objective function fixed to
the one found for the base type FBA solution [190].

FVA analysis was applied for each of the in silico simulations reported in here. It
was found that the model of B. anthracis under iron-poor conditions during Phase II was
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more flexible than in any of the other conditions. The number of fluxes with variable
ranges was higher in iron-poor conditions at Phase II; meaning that B. anthracis
metabolism under iron-poor conditions in Phase II had more alternative pathways and
was more adaptable to changes in the environment.

6.4.Results

6.4.1. METABOLIC NETWORK RECONSTRUCTION

An existing pathway genome database (PGDB) from Pathways tools (PT) version
16.0 [68] was refined using Pathologic from PT. Then MetaFlux through the instantiation
code [52] was used to create the specific reactions for the lipid biosynthesis pathway of
the major fatty acids of B. anthracis, such as palmitic and stearic acids [191]. Later,
GAFBA v1.1 [192] was used for evolving the initial model for B. anthracis under ironpoor condition Phase II (IRDM2). The following exchange fluxes were constrained to
their experimentally calculated values: glucose uptake rate, carbon dioxide secretion
rate, oxygen uptake rate, glutamic acid uptake rate, ferric iron uptake rate, petrobactin
secretion rate, bacillibactin secretion rate and 3-4-dihydroxybenzoate (protocatechuate)
secretion rate. The experimentally measured fluxes are presented in Table 11. GAFBA
v1.1 was run for 169 simulations to evolve only the model of B. anthracis under ironpoor condition at Phase II. The gotten model was used to study the metabolism of the
bacteria under the other three conditions by applying the experimentally measured fluxes
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for each condition as presented in Table 11. Thus, only one model was created and it was
evaluated under four experimental conditions.

The model accounted for 1,003

metabolites and 1,049 reactions. All 1,003 metabolites could be found in the intracellular
space, while 87 of them were also found in the extracellular space. Additionally, 1,007
(96%) reactions were intracellular, and 87 (4%) were exchange fluxes. The full model is
presented in Appendix 8.

Table 11. Experimentally measured fluxes for the growth of B. anthracis under ironpoor media and iron-rich media. The secretion/uptake rates for nine metabolites were
measured experimentally in all the conditions. IRDM1, iron reduced media Phase I.
IRM1, iron-replete media Phase 1. IRDM2, iron-reduced media Phase 2. IRM2, ironreplete media Phase 2. Positives values are production rates. Negative values are uptake
rates.
rates (mmol/gDW*h)
Glucose uptake rate
Carbon dioxide production rate
Lactate production/secretion rate
Oxygen uptake rate
Glutamate uptake rate
Iron uptake rate
Protocatechuate secretion rate
Petrobactin secretion rate
Bacillibactin secretion rate

IRDM1
-12.29
7.45
1.25
-9.29
-2.92
-0.005
0
0
0

IRM1
-9.84
5.48
1.01
-7.62
-4.12
-0.01
0
0
0

IRDM2
-13.16
6.29
-0.97
-6.74
-0.27
-0.00075
0.0241
0.0163
0.0023

IRM2
-8.54
4.96
-0.41
-4.65
-1.6
-0.0028
0.008
0.0055
0.00004

The biomass equation contained all the available published information for B.
anthracis and other similar Bacillus such as Bacillus cereus and Bacillus subtilis. The
ratios between the major biochemical components were adjusted based on data described
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in the literature. Protein values were determined experimentally using the Biuret method
[193,194]. RNA, DNA, and lipid values were taken from those determined for B. cereus
[191,195,196]. The cell wall, ions, and cofactors were calculated using the available
values for B. subtilis [197-199].

Lipids were classified as phospholipids and neutral lipids, and the relative ratios
were taken from published information for B. cereus [196]. Then, the phospholipids were
divided

into

cardiolipin,

phosphatidylgycerol,

phosphatidylserine,

and

phosphatidylethanolamine following the compositions presented by Koga et al. [200] for
B. cereus. Neutral lipids were just represented as diglycerides [198]. The fatty acid
compositions were determined using information for B. anthracis, and only the major
fatty acids, stearic acid and palmitic acid, were included [191,201].

The biomass equation did not include lipoteichoic acids (LTA) since
experimentally they have not been detected [202,203] in B. anthracis preparations. In
Staphylococus aureus, the product of the ltaS gene catalyzes the LTA synthesis.
Although Garufi et al. [204] reported homologues of ltaS gene in the genome of B.
antracis, the LTA biosynthesis has not been fully characterized and the stoichiometric
composition of LTA in the biomass has not been quantified.

Teichoic acids were not included in the biomass equation since the low phosphate
content of the bacteria cell wall does not allow its presence in the cell [202,205].
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Furthermore, no gene associated with the teichoic acid biosynthesis pathway has been
characterized [204,206]. Finally, the teichoic acid constituents have not been found in B.
anthracis envelope preparations [207].

The stoichiometric coefficient of iron in the biomass equation was taken from B.
subtilis growing in iron-rich conditions. No problems were found with this coefficient
during Phase I under both iron conditions or in iron-rich conditions during Phase II.
Nevertheless, in iron-poor conditions during Phase II (IRDM2), the experimentally
measured iron uptake rate was not enough to fulfill the requirements of iron for biomass
production using the B. subtilis coefficient. Thus, the stoichiometric coefficient was
adjusted using the experimentally measured growth rate and iron uptake rate under the
assumption that all the iron consumed was only for biomass production. This assumption
is based on the observation that many bacteria under iron starvation conditions
redistributed the intracellular iron for the most critical cellular functions such as
production of nucleic acids and amino acids, which are critical components for biomass
production [169,179,208,209]. The resulted biomass equations for each condition are
presented in Appendix 8.

The

non-growth

associated

maintenance

(NGAM)

was

set

to

−1 −1
5.47 mmol gDW h based upon the average of the experimentally measured values for

different Bacilli [138,210,211]. The growth-associated maintenance (GAM) was initially
calculated using the protocol from Thieles et al. [3]. However, the in silico calculations
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of the growth rate were higher than the experimentally determined growth rate for each of
the four cases. A likely explanation for this observation is that B. anthracis may be
expending energy in other processes not accounted for in the model. Furthermore, the
effect of the changes in GAM on the in silico growth rate was determined following
Puchalka et al.’s approach [189] of keeping NGAM as a constant. From these analyses,
it was clear that the GAM needed to be increased. Through the Thieles et al. [3]
methodology, only the energy required for macromolecular synthesis was taken into
account. Thus, an increase in GAM would include additional processes that require ATP
such as re-polymerization of degraded molecules, ATP consumption due to leaks, futile
cycles, and ATP consumed for maintenance of concentration gradients and electrical
potential [21,212]. As a consequence, the values selected for GAM were those that led to
a better match between in silco growth rate and the experimental growth rate values. The
NGAM, GAM, in silico growth rate, and experimental growth rate for each case is
presented in Table 12. Interestingly, the GAM values were of the same order of
magnitude as the reported value for Bacillus megaterium of 56.82 mmol /gDW*h [211].
Table 12. NGAM, GAM, in silico growth rate, and experimental growth rate
comparison for the four cases. IRDM1 – iron-reduced media (iron-poor) Phase I. IRM1
– iron-replete media (iron-rich) Phase 1. IRDM2 – iron-reduced media (iron-poor) Phase
2. IRM2, iron-replete media (iron-rich) Phase 2.
NGAM (mmol/gDW*h)
GAM (mmol/gDW)
In silico growth rate (h-1)
Experimental growth rate (h-1)

IRDM1
5.47
43.5
1.149
1.15

IRM1
5.47
26.5
1.252
1.25

IRDM2
5.47
64.2
0.359
0.372

IRM2
5.47
56.6
0.498
0.504
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6.4.2. SIDEROPHORES BIOSYNTHESIS, SECRETION, AND UPTAKE PATHWAYS

B. anthracis produces two known siderophores: bacillibactin and petrobactin.
Additionally, protocatechuate (3,4-DHB), one of the precursors of petrobactin, has been
detected in the broth of B. anthracis [149,167,213]. However, its function as a
siderophore is not well studied. Zawadzka et al. [187] reports that 3,4-DHB can serve as
a siderophore in B. cereus. They calculated the stoichiometry ratio of ferric-siderophore
complex formation with 3,4-DHB, which equals 1:3 iron to ligand. Furthermore, they
characterized the membrane-associated substrate-binding proteins (SBPs) for transport of
ferric-3,4-DHB. As a consequence, protocatechuate was added to the model as a potential
siderophore for B. anthracis.

A schematic representation of protocatechuate, petrobactin, and bacillibactin
biosynthesis, secretion, uptake of ferric-siderophore complex, and release of iron from
ferric-siderophore complex is presented in Figure 28. Additionally, the biosynthesis
pathways, specifically for petrobactin, protocatechuate and bacillibactin, are shown in
Appendix 7 at Figure S29 and S30. The pathways included the associated gene for each
reaction if it had been characterized.
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Figure 28. Representation of the siderophore secretion, iron loading, ferric-siderophore complex uptake, and iron
release from ferric-siderophore complex. The name of each reaction in the model appears next to the schematic reaction.
The question marks represent reactions without an assigned gene. Green arrows are extracellular reactions, blue arrows are
transport reactions, and black arrows are intracellular reactions. Blue cylinders are uptake transporters and purple cylinders are
secretion transporters.

The gene cluster asbABCDEF has been determined to be responsible for the
biosynthesis of petrobactin from spermidine, 3,4-dihydroxybenzoic acid, and citrate
[150,151]. Once petrobactin is synthesized, it is exported out of the cell. The mechanism
of the secretion of petrobactin has not been characterized. However, a simple reaction
was added to the model because petrobactin has been detected outside the cell in different
experiments [137,148,149,167,213]. Then, petrobactin is loaded with iron ion through a
spontaneous reaction. Next, the ferric-petrobactin complex is imported into the cell
through an ATP-binding cassette (ABC), which was identified in previous works
[142,152,175,187]. Finally, the iron is released from the ferric-siderophore complex.
There was no available information for ferric-petrobactin iron release. Thus, the
mechanism for iron release was chosen usinge the characteristic of aerobatic, a similar
siderophore of petrobactin as a guide [150]. The Ferric-siderophore formation constants
are similar for both siderophores: 𝐾!!"#$%&'(#)* = 10!" [142], and 𝐾!!"#$%!&'(& = 10!!.!"
[214]. As a result, they should have similar redox potentials, which for aerobactin is
-336 mV [214]. This redox potential falls in the range of physiological reductants.
Therefore, iron is likely released from the ferric-petrobactin complex through a reduction
of ferric ion to ferrous ion using flavins such as FMN, followed by a dissociation of the
siderophore [177,215-217]. Finally, petrobactin is recycled to its precursors because no
evidence has been found that B. anthracis accumulates or secretes the isomeric precursor
(3,4-DHB attached to the 4-carbon end of spermidine) [150].
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Protocatechuate is synthesized in the first step of petrobactin biosynthesis (Figure
S29) from 3-dehydroshikimate. Then, protocatechuate is secreted out of the cell through
an unknown mechanism, represented as a simple diffusion reaction in the model.
Protocatehuate spontaneously loads itself with iron following the stoichiometric
experimentally-determined ratio of 1:3 iron to ligand [187].

Next, an ATP-binding

cassette (ABC) transports the ferric-protocatechuate complex into the cell. It has been
reported that FatB enzyme is responsible for this transport [142,187]. Then, a binding site
protonation and/or conformational change releases the iron from the ferricprotocatechuate complex [177]. Finally, protocatechuate is recycled into its metabolism.

The dhb operon encodes the bacillibactin biosynthesis pathway [142] as shown in
supplementary Figure S30.

An MFS-type transporter exports bacillibactin as it is

reported for B. subtilis [174,218] and B. anthracis [142]. Next the ferric-bacillibactin
complex spontaneously forms. Then the FeuABC system is responsible for the uptake of
the iron-loaded siderophore through an ABC type porter [142,174,218]. The iron release
from the ferric-siderophore complex is more difficult than in petrobactin because of its
high formation constants, 𝐾!!"#$%%$!"#&$' = 10!".! [142], which results in a lower redox
potential that is out of the range of physiological reductants [219]. However, it has been
reported that for B. subtilis, an estearase, BesA encoded in the gene locus yuiI,carries out
the enzymatic hydrolysis of the ferric-bacillibactin complex [174,220]. Homologues of
this gene were found in B. anthracis [142]. As a consequence, the model included the
release of iron from the ferric-bacillibactin complex as an enzymatic hydrolysis. Finally,
bacillibactin is recycled to its precursors.
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Iron ions are then transported into the cell through the ferric-siderophore complex
or through the iron-ABC transport system. The iron may be used for biomass synthesis,
or it could be stored as shown in Figure 24. The iron storage in the model was
represented through a hypothetical metabolite, which represents ferritin or the
miniferritin DpS2. Both iron storage proteins have been found in B. anthracis [147,221].

6.4.3. MODEL APPLICATION:

METABOLIC ADAPTATION TO IRON-POOR CONDITIONS BY

B. ANTHRACIS

The model of B. anthracis was used to study the behavior of the bacteria under
different iron conditions. The experimentally measured fluxes were used as constraints on
the model. A total of four models were studied: iron-poor Phase I, iron-rich Phase I,
iron-poor Phase II, and iron-rich Phase II. The flux distributions from the models were
compared to find possible variations in the metabolism.
6.4.3.1.Comparison of the iron-poor and iron-rich cell metabolomes at Phase I.

A comparison of the major pathways in B. anthracis under iron-poor conditions
was made with those in iron-rich conditions. During the Phase I experiments, no
siderophores were detected in either of the two iron conditions. These results are in
agreement with the reported information that the production of siderophores starts in the
middle of the exponential phase and reaches a maximum in the stationary phase
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[149,167].

As a consequence, the biosyntheses of petrobactin, bacillibactin, and

protocatechuate were down-regulated in iron-poor and iron-rich conditions.

Figures 29a-29b show the amino acid uptake rates. The amino acids found in the
media, only three were not taken up in either of the two conditions: isoleucine (I),
methionine (M), and proline (P). Aspartate (D) uptake was up-regulated in iron-poor
conditons, and valine (V) uptake was up-regulated in iron-rich conditions. Meanwhile,
for the rest of the amino acids, the uptake rates showed minor changes between the two
iron conditions. Serine (S) was the exception since its uptake was three-folds higher in
iron-rich than in iron-poor conditions. Pyruvate and ammonia were produced from the
degradation of serine. The fluxes through the biosynthesis reactions for most of the amino
acid were the same at both conditions, as shown in Figure 29c, excluding aspartic acid
(D) and valine (V). The flux through aspartate biosynthesis reaction was higher by 3.5fold in iron-rich conditions. Meanwhile, the flux through valine biosynthesis reaction was
five-fold higher in iron-poor conditions compared to iron-rich conditions.
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Figure 29. Comparison of the amino acid uptake and biosynthesis in B. anthracis under iron-poor/rich conditions at Phase I.
The blue columns are iron-poor conditions, and orange columns are iron-rich conditions. The x-axis labels represent the single letter
amino acid abbreviations. Only the amino acids in the defined media were allowed to be taken up. (A) and (B) Amino acids uptake.
(C) Amino acid biosynthesis.
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The glycolysis pathway and the pentose phosphate pathway had only slight
changes in the flux distribution in both conditions. These pathways are shown in
Appendix 7 at Figures S31 and S32. However, the fluxes through glycolysis were higher
in iron-poor conditions than in iron-rich conditions, because more glucose was feeding
into the system in iron-poor conditions. Furthermore, it was observed that most of the
flux that entered the glycolysis pathway went to the final step into pyruvate without
diverging to any other pathways in both iron conditions. The oxidative branch of the
pentose phosphate pathway was inactive under both iron conditions. Meanwhile, the nonoxidative branch had similar fluxes in both conditions.

The TCA cycle was active under the two iron conditions, with similar fluxes at
the four initial reactions from oxaloacetate to 2-oxoglutarate as shown in Figure 30.
Beyond that, the fluxes were 1.6-fold higher in iron-rich conditions compared to ironpoor conditions until fumarate. This increase was a result of the assimilation of the
glutamic acid taken from the media since its uptake rate was higher in iron-rich
conditions. Next, at the fumarate hydratase reaction (E.C. 4.2.1.2), the flux in iron-poor
conditions was higher than in iron-rich conditions. This observation can be explained
with the assimilation of aspartate through the aspartase reaction (E.C. 4.3.1.1). This
reaction consumed the aspartate taken from the media and produced ammonia and
fumarate. At (S)-malate the flux was divided, going back to oxaloacetate through the
malate dehydrogenase reaction (E.C. 1.1.1.37) or to pyruvate through the malate
dehydrogenase-decarboxylating reaction (E.C. 1.1.1.40). The fluxes were similar under
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both conditions for the malate dehydrogenase reaction. However, for the malate
dehydrogenase-decarboxylating reaction, the fluxes were higher in iron-poor conditions.
The explanation for this phenomenon was that the assimilation of the amino acids
through the TCA cycle was incorporated into oxaloacetate and pyruvate metabolism
equitably in iron-rich conditions. On the contrary, pyruvate metabolism was preferred as
the final step of the TCA cycle under iron-poor conditions.

The secretion of byproducts was similar under both conditions. Acetate and
formate secretions were higher in iron-poor conditions. Meanwhile, a slight difference
was observed between the values at iron-poor and iron-rich conditions in the ethanol
secretion and lactate secretion fluxes. The comparison of the fluxes is presented in
Appendix 7 at Figure S33.
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Figure 30. Comparison of the TCA cycle pathway under iron-poor and iron-rich
conditions at Phase I. The words in red represent metabolites. The rectangular boxes
have at the top line the E.C. number for each reaction; the blue numbers correspond to the
flux values under iron-poor conditions, and the numbers in orange are the flux values
under iron-rich conditions.

6.4.3.2. Comparison of the iron-poor and iron-rich cells metabolomes at Phase II.

The biosynthesis pathways of the siderophore were active under both iron
conditions during Phase II. The fluxes through the bacillibactin production were two
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orders of magnitude higher in iron-poor conditions than those in iron-rich conditions, as
shown in Figure 31. Meanwhile, the fluxes through the petrobactin and protocatechuate
biosynthesis pathway were three-fold higher in iron-poor than in iron-rich conditions.
Figure 32 provides a schematic representation of the petrobactin and protocatechuate
biosynthesis pathways.

Figure 31. Comparison of the bacillibactin biosynthesis pathway under iron-poor
and iron-rich conditions during Phase II. The words in red represent metabolites. The
rectangular boxes have at the top line the E.C. number for each reaction. If no E.C has
been assigned to the reaction; the corresponding reaction’s name is shown instead. The
blue numbers correspond to the flux values at iron-poor conditions, and the numbers in
orange are the flux values at iron-rich conditions.
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Figure 32. Comparison of the protocatechuate and the petrobactin biosynthesis
pathway under iron-poor and iron-rich conditions during Phase II. The words in red
represent metabolites. The rectangular boxes have at the top line the E.C. number for
each reaction. If not E.C has been assigned to the reaction; the corresponding reaction’s
name is shown instead. The blue numbers correspond to the flux values at iron-poor
conditions, and the numbers in orange are the flux values at iron-rich conditions.

The effect of iron on the petrobactin biosynthesis pathway was not as marked as
the changes in the bacillibactin biosynthesis pathway between iron-poor/rich conditions.
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The bacillibactin pathway was severely affected by the presence of iron in the media.
Under iron-rich conditions, the fluxes were down-regulated to values near zero. This is in
agreement with Carlson et. al. [6], who observed in their transcriptional profiling that the
genes of the petrobactin biosynthesis pathway were not significantly up-regulated during
iron deprivation. On the contrary, genes from bacillibactin appeared to be most strongly
induced during iron starvation. Furthermore, previous studies have reported that
petrobactin production is not repressed by an increase in iron concentration
[148,149,171].

Additionally, bacillibacitn biosynthesis is highly regulated at the

transcriptional level by iron concentration [171].

The model included protocatechuate (3,4-dihydroxybenzoate) as a siderophore.
Under iron-rich conditions, iron was transported into the bacteria primarily through active
transport. A small amount was also transported via the ferric-protocatechuate complex.
Meanwhile, in iron-poor conditions, the transport of iron into the bacteria was mainly
through the ferric-protocatechuate complex transport and ferric-bacillibactin complex
transport. It was surprising that petrobactin did not contribute to iron transport. To
explain this situation, it is necessary to take into account three factors. First, Zawadzka et
al. [187] reported common transporter routes for the uptake of ferric-petrobactin and
ferric-protocatechuate complexes in B. cereus, which had a higher affinity for ferricprotocatechuate than for ferric-petrobactin. Second, the dissociation of ferricprotocatechuate complex is through a protonation and/or conformational change within
the complex, which is easier than the reduction of ferric ion to ferrous ion using flavins.
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Third, the rate of transport for ferric-petrobactin is higher than ferric-protocatechuate,
Thus, it is hypothesized that petrobactin is functional as an iron transporter under
severely reduced iron concentrations, which were not reached under the experimental
conditions used throughout the analysis in this work.

Under severely reduced iron

concentrations, the faster ferric-petrobactin transport rate will overcome the difficulty of
releasing the iron from the ferric-petrobactin complex.

More amino acids were consumed under iron-rich conditions than in iron-poor
conditions, as is shown in Figures 33a and 33b. Cysteine (C) and threonine (T) were only
taken up under iron-rich conditions. Meanwhile, aspartate (D) and serine (S) uptake were
1.6-fold higher in iron-poor conditions than in iron-poor conditions. In contrast, the
uptake of glutamate (E) and histidine (H) were five-fold higher and four fold higher
respectively in iron-rich conditions versus iron-poor conditions.
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Figure 33. Comparison of the amino acid uptake and biosynthesis in B. anthracis under iron-poor/rich conditions at
Phase II. The blue columns are iron-poor conditions, and orange columns are iron-rich conditions. The x-axis labels represent
the single letter amino acid abbreviations. Only the amino acids in the defined media were allowed to be taken up. (A) and (B)
Amino acids uptake. (C) Amino acid biosynthesis.

The comparison of the fluxes through the biosynthesis reactions of amino acids
under the two conditions is presented in Figure 33c. Cysteine (C), histidine (H), serine
(S), and threonine (T) were produced only in iron-poor conditions. Meanwhile, the flux
through the biosynthesis reaction of aspartate (D) was only active in iron-rich conditions.
Clearly, the iron status of the cell affected the transport of amino acids, which
resulted in an up-regulation of the biosynthesis of some amino acids in iron-poor
conditions.

Many amino acid permease family proteins have been reported as down-

regulated during iron starvation in the transcriptional profile of B. anthracis [6].
Furthemore, Friedman et al. [168] reported an up-regulation of cysteine synthetase in S.
aureus under iron-poor conditions. Moreover, in the transcriptional profile of B.
anthracis [6], the gene associated with histidinol phosphate aminotransferase was upregulated under iron-poor conditions. This reaction is part of the histidine biosynthesis
pathway.

The Glycolysis pathway schematic is represented in Appendix 7 at Figure S34.
The differences between the fluxes through the glycolysis pathway under iron-poor/rich
conditions were not significant. Similarly to Phase I, the fluxes through glycolysis in the
iron-poor condition were slightly higher than in the iron-rich condition, as a result of the
higher glucose uptake rate. Additionally, two bifurcation points along the glycolysis
pathway were found: one from D-fructose-6-phosphate into the pentose phosphate
pathway; and a second one from 3-phospo-D-glycerate into the serine biosynthesis.
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The non-oxidative branch of the pentose phosphate pathway was higher in ironpoor conditions by as much as six to eight times as is presented in Figure 34. This
pathway resulted in a net production of ribose-5-phosphate (R5P) and erythose-4phosphate (E4P). E4P was used in the synthesis of 3-dehydroshikimate, which is part of
the biosynthesis of petrobactin and bacillibactin.. Meanwhile, R5P was the precursor of
5-phosphoribosyl diphosphate (PRPP). PRPP is a key component in histidine
biosynthesis, which was up-regulated under iron-poor conditions. Furthermore, PRPP is
part of the adenine salvage pathway, which is connected with the autoinducer-2 (AI-2)
biosynthesis pathway.
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Figure 34. Comparison of the pentose phosphate pathway under iron-poor and
iron-rich conditions during Phase II. The words in red represent metabolites. The
rectangular boxes have at the top line the E.C. number for each reaction. The blue
numbers correspond to the flux values at iron-poor conditions, and the numbers in orange
are the flux values at iron-rich conditions.
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AI-2 biosynthesis pathways were more active under iron-poor conditions than in
iron-rich conditions. A schematic of this pathway is shown in Figure 35. AI-2 is not
directly linked to iron metabolism. It is known to be a signaling molecule used in quorum
sensing.

Nevertheless, in a proteomic analysis of Yersenia pestis, the S-

ribosylhomocysteinase lyase (LuxS) enzyme which is required for AI-2 synthesis, was
found to be moderately increased in iron depleted conditions [222]. In other bacteria
such as Actinobacillu actinomycetemcomitans [223,224], Vibrio vulnificus [225], and
Pophyromonas gingivalis [223] it has been suggested that the luxS gene may regulate
aspects of iron acquisition. Further, in A. actinomycetemcomitans [224] and A.
pleuropneumoniae [226], it has been shown that growth under iron depletion could be
regulated by LuxS through AI-2 production. From this result and the available
information, it is hypothesized that AI-2 may help B. anthracis during growth in ironpoor conditions. It was not possible through the modeling analysis to determine its
relation to the regulation of iron acquisition systems. This should be further investigated
experimentally.

One of the byproducts of AI-2 biosynthesis is adenine, which was recycled into
the adenine nucleotide pool through adenine phosphoribosyltransferase (E.C. 2.4.2.7). It
consumed PRPP and adenine in order to produce AMP. In this way, more AMP is
available for the production of adenosine nucleotides through the de novo biosynthesis
pathway.
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Figure 35. Comparison of the autoinducer-2 (AI-2) biosynthesis pathway under
iron-poor and iron-rich conditions during Phase II. The words in red represent
metabolites. Rectangular boxes have at the top line the E.C. number for each reaction. If
no E.C has been assigned to the reaction; the corresponding reaction’s name is shown
instead. The blue numbers correspond to the flux values at iron-poor conditions, and the
numbers in orange are the flux values at iron-rich conditions.
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The flux through the TCA cycle from oxaloacetate to 2-oxoglutarate was five-fold
higher in iron-poor than in iron-rich conditions, as is presented in Figure 36. The TCA
cycle was down-regulated in iron-poor conditions from 2-oxoglutarate to fumarate. The
fumarate hydratase reaction (E.C. 4.2.1.2) was 8.6-fold higher in iron-rich cultures than
in iron-poor cultures. The malate dehydrogenase reaction (E.C. 1.1.1.37) went in the
opposite direction under each condition. Specifically, in iron-poor conditions, the malate
dehydrogenase reaction consumed oxaloacetate to produce (S)-malate. The opposite
happened under iron-rich conditions. This behavior resulted from the inactivation of the
phosphoenolpyruvate carboxykinase reaction (E.C. 4.1.1.49) under iron-poor conditions.
Thus, the oxaloacetate produced from side reactions was converted to (S)-malate, and
then pyruvate. However, in iron-rich conditions, oxaloacetate was consumed to produce
phosphoenolpyruvate

through

the

phosphoenolpyruvate

carboxykinase

reaction.

Friedman et al. [168] reported a decrease in the activity of phosphoenolpyruvate
carboxykinase under iron-poor conditions in S. aureus. Three more reactions from the
TCA cycle have been reported to decrease under iron starvation conditions in S. aureus
[168] and B. subtilis [169,208]: succinate dehydrogenase, fumarate hydratase, and
aconitate hydratase.. The model predicted the inactivation of succinate dehydrogenase
and the downregulation of fumarate hydratase. However, aconitate hydratase was upregulated.

163

Figure 36. Comparison of the TCA cycle pathway under iron-poor and iron-rich
conditions during Phase II. The words in red represent metabolites. The rectangular
boxes have at the top line the E.C. number for each reaction, the blue numbers
correspond to the flux values at iron-poor conditions, and the numbers in orange are the
flux values at iron-rich conditions. The negative flux value indicates that the flux is going
in the other direction than the one displayed on the diagram.

The differences in the byproduct secretion between the iron-poor/rich conditions
were not significant, as is shown in Appendix 7 at Figure S35. Formate and ethanol
secretion were almost the same under both conditions, and acetate was only 0.85-fold
higher in iron-poor conditions than in iron-rich conditions. During Phase II, lactate was
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consumed. This behavior was independent of the iron status of the cell. It was not
possible to explain this shift with the available experimental information. However, the
model predicted that during Phase II, the two enzymes involved in lactate metabolism
would be active, as is shown in Appendix 7 at Figure S36. Lactate dehydrogenase
produced lactate from pyruvate. Then, lactate was converted back to pyruvate through
lactate oxidoreductase. Similar cycling behavior between lactate dehydrogenase and
lactate oxidoreductase was reported in in S. aureus under nitric oxide stress [166].

Additionally, lactate metabolism was up-regulated under iron-poor conditions.
The lactate permease increased 2.5-fold. Meanwhile, the lactate dehydrogenase and
lactate oxidoreductase increased 1.4-fold. The transcriptional profile of B. anthracis [6]
reported an up-regulation of lactate permease and lactate dehydrogenase under iron
deprivation conditions. However, lactate oxidoreductase was not reported, probably
because the gene has not been experimentally characterized and has only been found
through bioinformatic approaches [164].
6.5. Discussion

In this study, I have presented a genome scale metabolic model for the causative
agent of anthrax, B. anthracis. The model was constructed with all available information
from the literature concerning the bacteria, and has been well curated. A comprehensive
biomass equation was constructed using information from related Bacillus species, as
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well as from directly measured experimental components. Although it was not possible
to find information regarding the energy requirements of the bacteria, a methodology was
applied to get an estimation [189].

The analysis of metabolism under different iron conditions proved the predictive
capability of the model. Many of the reactions and behavior observed during the analysis
have been reported before for B. anthracis and other bacteria under similar study
conditions, such as the down-regulation of some of the reactions during the TCA cycle in
Phase II under iron-poor conditions [168,169,208], as well as a reduction in the uptake of
amino acids in the iron-poor conditions during Phase II [6].

The model included a fully functional pathway for petrobactin and bacillibactin,
two well-known siderophores of B. anthracis. Further, protocatechuate, one of the
precursors of petrobactin, was included as a siderophore based on the reported
information regarding its presence in the culture of B. anthracis [149,167,213].
Protocatechuate was the preferred siderophore for the uptake of iron under iron-rich/poor
conditions. As a result, more experimental studies are required to confirm the potential of
protocatechuate as a siderophore in B. anthracis.

The major pathways of B. anthracis exhibited similar behavior under ironpoor/rich conditions during Phase I.

Thus, the levels of iron during the iron-poor

conditions were enough to support almost normal growth of the bacteria. Some
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differences were observed in the preferred uptake of amino acids, such as the upregulation of the uptake of aspartic acid in iron-poor conditions. Most of the glucose
consumed was used for production of acetate, formate, ethanol, and lactate in both
conditions. Even when the glucose uptake rate was higher in iron-poor conditions, only a
slight difference in the profile of acetate and formate was observed. Ethanol and lactate
secretion were also similar. This was because the degradation of amino acids (glutamate
and serine) taken from the media in iron-rich conditions provided enough pyruvate to get
similar fermentation profiles.

The metabolism of B. anthracis under iron-poor conditions was more affected
during Phase II, as was observed by the changes in the main pathways. It was not a
surprise to see an increase in siderophore biosynthesis pathways with the reduction of
iron concentrations due to the siderophores’s ability to sequesterer iron.

The higher glucose uptake rates under iron-poor conditions as compared to ironrich conditions in Phase II were not correlated with an increase in byproduct secretion,
since similar profiles for byproducts were found. Instead, glucose was used for the
production of PRPP and amino acids, as was observed from the divergence of the
glycolysis pathway from D-fructose-6-phosphate into the pentose phosphate pathway,
and from the divergence at 3-phospo-D-glycerate into the serine biosynthesis.
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The depletion of iron at Phase II disturbed the TCA cycle by reducing some of the
fluxes through it. As a consequence, the amino acid uptake from the media was reduced,
since the catabolism of amino acids enter into different intermediates of the TCA cycle.
For instance, glutamate and histidine are assimilated through 2-oxoglutarate. To replenish
the amino acids, the biosynthesis pathways of some of them were upregulated, which
resulted in a higher glucose uptake rate.

Genome-scale metabolic models are useful to formulate hypotheses that lead to
biological discoveries. This study revealed an apparent correlation between AI-2 and the
growth

of B. anthracis under iron-poor conditions. Previous works reported this

correlation only in Gram-negative bacteria. Thus, experimental studies are required to
elucidate the role of AI-2 during iron starvation in B. anhtracis. Furthermore, the model
helped to explain the lactate shift observed during the experimental studies. However,
proof of the hypothesized cycling behavior in the lactate metabolism of B. anthracis
based upon modeling results needs to be determined in the laboratory.
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7.

AUTOINDUCER-2 CORRELATION THE GROWTH OF BACILLUS
ANTHRACIS UNDER IRON-POOR CONDITIONS

7.1.

Background

Genome scale metabolic models are constructed by compiling genomic,
biochemical, and physiological information on the desired organism [227]. Different
tools are available for the reconstruction process; most of them follow a protocol well
described in Thieles et al. [3]. These models are useful for connecting the organism’s
genotype and phenotype [139,228].

Furthermore, they provide a fundamental

understanding of global bacterial metabolism under diverse experimental conditions
[139]. It has been shown that siderophore biosynthesis is up-regulated at the
transcriptional level when B. anthracis grows inside the macrophages as compared to
bacterial growing under iron-rich conditions [140]. As a result, the in silico analysis of
the global metabolism under conditions similar to the one encountered inside the
macrophage allows for the analysis and discovery of interactions not easily deduced
experimentally, such as the up-regulation of the AI-2 biosynthesis pathway.

AI-2 is part of the signaling molecules used in quorum sensing [229,230].
Quorum sensing is a cell-to-cell communication system that activates the control of
bacterial gene expression in response to cell density [231]. As the number of bacteria
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increases, the number of signaling molecules accumulated in the environment does as
well. When a certain threshold is reached, changes in gene expression occurr [232]. Some
of the processes controlled by AI-2 are the synthesis of pathogenicity factors in
Streptococcus pyogens, toxin production in Clostridium perfingens, biofilm formation by
Streptococcus gordonii, Porphyromonas gingivalis, and Bacillus cereus [233], and
bioluminescence in Vibrio harveyi [234]. AI-2 is synthesized when the enzyme encoded
by the luxS gene cleaves S-ribosylhomocysteine to produce homocysteine, and 4,5dihydroxy-2,3-pentanedione (DPD) [232,235]. Then, DPD spontaneously cyclizes to
form furanone. Finally, furanone is complexed with borate to form AI-2 [236]. Jones et
al. [237] reported an ortholog of luxS in B. anthracis, which allows for the synthesis of
AI-2. Furthermore, the mutation of luxS in B. anthracis resulted in slow growth compared
to the wild type [237].

Previous works reported a possible connection between AI-2 and iron acquisition
systems in gram-negative bacteria such as Actinobacillu actinomycetemcomitans
[223,224], Vibrio vulnificus [225], and Pophyromonas gingivalis [232]. Furthermore, in
experiments with A. actinomycetemcomitans [224] and A. pleuropneumoniae [226]
growing under iron deplete conditions, it was observed that growth could be regulated by
LuxS through AI-2 production. It was additionally reported that ferric iron uptake and
ferric-hydroxamate transport by luxS were both up-regulated in Escherichia coli growing
in LB media supplemented with glucose [238].
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The goal of this study is the in silico analysis of the metabolic response to
different AI-2 conditions. It is an attempt to elucidate the role of AI-2 in the metabolism
of B. anthracis under different iron-poor conditions.
7.2 Materials and Methods
7.2.1

FLUX BALANCE ANALYSIS CONSTRAINTS

The constraints used for FBA in this chapter correspond to the iron-poor and ironrich conditions at Phase 2 in Chapter 6. They are shown in Table 13. The objective
function chosen for the optimization problem was the maximization of the biomass
reaction for B. anthracis.

Table 13. Experimentally measured fluxes for the growth of B. anthracis under ironreduced media (IRDM) and iron-replete media (IRM). Positive values are production
rates, negative values are uptake rates.
Rates (mmol/gDW*h)
Glucose uptake rate
Carbon dioxide production rate
Lactate production/secretion rate
Oxygen uptake rate
Glutamate uptake rate
Iron uptake rate
Protocatechuate secretion rate
Petrobactin secretion rate
Bacillibactin secretion rate

IRDM
-13.16
6.29
-0.97
-6.74
-0.27
-0.00075
0.0241
0.0163
0.0023

IRM
-8.54
4.96
-0.41
-4.65
-1.6
-0.0028
0.008
0.0055
0.00004
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7.2.2. FLUX VARIABILITY ANALYSIS (FVA)
FVA is a method that helps to investigate the metabolic network flexibility and
redundancy [188]. FVA determines the range of values where the fluxes can change
without affecting the value of the objective function [189]. As in Chapter 6, FVA analysis
was applied for each of the in silico simulations reported here.

7.3 Results and Discussion

One of the byproducts of the AI-2 biosynthesis pathway shown in Figure 37 is
adenine. S-adenosylhomocysteine nucleosidase (E.C. 3.2.2.9) converts S-adenosyl-lhomocysteine into adenine and S-ribosylhomocysteine. S-ribosylhomocysteine goes to
methionine recycle through the S-adenosyl-methionine (SAM) cycle [239]. Meanwhile,
adenine is also recycled through the adenine salvage pathway to go into adenosine
nucleotides de novo biosynthesis pathway. As a consequence, the role of the production
of AI-2 in adenosine de novo biosynthesis and growth rate were studied.
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Figure 37. Autoinducer-2 biosynthesis pathway connected to adenine salvage
pathway and adenosine de novo biosynthesis pathway. Intracellular fluxes are the
blue arrows, exchange flux is the yellow arrow, and the red-dot arrows are connection
reactions with other pathways. Metabolites are in black. The E.C. number for each
enzyme is provided in the box near each reaction.
7.3.1

LUXS MUTATION AFFECTS IN SILICO GROWTH

Fong et al. [224] and Li et al. [226]

show that the growth of A.

actinomycetemcomitans and A. pleuropneumoniae under iron restricted conditions was
reduced in strains with a mutation in the luxS gene. Nonetheless, the growth returned to
normal values when DPD was added to the media [226], or by complementation of the
strain with a functional plasmid-borne copy of luxS [224]. These results provided the
impetus for studying the effect of luxS gene on the growth rate of B. anthracis with an in
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silico mutation of luxS under iron restricted conditions. To simulate the luxS mutation,
the flux through the S-ribosylhomocysteinase reaction (E.C. 4.4.1.21) catalyzed by the
luxS product was constrained to zero. This mutation was lethal for B. anthracis, since an
in silico growth rate of zero was found. The discrepancy between the experimental results
of A. pleuropneumoniae and A. actinomycetemcomitans, and the in silico results could be
due to the fact that they are different bacteria. Furthermore, A. pleuropneumoniae and A.
actinomycetemcomitans were grown in nutritionally rich media. The in silico media for
B. anthracis was an iron-reduced media [137] composed of a defined media and
casamino acids.

7.3.2

AI-2

PRODUCTION INCREASES AMP AND ADP POOL

The AI-2 pathway is connected to energy metabolism through the production of
adenine from the S-adenosylhomocysteine nucleosidase (E.C. 3.2.2.9) reaction, as is
shown in Figure 38. Under iron-reduced conditions, the up-regulation of AI-2 resulted
in more adenine being utilized through the adenine phosphoribosyltransferase (E.C.
2.4.2.7). Then, AMP was converted to ADP through adenylate kinase (E.C. 2.7.4.3),
which was almost 3.5 times higher in iron-reduced than in iron-replete conditions. This
enzyme has also been reported to be up-regulated in iron-poor conditions in S. aureus
[168]. Finally, ADP could be used for ATP production through F0F1-ATPase (E.C.
3.6.3.14), or substrate level phosphorylation. The reactions that are part of these
pathways are shown in Table 14. The fluxes through the reaction under iron-poor
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conditions are higher than in iron-rich conditions, with a 2.2 times higher change through
the PEPDEPHOS-RXN.

Figure 38. Autoinducer-2 biosynthesis pathway connected to adenine salvage
pathway and adenosine de novo biosynthesis pathway under iron-reduced/replete
iron conditions. Intracellular fluxes are the blue arrows, exchange fluxes are the yellow
arrows, and the red-dot arrows are connection reactions with other pathways. Metabolites
are in black. The boxes near each reaction have in the first line the E.C. number for the
enzyme, the second line in blue is the flux under iron-reduced conditions, and the third
line in orange is the flux under iron-replete conditions.
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Table 14. Substrate level phosphorylation reactions and oxidative phosphorylation
reactions for B. anthracis grown under iron-poor/rich conditions. Iron-poor/ironreduced (IRDM) and iron-rich/iron-replete (IRM).

7.4.

Name

E.C.

IRDM

IRM

PEPDEPHOS-RXN
ACETATEKIN-RXN
ATPSYN-RXN
PHOSGLYPHOSRXN
SUCCCOASYNRXN

2.7.1.40
2.7.2.1
3.6.3.14

19.437
15.102
19.310

9.108
11.160
14.437

Fold change
(IRDM/IRM)
-2.187
-0.873
-0.839

2.7.2.3

19.830

16.387

-0.550

6.2.1.5

0

1.120

Impact

LuxS has two roles in metabolism. One is the synthesis of the precursor of AI-2.
The second is as part of the S-adenosyl-methionine (SAM) cycle. These double functions
have led to much debate about the real role of AI-2 – whether it is a quorum sensing
signal molecule, or a metabolic by-product [229,235,240]. In this chapter, the effect of
the synthesis of AI-2 on the metabolism of B. anthracis under different iron conditions
was analyzed through an in silico approach. As shown, the AI-2 production resulted in an
increase of the AMP and ADP pools under iron-reduced conditions through adenine
recycling, which resulted in an increase in the production of ATP through substrate level
phosphorylation reactions and oxidative phosphorylation reactions.
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The mutation of the luxS gene was lethal for the growth of B. anthracis under
iron-reduced conditions. However, this mutation has been reported to not be lethal for
other bacteria. As was pointed out, the discrepancies could result from differences in the
media used, as well as the species of bacteria. This mutation resulted in the disruption of
the SAM cycle, which is important to the production of the major methyl donor Sadenosyl-L-methionine, and for the recycling of methionine. This result highlights the
importance of the luxS gene’s product in the metabolism.

This work represents the first time that the relationship between AI-2 and the
growth and metabolism of B. anthracis under iron-reduced conditions has been studied.
The in silico analysis indicated a possible correlation between AI-2 and the growth of the
bacteria under iron deprivation conditions. Experimental studies are needed to confirm
these results, as well as to analyze the role of AI-2 as a signal molecule or as a metabolic
by-product.
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8 CONCLUSIONS

The work presented in this dissertation integrates genome-scale metabolic modeling
with experiments to study the microorganism’s metabolism and understand the impact of
varying iron levels on B. anthracis’ metabolism. This integration allowed for predictions
to determine metabolic interactions not easily observed experimentally, and for the
analysis of metabolic adaptations of bacteria to changes in the environment.

In this thesis, not only were genome-scale metabolic models created, but
additionally a novel methodology that facilitates the curation of genome-scale metabolic
networks was developed. Moreover, it was shown that GAFBA methodology aids in
fundamental studies of metabolism. Different tools were added to GAFBA v1.1 to speed
up, facilitate the curation process, and make it more user-friendly. I believe that in the
future, GAFBA v1.1 could evolve into a much faster methodology, which would result in
more models created through this approach.

The experimental growth of B. anthracis under different iron conditions
suggested a more active carbon metabolism during iron-poor conditions. Higher uptake
rates of glucose, oxygen, and lactate, as well as higher secretion rates for carbon dioxide
were all noted. This observation was difficult to reconcile at the beginning of these
studies given that under iron-poor conditions, lower growth rates were found. At this
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point, it was clear that either more experiments were required to measure additional
metabolites, or an in silico global metabolism analysis was needed. Given financial,
time, and expertise constraints, the second option was chosen.

The comparison of the global metabolism of B. anthracis under iron-poor/rich
conditions revealed the purpose of the higher carbon metabolism under iron poor
conditions. It was shown that reduced iron concentration had a negative impact on some
reactions of the TCA cycle, which resulted in the reduced catabolism of amino acids.
Thus, some amino acid biosynthesis pathways were up-regulated to supply the required
amino acids for growth and for siderophore biosynthesis. Additionally, under ironreduced conditions it is possible that other energy consuming processes in addition to
growth are likely occurring, such as maintenance, production of signaling molecules, and
biosynthesis of regulatory proteins or small RNAs.
Finally, a correlation between AI-2 and the growth of B. anthracis under ironpoor conditions was discovered for the first time. However, it is required to investigate
the real role of AI-2 as a signal molecule or as a metabolic byproduct.
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9

FUTURE WORK

Many hypotheses and a number of pursuable experimental avenues have arisen
from the work presented in this dissertation. This chapter highlights the most important
of them.

In Chapter 3, from the reconstruction and analysis of the metabolism of M.
gallisepticum, it was hypothesized that formate dehydrogenase (E.C. 1.2.1.2), NAD+
synthethase (E.C. 6.3.5.1), and Na-ATPase (E.C. 3.6.3.7) would be present in the
bacteria. This still needs to be experimentally verified. Furthermore, the role of the
methylerythitol phosphate pathway (MEP) in M. gallispecticum’s metabolism requires
further study, and its potential as a drug target should be considered.

GAFBA v1.1 could be further improved. The parallelization of the algorithm
should be considered a priority. Even with the run time efficiencies recently
implemented, the parallelism of the code has the potential to take advantage of massively
multi-core systems, and especially GPU based computing systems housed in the UConn
School of Engineering and the BECAT HPC cluster. This could be achieved using
Symmetric Multiprocessing LispWorks (SMP LispWorks). Another tool that would
enhance the user experience, is a text-mining tool based on K-means clustering to search
abstracts in Pubmed (http://pubmed.nih.org) and correlate metabolites and reactions that
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GAFBA v1.1 lists as problemmatic. It will provide more information for users to solve
the problems present in the metabolic network being analyzed. It could use the name of
the bacteria and the problematic metabolite as keywords to identify any relevant
compounds that are not currently linked to the metabolite in question. Thus, the user will
look for possible solutions in this set of generated documents. Work has already begun
on this text-mining tool; it needs to be optimized and connect its graphic user interface
(GUI) with GAFBA v1.1 GUI.

During the experiments presented in Chapter 5 for the growth of B. anthracis
under iron-reduced/replete conditions, a significant challenge that arose was how to
reduce the iron concentration to levels of starvation in the fermentor. It was observed
that the iron concentration of the media increased when transferred to the fermentor from
a value of 0.77 µM to 2.24 µM. It is possible that the stainless material retains some
traces of iron even after the cleaning process. There are two potential alternatives to
overcome this situation. One is to employ a Teflon vessel such as the one used in the
study of trace metal metabolism in Streptococcus mutans [241]. The second possibility is
to use single-use bioreactors (Applikon Biotechnolog, New Brunswick).

On the modeling front, the B. anthracis model could be integrated with the
existing human alveolar macrophage (HM) model iAB-AMØ-1410 created by Bordbar et
al [9]. The reconstruction process would allow GAFBA v1.1 to be evaluated in
multispecies cases. Moreover, this host/pathogen model may be used to identify new
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drug targets, characterize the mechanism of the action of drugs, optimize treatment
strategies, and enhance the early diagnosis and prompt treatment of the disease, since the
progression of anthrax is typically quite rapid once the systemic phase of infection
begins.

During the analysis of the metabolism of B. anthracis under different iron
conditions, the possibility of a connection between autoinducer-2 (AI-2) and the growth
of the bacteria under iron-reduced conditions arose. It is necessary to experimentally
measure the production of AI-2 in B. anthracis under iron-reduced/replete conditions.
The AI-2 concentrations could be monitored using the Vibrio harveyi MM32 reporter
strain [242,243]. This strain is an ideal reporter, since it cannot synthesize AI-2, and it
does not respond to N-Acyl homoserine lactone (AHL) signal molecules. Moreover, the
impact of AI-2 production in the growth of the bacteria under rich/poor conditions may
be evaluated by doing a mutation on the luxS gene in B. anthracis and growing the
mutant with/without the addition of exogenous AI-2 or the AI-2 precursor DPP.

The B. anthracis

model may be improved by adding more experimentally

measured fluxes, such as the byproduct secretion rates of acetate, formic acid, ethanol,
and amino acid uptake rate. The uptake/secretion rates could be measured using high
performance liquid chromatography, and/or gas chromatography. Moreover, carbon-13
measurements would also help to further verify the model [244,245].
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APPENDIX 1. EXAMPLES OF METHODOLOGIES FOR RESOLVING
INFEASIBLE MODELS.

Generally, four types of solution for the unbalanced metabolites can resolve
curation issues.

Case 1: The change of the directionality of a reaction may solve the problem.
Figure S1 has an example of this case. The ribulose-5 phosphate did not have a reaction
to be produced and the mass balance of ribose- 5 phosphate was dropped, because any of
the possible reactions to consume it were inactivated. If the reaction v278 catalyzed by
the enzyme ribose-5-phosphate isomerase (E.C. 5.3.1.6) was changed to reversible, it
could consume the ribose-5-phosphate.
From the Kyoto Encyclopedia of Genes and Genomes (KEGG) [96], this reaction
does indeed appear to be reversible, along with reaction v274 catalyzed by the enzyme
ribulose-phosphate 3-epimerase (E.C. 5.1.3.1).
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Figure S1. Case 1. Change directionality of reactions. The purple circle showed the
dropped metabolite. The blue arrows are the fluxes and the orange arrows are the
proposed solutions. The solid blue line is the plasma membrane and the dashed blue line
is the system boundary.

Case 2. The addition of an exchange flux may resolve the issue. In the case
highlighted in Figure S2, glycine was produced by two reactions involved in folate
transformations:

V140

(GLYOHMETRANS-RXN

E.C.

2.1.2.1)

and

V_95R

(GCVMULTI-RXN in Pathway tools nomenclature). However, these reactions were
unable to produce all the glycine required for the tRNA charging reaction, thus the
additional glycine had to be taken from the media. The literature reported the presence of
glycine in the media of the Mycoplasma laidlawii and the Mycoplasma genitalium,
related species to the M. gallispeticum (Suthers, et al., 2009; Tourtellotte, et al., 1964).
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Figure S2. Case 2. Add exchange flux. The purple circle showed the dropped
metabolite. The blue arrows are the intracellular fluxes and the orange arrow is the
proposed solutions. The solid blue line is the plasma membrane and the dashed blue line
is the system boundary. The red circle represents the Biomass pool.

Case 3: Figure S3 shows an example for the case when the addition of a reaction
could help to complete the mass balance of the metabolite. Here, the formate was
produced via reaction V256. The peptide deformylase enzyme (E.C. 3.5.1.88) catalyzed
this reaction and the biomass reaction. However, no reaction consuming formate was
present. Therefore, a simple degradation pathway present in other Mycoplasmas [89] was
added to the model.
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Figure S3. Case 3. Add reaction. (formate case). The purple circle showed the dropped
metabolite. The blue arrows are the fluxes, the blue thick arrows are the exchange
fluxes, and the orange arrow is the proposed solutions. The solid blue line is the plasma
membrane and the dashed blue line is the system boundary. The red circle represents the
Biomass pool.

Case 4: Finally, removing a reaction or metabolite from model may resolve the
issue. On some occasions, the deletion of a general reaction or general metabolite from
the model was required to fulfill the mass balance.

These general reactions and

metabolites were present in the model based on some of the software tools used to
generate the initial model from the genome annotation. Usually, a general reaction is first
created, and as the experimental data and information are available to confirm the
presence of the specific reactions, the general reaction is expanded to the specific ones.
Occasionally this may require the manual intervention of the curator.
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APPENDIX 2. EXPERIMENTAL PROTOCOLS FOR M. GALLISEPTICUM
MODEL

A2.1. Strains, Culture Conditions

A previously sequenced clonal isolate of M. gallisepticum Rlow, Rlow Clone 2
(RLC2) [31] was used. The bacteria were grown in complete Hayflick’s medium [246]
with an initial concentration 3.5 g/L glucose .
A2.2. Determining Dry Cell Weight and CFU/ml

The CFU/ml concentrations for all experiments were calculated using a
previously determined correlation [247] between CFUs/ml and the absorbance of cell
culture at 620 nm. A correlation between dry cell weight and absorbance was generated
by directly measuring the weight of dried cell pellet, volume of the supernatant, and
OD620 of the culture. To accomplish this, 500 ml of RLC2 was grown in Hayflick’s
media [246] at 37°C to mid-log phase. The absorbance of the culture was measured at
620 nm. The culture was then quickly chilled to 4°C. 30 ml of the culture was placed in a
50 ml Falcon Tube and centrifuged at 15,000 x g at 4°C for 15 mins. The supernatant was
transferred to a graduated cylinder for measurement without disturbing the pellet, and
another 30 ml of culture was added to the same tube and centrifuged at the conditions
mentioned above. This was repeated until all 500 ml of culture had been centrifuged into
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one large pellet. The pellet in the 50 ml centrifuge tube was dried for two weeks at 37°C.
The tube was then capped stored at 23°C for two months. The dried flaking pellet was
then scraped off and measured using a scale accurate to the nearest mg. This protocol was
repeated for four different cell concentrations in mid-log phase growth and one control
using only medium.
A2.3. Metabolism Experimental Design

100 ml aliquots of Hayflick’s media with 3.5 g/L of glucose in 250 ml plastic flatbottom centrifuge tubes were inoculated with mid-log cultures of RLC2 and incubated at
37oC.

Sampling of these vessels was initiated approximately 15-19 hours post-

inoculation, when the dry cell density in each vessel reached 46.89 mg/L (7.27e7
CFU/ml) and ended once the dry cell density exceeded 125 mg/L. Samples of culture
were taken at nearly one-hour intervals over the aforementioned period during late loggrowth. This allowed for four to five individual sample points to be taken during this late
log-phase growth for each run. From these samples, cell dry weight concentration,
glucose concentration, and lactate concentration were determined by the assays described
below. Seven runs were completed for RLC2. Three sets of runs were performed on
separate days. Each set included approximately three RLC2 runs.
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A2.4.

Sampling and Cell Growth Assay

106 CFUs of RLC2 (growing in late log-phase) was added to 100 ml of media in a
250 ml plastic flat bottom centrifuge tube. This tube was incubated at 37°C while being
shaken at 140 rpm for 15-19 hrs. 1 ml samples from each flat bottom centrifuge tube
were then placed into 1.5 ml microfuge tubes. A 700 µL volume of each sample was
immediately centrifuged at 20,000 x g for 15 minutes at 4°C in an Eppendorf 5417
microfuge using a fixed-angle aerosol-tight rotor (FA-45-30-11) for 1.5-2.0 ml tubes.

The supernatant was transferred into new 1.5 ml microfuge tubes and placed in a 80°C freezer for storage until further analysis. The OD620 of the remaining 300 µL of
each sample was measured while the other 700 µL was being centrifuged. This OD620
reading was used to determine the biomass concentration using the experimentally
determined correlation between cell dry weight and OD620. This sampling process was
repeated until the dry cell density in each vessel reached 125 mg/L. At this point,
sampling ended and the remaining culture was allowed to grow overnight and was
checked 24 hours later for visible signs of contamination. No contamination occurred.
A2.5. Glucose and Lactate Assays

After two to five days of storage at -80˚C, the 700 µL supernatant samples were
thawed and prepared for analysis using a YSI 2700 SELECT single-channel
Biochemistry Analyzer. Supernatant samples were filtered with 13mm GHP 0.2 micron
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syringe filters (WAT097962) to remove any remaining cellular debris. The supernatant
samples were then placed in a -80°C freezer for another 1-7 days.

To assay for lactate, the standard YSI 2700 SELECT protocol for measuring Llactate concentration using a L-lactate membrane (part # 2329) was followed. Standard
buffer (part # 2357) and L-lactate calibration standard (part # 2776) were used. 25 µL of
sample was taken and analyzed for a 30 second period before being flushed. Two
readings were performed for each supernatant sample. Six supernatant samples at a time
were thawed, assayed, and then refrozen to -80°C.

To assay for glucose, the standard YSI 2700 SELECT protocol for measuring
glucose concentration using a glucose membrane (part # 2365) was followed. Standard
buffer (part # 2357) and glucose calibration standard (part # 2776) were used. 25 µL of
sample was taken and analyzed for a 30 second period before flush. For each supernatant
sample, three replicates were performed and averaged. Six supernatant samples at a time
were thawed, assayed, and then refrozen to -80°C.
A2.6. Dry Weight Measurement

The correlation between optical density and dry cell weight per ml is shown in
Table S1. Consistent readings were achieved for four points within the range of optical
densities covered by the metabolism experiment.
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Table S1. OD/(g/cfu) Correlation. Calculations of the g/cfu conversion.
Run

OD620

Control
1
2
3
4

0
0.089
0.084
0.098
0.094

Pellet
Weight
(g)
0
0.051
0.05
0.053
0.052

Supernatant
Concentration
Volume
(g/ml)
(ml)
432
0.000E+00
478
1.067E-04
480
1.042E-04
480
1.146E-04
482
1.120E-04

cfu/ml

g/cfu

N/A
1.66E+08
1.56E+08
1.83E+08
1.75E+08
average:
std:

N/A
6.44E-13
6.68E-13
6.26E-13
6.39E-13
6.45E-13
1.75E-14

A.2.7. Determination of biomass equation

The biomass equation was determined by incorporating all available published
information about the makeup of M. gallisepticum and other similar mycoplasmas. The
starting equation was taken from a metabolic reconstruction of M. genitalium, one of M.
gallisepticum’s closest relatives [58]. Metabolites added in by the GrowMatch portion of
that reconstruction were discarded due to lack of supporting evidence. Other cofactors
not conducive with Mycoplasma metabolism that did not possess any cited synthesis or
absorption pathways, such as Menaquinol 7, were modified or removed. The relative
ratios of the various components of DNA, RNA, and amino acids reported in the M.
genitalium reconstruction were kept due to the similar GC content and large number of
shared proteins between the two organisms [248]. However, the ratios between the major
biochemical components, consisting of DNA, RNA, amino acids, cofactors, ions, and
lipids, were adjusted to reflecting a previously reported chemical composition analysis of
M. gallisepticum [249].
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The composition of the lipid fraction was calculated from published data on the
lipid fractions of M. gallisepticum and other related Mycoplasmas. First, the ratios of the
classes phospholipid, sterol, and triglyceride were determined relative to each other from
previously published work [91,249]. Though recent studies suggest that M. gallisepticum
may possess a capsule, it has not been directly shown that its capsule or M. gallisepticum
itself contains glycolipids [250]. Because of this uncertainty, and due to the small
amounts of carbohydrates found in M. gallisepticum’s chemical composition relative to
other related glycolipid possessing species, glycolipids were not included in the biomass
composition [249].

The ratios of the subclasses of sterol and phospholipid groups relative to each
other were then analyzed. First, sterols was analyzed. The amount of cholesterol and
cholesterol ester was calculated using published ratios of cholesterol to cholesterol ester
[83,91].

Next, phospholipids were analyzed. The amount of sphingomyelin present in M.
gallisepticum’s membrane was estimated from previously reported values [83,91]. The
percent of the phospholipid fraction made up of phosphatidylcholine was estimated by
using a reported ratio between phosphatidylcholine and sphingomylin in M.
gallisepticum’s membrane along with the reported sphingomyelin membrane fraction
[83,91]. The phosphatidic acid (1,2-diacylglycerol-3-phosphate) percent was estimated
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using a lipid percent reported by Tourtellotte et al. The amount of phosphatidic acid was
decreased by 25% before incorporation into the biomass equation due to an author
statement suggesting the value was higher than it should have been [91]. No conclusive
assays of the existence or membrane percent of phosphatidylethanolamine have been
published. Phosphatidyl-ethanolamine was shown to be absent by a complement fixing
antigen assay of the membrane of Mycoplasma pneumoniae [251]. Because of the
similarity between these two organisms, it was assumed that M. gallisepticum lacked this
phospholipid as well. Tourtellotte et al. reported that phosphatidylglycerol likely made up
less than 10% of the phospholipids. Since no definitive quantitative assay of
phosphatidyl-glycerol have been performed on M. gallisepticum or any of its close
relatives, the phospholipid percent of phosphatidyl-glycerol was estimated from a
published value in A. ladwaii [252]. Cardiolipin’s composition or existence in M.
gallisepticum has yet to be studied. However, cardiolipin has been shown to be present in
Mycoplasma pneumoniae’s membrane [253]. In a recent study, M. pneumoniae was
shown to have the metabolic reactions necessary to biosynthesize cardiolipin from fatty
acids and glycerol [89]. Cardiolipin is speculated to be the dominant phospholipid in
other more distantly related Mycoplasma such as M. mycoides and M. hyopneumonaie
[254]. Therefore, the remaining phospholipid fraction was assumed to be comprised
primarily of cardiolipin. Table S2 summarizes the calculated composition of the lipid
fraction used in the biomass equation.
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Table S2. Lipid Fraction Estimation. Percent composition of the lipid fraction of M.
gallisepticum, the estimated molecular weights, and the relevant references used to
generate these percentages.

Lipid Type

%of
Total
Lipid
Mass

phospholipi
d

70.3

Lipid Name

Mass %
of Lipid
Type

g/gDW

1524.7

49.5

0.0546

[83,89,253,254
]

651.3

7.5

0.0083

[91]

819.5

23.8

0.0283

[83,91]

771.8

9.2

0.0102

[91]

776.4

0

0.0000

[91,251]

807.4

10

0.0110

[91,252]

cholesterol
cholesterol ester

386.7
643.7

90.6
9.3

0.0312
0.0032

triacylglyceride

794.1

100

0.0121

1,2diacylglycerol-3phosphate
phosphatidylcholine
sphingo-myelin
phosphatidylethanolamine
phosphatidylglycerol
21.9

triglycerides

7.7

glycolipids

0

Citations
[91]

cardiolipin

Sterols

MW

[91,249]
[83,255]
[255]
[91]
[83,91]
[250]

The average molecular weight of M. gallisepticum’s phospholipids, sterols, and
triglycerides R groups were by weighted averaging the molecular weights of the
constituent fatty acids (Table S3). The fatty acid compositions of each of the three lipid
types were taken from a previously reported study [91]. Using these R group molecular
weight estimations, the full lipid molecular weights were calculated using the chemical
structures of the major lipid components (Table S4). Using these molecular weights, the
mmol/gDW values for each of the major lipid components were calculated from the mass
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percents shown in supplementary Table S2. The final biomass reaction is presented in the
appendix A3.5
Table S3. Average Fatty Acid Molecular Weight. The calculation of the average fatty
acid molecular weight from the fatty acid composition of Mycoplasma gallisepticum as
reported by Tourtelloute et al. [91]

Caproic
Caprylic
Capric
Unidentified
Lauric
Myristic
Myrisroleic
Pentadecanoic
Palmitic
Palmitoleic
Heptadecanoic
Stearic
Oleic
Linoleic

MW
(g/mol)
116.16
144.22
172.27
172.27
200.32
228.36
240.4
242.4
256.43
256.43
270.45
284.48
282.47
278.43

Average Fatty
Acid MW

Phospholipids
%
0
0
0
0
0.7
3.3
2.2
0
24.8
2.9
2.4
36
20.4
7.3

cholesterol
esters %
0
0
0
0
0
1.2
0.3
0.3
23.4
6.3
1.2
13.1
54.2
0

triglycerides
%
0.6
0.9
6.1
0.6
6.3
14.3
1.4
1.1
32.2
1.1
0.5
10.1
21.9
3.9

272.1

274
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Table S4. Estimation of molecular weights for major lipid components making up
biomass. Using the chemical structure, the molecular weights of each molecule, and the
estimated molecular weights of the R group, whose calculations are shown in Table S3,
the molecular weight of each major lipid component was estimated.
Component

MW

O
C
H
P
N
R groups

16
12.01
1.01
82
14
228.1

a 1,2diacylglycerol3-phosphate
8
5
7
1
0
2

a phosphotidylcholine

cardiolipin

8
10
19
1
1
2

17
13
20
2
0
4
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Component

MW

Estimated
Total MW

a 1,2diacylglycerol3-phosphate

a phosphotidylcholine

cardiolipin

733.32

819.49

1524.73

Component

MW

a
sphingomyelin

O
C
H
P
N
R groups
Estimated
Total MW

16
12.01
1.01
82
14
228.1

6
24
49
1
2
1

an L-1Phosphatidylethanolamine
8
7
12
1
1
2

771.83

776.39

807.41

Component

MW

cholesterol

a cholesterol ester

MW

O
C
H
P
N
R groups
Estimated
Total MW

16
12.01
1.01
82
14
230

1
27
46
0
0
0

2
28
45
0
0
1

169
12.01
1.01
82
14
207

386.73

643.73

an L-1phosphatidylglycerol
10
8
13
1
0
2
a
triacylglycerol
6
6
5
0
0
3
794.11
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APPENDIX 3. GENOME-SCALE METABOLIC MODEL OF M.
GALLISEPTICUM
A3.1. Metabolites located in the cytosol space
Table S5. Metabolites in the cytosol space for M. gallisepticum model. The name, id,
and formula for each species are provided.
Species id
10-FORMYL-THF[c]
2-3-4-Saturated-LPhosphatidates[c]
2-C-METHYL-DERYTHRITOL-4PHOSPHATE[c]
2-KETOGLUTARATE[c]
2-PG[c]
2-PHOSPHO-4-CYTIDINE-5DIPHOSPHO-2-C-MET[c]
2C-METH-D-ERYTHRITOLCYCLODIPHOSPHATE[c]

Species name
10-formyl-tetrahydrofolate

Formula
C20H23N7O7

a 2,3,4-saturated L-phosphatidate

C11H17O8RR2P

2-C-methyl-D-erythritol-4-phosphate

C5H11O7P

2-oxoglutarate
2-phospho-D-glycerate
2-phospho-4-{cytidine 5'-diphospho}-2C-methyl-D-erythritol
2-C-methyl-D-erythritol-2,4cyclodiphosphate

C5H4O5
C3H4O7P
C14H22N3O17P
3

3-5-ADP[c]

adenosine 3',5'-bisphosphate

C5H10O9P2

acetoacetate

C10H11N5O10P
2
C27H39N7O20P
3S
C4H5O3

a nucleoside 3'-phosphate

C5H10O7RP

3-HYDROXY-3-METHYLGLUTARYL-COA[c]
3-KETOBUTYRATE[c]
3-Prime-RibonucleosideMonophosphates[c]
3-terminal-unsaturated-sugars[c]
4-AMINOBUTYRALDEHYDE[c]
4-AMINO-BUTYRATE[c]
4-CYTIDINE-5-DIPHOSPHO2-C[c]
5-10-METHENYL-THF[c]
5-FORMYL-THF[c]
5-Phosphopolynucleotides[c]
Acceptor[c]
ACET[c]

4-aminobutanal

C4H10NO

4-aminobutyrate
4-{cytidine 5'-diphospho}-2-C-methyl-Derythritol
5,10-methenyltetrahydrofolate
5-formyl-tetrahydrofolate
a 5'-phosphopolynucleotide
an oxidized electron acceptor
acetate

C4H9NO2
C14H23N3O14P
2
C20H22N7O6
C20H21N7O7

ACETOACETYL-COA[c]

acetoacetyl-CoA

ACETYL-COA[c]

acetyl-CoA

{S}-3-hydroxy-3-methylglutaryl-CoA

a 3'-terminal unsaturated sugar

C2H3O2
C25H36N7O18P
3S
C23H34N7O17P
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Species id

Species name

ACETYL-P[c]

acetylphosphate

ACP[c]

a holo-[acp]

ACYL-ACP[c]

an acyl-[acp] Coavholo-[acp]R

ACYL-COA[c]

an acyl-CoA

Acyl-Phosphates[c]
ACYL-SN-GLYCEROL-3P[c]
ADENINE[c]
ADENOSINE[c]
ADENOSYL-HOMO-CYS[c]
ADENYLOSUCC[c]

an acyl phosphate
a 1-acyl-sn-glycerol-3-phosphate
adenine
adenosine
S-adenosyl-L-homocysteine
adenylo-succinate

ADP[c]

ADP

ALA-tRNAs[c]
ALPHA-GLC-6-P[c]
Amino-Acids-20[c]
AMMONIA[c]
AMMONIUM[c]
AMP[c]
ANTHRANILATE[c]

apo-ACP[c]
ARG-tRNAs[c]
ARG[c]
ARSENATE[c]
ASN-tRNAs[c]
ASN[c]
ASP-tRNAs[c]

tRNAala
alpha-D-glucose 6-phosphate
a standard alpha amino acid
ammonia
NH4+
AMP
anthranilate
an AP{apurinic or apyrimidinic} site
created by glycosylic bond cleavage
an apo-[acp]
tRNAarg
L-arginine
arsenate
tRNAasn
L-asparagine
tRNAasp

ATP[c]

ATP

BCAA-dehydrogenase-DHlipoyl[c]

BIOMASS[c]
BUTYRIC_ACID[c]

lipoamide acyltransferase N6{dihydrolipoyl}lysine
lipoamide acyltransferase N6{lipoyl}lysine
biomass
butyrate

BUTYRYL-COA[c]

butyryl-CoA

CA-2[c]

Ca2+

AP-Site-Created[c]

BCAA-dehydrogenase-lipoyl[c]

Formula
3S
C2H3O5P
C14H25N3O8a
holo-[acp]2PS
C22H35N7O17R
P3S
CH2O5RP
C4H8O7RP
C5H5N5
C10H13N5O4
C14H20N6O5S
C14H14N5O11P
C10H12N5O10P
2
C6H11O9P
C2H4NO2R
NH3
NH4
C10H12N5O7P
C7H6NO2

C6H15N4O2
HO4As
C4H8N2O3
C10H13N5O13P
3

C4H7O2
C25H38N7O17P
3S
Ca2+
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Species id
CARBON-DIOXIDE[c]

Species name
CO2

CARDIOLIPIN[c]

cardiolipin

Cations[c]
CDP-2-3-4-SaturatedDiacylglycerols[c]

a cation
a CDP-2,3,4-saturated-diacylglycerol

CDP-CHOLINE[c]

CDP-choline

CDP[c]

CDP

CDPDIACYLGLYCEROL[c]

a CDP-diacylglycerol

Ceramides[c]
Charged-ALA-tRNAs[c]
Charged-ARG-tRNAs[c]
Charged-ASN-tRNAs[c]
Charged-ASP-tRNAs[c]
Charged-CYS-tRNAs[c]
Charged-GLN-tRNAs[c]

a ceramide
L-alanyl-tRNAala
L-arginyl-tRNAarg
L-asparaginyl-tRNAasn
L-aspartyl-tRNAasp
L-cysteinyl-tRNAcys
L-glutaminyl-tRNAgln

Charged-GLT-tRNAs[c]

L-glutamyl-tRNAGlu

Charged-GLY-tRNAs[c]
Charged-HIS-tRNAs[c]
Charged-ILE-tRNAs[c]
Charged-LEU-tRNAs[c]
Charged-LYS-tRNAs[c]
Charged-MET-tRNAs[c]
Charged-PHE-tRNAs[c]
Charged-PRO-tRNAs[c]
Charged-SER-tRNAs[c]
Charged-THR-tRNAs[c]
Charged-TRP-tRNAs[c]
Charged-TYR-tRNAs[c]
Charged-VAL-tRNAs[c]
Cholesterol-esters[c]
CHOLESTEROL[c]
CHOLINE[c]
CL[c]
CMP[c]
CO-2[c]

glycyl-tRNAgly
L-histidyl-tRNAhis
L-isoleucyl-tRNAile
L-leucyl-tRNAleu
L-lysyl-tRNAlys
L-methionyl-tRNAmet
L-phenylalanyl-tRNAphe
L-prolyl-tRNApro
L-seryl-tRNAser
L-threonyl-tRNAthr
L-tryptophanyl-tRNAtrp
L-tyrosyl-tRNAtyr
L-valyl-tRNAval
a cholesterol ester
cholesterol
choline
chloride
CMP
Co2+

CO-A[c]

coenzyme A

Formula
CO2
C13H20O17R4P
2
C20H29N3O15R
2RP2
C14H27N4O11P
2
C9H12N3O11P2
C14H19N3O15R
1R2P2
C19H36NO3R

C5H8NO3tRNA
Glu

C28H45O2R
C27H46O
C5H14NO
Cl
C9H12N3O8P
Co2+
C21H32N7O16P
3S
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Species id
CPD-10226[c]
CPD-10227[c]

Species name
3-amino-3-deoxy-D-fructose 6-phosphate
1-deoxy-1-imino-D-erythrose 4phosphate

CPD-10363[c]

a beta,beta digalactosyldiacylglycerol

CPD-1181[c]
CPD-1241[c]
CPD-3[c]
CPD-4211[c]
CPD-448[c]

salicin-6-phosphate
D-galactose 6-phosphate
molybdate
dimethylallyl diphosphate
beta-D-glucose 1-phosphate
5,10-methenyl-tetrahydropteroyl[gamma-Glu]{n}
1-pyrroline
hydrogen selenide
AP site removed form DNA
AP site on created by glycosylase in
repair process

CPD-5727[c]
CPD-6124[c]
CPD-678[c]
CPD-8532[c]
CPD-8533[c]

Formula
C6H13NO8P
C4H9NO6P
C17H26O15R1R
2
C13H19O10P
C6H11O9P
O4Mo
C5H9O7P2
C6H11O9P
C8H10N6OR
C4H8N
Se

CPD-8537[c]

tRNA pseudouridine

CPD-8538[c]

tRNA uridine

CPD-8989[c]
CPD0-1147[c]
CPD0-1148[c]
CTP[c]
CU-2[c]
Cyclic-2-3-RibonucleosideMonophosphates[c]
CYS-tRNAs[c]
CYS[c]
CYTIDINE[c]
CYTOSINE[c]
D-Galactosyl-12-diacylglycerols[c]
D-SEDOHEPTULOSE-7-P[c]
DADP[c]
Damaged-DNA-Pyrimidine[c]
DAMP[c]

L-methionine-{S}-S-oxide
methyl red
N,N'-dimethyl-p-phenylenediamine
CTP
Cu2+

C37H49N13O32
R2P5
C37H49N13O32
R1P5
C5H11NO3S
C15H14N3O2
C8H12N2
C9H12N3O14P3
Cu2+

a nucleoside 2',3'-cyclic phosphate

C5H8O6RP

DATP[c]

dATP

DCDP[c]
DCMP[c]

dCDP
dCMP

tRNAcys
L-cysteine
cytidine
cytosine
a monogalactosyldiacylgycerol
D-sedoheptulose-7-phosphate
2'-deoxyadenosine-5'-diphosphate
a damaged DNA pyrimidine
dAMP

C3H7NO2S
C9H13N3O5
C4H5N3O
C11H16O10R1R
2
C7H13O10P
C10H12N5O9P2
C10H12N5O6P
C10H13N5O12P
3
C9H12N3O10P2
C9H12N3O7P
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Species id
DCTP[c]

Species name
dCTP

DEAMIDO-NAD[c]

nicotinate adenine dinucleotide

DEOXY-D-RIBOSE-1PHOSPHATE[c]
Deoxy-RibonucleosideDiphosphates[c]
Deoxy-RibonucleosideMonophosphates[c]
Deoxy-RibonucleosideTriphosphates[c]
Deoxy-Ribonucleosides[c]
DEOXY-RIBOSE-1P[c]
DEOXYADENOSINE[c]
DEOXYCYTIDINE[c]
DEOXYGUANOSINE[c]
DEOXYINOSINE[c]
Deoxynucleotides[c]

Formula
C9H12N3O13P3
C21H24N6O15P
2

deoxy-D-ribose 1-phosphate

C5H9O7P

a 2'-deoxyribonucleoside diphosphate

C5H11O9R1P2

a 2'-deoxyribonucleoside monophosphate

C5H10O6RP

a 2'-deoxyribonucleoside triphosphate

C5H12O12R1P3

a deoxynucleoside
deoxyribose-1-phosphate
2'-deoxyadenosine
deoxycytidine
deoxyguanosine
deoxyinosine
a deoxynucleotide

C5H9O3R
C5H9O7P
C10H13N5O3
C9H13N3O4
C10H13N5O4
C10H12N4O4
C15H25O13RR1
R2P2
C9H12N2O5
C5H9O7P
C21H33N7O13P
2S
C10H12N5O10P
2
C10H12N5O7P
C10H12N5O13P
3
C5H6O5R1R2

DEOXYNUCLEOTIDESM[c]

{deoxynucleotides}{m}

DEOXYURIDINE[c]
DEOXYXYLULOSE-5P[c]

deoxyuridine
1-deoxy-D-xylulose 5-phosphate

DEPHOSPHO-COA[c]

dephospho-CoA

DGDP[c]

2'-deoxyguanosine-5'-diphosphate

DGMP[c]

dGMP

DGTP[c]

dGTP

DIACYLGLYCEROL[c]
Dihydro-Lipoyl-Proteins[c]
DIHYDROFOLATE[c]
DIHYDROLIPOAMIDE[c]

a 1,2-diacylglycerol
protein N6-{dihydrolipoyl}lysine
7,8-dihydrofolate
dihydrolipoamide

DIHYDROLIPOYL-GCVH[c]

H-Gcv-protein-{dihydrolipoyl}lysine

DIHYDROXY-ACETONEPHOSPHATE[c]

dihydroxyacetone phosphate

C3H5O6P

DIPEPTIDES[c]

a dipeptide

C4H6N2O3R1R
2

DNA-containing-aApyrimidinic-Sites[c]
DNA-containing-abasic-Sites[c]
DNA-N[c]

C19H21N7O6
C8H17NOS2
C8H15OS2ApoGcvH

a DNA containing a apyrimidinic site
a DNA containing abasic site
DNAn
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Species id
DNA-with-Uracils[c]
Donor-H2[c]
DPG[c]
DUDP[c]
DUMP[c]
DUTP[c]
ENZYME-SSULFANYLCYSTEINE[c]
ERYTHROSE-4P[c]

Species name
a DNA with uracil
a reduced electron acceptor
1,3-diphosphateglycerate
dUDP
dUMP
dUTP

Formula

FAD[c]

FAD

Fatty-Acids[c]

a fatty acid

Fatty-Acyl-CoA[c]

a fatty acyl CoA

FE-2[c]
FE-3[c]
FMN[c]
FORMATE[c]
FORMYL-L-METHIONYLPEPTIDE[c]
FORMYL-THF-GLU-N[c]
FRU[c]
FRU1P[c]
FRUCTOSE-16DIPHOSPHATE[c]
FRUCTOSE-6P[c]
FUM[c]
G3P[c]
GAP[c]

Fe2+
Fe3+
FMN
formate

an N10-formyl-tetrahydrofolate
D-fructose
fructose-1-phosphate

C3H4O10P2
C9H11N2O11P2
C9H11N2O8P
C9H11N2O14P3
C3H5NOProtein
2S2
C4H7O7P
C27H30N9O15P
2
C4H6O2R
C22H35N7O17R
P3S
Fe2+
Fe3+
C17H18N4O9P
CHO2
C12H17N4O6R3
S
C20H23N7O6R1
C6H12O6
C6H11O9P

fructose-1,6-bisphosphate

C6H10O12P2

D-fructose-6-phosphate
fumarate
3-phospho-D-glycerate
D-glyceraldehyde-3-phosphate

GDP[c]

GDP

C6H11O9P
C4H2O4
C3H4O7P
C3H5O6P
C10H12N5O11P
2

General-Phos-ProteinSubstrates[c]
General-Protein-Substrates[c]
GLC-6-P[c]
GLC[c]
GLN-tRNAs[c]
GLN[c]
GLT-tRNAs[c]
GLT[c]
GLUTAMINYL-TRNA-GLN[c]
GLUTAMYL-TRNA-GLN[c]

a protein-S-sulfanylcysteine
D-erythrose-4-phosphate

formyl-L-methionyl peptide

a phosphoprotein
a protein
beta-D-glucose-6-phosphate
beta-D-glucose
tRNAgln
L-glutamine
tRNAGlu
L-glutamate
L-glutaminyl-tRNAGln
L-glutamyl-tRNAGln

C6H11O9P
C6H12O6
C5H10N2O3
C5H8NO4
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Species id
GLY-tRNAs[c]
GLY[c]
GLYCERALD[c]
GLYCEROL-3P[c]
GLYCEROL[c]
GLYOX[c]
GMP[c]

Species name
tRNAgly
glycine
D-glyceraldehyde
sn-glycerol-3-phosphate
glycerol
glyoxylate
guanosine-5'-phosphate

GTP[c]

GTP

GUANINE[c]

guanine

GUANOSINE-5DP-3DP[c]

ppGpp

GUANOSINE[c]
HCO3[c]
HIS-tRNAs[c]
HIS[c]
HYDROGEN-PEROXIDE[c]
HYDROXY-METHYLBUTENYL-DIP[c]
HYPOXANTHINE[c]
ILE-tRNAs[c]
ILE[c]
IMP[c]
INOSINE[c]
K[c]
L-1-PHOSPHATIDYLGLYCEROL-P[c]
L-1-PHOSPHATIDYLGLYCEROL[c]
L-ALPHA-ALANINE[c]
L-ASPARTATE[c]
L-aspartyl-tRNAAsn[c]
L-CITRULLINE[c]
L-LACTATE[c]
L-PHOSPHATIDATE[c]
L-SELENOCYSTEINE[c]
L-seryl-SEC-tRNAs[c]
LACTOSE-6P[c]
LACTOSE[c]
Leader-Sequences[c]
LEU-tRNAs[c]

guanosine
bicarbonate
tRNAhis
L-histidine
hydrogen peroxide
1-hydroxy-2-methyl-2-{E}-butenyl 4diphosphate
hypoxanthine
tRNAile
L-isoleucine
inosine-5'-phosphate
inosine
K+

Formula
C2H5NO2
C3H6O3
C3H7O6P
C3H8O3
C2HO3
C10H12N5O8P
C10H12N5O14P
3
C5H5N5O
C10H11N5O17P
4
C10H13N5O5
CHO3
C6H9N3O2
H2O2
C5H9O8P2
C5H4N4O
C6H13NO2
C10H11N4O8P
C10H12N4O5
K+

an L-1-phosphatidylglycerol-phosphate

C8H14O13R2P2

an L-1-phosphatidyl-glycerol

C8H13O10R12P

L-alanine
L-aspartate
L-aspartyl-tRNAasn
L-citrulline
L-lactate
a 1,2-diacylglycerol-3-phosphate
L-selenocysteine
L-seryl-tRNAsec
lactose 6-phosphate
lactose
a leader sequence
tRNAleu

C3H7NO2
C4H6NO4
C6H13N3O3
C3H5O3
C5H7O8R1R2P
C3H6NO2Se
C12H21O14P
C12H22O11
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Species id
LEU[c]
LIPID[c]
LIPOAMIDE[c]
LIPOIC-ACID[c]

Species name
L-leucine
lipid
lipoamide
lipoate

LIPOYL-AMP[c]

lipoyl-AMP

Lipoyl-Protein[c]
Long-Chain-Polyphosphate[c]
LYS-tRNAs[c]
LYS[c]
MAL[c]
MALTOSE[c]
MANNITOL-1P[c]
MANNOSE-1P[c]
MANNOSE-6P[c]
MET-tRNAs[c]
MET[c]

protein N6-{lipoyl}lysine
long chain polyphosphate
tRNAlys
L-lysine
{S}-malate
maltose
mannitol-1-phosphate
alpha-D-mannose 1-phosphate
D-mannose-6-phosphate
tRNAmet
L-methionine

METHIONYL-PEPTIDE[c]

methionyl peptide

METHYLENE-THF[c]
MEVALONATE[c]
MG-2[c]
MN-2[c]
Multidrug[c]
N-formyl-L-methionyltRNAfmet[c]
N-Substituted-Amino-Acids[c]
N-Substituted-AminoacyltRNA[c]
NAD(P)[c]
NAD(P)H[c]
NA[c]

5,10-methylene-THF
{R}-mevalonate
Mg2+
Mn2+
multidrug

Formula
C6H13NO2
C8H15NOS2
C8H13O2S2
C18H25N5O8PS
2
H7O16P5
C6H15N2O2
C4H4O5
C12H22O11
C6H15O9P
C6H11O9P
C6H11O9P
C5H11NO2S
C11H17N4O5R3
S
C20H23N7O6
C6H11O4
Mg2+
Mn2+

N-formyl-L-methionyl-tRNAfmet
an N-substituted amino acid

C2H4NO2R1

N-substituted aminoacyl-tRNA
NAD{P}+
NAD{P}H
Na+

NAD[c]

NAD+

NADH[c]

NADH

NADP[c]

NADP+

NADPH[c]

NADPH

NI-2[c]
NIACINE[c]

Ni2+
nicotinate

Na+
C21H26N7O14P
2
C21H27N7O14P
2
C21H25N7O17P
3
C21H26N7O17P
3
Ni2+
C6H4NO2
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Species id
NICOTINAMIDE_NUCLEOTI
DE[c]
NICOTINATE_NUCLEOTIDE[
c]
Nucleoside-Triphosphates[c]
OLIGOPEPTIDE[c]
Ox-Thioredoxin[c]
OXALACETIC_ACID[c]
Oxidized-ferredoxins[c]
Oxidized-NrdH-Proteins[c]
Oxo-glutarate-dehydrogenaseDH-lipoyl[c]
Oxo-glutarate-dehydrogenaselipoyl[c]
OXYGEN-MOLECULE[c]
Peptides-with-LeaderSequence[c]
Peptides[c]
PHE-tRNAs[c]
PHE[c]
PHOSPHATIDYLCHOLINE[c]
PHOSPHO-ENOLPYRUVATE[c]
PHOSPHORYL-CHOLINE[c]
Pi[c]
PPI[c]
Prenyl-tRNAs[c]
PRO-tRNAs[c]
PRO[c]
PROPIONATE[c]
PROPIONYL-P[c]
PROT-CYS[c]
Protein-3-phospho-Lhistidines[c]
Protein-6-N-lipoyl-lysine[c]
Protein-Histidines[c]
Protein-L-methionine-R-Soxides[c]
Protein-L-methionine[c]

Species name

Formula

nicotinamide mononucleotide

C11H14N2O8P

nicotinate mononucleotide

C11H12NO9P

a nucleoside triphosphate
oligopeptide
an oxidized thioredoxin
oxaloacetate
an oxidized ferredoxin
an oxidized NrdH glutaredoxin-like
protein
dihydrolipoyltranssuccinylase N6{dihydrolipoyl}lysine

C5H12O13RP3

dihydrolipoyltranssuccinylase
oxygen

C4H2O5

N6{lipoyl}lysine
O2

a peptide with a leader sequence
a peptide
tRNAphe
L-phenylalanine
a phosphatidylcholine

C9H11NO2
C10H19NO8R2
R1P

phosphoenolpyruvate

C3H2O6P

phosphoryl-choline
phosphate
diphosphate
prenyl-tRNA
tRNApro
L-proline
propionate
propionyl-P

C5H13NO4P
HO4P
HO7P2

a protein L-cysteine
a protein-Npi-phospho-L-histidine

C5H9NO2
C3H5O2
C3H5O5P
C3H6N2OProtei
n2S
C6H8N3O5Prote
in2P

a protein 6-N-{lipoyl}lysine
a protein histidine

C6H7N3OProtei
n2

a protein-L-methionine-{R}-S-oxide
a protein L-methionine
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Species id

Species name

PROTEIN-LIPOYLLYSINE[c]

H-Gcv-protein-{lipoyl}lysine

PROTON[c]
PRPP[c]
Purine-Bases[c]
Purine-Ribonucleosides[c]
PUTRESCINE[c]
PYRIDOXAL[c]
PYRIDOXAL_PHOSPHATE[c]
Pyruvate-dehydrogenaseacetylDHlipoyl[c]
Pyruvate-dehydrogenasedihydrolipoate[c]
Pyruvate-dehydrogenaselipoate[c]
PYRUVATE[c]
Red-Thioredoxin[c]
Reduced-ferredoxins[c]
Reduced-NrdH-Proteins[c]
RIBOFLAVIN[c]
Ribonucleoside-Diphosphates[c]
RIBOSE-1-ARSENATE[c]
RIBOSE-1P[c]
RIBOSE-5P[c]
RIBULOSE-5P[c]
RNA-N[c]
SACETYLDIHYDROLIPOAMID
E[c]
SADENOSYLMETHIONINE[c]
Saturated-2Lysophosphatidates[c]

H+
5-phosphoribosyl 1-pyrophosphate
a purine base
a purine ribonucleoside
putrescine
pyridoxal
pyridoxal 5'-phosphate
lipoate acetyltransferase N6-{Sacetyldihydrolipoyl}lysine
lipoate acetyltransferase N6{dihydrolipoyl}lysine
lipoate acetyltransferase N6{lipoyl}lysine
pyruvate
a reduced thioredoxin
a reduced ferredoxin
a reduced NrdH glutaredoxin-like protein
riboflavin
a ribonucleoside diphosphate
ribose-1-arsenate
alpha-D-ribose-1-phosphate
D-ribose-5-phosphate
D-ribulose-5-phosphate
RNA{n}

Formula
C8H13OS2ApoGcvH
H+
C5H8O14P3

C4H14N2
C8H9NO3
C8H8NO6P

C3H3O3

C17H19N4O6
C5H9O8As
C5H9O8P
C5H9O8P
C5H9O8P

S-acetyldihydrolipoamide

C10H19NO2S2

S-adenosyl-L-methionine

C15H23N6O5S

a 2,3,4-saturated 2-lysophosphatidate

C7H12O7RP

Saturated-Fatty-Acyl-ACPs[c]

a 2,3,4-saturated fatty acyl-[acp]

C4H6Oa holo[acp]R

SEC-tRNAs[c]
SER-tRNAs[c]
SER[c]
Some-tRNA[c]
SPERMIDINE[c]

tRNAsec
tRNAser
L-serine
a tRNA
spermidine

C3H7NO3

Sphingomyelins[c]

a sphingomyelin

C7H22N3
C24H49N2O6R1
P
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Species id

Species name

SUC-COA[c]

succinyl-CoA

SUC[c]
Sugar-Phosphate[c]
Sugar[c]
SULFATE[c]
TAGATOSE-6-PHOSPHATE[c]

succinate
a sugar phosphate
a sugar
sulfate
tagatose-6-phosphate

TDP[c]

dTDP

THF[c]
THIAMINE-P[c]
THIAMINEPYROPHOSPHATE[c]
THIAMINE[c]
THR-tRNAs[c]
THR[c]
THYMIDINE[c]
THYMINE[c]
TMP[c]

tetrahydrofolate
thiamine-phosphate
thiamine diphosphate
thiamin
tRNAthr
L-threonine
thymidine
thymine
dTMP

Triacylglycerols[c]

a triacylglycerol

tRNA-Containing6Isopentenyladenosine[c]
tRNA-Containing-N1Methylguanine[c]
tRNA-precursors[c]
tRNAs-with-N7-methylguanine[c]
TRP-tRNAs[c]
TRP[c]

tRNA containing N6dimethylallyladenosine

Formula
C25H35N7O19P
3S
C4H4O4

SO4
C6H11O9P
C10H13N2O11P
2
C19H23N7O6
C12H16N4O4PS
C12H16N4O7P2
S
C12H17N4OS
C4H9NO3
C10H14N2O5
C5H6N2O2
C10H13N2O8P
C6H5O6R1R2R
3

tRNA containing N1-methylguanine
a tRNA precursor
a tRNA containing N7-methylguanine
tRNAtrp
L-tryptophan

TTP[c]

dTTP

TYR-tRNAs[c]
TYR[c]

tRNAtyr
L-tyrosine

UDP-GALACTOSE[c]

UDP-D-galactose

UDP[c]
UMP[c]
URACIL[c]
URIDINE[c]
UTP[c]
VAL-tRNAs[c]

uridine-5'-diphosphate
uridine-5'-phosphate
uracil
uridine
UTP
tRNAval

C11H12N2O2
C10H13N2O14P
3
C9H11NO3
C15H22N2O17P
2
C9H11N2O12P2
C9H11N2O9P
C4H4N2O2
C9H12N2O6
C9H11N2O15P3
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Species id
VAL[c]
WATER[c]
XANTHOSINE-5PHOSPHATE[c]
XYLULOSE-5-PHOSPHATE[c]
ZN-2[c]

Species name
L-valine
H2O

Formula
C5H11NO2
H2O

xanthosine-5-phosphate

C10H11N4O9P

D-xylulose-5-phosphate
Zn2+

C5H9O8P
Zn2+

A3.2. Metabolites located in the extracellular space
Table S6. Metabolites in the extracellular space for M. gallisepticum model. The
name, id, and formula for each species are provided
Species name
2-KETOGLUTARATE[e]
ACET[e]

Species id
2-ketoglutarate
acetate

ACYL-COA[e]

acyl-CoA

ADENINE[e]
Amino-Acids-20[e]
AMMONIUM[e]
AMP[e]
ARG[e]
ASN[e]
CA-2[e]
Cations[e]
Ceramides[e]
Cholesterol-esters[e]
CHOLESTEROL[e]
CHOLINE[e]
CMP[e]
CO-2[e]
CO-A[e]
CPD-1142[e]
CPD-3[e]
CU-2[e]
CYTOSINE[e]
DATP[e]
Deoxy-Ribonucleosides[e]
DGTP[e]
DIHYDROFOLATE[e]
DIPEPTIDES[e]

adenine
a standard alpha amino acid
NH4+
AMP
L-arginine
L-asparagine
Ca2+
a cation
a ceramide
a cholesterol ester
cholesterol
choline
CMP
Co2+
coenzyme
salicin
molybdate
Cu2+
cytosine
dATP
a deoxynucleoside
dGTP
7,8-dihydrofolate
a dipeptide

Formula
C5H6O5
C2H3O2
C22H35N7O17RP3
S
C5H5N5
C2H4NO2R
H4N
C10H14N5O7P
C6H14N4O2
C4H8N2O3
Ca2+

C28H45O2R
C27H46O
C5H14NO
C9H14N3O8P
Co2+
C21H36N7O16P3S
C13H18O7
O4Mo
Cu2+
C4H5N3O
C10H16N5O12P3
C5H9O3R
C10H16N5O13P3
C19H22N7O6
C4H6N2O3R1R2
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Species name
Fatty-Acids[e]
FE-2[e]
FE-3[e]
FRU[e]
GLC[e]
GLT[e]
GLYCEROL-3P[e]
GLYCEROL[e]
GMP[e]
GTP[e]
GUANINE[e]
HIS[e]
ILE[e]
K[e]
L-1-PHOSPHATIDYLGLYCEROL[e]
L-LACTATE[e]
L-PHOSPHATIDATE[e]
LEU[e]
LIPID[e]
LYS[e]
MALTOSE[e]
MANNITOL[e]
MANNOSE[e]
MET[e]
MG-2[e]
MN-2[e]
Multidrug[e]
NA[e]
NI-2[e]
NIACINE[e]
OLIGOPEPTIDE[e]
PHE[e]
PHOSPHATIDYLCHOLINE[e
]
Pi[e]
PRO[e]
PROPIONATE[e]
PROTON[e]

Species id
a fatty acid
Fe2+
Fe3+
D-fructose
beta-D-glucose
L-glutamate
sn-glycerol-3-phosphate
glycerol
GMP
GTP
guanine
L-histidine
L-isoleucine
K+

Formula
C4H7O2R
Fe2+
Fe3+
C6H12O6
C6H12O6
C5H9NO4
C3H7O6P
C3H8O3
C10H14N5O8P
C10H16N5O14P3
C5H5N5O
C6H9N3O2
C6H13NO2
K+

an L-1-phosphatidyl-glycerol

C8H13O10R12P

L-lactate
a 1,2-diacylglycerol-3phosphate
L-leucine
lipid
L-lysine
maltose
D-mannitol
D-mannose
L-methionine
Mg2+
Mn2+
multidrug
Na+
Ni2+
nicotinate
oligopeptide
L-phenylalanine

C3H5O3
C5H7O8R1R2P
C6H13NO2
C6H14N2O2
C12H22O11
C6H14O6
C6H12O6
C5H11NO2S
Mg2+
Mn2+
Na+
Ni2+
C6H5NO2
C9H11NO2

a phosphatidylcholine

C10H19NO8R2R1P

phosphate
L-proline
propionate
H+

HO4P
C5H9NO2
C3H6O2
H+
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Species name
PUTRESCINE[e]
PYRIDOXAL[e]
RIBOFLAVIN[e]
SER[e]
SPERMIDINE[e]
Sphingomyelins[e]
Sugar[e]
SULFATE[e]
THIAMINE[e]
THYMIDINE[e]
THYMINE[e]
Triacylglycerols[e]
TRP[e]
TYR[e]
UMP[e]
URACIL[e]
VAL[e]
ZN-2[e]

Species id
putrescine
pyridoxal
riboflavin
L-serine
spermidine
a sphingomyelin
a sugar
sulfate
thiamin
thymidine
thymine
a triacylglycerol
L-tryptophan
L-tyrosine
UMP
uracil
L-valine
Zn2+

Formula
C4H14N2
C8H9NO3
C17H20N4O6
C3H7NO3
C7H22N3
C24H49N2O6R1P
O4S
C12H17N4OS
C10H14N2O5
C5H6N2O2
C6H5O6R1R2R3
C11H12N2O2
C9H11NO3
C9H13N2O9P
C4H4N2O2
C5H11NO2
Zn2+

A3.3. Intracellular reactions
Table S7. Intracellular reactions for M. gallisepticum model. The name and gene(s)
locus for each reaction are provided. *Monomer97n-### refers to genes created by the
curator which could no be found an associated gene, but where inferred from literature
review.
Name
FHLMULTIRXN
TRANSRXN7TV-7128
DXPREDISO
M-RXN
GLYC3PDEH
YDROGBIOS
YN-RXN
L-LACTATEDEHYDROGE

Reaction
1*FORMATE[c]+1*NAD[c] -->
1*NADH[c]+1*CARBON-DIOXIDE[c]

Locus*

1*GLC[c] --> 1*GLC[e]
1*PROTON[c]+1*NADPH[c]+1*DEOXYX
YLULOSE-5P[c] --> 1*NADP[c]+1*2-CMETHYL-D-ERYTHRITOL-4PHOSPHATE[c]
1*PROTON[c]+1*NAD(P)H[c]+1*DIHYDR
OXY-ACETONE-PHOSPHATE[c] <-->
1*NAD(P)[c]+1*GLYCEROL-3P[c]
1*PYRUVATE[c]+1*NADH[c]+1*PROTO
N[c] --> 1*L-LACTATE[c]+1*NAD[c]

MGA-0787

MGA-1133
MGA-0746
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Name
NASE-RXN
MALATEDEH-RXN
GLYCEROL3PHOSPHATEOXIDASERXN
ADPREDUCT
-RXN
CDPREDUCTRXN
GDPREDUCT
-RXN
RIBONUCLE
OSIDE-DIPREDUCTIRXN
RIBONUCLE
OSIDE-DIPREDUCTIIRXN
TRANSRXN7TV-3819
RXN0-722
RXN0-747
RXN0-748
UDPREDUCT
-RXN
RXN0-882

Reaction
1*NAD[c]+1*MAL[c] <-->
1*NADH[c]+1*OXALACETIC_ACID[c]+1
*PROTON[c]
1*GLYCEROL-3P[c]+1*OXYGENMOLECULE[c] --> 1*DIHYDROXYACETONEPHOSPHATE[c]+1*HYDROGENPEROXIDE[c]
1*Red-Thioredoxin[c]+1*ADP[c] -->
1*WATER[c]+1*OxThioredoxin[c]+1*DADP[c]
1*Red-Thioredoxin[c]+1*CDP[c] -->
1*WATER[c]+1*OxThioredoxin[c]+1*DCDP[c]
1*Red-Thioredoxin[c]+1*GDP[c] -->
1*WATER[c]+1*OxThioredoxin[c]+1*DGDP[c]
1*WATER[c]+1*OxThioredoxin[c]+1*Deoxy-RibonucleosideDiphosphates[c] --> 1*RedThioredoxin[c]+1*RibonucleosideDiphosphates[c]
1*Oxidized-NrdH-Proteins[c]+1*CDP[c] -->
1*WATER[c]+1*Reduced-NrdHProteins[c]+1*DCDP[c]
1*L-1-PHOSPHATIDYL-GLYCEROL[e] <-> 1*L-1-PHOSPHATIDYL-GLYCEROL[c]
1*Reduced-NrdH-Proteins[c]+1*UDP[c] -->
1*WATER[c]+1*Oxidized-NrdHProteins[c]+1*DUDP[c]
1*Reduced-NrdH-Proteins[c]+1*ADP[c] -->
1*WATER[c]+1*Oxidized-NrdHProteins[c]+1*DADP[c]
1*Reduced-NrdH-Proteins[c]+1*GDP[c] -->
1*WATER[c]+1*Oxidized-NrdHProteins[c]+1*DGDP[c]
1*Red-Thioredoxin[c]+1*UDP[c] -->
1*WATER[c]+1*OxThioredoxin[c]+1*DUDP[c]
2*Reduced-ferredoxins[c]+1*2C-METH-DERYTHRITOL-CYCLODIPHOSPHATE[c] -> 1*WATER[c]+2*Oxidizedferredoxins[c]+1*HYDROXY-METHYL-

Locus*

MGA-0746

MGA-0646

MGA-0695,MGA-0698
MGA-0695,MGA-0698
MGA-0695,MGA-0698

MGA-0698,MGA-0695

MGA-0695

MGA-0695
MGA-0695
MGA-0695
MGA-0695,MGA-0698

MGA-1156
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Name
1.2.1.9-RXN
1.5.1.35-RXN
AMINOBUTD
EHYDROGRXN
GAPOXNPHO
SPHN-RXN
TRANSRXN7TV-3818
PYRUVDEHRXN
PYRUVATED
ECARB-RXN

RXN0-1134
1.5.1.15-RXN
DIHYDROFO
LATEREDUC
T-RXN
METHYLENE
THFDEHYDR
OG-NADPRXN
PYRNUTRAN
SHYDROGEN
-RXN
RXN0-5375

1.8.1.4-RXN
DIHYDLIPOX

Reaction
BUTENYL-DIP[c]
1*WATER[c]+1*NADP[c]+1*GAP[c] -->
1*NADPH[c]+1*G3P[c]+2*PROTON[c]
2*WATER[c]+1*NAD[c]+1*CPD-6124[c] -> 2*PROTON[c]+1*NADH[c]+1*4AMINO-BUTYRATE[c]
1*WATER[c]+1*NAD[c]+1*4-AMINOBUTYRALDEHYDE[c] -->
2*PROTON[c]+1*NADH[c]+1*4-AMINOBUTYRATE[c]
1*NAD[c]+1*Pi[c]+1*GAP[c] <-->
1*NADH[c]+1*DPG[c]+1*PROTON[c]
1*Sphingomyelins[e] <-->
1*Sphingomyelins[c]
1*NAD[c]+1*CO-A[c]+1*PYRUVATE[c] -> 1*NADH[c]+1*CARBONDIOXIDE[c]+1*ACETYL-COA[c]
1*LIPOAMIDE[c]+1*PYRUVATE[c]+1*PR
OTON[c] --> 1*CARBONDIOXIDE[c]+1*SACETYLDIHYDROLIPOAMIDE[c]
1*Pyruvate-dehydrogenaselipoate[c]+1*PYRUVATE[c] -->
1*CARBON-DIOXIDE[c]+1*Pyruvatedehydrogenase-acetylDHlipoyl[c]
1*NAD[c]+1*METHYLENE-THF[c] -->
1*NADH[c]+1*5-10-METHENYL-THF[c]

Locus*
MGA-0860
MGA-0590

MGA-0590
MGA-0330,MGA-1184

MGA-0161

MGA-0165,MGA-0164

MGA-0165,MGA-0164
MGA-0596

1*DIHYDROFOLATE[c]+1*NADPH[c]+1*
PROTON[c] --> 1*THF[c]+1*NADP[c]

MGA-0701

1*NADP[c]+1*METHYLENE-THF[c] -->
1*5-10-METHENYL-THF[c]+1*NADPH[c]

MGA-0596

1*NADPH[c]+1*NAD[c] -->
1*NADP[c]+1*NADH[c]

MGA-0161

2*NADH[c]+1*CPD01147[c]+2*PROTON[c] -->
2*NAD[c]+1*CPD01148[c]+1*ANTHRAATE[c]
1*NAD[c]+1*Dihydro-Lipoyl-Proteins[c] -->
1*PROTON[c]+1*NADH[c]+1*LipoylProtein[c]
1*NAD[c]+1*DIHYDROLIPOAMIDE[c] --

MGA-0243

MGA-0161
MGA-0161
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Name
N-RXN
TRANSRXN7TV-3817
RXN-7716

RXN-7719

RXN-8629

RXN0-1132
THIOREDOXI
N-REDUCTNADPH-RXN
1.8.4.12-RXN

RXN-8669
THYMIDYLA
TESYN-RXN
TRNAGUANINEN1-METHYLTRA
NSFERASERXN
TRNAGUANINEN7-METHYLTRA
NSFERASERXN

Reaction
>
1*NADH[c]+1*LIPOAMIDE[c]+1*PROTO
N[c]
1*PHOSPHATIDYLCHOLINE[e] <-->
1*PHOSPHATIDYLCHOLINE[c]
1*NAD[c]+1*Oxo-glutarate-dehydrogenaseDH-lipoyl[c] -->
1*PROTON[c]+1*NADH[c]+1*Oxoglutarate-dehydrogenase-lipoyl[c]
1*NAD[c]+1*BCAA-dehydrogenase-DHlipoyl[c] -->
1*PROTON[c]+1*NADH[c]+1*BCAAdehydrogenase-lipoyl[c]
1*NAD[c]+1*DIHYDROLIPOYL-GCVH[c]
-->
1*PROTON[c]+1*NADH[c]+1*PROTEINLIPOYLLYSINE[c]
1*NAD[c]+1*Pyruvate-dehydrogenasedihydrolipoate[c] -->
1*PROTON[c]+1*NADH[c]+1*Pyruvatedehydrogenase-lipoate[c]
1*PROTON[c]+1*NADPH[c]+1*OxThioredoxin[c] --> 1*NADP[c]+1*RedThioredoxin[c]
1*WATER[c]+1*OxThioredoxin[c]+1*Protein-L-methionine[c] -> 1*Red-Thioredoxin[c]+1*Protein-Lmethionine-R-S-oxides[c]
1*WATER[c]+1*OxThioredoxin[c]+1*MET[c] --> 1*RedThioredoxin[c]+1*CPD-8989[c]
1*DUMP[c]+1*METHYLENE-THF[c] <-->
1*DIHYDROFOLATE[c]+1*TMP[c]

Locus*

MGA-0161

MGA-0161

MGA-0161

MGA-0161

MGA-0124,MGA-1221

MGA-0149

MGA-0571
MGA-0699

1*SADENOSYLMETHIONINE[c]+1*SometRNA[c] --> 1*tRNA-Containing-N1Methylguanine[c]+1*ADENOSYL-HOMOCYS[c]

MGA-0439

1*SADENOSYLMETHIONINE[c]+1*SometRNA[c] --> 1*tRNAs-with-N7-methylguanine[c]+1*ADENOSYL-HOMO-CYS[c]

MGA-1194
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Name
TRANSRXN7TV-3816

Reaction

Locus*

1*Ceramides[e] <--> 1*Ceramides[c]

GLYOHMETR
ANS-RXN

1*THF[c]+1*SER[c] -->
1*WATER[c]+1*GLY[c]+1*METHYLENETHF[c]

MGA-1146

METHIONYLTRNAFORMYLTRA
NSFERASERXN

1*WATER[c]+1*Charged-METtRNAs[c]+1*10-FORMYL-THF[c] --> 1*Nformyl-L-methionyl-tRNAfmet[c]+1*THF[c]

MGA-0846

1TRANSKET
O-RXN
2TRANSKET
O-RXN
DXS-RXN
RXN-9583

1*XYLULOSE-5PHOSPHATE[c]+1*RIBOSE-5P[c] <-->
1*GAP[c]+1*D-SEDOHEPTULOSE-7-P[c]
1*XYLULOSE-5PHOSPHATE[c]+1*ERYTHROSE-4P[c] <-> 1*GAP[c]+1*FRUCTOSE-6P[c]
1*GAP[c]+1*PYRUVATE[c]+1*PROTON[c
] --> 1*CARBONDIOXIDE[c]+1*DEOXYXYLULOSE-5P[c]
1*RIBOSE-5P[c]+1*CPD-10226[c] --> 1*DSEDOHEPTULOSE-7-P[c]+1*CPD10227[c]

MGA-0342,MGA-0666
MGA-0342,MGA-0666
MGA-1267
MGA-0342,MGA-0666

1ACYLGLYCE
ROL-3-PACYLTRANS
FER-RXN

1*ACYL-ACP[c]+1*ACYL-SNGLYCEROL-3P[c] --> 1*ACP[c]+1*LPHOSPHATIDATE[c]

MGA-0039

DIHYDLIPAC
ETRANSRXN

1*DIHYDROLIPOAMIDE[c]+1*ACETYLCOA[c] --> 1*SACETYLDIHYDROLIPOAMIDE[c]+1*COA[c]

MGA-0162

PHOSACETY
LTRANSRXN

1*ACETYL-COA[c]+1*Pi[c] --> 1*COA[c]+1*ACETYL-P[c]

MGA-0432

RXN-1623
TRANSRXN7TV-3815
RXN0-1133
RXN0-5514

1*ACYL-SN-GLYCEROL-3P[c]+1*FattyAcyl-CoA[c] --> 1*CO-A[c]+1*LPHOSPHATIDATE[c]
1*L-PHOSPHATIDATE[e] <--> 1*LPHOSPHATIDATE[c]
1*Pyruvate-dehydrogenaseacetylDHlipoyl[c]+1*CO-A[c] -->
1*Pyruvate-dehydrogenasedihydrolipoate[c]+1*ACETYL-COA[c]
1*Saturated-Fatty-AcylACPs[c]+1*Saturated-2-

MGA-0039

MGA-0162
MGA-0039
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Name

HYDROXYM
ETHYLGLUT
ARYL-COASYNTHASERXN
MALSYNRXN
2.4.1.46-RXN
MALTOSEPHOSPHORY
LASE-RXN
RXN-1226
ADENPHOSP
HOR-RXN
ADENPRIBOS
YLTRANRXN
DEOXYURIDI
NEPHOSPHORY
LASE-RXN
TRANSRXN7TV-3814
GUANPRIBO
SYLTRANRXN
HYPOXANPR
IBOSYLTRA
N-RXN
INOPHOSPH
OR-RXN
NICOTINATE
PRIBOSYLTR
ANS-RXN
PNP-RXN

Reaction
Lysophosphatidates[c] --> 1*ACP[c]+1*2-34-Saturated-L-Phosphatidates[c]
1*ACETYLCOA[c]+1*WATER[c]+1*ACETOACETYL
-COA[c] --> 1*3-HYDROXY-3-METHYLGLUTARYL-COA[c]+1*COA[c]+1*PROTON[c]
1*GLYOX[c]+1*WATER[c]+1*ACETYLCOA[c] --> 1*COA[c]+1*MAL[c]+1*PROTON[c]
1*UDPGALACTOSE[c]+1*DIACYLGLYCEROL[c
] --> 1*UDP[c]+1*D-Galactosyl-12-diacylglycerols[c]
1*MALTOSE[c]+1*Pi[c] -->
1*GLC[c]+1*CPD-448[c]
2*D-Galactosyl-12-diacyl-glycerols[c] -->
1*DIACYLGLYCEROL[c]+1*CPD10363[c]
1*Pi[c]+1*ADENOSINE[c] <-->
1*ADENINE[c]+1*RIBOSE-1P[c]

Locus*

MONOMER97N-9 HMGCoA Synthase
MONOMER97N-294 Malate
Synthase
MGA-1315

MGA-1265
MGA-1315
MGA-0364

1*PPI[c]+1*AMP[c] <-->
1*ADENINE[c]+1*PRPP[c]

MGA-0955

1*Pi[c]+1*DEOXYURIDINE[c] -->
1*DEOXY-D-RIBOSE-1PHOSPHATE[c]+1*URACIL[c]

MONOMER97N-556
(deoxyuridine phosphorylase )

1*Cholesterol-esters[e] <--> 1*Cholesterolesters[c]
1*GUANINE[c]+1*PRPP[c] -->
1*GMP[c]+1*PPI[c]

MGA-0658

1*HYPOXANTHINE[c]+1*PRPP[c] -->
1*IMP[c]+1*PPI[c]

MGA-0658

1*Pi[c]+1*INOSINE[c] -->
1*HYPOXANTHINE[c]+1*RIBOSE-1P[c]
1*PRPP[c]+1*NIACINE[c]+1*PROTON[c] ->
1*PPI[c]+1*NICOTINATE_NUCLEOTIDE[
c]
1*Pi[c]+1*Purine-Ribonucleosides[c] -->
1*RIBOSE-1P[c]+1*Purine-Bases[c]

MGA-0364
MGA-0428
MGA-0364
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Name
RXN-7001
RXN0-5199
THYMPHOSPH-RXN
URACILPRIBOSYLTR
ANS-RXN
URPHOSRXN
TRANSRXN7TV-3813
RXN-4543
SADENMETSY
N-RXN
TRNAISOPENTENY
LTRANSFER
ASE-RXN
ASPAMINOT
RANS-RXN
1PFRUCTPHO
SN-RXN
2.7.1.145-RXN

2.7.1.148-RXN

2.7.1.69-RXN
6PFRUCTPHO
S-RXN

Reaction
1*ARSENATE[c]+1*PurineRibonucleosides[c] --> 1*PurineBases[c]+1*RIBOSE-1-ARSENATE[c]
1*Pi[c]+1*GUANOSINE[c] <-->
1*GUANINE[c]+1*RIBOSE-1P[c]
1*THYMIDINE[c]+1*Pi[c] -->
1*THYMINE[c]+1*DEOXY-RIBOSE-1P[c]
1*URACIL[c]+1*PRPP[c] -->
1*UMP[c]+1*PPI[c]
1*URIDINE[c]+1*Pi[c] -->
1*URACIL[c]+1*RIBOSE-1P[c]
1*CHOLESTEROL[e] <-->
1*CHOLESTEROL[c]
1*CPD-4211[c]+1*Some-tRNA[c] -->
1*PPI[c]+1*Prenyl-tRNAs[c]
1*WATER[c]+1*MET[c]+1*ATP[c] -->
1*SADENOSYLMETHIONINE[c]+1*PPI[c]+1*
Pi[c]+1*PROTON[c]
1*CPD-4211[c]+1*Some-tRNA[c] -->
1*PPI[c]+1*tRNA-Containing6Isopentenyladenosine[c]
1*2-KETOGLUTARATE[c]+1*LASPARTATE[c] <-->
1*OXALACETIC_ACID[c]+1*GLT[c]
1*FRU1P[c]+1*ATP[c] --> 1*FRUCTOSE16DIPHOSPHATE[c]+1*ADP[c]+2*PROTON[
c]
1*ATP[c]+1*Deoxy-Ribonucleosides[c] -->
1*ADP[c]+1*Deoxy-RibonucleosideMonophosphates[c]
1*ATP[c]+1*4-CYTIDINE-5-DIPHOSPHO2-C[c] --> 1*ADP[c]+1*2-PHOSPHO-4CYTIDINE-5-DIPHOSPHO-2-CMET[c]+2*PROTON[c]
1*Sugar[c]+1*Protein-3-phospho-Lhistidines[c] --> 1*SugarPhosphate[c]+1*Protein-Histidines[c]
1*FRUCTOSE-6P[c]+1*ATP[c] -->
1*FRUCTOSE-16DIPHOSPHATE[c]+1*ADP[c]+2*PROTON[
c]

Locus*
MGA-0364
MGA-0364
MGA-0362
MGA-1159
MONOMER97N-546 (uridine
phosphorylase)

MGA-0914
MGA-0128

MGA-0914
MONOMER97N-539
(Asparate aminotransferase)
MONOMER97N-1269
(Fructose-1-phosphate kinase)
MGA-0175,MGA-0174

MGA-0635

MGA-0508,MGA-0855

MGA-0157
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Name
CHOLINEKINASE-RXN
TRANSRXN7TV-3812
CYTIDINEKI
N-RXN
CYTIKINRXN
DEOXYADEN
OSINEKINASE-RXN
DEOXYGUA
NOSINEKINASE-RXN
DEPHOSPHO
COAKINRXN
DURIDKIRXN
FRUCTOSEP
HOSPHORXN
GLYCEROLKIN-RXN
LACTOSEPH
OSPHO-RXN
NAD-KINRXN
TRANSRXN7TV-3811
NADHKINASE-RXN
PEPDEPHOSRXN
PYRIDOXKIN
-RXN
RIBOFLAVIN
KIN-RXN
THIKIN-RXN

Reaction
1*ATP[c]+1*CHOLINE[c] -->
1*ADP[c]+1*PHOSPHORYLCHOLINE[c]+2*PROTON[c]
1*Triacylglycerols[e] <-->
1*Triacylglycerols[c]
1*GTP[c]+1*CYTIDINE[c] -->
1*GDP[c]+1*CMP[c]+1*PROTON[c]
1*ATP[c]+1*CYTIDINE[c] -->
1*ADP[c]+1*CMP[c]+2*PROTON[c]

Locus*
MGA-0931

MGA-0106
MGA-0106

1*ATP[c]+1*DEOXYADENOSINE[c] -->
1*ADP[c]+1*DAMP[c]+2*PROTON[c]

MGA-0174

1*ATP[c]+1*DEOXYGUANOSINE[c] -->
1*ADP[c]+1*DGMP[c]+2*PROTON[c]

MGA-0174

1*ATP[c]+1*DEPHOSPHO-COA[c] -->
1*ADP[c]+1*CO-A[c]+2*PROTON[c]

MGA-1054N

1*ATP[c]+1*DEOXYURIDINE[c] -->
1*ADP[c]+1*DUMP[c]+2*PROTON[c]
1*Protein-3-phospho-Lhistidines[c]+1*FRU[c] -->
1*WATER[c]+1*FRU1P[c]+1*ProteinHistidines[c]
1*ATP[c]+1*GLYCEROL[c] -->
1*ADP[c]+1*GLYCEROL3P[c]+2*PROTON[c]
1*LACTOSE[c]+1*Protein-3-phospho-Lhistidines[c] --> 1*LACTOSE6P[c]+1*Protein-Histidines[c]
1*ATP[c]+1*NAD[c] -->
1*ADP[c]+1*NADP[c]+2*PROTON[c]

MGA-0502
MGA-0508,MGA-0855

MGA-0644
MGA-0508,MGA-0855
MGA-0291

1*Fatty-Acids[e] <--> 1*Fatty-Acids[c]
1*ATP[c]+1*NADH[c] -->
1*ADP[c]+1*NADPH[c]+2*PROTON[c]
1*PHOSPHO-ENOLPYRUVATE[c]+1*ADP[c]+2*PROTON[c] -> 1*PYRUVATE[c]+1*ATP[c]
1*PYRIDOXAL[c]+1*ATP[c] -->
1*PYRIDOXAL_PHOSPHATE[c]+1*ADP[c
]+2*PROTON[c]
1*ATP[c]+1*RIBOFLAVIN[c] -->
1*ADP[c]+1*FMN[c]+2*PROTON[c]
1*ATP[c]+1*THIAMINE[c] -->

MGA-0291
MGA-0156
MONOMER97N-1194
(Pyridoxamine kinase)
MGA-0832
MONOMER97N-5510
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Name

THYKI-RXN
URIDINEKINRXN
URKI-RXN
PROTEINKINASE-RXN
ACETATEKI
N-RXN
3.6.3.2-RXN
PHOSGLYPH
OS-RXN
RXN-7958
2.7.3.9-RXN
2.7.4.22-RXN
ADENYLKIN-RXN
CDPKIN-RXN
CMPKI-RXN
DADPKINRXN
3.6.3.27-RXN
DCDPKINRXN
DGDPKINRXN
DTDPKINRXN
DTMPKI-RXN
DUDPKINRXN

Reaction
1*ADP[c]+1*THIAMINEP[c]+2*PROTON[c]
1*ATP[c]+1*THYMIDINE[c] -->
1*ADP[c]+1*TMP[c]+2*PROTON[c]
1*ADP[c]+1*UMP[c]+2*PROTON[c] -->
1*ATP[c]+1*URIDINE[c]
1*GTP[c]+1*URIDINE[c] -->
1*GDP[c]+1*UMP[c]+1*PROTON[c]
1*ATP[c]+1*General-Protein-Substrates[c] -> 1*ADP[c]+1*General-Phos-ProteinSubstrates[c]
1*ACETYL-P[c]+1*ADP[c]+1*PROTON[c]
--> 1*ACET[c]+1*ATP[c]
1*ATP[c]+1*WATER[c]+1*MG-2[e] -->
1*ADP[c]+1*Pi[c]+1*MG-2[c]
1*ATP[c]+1*G3P[c] <-->
1*ADP[c]+1*DPG[c]+1*PROTON[c]
1*PROPIONATE[c]+1*ATP[c] -->
1*PROPIONYLP[c]+1*ADP[c]+1*PROTON[c]
1*Protein-Histidines[c]+1*PHOSPHOENOL-PYRUVATE[c] --> 1*Protein-3phospho-L-histidines[c]+1*PYRUVATE[c]
1*UMP[c]+1*ATP[c] -->
1*UDP[c]+1*ADP[c]+1*PROTON[c]
1*ATP[c]+1*AMP[c] -->
2*ADP[c]+1*PROTON[c]
1*ATP[c]+1*CDP[c] <-->
1*ADP[c]+1*CTP[c]+1*PROTON[c]
1*CMP[c]+1*ATP[c] -->
1*CDP[c]+1*ADP[c]+1*PROTON[c]
1*ATP[c]+1*DADP[c] -->
1*ADP[c]+1*DATP[c]
1*Pi[e]+1*WATER[c]+1*ATP[c] -->
2*Pi[c]+1*ADP[c]
1*ATP[c]+1*DCDP[c] -->
1*ADP[c]+1*DCTP[c]+1*PROTON[c]
1*ATP[c]+1*DGDP[c] -->
1*ADP[c]+1*DGTP[c]+1*PROTON[c]
1*ATP[c]+1*TDP[c] -->
1*ADP[c]+1*TTP[c]+1*PROTON[c]
1*TMP[c]+1*ATP[c] -->
1*TDP[c]+1*ADP[c]+1*PROTON[c]
1*ATP[c]+1*DUDP[c] -->
1*ADP[c]+1*DUTP[c]+1*PROTON[c]

Locus*
(Thiamin kinase)
MGA-0502
MGA-0106
MGA-0106
MGA-0459
MGA-0169
MGA-1061
MGA-1187
MGA-0169
MGA-0763
MGA-0783
MGA-0743
MGA-0156
MGA-0900
MGA-0156
MGA-0693
MGA-0156
MGA-0156
MGA-0156
MGA-0606
MGA-0156
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Name
GDPKIN-RXN
GUANYLKIN-RXN
RXN-7913
THI-P-KINRXN
UDPKIN-RXN
3.6.3.29-RXN
UMPKI-RXN
GDPPYPHOS
KIN-RXN
PRPPSYNRXN
2.7.7.15-RXN

2.7.7.60-RXN
CDPDIGLYS
YN-RXN
DNADIRECTEDDNAPOLYMERAS
E-RXN
DNADIRECTEDRNAPOLYMERAS
E-RXN
FADSYNRXN
NICONUCAD
ENYLYLTRA
N-RXN

Reaction
1*ATP[c]+1*GDP[c] -->
1*ADP[c]+1*GTP[c]+1*PROTON[c]
1*ATP[c]+1*GMP[c] -->
1*ADP[c]+1*GDP[c]+1*PROTON[c]
1*DCMP[c]+1*ATP[c] -->
1*DCDP[c]+1*ADP[c]+1*PROTON[c]
1*ATP[c]+1*THIAMINE-P[c] -->
1*ADP[c]+1*THIAMINEPYROPHOSPHATE[c]+1*PROTON[c]
1*ATP[c]+1*UDP[c] -->
1*ADP[c]+1*UTP[c]+1*PROTON[c]
1*ATP[c]+1*WATER[c]+1*CPD-3[e] -->
1*ADP[c]+1*Pi[c]+1*CPD-3[c]
1*UMP[c]+1*ATP[c] -->
1*UDP[c]+1*ADP[c]+1*PROTON[c]
1*GDP[c]+1*ATP[c] --> 1*GUANOSINE5DP-3DP[c]+1*AMP[c]+2*PROTON[c]
1*RIBOSE-5P[c]+1*ATP[c] -->
1*AMP[c]+1*PRPP[c]+2*PROTON[c]
1*CTP[c]+1*PHOSPHORYL-CHOLINE[c] -> 1*PPI[c]+1*CDP-CHOLINE[c]
1*CTP[c]+1*2-C-METHYL-DERYTHRITOL-4PHOSPHATE[c]+1*PROTON[c] -->
1*PPI[c]+1*4-CYTIDINE-5-DIPHOSPHO2-C[c]
1*L-PHOSPHATIDATE[c]+1*CTP[c] -->
1*PPI[c]+1*CDPDIACYLGLYCEROL[c]

Locus*
MGA-0156
MGA-0462
MGA-0900
MONOMER97N-5666
(Thiamine-monophosphate
kinase)
MGA-0156
MONOMER7TV-43
(molybdate-transporting
atpase)
MGA-0900
MGA-0950
MGA-0348
MONOMER97N-1669
(Phosphorylcholine
transferase)
MGA-1069

MGA-0785

1*DNA-N[c]+1*Deoxy-RibonucleosideTriphosphates[c] --> 1*DNA-N[c]+1*PPI[c]

MGA-0618,MGA0605,MGA-0401,MGA1048,MGA-0791,MGA0344,MGA-0336

1*RNA-N[c]+1*Nucleoside-Triphosphates[c]
--> 1*RNA-N[c]+1*PPI[c]

MGA-0443,MGA1005,MGA-1000,MGA-0497

1*ATP[c]+1*FMN[c] -->
1*PPI[c]+1*FAD[c]

MGA-0832

1*NICOTINATE_NUCLEOTIDE[c]+1*ATP
[c] --> 1*DEAMIDO-NAD[c]+1*PPI[c]

MGA-0052
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Name
3.6.3.35-RXN
RXN-8654
RXN-8655
RXN0-5515

2.7.8.27-RXN
CARDIOLIPS
YN-RXN
HOLO-ACPSYNTH-RXN
PHOSPHAGL
YPSYN-RXN
GAPDHSYNE
C-RXN
RXN-5781

PEPSYNTHRXN
RXN0-308
3.6.3.4-RXN
R11-RXN
RXNI-2
AMINOCYLTRNAHYDROLASE

Reaction
1*ATP[c]+1*WATER[c]+1*MN-2[e] -->
1*ADP[c]+1*Pi[c]+1*MN-2[c]
1*LIPOIC-ACID[c]+1*ATP[c] -->
1*LIPOYL-AMP[c]+1*PPI[c]
1*General-Protein-Substrates[c]+1*LIPOYLAMP[c] --> 1*AMP[c]+1*Protein-6-Nlipoyl-lysine[c]
1*2-3-4-Saturated-LPhosphatidates[c]+1*CTP[c] --> 1*CDP-2-34-Saturated-Diacylglycerols[c]+1*PPI[c]
1*PHOSPHATIDYLCHOLINE[c]+1*Ceram
ides[c] -->
1*DIACYLGLYCEROL[c]+1*Sphingomyeli
ns[c]
2*L-1-PHOSPHATIDYL-GLYCEROL[c] -> 1*GLYCEROL[c]+1*CARDIOLIPIN[c]
1*CO-A[c]+1*apo-ACP[c] -->
1*ACP[c]+1*3-5-ADP[c]
1*GLYCEROL3P[c]+1*CDPDIACYLGLYCEROL[c] -->
1*CMP[c]+1*L-1-PHOSPHATIDYLGLYCEROL-P[c]
1*Pi[c]+1*GAP[c]+1*NAD(P)[c] <-->
1*DPG[c]+1*NAD(P)H[c]
1*CDPCHOLINE[c]+1*DIACYLGLYCEROL[c] ->
1*CMP[c]+1*PHOSPHATIDYLCHOLINE[c
]
1*ATP[c]+1*PYRUVATE[c]+1*WATER[c]
--> 1*AMP[c]+1*PHOSPHO-ENOLPYRUVATE[c]+1*Pi[c]+3*PROTON[c]
1*CYS[c]+1*PROT-CYS[c] --> 1*LALPHA-ALANINE[c]+1*ENZYME-SSULFANYLCYSTEINE[c]
1*ATP[c]+1*WATER[c]+1*CU-2[e] -->
1*ADP[c]+1*Pi[c]+1*CU-2[c]
1*ACET[c]+1*BUTYRYL-COA[c] -->
1*ACETYL-COA[c]+1*BUTYRIC_ACID[c]
1*3-KETOBUTYRATE[c]+1*SUC-COA[c]
--> 1*ACETOACETYL-COA[c]+1*SUC[c]
1*N-Substituted-AminoacyltRNA[c]+1*WATER[c] --> 1*N-SubstitutedAmino-Acids[c]+1*Some-tRNA[c]

Locus*
MGA-1061
MGA-0158
MGA-0158
MGA-0785
MONOMER97N-5687
(Sphingomyelin synthase)
MONOMER97N-1654
(Cardiolipin synthase)
MGA-0041
MGA-1067
MGA-0860
MONOMER97N-1677
(Diacylglycerol
cholinephosphotransferase)
MGA-0763
MGA-1128
MGA-1061
MONOMER97N-35
(Coenzyme A Transphorase),
MGA-0833
MONOMER97N-50
(Coenzyme A Transphorase)
MGA-0506
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Name
-RXN
ACETYLCOAHYDROLASE
-RXN
3.1.21.2-RXN
RXN0-2582
3.1.26.5-RXN
325BISPHOSPHA
TENUCLEOTID
ASE-RXN
AMPDEPHOSPHO
RYLATIONRXN
PGPPHOSPH
A-RXN
ACH1-RXN
PHOSPHATID
ATEPHOSPHATA
SE-RXN
RXN-7609
RXN7TV-27
CYCPHOSDIE
STER-RXN
PPGPPSYNRXN
RXN0-2584
3.4.11.1-RXN
3.4.21.89-RXN
3.5.1.88-RXN

Reaction

Locus*

1*ACETYL-COA[c]+1*WATER[c] -->
1*CO-A[c]+1*ACET[c]+1*PROTON[c]

MGA-0833

1*AP-Site-Created[c] --> 1*CPD-8532[c]
1*CPD-8533[c] --> 1*CPD-8532[c]
1*tRNA-precursors[c] --> 1*Some-tRNA[c]

MGA-1293
MGA-1293
MGA-0630

1*WATER[c]+1*3-5-ADP[c] -->
1*AMP[c]+1*Pi[c]

MONOMER97N-7997

1*WATER[c]+1*AMP[c] -->
1*Pi[c]+1*ADENOSINE[c]

MONOMER97N-384

1*WATER[c]+1*L-1-PHOSPHATIDYLGLYCEROL-P[c] --> 1*Pi[c]+1*L-1PHOSPHATIDYL-GLYCEROL[c]
1*NA[e]+1*CHOLINE[e] -->
1*NA[c]+1*CHOLINE[c]
1*WATER[c]+1*L-PHOSPHATIDATE[c] -> 1*Pi[c]+1*DIACYLGLYCEROL[c]
1*WATER[c]+1*GMP[c] -->
1*Pi[c]+1*GUANOSINE[c]
1*WATER[c]+1*DAMP[c] -->
1*PROTON[c]+1*Pi[c]+1*DEOXYADENO
SINE[c]
1*WATER[c]+1*Cyclic-2-3-RibonucleosideMonophosphates[c] --> 1*3-PrimeRibonucleoside-Monophosphates[c]
1*WATER[c]+1*GUANOSINE-5DP-3DP[c]
--> 1*GDP[c]+1*PPI[c]
1*DNA-with-Uracils[c] -->
1*URACIL[c]+1*AP-Site-Created[c]
1*WATER[c]+1*Peptides[c] -->
1*Peptides[c]+1*Amino-Acids-20[c]
1*Peptides-with-Leader-Sequence[c] -->
1*Leader-Sequences[c]+1*Peptides[c]
1*FORMYL-L-METHIONYLPEPTIDE[c]+1*WATER[c] -->
1*FORMATE[c]+1*METHIONYL-

MONOMER97N-525
MONOMER7TV-185
MONOMER97N-2
MONOMER97N-392
MONOMER97N-417
MGA-0141
MGA-0950
MGA-0415
MGA-0114
MGA-1091
MGA-0463
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Name
ARGININEDEIMINASERXN
TRANS-RXN185
CYTIDEAMRXN
CYTIDEAM2RXN
DCMPDEAMINASERXN
METHENYLT
HFCYCLOHY
DRO-RXN
RXN-6282
EXOPOLYPH
OSPHATASERXN
INORGPYRO
PHOSPHATRXN
RXN0-5462
F16ALDOLAS
E-RXN
RXN-8631
TRANSRXN7TV-0
2PGADEHYD
RAT-RXN
4.2.99.18-RXN
RXN0-2601
AMPSYNRXN
SELENOCYS

Reaction
PEPTIDE[c]+1*PROTON[c]
1*ARG[c]+1*WATER[c] --> 1*LCITRULLINE[c]+1*AMMONIA[c]+1*PRO
TON[c]
1*K[e] --> 1*K[c]
1*DEOXYCYTIDINE[c]+1*WATER[c] -->
1*AMMONIA[c]+1*DEOXYURIDINE[c]
1*CYTIDINE[c]+1*WATER[c] <-->
1*AMMONIA[c]+1*URIDINE[c]
1*WATER[c]+1*DCMP[c] -->
1*DUMP[c]+1*AMMONIA[c]
1*5-10-METHENYL-THF[c]+1*WATER[c]
<--> 1*10-FORMYLTHF[c]+1*PROTON[c]
1*WATER[c]+1*CPD-5727[c] -->
1*FORMYL-THF-GLU-N[c]
1*WATER[c]+1*Long-ChainPolyphosphate[c] --> 1*Pi[c]+1*Long-ChainPolyphosphate[c]
1*PPI[c]+1*WATER[c] -->
2*Pi[c]+1*PROTON[c]
1*WATER[c]+1*GTP[c] -->
1*Pi[c]+1*GDP[c]+1*PROTON[c]
1*FRUCTOSE-16-DIPHOSPHATE[c] <-->
1*GAP[c]+1*DIHYDROXY-ACETONEPHOSPHATE[c]
1*FRU1P[c] -->
1*GLYCERALD[c]+1*DIHYDROXYACETONE-PHOSPHATE[c]
1*PROTON[e]+1*RIBOFLAVIN[e] -->
1*PROTON[c]+1*RIBOFLAVIN[c]
1*2-PG[c] <-->
1*WATER[c]+1*PHOSPHO-ENOLPYRUVATE[c]
1*DNA-containing-abasic-Sites[c] --> 1*3terminal-unsaturated-sugars[c]+1*5Phosphopolynucleotides[c]
1*Damaged-DNA-Pyrimidine[c] --> 1*DNAcontaining-a-Apyrimidinic-Sites[c]
1*ADENYLOSUCC[c] -->
1*AMP[c]+1*FUM[c]
1*L-SELENOCYSTEINE[c]+1*Donor-H2[c]

Locus*

MGA-0105,MGA-1220
MGA-0171
G97N-539, MGA-0361
MGA-0361
MGA-0701
MGA-0596
MGA-0596
MGA-0683
MGA-1121
MGA-0339,MGA0110,MGA-0053,MGA-0898
MGA-0498
MGA-0498
MONOMER7TV-1
MGA-0209
MGA-1053
MGA-1053
MONOMER97N-503
MGA-1128
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Name
TEINELYASE-RXN
RXN0-302
RIBULP3EPI
M-RXN
LACTOSE-6PHOSPHATEISOMERASERXN
MANNPISOM
-RXN
PGLUCISOMRXN
TRANSRXN7TV-102
RIB5PISOMRXN
RXN-6182
TRIOSEPISO
MERIZATION
-RXN
3PGAREARRRXN
BETAPHOSPHOGL
UCOMUTASE
-RXN
PHOSMANM
UT-RXN
PPENTOMUT
-RXN
TRNAPSEUDOURI
DINESYNTHASE-IRXN
ALANINE-TRNALIGASE-RXN
ARGININE--

Reaction
--> 1*CPD-678[c]+1*L-ALPHAALANINE[c]+1*Acceptor[c]
1*2-PHOSPHO-4-CYTIDINE-5DIPHOSPHO-2-C-MET[c] -->
1*CMP[c]+1*2C-METH-D-ERYTHRITOLCYCLODIPHOSPHATE[c]
1*RIBULOSE-5P[c] <--> 1*XYLULOSE-5PHOSPHATE[c]

Locus*

MGA-0657
MGA-0455

1*CPD-1241[c] --> 1*TAGATOSE-6PHOSPHATE[c]

MGA-0866

1*MANNOSE-6P[c] <--> 1*FRUCTOSE6P[c]

MGA-0514

1*GLC-6-P[c] <--> 1*FRUCTOSE-6P[c]

MGA-0457

1*FE-2[e] --> 1*FE-2[c]

MGA-0171

1*RIBULOSE-5P[c] <--> 1*RIBOSE-5P[c]

MGA-0886

1*ALPHA-GLC-6-P[c] --> 1*FRUCTOSE6P[c]

MGA-0457

1*DIHYDROXY-ACETONEPHOSPHATE[c] <--> 1*GAP[c]

MGA-0357

1*G3P[c] <--> 1*2-PG[c]

MGA-0356

1*CPD-448[c] --> 1*GLC-6-P[c]

MGA-1263

1*MANNOSE-6P[c] --> 1*MANNOSE1P[c]

MGA-0358

1*RIBOSE-1P[c] --> 1*RIBOSE-5P[c]

MGA-0358

1*CPD-8538[c] --> 1*CPD8537[c]+1*PROTON[c]

MGA-1331D,MGA-0831

1*ATP[c]+1*L-ALPHAALANINE[c]+1*ALA-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-ALAtRNAs[c]
1*ATP[c]+1*ARG[c]+1*ARG-tRNAs[c] -->

MGA-0834
MGA-0636
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Name
TRNALIGASE-RXN
TRANSRXN7TV-104
ASPARAGIN
E--TRNALIGASE-RXN
ASPARTATE-TRNALIGASE-RXN
CYSTEINE-TRNALIGASE-RXN
GLURS-RXN
GLUTAMINE-TRNALIGASE-RXN
GLYCINE-TRNALIGASE-RXN
HISTIDINE-TRNALIGASE-RXN
ISOLEUCINE-TRNALIGASE-RXN
LEUCINE-TRNALIGASE-RXN
LYSINE-TRNALIGASE-RXN
TRANSRXN7TV-109
METHIONINE
--TRNALIGASE-RXN
PHENYLALA
NINE--TRNALIGASE-RXN
PROLINE-TRNA-

Reaction
1*AMP[c]+1*PPI[c]+1*Charged-ARGtRNAs[c]

Locus*

1*FE-3[e] --> 1*FE-3[c]

MGA-0171

1*ATP[c]+1*ASN[c]+1*ASN-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-ASNtRNAs[c]
1*ATP[c]+1*L-ASPARTATE[c]+1*ASPtRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-ASPtRNAs[c]
1*ATP[c]+1*CYS[c]+1*CYS-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-CYStRNAs[c]
1*ATP[c]+1*GLT[c]+1*GLT-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-GLTtRNAs[c]
1*ATP[c]+1*GLN[c]+1*GLN-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-GLNtRNAs[c]
1*ATP[c]+1*GLY[c]+1*GLY-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-GLYtRNAs[c]
1*ATP[c]+1*HIS[c]+1*HIS-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-HIStRNAs[c]
1*ATP[c]+1*ILE[c]+1*ILE-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-ILEtRNAs[c]
1*ATP[c]+1*LEU-tRNAs[c]+1*LEU[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-LEUtRNAs[c]
1*ATP[c]+1*LYS[c]+1*LYS-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-LYStRNAs[c]
1*PROTON[e]+1*THYMINE[e] -->
1*PROTON[c]+1*THYMINE[c]
1*ATP[c]+1*MET[c]+1*MET-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-METtRNAs[c]
1*ATP[c]+1*PHE[c]+1*PHE-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-PHEtRNAs[c]
1*ATP[c]+1*PRO-tRNAs[c]+1*PRO[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-PRO-

MGA-1065,MGA-1100

MGA-0948

MGA-0533
MGA-0594
MGA-0594
MGA-0015
MGA-0947
MGA-1196
MGA-0087
MGA-0753
MONOMER7TV-110
MGA-0893,MGA-0884
MGA-1281,MGA-1278
MGA-1022
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Name
LIGASE-RXN
RXN0-2161
RXN490-3616
SERINE-TRNALIGASE-RXN
THREONINE-TRNALIGASE-RXN
TRYPTOPHA
N--TRNALIGASE-RXN
TYROSINE-TRNALIGASE-RXN
VALINE-TRNALIGASE-RXN
TRANSRXN7TV-11
ACYLACPSY
NTH-RXN
ASNSYNARXN
5-FORMYLTHF-CYCLOLIGASE-RXN
ADENYLOSU
CCINATESYNTHASERXN
CTPSYN-RXN

6.3.5.7-RXN

Reaction
tRNAs[c]
1*ATP[c]+1*SER[c]+1*SEC-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*L-seryl-SECtRNAs[c]
1*ATP[c]+1*L-ASPARTATE[c]+1*ASNtRNAs[c] --> 1*AMP[c]+1*PPI[c]+1*Laspartyl-tRNAAsn[c]
1*ATP[c]+1*SER[c]+1*SER-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-SERtRNAs[c]
1*ATP[c]+1*THR[c]+1*THR-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-THRtRNAs[c]
1*TRP[c]+1*TRP-tRNAs[c]+1*ATP[c] -->
1*Charged-TRPtRNAs[c]+1*PPI[c]+1*AMP[c]
1*ATP[c]+1*TYR-tRNAs[c]+1*TYR[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-TYRtRNAs[c]
1*ATP[c]+1*VAL[c]+1*VAL-tRNAs[c] -->
1*AMP[c]+1*PPI[c]+1*Charged-VALtRNAs[c]
1*ACYL-COA[e] --> 1*ACYL-COA[c]
1*ATP[c]+1*ACP[c]+1*Fatty-Acids[c] -->
1*PPI[c]+1*AMP[c]+1*ACYL-ACP[c]
1*ATP[c]+1*LASPARTATE[c]+1*AMMONIA[c] -->
1*AMP[c]+1*PPI[c]+1*ASN[c]+1*PROTO
N[c]
1*ATP[c]+1*5-FORMYLTHF[c]+1*PROTON[c] <-->
1*Pi[c]+1*ADP[c]+1*5-10-METHENYLTHF[c]
1*GTP[c]+1*IMP[c]+1*L-ASPARTATE[c] ->
1*GDP[c]+1*Pi[c]+1*ADENYLOSUCC[c]+
2*PROTON[c]
1*WATER[c]+1*GLN[c]+1*UTP[c]+1*ATP
[c] -->
1*GLT[c]+1*CTP[c]+1*Pi[c]+1*ADP[c]+3*
PROTON[c]
1*ATP[c]+1*GLUTAMYL-TRNAGLN[c]+1*GLN[c] -->
1*ADP[c]+1*Pi[c]+1*GLUTAMINYL-

Locus*

MGA-0608
MGA-1065
MGA-0608
MGA-0925
MGA-0293
MGA-1144
MGA-0338
MONOMER7TV-12
MONOMER97N-5692
MGA-0424

MGA-1310

MONOMER97N-473

MGA-0953

MGA-0413
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Name

GMP-SYNGLUT-RXN

RXN490-3617
PYRUVATECARBOXYLA
SE-RXN
DNALIGASENAD+-RXN
TRANSRXN7TV-12
RXN-9591
RXN-9590
TRANSRXN7TV-13
TRANSRXN7TV-17
TRANSRXN7TV-1717
TRANSRXN7TV-1719
TRANSRXN7TV-18
TRANSRXN7TV-19
TRANSRXN7TV-2
3.6.3.7-RXN
TRANSRXN7TV-22
TRANS-

Reaction
TRNA-GLN[c]+1*GLT[c]
1*ATP[c]+1*GLN[c]+1*WATER[c]+1*XA
NTHOSINE-5-PHOSPHATE[c] -->
1*AMP[c]+1*PPI[c]+1*GMP[c]+1*GLT[c]+
3*PROTON[c]
1*ATP[c]+1*L-aspartyltRNAAsn[c]+1*GLN[c] -->
1*ADP[c]+1*Pi[c]+1*Charged-ASNtRNAs[c]+1*GLT[c]
1*ATP[c]+1*PYRUVATE[c]+1*HCO3[c] ->
1*ADP[c]+1*OXALACETIC_ACID[c]+1*Pi
[c]+2*PROTON[c]
1*NAD[c]+1*DEOXYNUCLEOTIDESM[c]
+1*Deoxynucleotides[c] -->
1*AMP[c]+1*NICOTINAMIDE_NUCLEOT
IDE[c]+1*Deoxynucleotides[c]
1*WATER[c]+1*ATP[c]+1*CO-2[e] -->
1*Pi[c]+1*PROTON[c]+1*ADP[c]+1*CO2[c]
1*Acyl-Phosphates[c]+1*GLYCEROL-3P[c]
--> 1*Pi[c]+1*ACYL-SN-GLYCEROL-3P[c]
1*Pi[c]+1*ACYL-ACP[c] -->
1*ACP[c]+1*Acyl-Phosphates[c]
1*DGTP[e] --> 1*DGTP[c]
1*PROTON[e]+1*ADENINE[e] <-->
1*PROTON[c]+1*ADENINE[c]
1*PROTON[e]+1*2-KETOGLUTARATE[e]
<--> 1*PROTON[c]+1*2KETOGLUTARATE[c]
1*PROTON[c]+1*ACET[c] -->
1*PROTON[e]+1*ACET[e]
1*PROTON[e]+1*CYTOSINE[e] -->
1*PROTON[c]+1*CYTOSINE[c]
1*PHOSPHO-ENOLPYRUVATE[c]+1*MANNOSE[e] -->
1*PYRUVATE[c]+1*MANNOSE-6P[c]
1*CO-A[e] --> 1*CO-A[c]
1*WATER[c]+1*ATP[c]+1*NA[c] -->
1*ADP[c]+1*Pi[c]+1*NA[e]
1*PROTON[e]+1*THIAMINE[e] -->
1*PROTON[c]+1*THIAMINE[c]
1*AMMONIUM[e] <--> 1*AMMONIUM[c]

Locus*

MGA-0650

MGA-0413

MONOMER97N-316

MGA-0569

MGA-0353, MGA-0351
MGA-0008
MGA-0181
MONOMER7TV-14
MONOMER7TV-18
MONOMER7TV-6
MONOMER7TV-0
MONOMER7TV-19
MONOMER7TV-20
MONOMER7TV-3

MONOMER7TV-23
MGA-0171,MONOMER7TV-
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Name
RXN7TV-23
TRANSRXN7TV-25
TRANSRXN7TV-258
TRANSRXN7TV-27
TRANSRXN7TV-28
TRANSRXN7TV-304
TRANSRXN7TV-310
TRANSRXN7TV-313
TRANSRXN7TV-315
3.6.3.19-RXN
TRANSRXN7TV-317
TRANSRXN7TV-320
TRANSRXN7TV-323
TRANSRXN7TV-325
TRANSRXN7TV-327
TRANSRXN7TV-329
TRANSRXN7TV-331
TRANSRXN7TV-333
TRANSRXN7TV-335
TRANSRXN7TV-338
TRANSRXN7TV-8750
TRANSRXN7TV-53
TRANS-

Reaction

Locus*
24

1*PHOSPHO-ENOLPYRUVATE[c]+1*FRU[e] -->
1*PYRUVATE[c]+1*FRU1P[c]

MONOMER7TV-26

1*ZN-2[e] <--> 1*ZN-2[c]

MGA-0171

1*PROTON[e]+1*DIHYDROFOLATE[e] -> 1*PROTON[c]+1*DIHYDROFOLATE[c]
1*PROTON[e]+1*THYMIDINE[e] -->
1*PROTON[c]+1*THYMIDINE[c]
1*PROTON[e]+1*ARG[e] -->
1*PROTON[c]+1*ARG[c]
1*PROTON[e]+1*ASN[e] -->
1*PROTON[c]+1*ASN[c]
1*PROTON[e]+1*GLT[e] -->
1*PROTON[c]+1*GLT[c]
1*PROTON[e]+1*HIS[e] -->
1*PROTON[c]+1*HIS[c]
1*ATP[c]+1*WATER[c]+1*MALTOSE[e] -> 1*ADP[c]+1*Pi[c]+1*MALTOSE[c]
1*PROTON[e]+1*ILE[e] -->
1*PROTON[c]+1*ILE[c]
1*PROTON[e]+1*LEU[e] -->
1*PROTON[c]+1*LEU[c]
1*PROTON[e]+1*LYS[e] -->
1*PROTON[c]+1*LYS[c]
1*PROTON[e]+1*MET[e] -->
1*PROTON[c]+1*MET[c]
1*PROTON[e]+1*PHE[e] -->
1*PROTON[c]+1*PHE[c]
1*PROTON[e]+1*PRO[e] -->
1*PROTON[c]+1*PRO[c]
1*PROTON[e]+1*SER[e] -->
1*PROTON[c]+1*SER[c]
1*PROTON[e]+1*TRP[e] -->
1*PROTON[c]+1*TRP[c]
1*PROTON[e]+1*VAL[e] -->
1*PROTON[c]+1*VAL[c]
1*PROTON[e]+1*TYR[e] -->
1*PROTON[c]+1*TYR[c]

MONOMER7TV-28
MONOMER7TV98,MONOMER7TV-29
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287
MGA-1188,MGA0963,MGA-0287

1*GMP[e] --> 1*GMP[c]
1*NIACINE[e] --> 1*NIACINE[c]

MGA-1188

1*PYRIDOXAL[e] --> 1*PYRIDOXAL[c]

MONOMER7TV-57
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Name
RXN7TV-56
TRANSRXN7TV-60
TRANSRXN7TV-62
TRANSRXN7TV-63
TRANSRXN7TV-65
TRANSRXN7TV-7
TRANSRXN7TV-77
TRANSRXN7TV-8
TRANSRXN7TV-82
TRANSRXN7TV-8749
TRANSRXN7TV-9

Reaction

Locus*

1*GTP[e] --> 1*GTP[c]

MONOMER7TV-61

1*PROTON[e]+1*SULFATE[e] -->
1*PROTON[c]+1*SULFATE[c]

MONOMER7TV-64

1*CA-2[e] <--> 1*CA-2[c]

MGA-0171

1*PROTON[e]+1*PROPIONATE[e] <-->
1*PROTON[c]+1*PROPIONATE[c]

MONOMER7TV-66

1*DATP[e] --> 1*DATP[c]

MONOMER7TV-8

1*PROTON[e]+1*URACIL[e] -->
1*PROTON[c]+1*URACIL[c]
1*PHOSPHO-ENOLPYRUVATE[c]+1*CPD-1142[e] -->
1*PYRUVATE[c]+1*CPD-1181[c]
1*PROTON[e]+1*GUANINE[e] -->
1*GUANINE[c]+1*PROTON[c]

1*L-LACTATE[c] <--> 1*L-LACTATE[e]

TRANSRXN7TV-3950
TRANSRXN7TV-3966
TRANSRXN7TV-21
TRANSRXN7TV-24

1*WATER[c]+1*ATP[c]+1*Multidrug[e] -->
1*Pi[c]+1*ADP[c]+1*Multidrug[c]

TRANSRXN7TV-36

1*WATER[c]+1*ATP[c]+1*Cations[e] -->
1*Pi[c]+1*ADP[c]+1*Cations[c]
1*WATER[c]+1*ATP[c]+1*SPERMIDINE[
e] -->
1*Pi[c]+1*ADP[c]+1*SPERMIDINE[c]

TRANSRXN7TV-3933

MONOMER7TV-9
MONOMER7TV-84

1*UMP[e] --> 1*UMP[c]

1*PROTON[e]+1*Deoxy-Ribonucleosides[e]
--> 1*PROTON[c]+1*DeoxyRibonucleosides[c]
1*PROTON[e]+1*Amino-Acids-20[e] -->
1*PROTON[c]+1*Amino-Acids-20[c]
1*PROTON[e]+1*GLYCEROL[e] -->
1*PROTON[c]+1*GLYCEROL[c]
1*WATER[c]+1*ATP[c]+1*LIPID[e] -->
1*Pi[c]+1*ADP[c]+1*LIPID[c]

TRANSRXN7TV-96

MONOMER7TV-78

TRANSRXN7TV-3939

1*WATER[c]+1*ATP[c]+1*NI-2[e] -->
1*Pi[c]+1*ADP[c]+1*NI-2[c]

TRANS-

1*WATER[c]+1*ATP[c]+1*OLIGOPEPTID

G7TV-11
MONOMER7TV-98
MGA-0287,MGA0963,MGA-1188
MGA-0641
MGA-0625A,MGA-0626
MGA-0625A,MGA0626,MGA-0806,MGA1287,,MGA-1140,,MGA-1138
MGA-1061
MGA-0131,MGA-0132,
MGA-0132
MGA-1061,MGA0224,MGA-0220,MGA0218,MGA-0223,MGA0221,MGA-0230, MGA-0232,
MGA-0234,MGA-0235
MGA-0224,MGA-
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Name
RXN7TV-3942

TRANSRXN7TV-8748
TRANSRXN7TV-3945
TRANSRXN7TV-3969
TRANSRXN7TV-3989
TRANSRXN7TV-4008
TRANSRXN7TV-43
TRANSRXN7TV-3953
TRANSRXN7TV-3984
TRANSRXN7TV-16
TRANSRXN7TV-31
TRANSRXN7TV-3930
TRANSRXN7TV-8747
ATP_maintena
nce_requireme
nt
ammonia_conv
ersion_spontan
eous
DEOXYADEN
PHOSPHORRXN
DEOXYGUA

Reaction
E[e] -->
1*Pi[c]+1*ADP[c]+1*OLIGOPEPTIDE[c]

Locus*
0220,MGA-0218,MGA0223,MGA-0221,MGA-0230,
MGA-0232, MGA0234,MGA-0235,MGA-0237

1*CMP[e] --> 1*CMP[c]
1*WATER[c]+1*ATP[c]+1*DIPEPTIDES[e]
--> 1*Pi[c]+1*ADP[c]+1*DIPEPTIDES[c]
1*WATER[c]+1*ATP[c]+1*GLYCEROL3P[e] -->
1*Pi[c]+1*ADP[c]+1*GLYCEROL-3P[c]
1*WATER[c]+1*ATP[c]+1*PUTRESCINE[
e] -->
1*Pi[c]+1*ADP[c]+1*PUTRESCINE[c]
1*WATER[c]+1*ATP[c]+1*Pi[e] -->
2*Pi[c]+1*ADP[c]
1*WATER[c]+1*ATP[c]+1*Sugar[e] -->
1*Pi[c]+1*ADP[c]+1*Sugar[c]
1*PHOSPHO-ENOLPYRUVATE[c]+1*GLC[e] -->
1*PYRUVATE[c]+1*GLC-6-P[c]
1*PHOSPHO-ENOLPYRUVATE[c]+1*MANNITOL[e] -->
1*PYRUVATE[c]+1*MANNITOL-1P[c]

MGA-0224,MGA0220,MGA-0218,MGA0223,MGA-0221,MGA-0230,
MGA-0232, MGA0234,MGA-0235
MGA-0682, MGA-0680,
MGA-0677
MGA-0132, MGA-0134
MGA-0689, MGA-0687
MGA-1078, MGA-1077,
MGA-1076
MGA-0289
MGA-1283

1*Cations[e] --> 1*Cations[c]

MGA-0171

1*Pi[e] --> 1*Pi[c]

MGA-0694

1*PROTON[e]+1*K[e] -->
1*PROTON[c]+1*K[c]

MGA-0085

1*AMP[e] --> 1*AMP[c]
1*WATER[c]+1*ATP[c] -->
1*Pi[c]+1*PROTON[c]+1*ADP[c]
1*PROTON[c]+1*AMMONIA[c] -->
1*AMMONIUM[c]
1*Pi[c]+1*DEOXYADENOSINE[c] -->
1*DEOXY-RIBOSE-1P[c]+1*ADENINE[c]

MGA-0364

1*Pi[c]+1*DEOXYGUANOSINE[c] <-->

MGA-0364
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Name
NPHOSPHORRXN
DEOXYINOP
HOSPHORRXN
GCVMULTIRXN
RXN-6321
RXN-9386
URAPHOSPH-RXN
1.1.1.34-RXN

2.3.1.15-RXN
6.2.1.3-RXN

Reaction
1*DEOXY-RIBOSE-1P[c]+1*GUANINE[c]
1*Pi[c]+1*DEOXYINOSINE[c] <-->
1*DEOXY-RIBOSE1P[c]+1*HYPOXANTHINE[c]
1*NAD[c]+1*THF[c]+1*GLY[c] <-->
1*NADH[c]+1*CARBONDIOXIDE[c]+1*METHYLENETHF[c]+1*AMMONIA[c]+1*PROTON[c]
1*WATER[c]+1*5-10-METHENYL-THF[c]
--> 1*5-FORMYL-THF[c]+3*PROTON[c]
1*ATP[c]+1*GLT[c]+1*GLN-tRNAs[c] -->
1*PPI[c]+1*AMP[c]+1*GLUTAMYLTRNA-GLN[c]
1*DEOXYURIDINE[c]+1*Pi[c] -->
1*URACIL[c]+1*DEOXY-RIBOSE-1P[c]
1*3-HYDROXY-3-METHYL-GLUTARYLCOA[c]+2*NADPH[c]+2*PROTON[c] -->
1*MEVALONATE[c]+1*COA[c]+2*NADP[c]
1*Fatty-Acyl-CoA[c]+1*GLYCEROL-3P[c]
--> 1*CO-A[c]+1*ACYL-SN-GLYCEROL3P[c]
1*ATP[c]+1*CO-A[c]+1*Fatty-Acids[c] <-> 1*AMP[c]+1*PPI[c]+1*Fatty-Acyl-CoA[c]

ATPSYNRXN

1*ATP[c]+1*WATER[c]+3*PROTON[c] <-> 1*ADP[c]+1*Pi[c]+4*PROTON[e]

NAD-SYNTHGLN-RXN

1*ATP[c]+1*DEAMIDONAD[c]+1*GLN[c]+1*WATER[c] -->
1*PROTON[c]+1*GLT[c]+1*AMP[c]+1*PP
I[c]+1*NAD[c]

Locus*

MGA-0364

MGA-0161
MGA-1146
MGA-0594
MGA-0362
MONOMER97N-281

MGA-1168,MGA1164,MGA-1167,MGA1170,MGA-1172,MGA1174,MGA-1177,MGA1179,MGA-0488,MGA-0491

A3.4. Exchanges fluxes
Table S8. Exchange fluxes for nutrients and secretion in the M. gallisepticum
model. The name, upper and lower boundary for each exchange fluxes is presented.
Nutrient
name

reaction

2-KETOGLUTARATE-Ex-

1*2-KETOGLUTARATE[e]

low
boundary
-1000

up
boundary
1000
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Flux
CYTOSINE-Ex-Flux
GLC-Ex-Flux
DIHYDROFOLATE-ExFlux
GLYCEROL-Ex-Flux
GLYCEROL-3P-Ex-Flux
WATER-Ex-Flux
FE-2-Ex-Flux
FE-3-Ex-Flux
MG-2-Ex-Flux
MN-2-Ex-Flux
CPD-3-Ex-Flux
NI-2-Ex-Flux
NIACINE-Ex-Flux
Pi-Ex-Flux
K-Ex-Flux
PUTRESCINE-Ex-Flux
RIBOFLAVIN-Ex-Flux
SPERMIDINE-Ex-Flux
THIAMINE-Ex-Flux
ADENINE-Ex-Flux
THYMIDINE-Ex-Flux
URACIL-Ex-Flux
ZN-2-Ex-Flux
CYTIDINE-Ex-Flux
PYRIDOXAL-Ex-Flux
CHOLINE-Ex-Flux
SULFATE-Ex-Flux
Fatty-Acids-Ex-Flux
Triacylglycerols-Ex-Flux
CHOLESTEROL-Ex-Flux
AMMONIUM-Ex-Flux
Cholesterol-esters-Ex-Flux
AMP-Ex-Flux
CMP-Ex-Flux
UMP-Ex-Flux
GMP-Ex-Flux
OXYGEN-MOLECULE-ExFlux
CL-Ex-Flux

<-->
1*CYTOSINE[e] <-->
1*GLC[e] <-->
1*DIHYDROFOLATE[e] <->
1*GLYCEROL[e] <-->
1*GLYCEROL-3P[e] <-->
1*WATER[e] <-->
1*FE-2[e] <-->
1*FE-3[e] <-->
1*MG-2[e] <-->
1*MN-2[e] <-->
1*CPD-3[e] <-->
1*NI-2[e] <-->
1*NIACINE[e] <-->
1*Pi[e] <-->
1*K[e] <-->
1*PUTRESCINE[e] <-->
1*RIBOFLAVIN[e] <-->
1*SPERMIDINE[e] <-->
1*THIAMINE[e] <-->
1*ADENINE[e] <-->
1*THYMIDINE[e] <-->
1*URACIL[e] <-->
1*ZN-2[e] <-->
1*CYTIDINE[c] <-->
1*PYRIDOXAL[e] <-->
1*CHOLINE[e] <-->
1*SULFATE[e] <-->
1*Fatty-Acids[e] <-->
1*Triacylglycerols[e] <-->
1*CHOLESTEROL[e] <-->
1*AMMONIUM[e] <-->
1*Cholesterol-esters[e] <-->
1*AMP[e] <-->
1*CMP[e] <-->
1*UMP[e] <-->
1*GMP[e] <-->
1*OXYGEN-MOLECULE[c]
<-->
1*CL[c] <-->

-1000
-16.53

1000
-16.53

-1000

1000

-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
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1000

-1000

1000
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GLN-Ex-Flux
CA-2-Ex-Flux
CYS-Ex-Flux
THR-Ex-Flux
L-ALPHA-ALANINE-ExFlux
ARG-Ex-Flux
ASN-Ex-Flux
L-ASPARTATE-Ex-Flux
GLT-Ex-Flux
GLY-Ex-Flux
HIS-Ex-Flux
ILE-Ex-Flux
CARBON-DIOXIDE-ExFlux
LEU-Ex-Flux
LYS-Ex-Flux
MET-Ex-Flux
PHE-Ex-Flux
PRO-Ex-Flux
SER-Ex-Flux
TRP-Ex-Flux
TYR-Ex-Flux
VAL-Ex-Flux
Ceramides-Ex-Flux
CO-2-Ex-Flux
NA-Ex-Flux
CO-A-Ex-Flux
CU-2-Ex-Flux

1*GLN[c] <-->
1*CA-2[e] <-->
1*CYS[c] <-->
1*THR[c] <-->
1*L-ALPHA-ALANINE[c]
<-->
1*ARG[e] <-->
1*ASN[e] <-->
1*L-ASPARTATE[c] <-->
1*GLT[e] <-->
1*GLY[c] <-->
1*HIS[e] <-->
1*ILE[e] <-->
1*CARBON-DIOXIDE[c] <->
1*LEU[e] <-->
1*LYS[e] <-->
1*MET[e] <-->
1*PHE[e] <-->
1*PRO[e] <-->
1*SER[e] <-->
1*TRP[e] <-->
1*TYR[e] <-->
1*VAL[e] <-->
1*Ceramides[e] <-->
1*CO-2[e] <-->
1*NA-[e] <-->
1*CO-A[e] <-->
1*CU-2[e] <-->

-1000
-1000
-1000
-1000

1000
1000
1000
1000

-1000

1000

-1000
-1000
-1000
-1000
-1000
-1000
-1000

1000
1000
1000
1000
1000
1000
1000

-1000

1000

-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000
1000

low
boundary
10.29
0

up
boundary
10.29
1000

0

1000

0
0
0

1000
1000
1000

Secretion
name

reaction

L-LACTATE-Ex-Flux
ACET-Ex-Flux
HYDROGEN-PEROXIDEEx-Flux
BIOMASS-Ex-Flux
HCO3-Ex-Flux
MAL-Ex-Flux

1*L-LACTATE[e] <-->
1*ACET[e] <-->
1*HYDROGENPEROXIDE[c] <-->
1*BIOMASS[c] <-->
1*HCO3[c] <-->
1*MAL[c] <-->
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PROTON-Ex-Flux

PROTON[e] <-->

0

1000

A3.5. Biomass reaction
Table S9. Reactants of Biomass reactions for M. gallisepticum model. The name and
stoichiometric coefficients for each species are given.
Name
GTP
CTP
UTP
dATP
dGTP
dCTP
dTTP
Ca
Chloride
Co2+
Cu2+
Fe2+
Fe3+
K
Mg
Mn2+
Molybdate
Ammonium
Sulfate
Zn2+
10-Formyltetrahydrofolate
S-Adenosyl-L-methionine
Coenzyme A
FAD
5,10-Methylenetetrahydrofolate
NAD
NADP
Putrescine
Pyridoxal 5'-phosphate
Riboflavin
Spermidine
Tetrahydrofolate

Stoichiometric coefficients
0.06313
0.03898
0.06872
0.03180
0.01474
0.01474
0.03166
0.00412
0.00609
0.00406
0.00406
0.00914
0.00437
0.90830
0.13079
0.00406
0.00406
0.01523
0.00508
0.00406
0.00051
0.00029
0.00074
0.00029
0.00029
0.02083
0.00116
0.04501
0.00029
0.00029
0.00900
0.00029

233

Name
Thiamine diphosphate
cardiolipin
a 1,2-diacylglycerol-3-phosphate
a phosphatidyl-choline
a sphingomyelin
an L-1-Phosphatidyl-glycerol
cholesterol
a cholesterol ester
a triacylglycerol
charged-ALA-trnas
charged-ARG-trnas
charged-ASN-trnas
charged-ASP-trnas
Charged-CYS-tRNAs
Charged-GLN-tRNAs
Charged-GLT-tRNAs
Charged-GLY-tRNAs
Charged-HIS-tRNAs
Charged-ILE-tRNAs
Charged-LEU-tRNAs
Charged-LYS-tRNAs
Charged-MET-tRNAs
Charged-PHE-tRNAs
Charged-PRO-tRNAs
Charged-SER-tRNAs
Charged-THR-tRNAs
Charged-TRP-tRNAs
Charged-TYR-tRNAs
Charged-VAL-tRNAs
N-Formyl-L-methionyl-tRNAfmet
ATP
water

Stoichiometric coefficients
0.00029
0.03583
0.01271
0.03205
0.01316
0.01367
0.08056
0.00497
0.01522
0.32989
0.23855
0.18293
0.18293
0.07008
0.32173
0.32185
0.50466
0.10098
0.33360
0.42815
0.39935
0.14004
0.21741
0.19850
0.26722
0.23027
0.06711
0.13695
0.37908
0.00705
73.2236
68.0887

Table S10. Products of Biomass reactions for M. gallisepticum model. The name
and stoichiometric coefficients for each species are given.
Name
ALA-trnas
ARG-trnas
ASN-trnas

Stoichiometric coefficients
0.32989
0.23855
0.18293
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Name
ASP-trnas
CYS-tRNAs
GLN-tRNAs
GLT-tRNAs
GLY-tRNAs
HIS-tRNAs
ILE-tRNAs
LEU-tRNAs
LYS-tRNAs
MET-tRNAs
PHE-tRNAs
PRO-tRNAs
SER-tRNAs
THR-tRNAs
TRP-tRNAs
TYR-tRNAs
VAL-tRNAs
MET-tRNAs
formate
biomass
ADP
PI
PPI
Protons

Stoichiometric coefficients
0.18293
0.07008
0.32173
0.32185
0.50466
0.10098
0.33360
0.42815
0.39935
0.14004
0.21741
0.19850
0.26722
0.23027
0.06711
0.13695
0.37908
0.00705
0.00705
1
73.1400
73.1215
0.3463
73.1400

A3.6. Experimentally measured fluxes
Table S11. Measured fluxes for M. gallisepticum model.
Flux name
ATP_maintenance_requirement
GLC-Ex-Flux
L-LACTATE-Ex-Flux

Low
boundary
8.4
-16.53
10.29

Up
boundary
1000
-16.53
10.29
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APPENDIX 4. GAFBA v1.1 USER MANUAL

A4.1. Introduction

Metabolic engineering requires a high-quality genome scale metabolic networks
to get results near to the physiological behavior. Many of the available metabolic models
are incomplete because of lack of information.
GAFBA v1.1 is a tool design to help in the curation of genome scale metabolic
models. The software guides the user through the curation process and aids in the
determination of metabolites participating in unaccounted for reactions. With this tool, it
is possible to quickly identify the key metabolites to focus on for detailed curation,
reducing overall curation time. The software is based on a genetic algorithm approach
that identifies problematic metabolites.
The tool has an user-friendly interface that receives all the information and
generate files that contain the flux distribution, and the list of metabolites which mass
balance constraint was unenforced.
A4.2. Development.

GAFBA v1.1 software is a project from Dr. Srivastava research's lab at
University of Connecticut 2013.The software platform was developed in Common Lisp
and compiled using the LispWorks 6.0.1 Professional Edition compiler. The software is
freely available under the BSD Open Source License. The software package carries out
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linear programming by calling the GNU Linear Programming Kit1. The software is
available for Windows, OS X, and Linux.
A4.3. Getting Started

In order to use you only have to click on the executable file named GAFBA v1.1.
For using GAFBA v1.1 you will need to have:
1. A SBML file that has the metabolic network representation.
2. A biomass reaction
3. Experimental conditions: media composition, measured fluxes, genotype of the
bacteria.
4. A desired objective function
5. Desired genetic algorithm (GA) parameters.
A4.4. Quick tour through GAFBA v1.1

GAFBA v1.1 graphic user interface is divided into three main parts as it is shown
in Figure S4. The first one receives the information corresponding to the SBML file
name, model name, and the location of the glpsol executable. The second is a tabulated
panel where the information of biomass reaction, objective function, exchange fluxes,
measured fluxes, medium composition, knockout reaction, GA parameters, and frequency
analysis are received. The last part corresponds to the option buttons to start GAFBA

1

http://www.gnu.org/software/glpk/
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v1.1, to load a pre-existing input file and to save the information submitted to GAFBA
v1.1 through the GUI in an input file, and the “about button” which has the information
about the copyrights of GAFBA v1.1.

Figure S4. GAFBA v1.1 structure. The three main part of the interface are labeled with
the corresponding number.

When GAFBA v1.1 starts to run a log file with the actual status of the program is
written. In this log file, you can find any problem that can occur during the simulation.
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When, GAFBA v1.1 reaches the termination criteria, it will generate the output files and
a termination message is shown.

A4.5.

Creating the model

Defining a model name, loading network file and location of glpsol
executable. In the first panel, the user can define the desired name for the model. It is
necessary click the check button after enter the name. Then the location of the glpsol
executable has to be specified by searching it through the folder button. Finally, a SBML
file is required to be specified in the second panel by selecting the folder button. A
window will appear, as it is showed at Figure S5, in this window, you can search for the
desired file and then click on the check button.

The SBML file is a representation format, based on XML, for communicating and
storing computational models of the biological process [256]. It may be generated from
the Pathway Tools bioinformatics suite [66] after a Pathway/Genome Database (PGDB)
has been generated with PathoLogic [257] or from an existing PGDB.
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Figure S5. Choosing a SBML file

Submitting Biomass Reaction. The biomass reaction accounts for all the key
cofactors and biosynthetic precursors to produce a 1 gDW of bacteria biomass [128]. All
these metabolites have to be given in a relative amount. Thus, the user additional to
specify the species id of the metabolite, it is also necessary to enter the stoichiometry
coefficient. A special format has to be followed, similar to the one show on Figure S6.
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The structure for defined any metabolite should be: “species id” and the stoichiometry
coefficient has to be specified between quotes “2.3”. Then, they are joined by a
parenthesis (“species id” “2.3") and all the reactants/products components are joined with
an additional parenthesis ((“species id” “2.3”) (“species id” “1.3”)), remember to click on
the check button at the right part of the window.

Figure S6. Creating a biomass reaction.
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The biomass composition may be getting experimentally for cell growing at the
exponential phase or from literature review, Thiele et al. [3] explain more about the
procedure.

Submitting Objective function. In order to get the flux distribution with linear
programing, it is required to choose an objective function and a case of optimization:
maximization or minimization. GAFBA v1.1 has three options to define the objective
function: predefined, choose a reaction present in the SBML file, or create a new
objective function as it is shown in Figure S7. Each of them is explained below.

•

Predefined objective functions.
Biomass. Biomass is one of the most-used objective functions in FBA. It
is hypothesized that the bacteria have evolved for optimization of the specific
growth rate under several conditions [3,44].

ATP. This function is related with the efficient of energy use by the
bacteria. Minimization of ATP production rate means to reduce the energy
consumed during the cell growth, thereby conserving. Maximization of ATP
means direct the bacteria growth to produce as much energy as it can do [26].
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Figure S7. Choose an objective function

•

Existing reaction in the model as an objective function. If the desired objective
function is one present on the SBML file. The user should click on other button. It
will appear a window (Figure S8) asking if you need to create a reaction, the user
should select No. Then a new window will pop up asking about the name of the
reaction. The user should type the name of the reaction as appear in the SBML file.
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Figure S8. Existing reaction in the model

•

Creating a new reaction to be the objective function. If the user wants to create a
different objective function should select other button and when the program asks if
you need to create a reaction, the user should select yes (Figure S9). Then, the name
for the new reaction has to be specified following a special format:
name_of_reaction_r or name_of_reaction_i. The name of the reaction must not have
any space, instead use low dash (_). At the end of the name, you should use r if the
reaction is reversible, or i for irreversible reaction.

The reactants and products for the new reaction have to be entered through the
interface window as it shows in Figure S10. It is required to use the same format as
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the components of the biomass reaction and also click on the check button at the right
part of the window.

Figure S9. Create a new reaction

Figure S10. Defining reactants and products of the new reaction.
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Submitting exchange fluxes. The exchange fluxes are the metabolites capable of
leaving the cell like byproducts and the metabolites taken in from the media to guarantee
the growth of the bacteria. In this part of the software, you should list all of them
(secreted fluxes and uptake fluxes). At the Ex-fluxes tab, the user can decide to add or not
add the exchange fluxes by clicking on yes or no. It is important to add exchange fluxes
to permit the interchange of components between the bacteria and the media.

Figure S11. Defining the exchange fluxes.
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The id and the name for each of the metabolites to be interchange have to be
specified between quotation marks and parenthesis as showed in Figure S11. For
example: ((”id” “name”) (“id” “name”)). It is required to click on the check button at the
right side of the panel to submit the information to GAFBA v1.1.

Declaring experimental measured fluxes. The measured fluxes are constraints
used in flux balance analysis (FBA) to reflect previous known conditions and fluxes
experimentally measured [258]. It is important that each of the metabolites with a
measured flux was already defined in the exchange fluxes section.

The software permits to declare the fluxes or not. If no measured fluxes are
entered, FBA will generate a flux distribution that probably is not going to be reflect the
real behavior of the bacteria. The format to submit the measured fluxes is as follows
(Figure S12):
((“species id Exchange FLUX” “lower flux value” “upper flux value")
(“species id Exchange FLUX” “lower flux value” “upper flux value”))
Remember to click on the check button after finish to enter all the experimental
measured fluxes.
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Figure S12. Measured fluxes.

Submitting medium composition.

The media composition represents the

constraints imposed to the cells by the environment around them. The growth of the
bacteria depends on the presence or absence of certain components [259]. If a metabolite
defined in the exchange fluxes is present at the medium composition, it means that the
metabolite can go in and go out freely (lower boundary of -1000 and upper boundary of
1000). On the contrary, if the metabolite is presented at the exchange fluxes but not at the
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medium composition, the metabolite just can go out the bacteria (secretion) lower
boundary of 0 and upper boundary of 1000.
In order to declare the medium composition, first the yes button has to be pressed,
then the medium composition has to be enter following the format, finally the user has to
click on the check button on the right. The format is shown on Figure S13. It should be
used the id of the reaction responsible for the interchange of the metabolite to/from
outside from/to inside.

Figure S13. Medium composition.
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Submitting knockouts. Some reactions are knocked out because of gene
regulation under different environmental conditions or because of the genotype of the
bacteria. In this part of the interface, the user can enter such as reactions. The user can
decide to do/not do the knockouts by clicking on yes/or no button. If yes button was
pressed the name of the reactions have to be declared on quotes and parenthesis as it is
shown on Figure S14. Then the green check button on the right side has to be clicked on.

Figure S14. Regulatory constraints.
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Genetic algorithm preferences. At the GA tab, GAFBA v1.1 permits to run just
a FBA simulation by clicking on no button or a GAFBA v1.1 simulation by clicking on
yes button. The user can define the values for probability of crossover (pc), number of
point crossover (npc), probability of mutation (pm), elite fraction (ef), population size
(ps), number of generations (ng), number of simulation (ns), bottom re-seed fraction
(brsf), frequency of bottom re-seed (fbrs), and the condition for the initial population (ip)
under this tab as it is shown on Figure S15.

Figure S15. Genetic algorithm preferences.
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For the number of n-point crossover, many studies suggested that when the
population size is less than 50, it is good to have more than two-point crossover [260262].

The condition of the initial population represents the way of GAFBA v1.1 has to
generate the first population to be used for the GA part. It can be random or using a
previous population (customize). When customize button is clicked on, a new window
appears asking for the file that contains the desired initial population. Customize
population is useful when the user wants to re-use a previous generated population after
make some changes but not metabolites had been added/removed. In all the other cases,
the population needs to be re-initialized randomly.

Bottom re-seed replaces chromosomes of the bottom part of the population with
new randomly generated chromosomes. The user can decide of do/not do it, by selecting
yes or no. Also, it needs to define the bottom fraction of the population to be replaced,
and the frequency which this process will be repeated. This scheme is useful when the
user observed that the population was rapidly becoming uniform [261]. For example, if
the user observed that after 2000 generation with a population size of 30 and elite fraction
of 0.2, more than the top six chromosomes are the same, it will be useful to do reseeding.
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The number of generation is the limit of runs of GAFBA v1.1 desired. The
number of simulations is the times that the user wants to run a model before make any
change, for example: a run of GAFBA v1.1 with four simulations and 2000 generations
means that the software is going to make a total of 8000 runs of GAFBA v1.1 before the
program stop, as it is shown on Figure 15, where the complete structure of GAFBA v1.1
is presented.

If the user does not enter any value for the parameters, and the software is going
to run GAFBA v1.1, predefined values are going to be used: pc=0.7, npc=2, pm=0.01,
ef=0.2, ns=1, gn=200, ps=30, brsf= 0.2, fbrs=100, and ip= random.

A4.6. Saving input information in a file.

GAFBA v1.1 permits save the information submitted through the interface by
clicking on the save configuration button. A window will appear asking for the name of
the file to save the information. The file is saved in the same folder as the GAFBA v1.1
executable. The format of the file is explaining on the section number A4.9.
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A4.7.Load a previous input file.

GAFBA v1.1 has the possibility to load a previous configuration by clicking on
the load button. A window will open, as it is shown in Figure S16, it asks about the name
of the file. The file can be searched through this window.

Figure S16. Loading a saved input file.

254

A4.8.

Start GAFBA.

After the required information is entered through the interface or through a
previous file, the start button can be clicked. GAFBA v1.1 starts to run and the status of
the simulation is going to be printed out in a .log file. When, GAFBA v1.1 is done with
the simulation, a message will appear letting know that the process has finished.
A4.9. Results files.

GAFBA v1.1 generates five output files that contain the best solution to the FBA
problem, the best model of the bacteria, the last population, the record of the best
chromosome each one hundred generations and the file with the list of problematic
metabolites. Each of these files is explained in the following sections.

•

Model file. This is the input file for running the linear programming solver glpsol.
You can find here the variables associated with each of the reactions. There are two
kinds of variables b_n and Vn where n is an integer, the first one refers to exchange
fluxes and the second one are the rest of reactions (transport reactions, internal
reactions, spontaneous reactions).
Model file also has the objective function, the upper and the lower boundaries
for the fluxes and the mass balance for each metabolite in the model. The name of the
file is: modelname#.txt, the number refers to the simulation number.
255

•

Flux distribution file. The flux distribution file is the one with the name in this
format modelnamesoln#.txt, the number refers to the simulation number. It has the
final result for each of the fluxes present in the metabolic network, the result for the
objective function and the final status of the model. It is required that in front of the
word “Status” always appears OPTIMAL. If the status is different than OPTIMAL, it
is necessary to run GAFBA v1.1 for more generation. The value for the objective
function is shown in front of the word “Objective:”. The flux for each the reactions is
at the middle of the document, in this part you will find a column with a sequence of
numbers, then a column with the variables names and the fourth column under the
activity title is the flux value for the reaction in mmol gDW-1 h-1. An example of the
flux distribution file is shown on Figure S17.

256

Figure S17. FBA solution file

•

Problematic metabolites file. The problematic metabolites are listed on the file with
the name resultsanalysis#.txt . This file has the number of mass balance constraints
kept, the number of mass balance leaving open, the value of the objective function
and the list of the metabolites which mass balances were not fulfilled.
It is desired that the number of mass balance constraints dropped are similar to
zero.
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The user should review this file carefully, since the metabolites listed in here
require some adjusted to the reaction or addition of new reaction to complete the mass
balance. Since at the beginning of the process many metabolites are dropped. It is
advisable to run the model for at least 14000 generations for models with more than
1000 metabolites or 8000 generations for models with less than 1000 metabolites
before to review the problematic metabolites file.

•

Population file. This is the file label as modelnamepopulationsoln#.txt. It has the last
population used in GAFBA v1.1 after each simulation. The population is formed by n
chromosome, n is defined by the user with the population size parameter. This file is
useful when it is wanted to start the program with a customize population, usually
when some changes had been made to the model but not metabolites had been
added/removed. Thus, when a new simulation is going to start, in the genetic
algorithm preferences tab should be chosen customize population and then search for
this file.

•

Best chromosome recorded file. This file keeps tracking the best chromosome each
one hundred generations. The name of the file is: modelnamebestchromo#.txt, were
again the number refers to the simulation number. It gives an advantage to the user to
review the progress of the model.
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A4.10. Possible solutions to fill gaps

The potential solutions for adjust the model are five: 1) change the directionality
of a reaction, 2) add an exchange flux for the metabolite, 3) add a transport or
intracellular reaction, 4) remove a reaction or metabolite from the model, and 5) no
change. The decision taken has to be based on literature survey or information from
related species. More information about this topic and examples are available in Bautista
et al. [192]
A.4.11. Running a new simulation

There are two kinds of modes for restarting the program, and they depends on the
changes made to the model.
1. Enter again all the information through the interface and use a random
population: it is applied when the user added/removed a metabolite from the previous
model.
2. Enter the information through a saved file, or through the interface and use a
customize population: it is implemented when the changes to the model were on the
directionality of reactions, added/removed exchange fluxes, or transport reactions, or
intracellular reactions, or not change was done to the model.
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A.4.12. Input file

GAFBA v1.1 automatically creates the input file by clicking on save button after
enter the information through the interface. The format used to write the input file is
based on LISP programing language. The file can be modified, but you always should
keep in mind the specified format for each part.
A.4.13.Frequency analysis

After, some simulation had been carried; a frequency analysis could be done by
selecting the frequency analysis tab in the GAFBA v1.1 GUI, which is shown in Figure
S18. It will need to provide with the population (modelnamepopulationsoln#.txt), and the
file with the model (modelname#.txt), where the number symbol refers to the simulation
number to be studied (n). Furthermore, it is required to specify the number of top
chromosomes to be analyzed (y). Usually this number should be near to the elite
chromosomes. For example, if the elite fraction was 0.2 and the population size was 30
the elite chromosomes are 6. Thus, a good value for y should be 10. After enter all the
information through the gui for the frequency analysis, the Results botton could be
pressed it, and a file with the name analysis-constraint.txt is created that have the
metabolites with mass balance constraints that were presented in all the y chromosomes.
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Figure S18. Frequency analysis input information.

The rationale behind the frequency analysis is as a follow, when minimizing the
number of relaxed constraints, the GA generated a population of models represented by
chromosomes indicating which metabolic constraints had to be relaxed. It is possible to
determine the frequency with which a metabolic constraint is relaxed across the
population of chromosomes. The metabolic constraints with the highest frequency of
relaxation were likely the most pathologic to the generation of a feasible metabolic
model. As a further point of reference, as populations evolved, frequencies should be
tracked across generations. Doing this provided further information regarding how
critical a particular metabolic constraint is to the viability of the model.
The process begins by randomly selecting the final populations of two different
simulations n and n+x, from GAFBA v1.1 for comparison. Each simulation consisted of
evolving model populations for the desired generations. Constraints that were
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consistently relaxed in the top y chromosomes of each of the final populations were
selected. Relaxed metabolic constraints that arose in both in the top y chromosomes of
each population were considered the most pathological metabolites. Therefore, they were
the first metabolites to be analyzed. The algorithm representation of the frequency
analysis is presented in Figure 11. More information about this methodology can be
found in Bautista et al. [127].
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APPENDIX 5. ADDITIONAL EXPERIMENTAL METHODS

Metabolites uptake and secretion rates calculation. The glucose uptake rate,
iron uptake rate, and glutamic acid uptake rate were calculated by solving the dynamic
mass balance [23,24]:
𝑑 𝑉 ∙    𝑆
𝑑𝑡

= −𝑞! ∙ 𝑉 ∙ 𝑋!

Eq. (1)

where V (L) is the culture volume, 𝑆 (mM) is the metabolite concentration in the
media, 𝑞! (mmol/gDW*h) is the glucose uptake, or iron uptake rate, or glutamic acid
uptake rate, and 𝑋! (gDW/L) is the biomass concentration at time= t (hr).

Oxygen uptake rate was calculated using the Equation 2. The equation is slightly
different to Equation 1, because an additional term for diffusion of oxygen into the
system is included [23,24]
𝑑 𝑉 ∙    𝑂!
𝑑𝑡

= 𝑘! 𝑎 ∙ 𝑂!!"# − 𝑂!

− 𝑞!! ∙ 𝑉 ∙ 𝑋!

Eq. (2)

where V (L) is the culture volume, 𝑂! is concentration of oxygen in the
medium, 𝑂!!"# is the saturation oxygen concentration at time = t, and 𝑘! 𝑎 is the mass
transfer parameter estimated by using the absorption dynamic method [263,264]. The
𝑘! 𝑎 was determined to be 52.2 h-1. Since, the response time of the electrode was
calculated to be 18 s, not correction was applied to the model.
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Lactate secretion rate, and catechol siderophores secretion rate were calculated by
solving the following equation [23,24],
𝑑 𝑉 ∙    𝑃
𝑑𝑡

= 𝑞! ∙ 𝑉 ∙ 𝑋!

Eq. (3)

The terms in Equation 3 are similar to those in Equation 1, however because is
secretion rate, the first term is positive.
Carbon dioxide uptake rate was calculated using Equation 4 [265,266],
𝑑 𝑉 ∙    𝐶𝑂!
𝑑𝑡

= 𝑘! 𝑎 ∙

𝐶𝑂!!"#

− 𝐶𝑂!

𝑑 𝑉 ∙    𝐻𝐶𝑂!!
+ 𝑞!"! ∙ 𝑉 ∙ 𝑋! −
𝑑𝑡

Eq. (4)

The first term represents the diffusion of carbon dioxide from the medium to the
surrounding atmosphere, the second terms is the carbon dioxide produced by the cell, and
the third term is the chemical transformation of carbon dioxide into/from the hydrogen
carbonate buffer.

The 𝑘! 𝑎 for carbon dioxide was calculated using the correlation from equation 5.
It could be applied because the mass transfer parameter for oxygen and carbon dioxide
involve the same interfacial area, the same solvent properties, and the same agitation
variables [267,268]. Thus, 𝑘! 𝑎 for carbon dioxide was 46.46 h-1.
𝑘! 𝑎!"!
= 0.89
𝑘! 𝑎!!

Eq. (5)
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The third term of Equation 4 was determined using the following equation [265],
𝑑 𝑉 ∙    𝐻𝐶𝑂!!
𝑑𝑡
𝐾!"!
=
ln 10 ∙ 10pH
𝑓

!

𝑑pH 𝑡
∙ 𝑉 ∙ 𝐶𝑂! 𝑡    ∙
+    10pH
𝑑𝑡

!

𝑑 𝑉 ∙    𝐶𝑂!
∙
𝑑𝑡

Eq. (6)

where 𝐾!"! is the mass action constant for carbon dioxide in water at 37°C with a
value of 4.21 ∙ 10!!   mol l-1 [265], 𝑓 is the individual hydrogen carbonate activity which
was calculated using the semi-empirical Debye-Hückel equation [269], and it has a value
of 0.88. The calculation of the hydrogen carbonate activity are shown in Table S12 and
Table S13.

265

Table S12. Calculation of Hydrogen carbonate activity for iron-reduced media. * Debye-Hückel Equation because ionic
strength is less than 0.1

Salt/Buffer
MgSO4
MnSO4
KH2PO4
K2HPO4
FeSO4

Mass
concentration
(g l-1)
0.01
0.001
0.68
0.872

Molar
Mass Mi
(g mol-1)
120.366
151
136.09
174.2

Molar
concentration
ci (mol l-1)
8.30799E-05
6.62252E-06
0.004996693
0.005005741
0.00000224

Ion
Mg+2
Mn+2
K+
H2PO4HPO4-2
Fe+2
SO4-2

Molar
concentration
ci (mol l-1)2
8.30799E-05
6.62252E-06
0.015008174
0.004996693
0.005005741
0.00000224
9.19425E-05

Charge zi
(-)
2
2
1
-1
-2
2
-2
Summation
Ionic
strength (I)
A
B
ao HCO3I^1/2
*log f
f

Product ci*zi2
0.00033232
2.64901E-05
0.015008174
0.004996693
0.020022962
0.00000896
0.00036777
0.04076337
0.020381685
0.47
33150000
0.000000054
0.142764438
-0.053441608
0.884216046
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Table S13. Calculation of Hydrogen carbonate activity for iron-replete media. * Debye-Hückel Equation because ionic
strength is less than 0.1

Salt/Buffer
MgSO4
MnSO4
KH2PO4
K2HPO4
FeSO4

Mass
concentrat
ion (g l-1)
0.01
0.001
0.68
0.872

Molar Mass
Mi (g mol-1)
120.366
151
136.09
174.2

Molar
concentration ci
(mol l-1)
8.30799E-05
6.62252E-06
0.004996693
0.005005741
0.00002

Ion
Mg+2
Mn+2
K+
H2PO4HPO4-2
Fe+2
SO4-2

Molar
concentration
ci (mol l-1)2
8.30799E-05
6.62252E-06
0.015008174
0.004996693
0.005005741
0.00002
0.000109702

Charge zi (-)
2
2
1
-1
-2
2
-2
Summation
Ionic strength (I)
A
B
ao HCO3I^1/2
log f
f

Product ci*zi2
0.00033232
2.64901E-05
0.015008174
0.004996693
0.020022962
0.00008
0.00043881
0.04090545
0.020452725
0.47
33150000
0.000000054
0.143013023
-0.053515695
0.884065218

267

APPENDIX 6. TRIPLICATED EXPERIMENTAL DATA

Figure S19. Levels of biomass under iron-reduced conditions (IRDM) for triplicated
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).

Figure S20. Levels of glucose under iron-reduced conditions (IRDM) for triplicated
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).
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Figure S21. Levels of lactate under iron-reduced conditions (IRDM) for triplicated
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).

Figure S22. Levels of carbon dioxide under iron-reduced conditions (IRDM) for triplicated
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).
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Figure S23. Levels of oxygen under iron-reduced conditions (IRDM) for triplicated
experiments. IRDM1 (red squares), IRDM2 (blue diamonds), IRDM3 (purple stars).

Figure S24. Levels of biomass under iron-replete conditions (IRM) for triplicated
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).
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Figure S25. Levels of glucose under iron-replete conditions (IRM) for triplicated
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).

Figure S26. Levels of lactate under iron-replete conditions (IRM) for triplicated
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).

271

Figure S27. Levels of carbon dioxide under iron-replete conditions (IRM) for triplicated
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).

Figure S28. Levels of oxygen under iron-replete conditions (IRM) for triplicated
experiments. IRM1 (red squares), IRM2 (blue diamonds), IRM3 (purple stars).
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APPENDIX 7. SUPPLEMENTARY FIGURES

Figure S29. Biosynthesis pathway of petrobactin and protocatechaute. Metabolites are in red. Reactants or products of the
reactions in yellow are acyl carrier proteins. The name of the enzyme that catalyzed each reaction is in yellow next to reaction. The
genes associated to each enzyme are in purple, and also the E.C. number for each enzyme has been displayed.
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Figure S30. Biosynthesis pathway of bacillibactin. Metabolites are in red. The name of the enzyme that catalyzed each reaction is in
yellow. The genes associated to each enzyme are in purple, and also the E.C. number for each enzyme has been displayed.
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Figure S31. Comparison of the glycolysis pathway under iron-poor/rich at
Phase I. The words in red represent the metabolites. Rectangular boxes have at the
top line the E.C. number for each reaction, the blue numbers correspond to the
fluxes value at iron-poor conditions, and the numbers in orange are the fluxes value
at iron-rich conditions.
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Figure S32. Comparison of the pentose phosphate pathway under iron-poor
and iron-rich conditions at Phase I. The words in red represent metabolites.
Rectangular boxes have at the top line the E.C. number for each reaction, the blue
numbers correspond to the fluxes value at iron-poor conditions, and the numbers in
orange are the fluxes value at iron-rich conditions.
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Figure S33. Comparison of the by-product secretion in B. anthracis under
iron-poor/rich conditions at Phase I. The blue columns are iron-poor conditions,
and orange columns are iron-rich conditions.
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Figure S34. Comparison of the glycolytic pathway under iron-poor/rich
conditions at Phase II. The words in red represent metabolites. Rectangular boxes
have at the top line the E.C. number for each reaction, the blue numbers correspond
to the fluxes value at iron-poor conditions, and the numbers in orange are the fluxes
value at iron-rich conditions.
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Figure S35. Comparison of the by-product secretion and L-lactate uptake in
B. anthracis under iron poor/rich conditions at Phase I. The blue columns are
iron-poor conditions, and orange columns are iron-rich conditions.

Figure S36. Lactate metabolism at Phase II. The metabolites are in black. The
exchange flux of lactate is the yellow arrow, transport reactions are the green
arrows, and intracellular reactions are the blue arrows. The purple boxes have the
enzyme’s name that catalyzed each reaction. The values for each flux are next to
each reaction. Top value for iron-poor conditions and bottom value for iron-rich
conditions.
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APPENDIX 8. GENOME-SCALE METABOLIC MODEL FOR BACILLUS
ANTHRACIS STERNE
A8.1. Extracellular metabolites
Table S14. Metabolites in the extracellular space for B. anthracis. The name, id,
and formula for each species are provided.
Species name
SER[e]
TRP[e]
CARBON-DIOXIDE[e]
CA-2[e]
RIBOSE[e]
ARSENATE[e]
OXYGEN-MOLECULE[e]
CU-2[e]
INOSINE[e]
L-ORNITHINE[e]
GLUCONATE[e]
ACET[e]
NITRATE[e]
NITRITE[e]
AMMONIUM[e]
TYR[e]
GLYCEROL[e]
CYTIDINE[e]
ARG[e]
Nucleosides[e]
CIT[e]
L-ASPARTATE[e]
GLN[e]
THIAMINE[e]
LYS[e]
PHE[e]
CL-[e]
DEOXYADENOSINE[e]
HIS[e]

Species id
L-serine C3H7NO3
L-tryptophan C11H12N2O2
CO2 CO2
Ca2+ Ca
D-ribose C5H10O5
arsenate HO4As
oxygen O2
Cu2+ Cu
inosine C10H12N4O5
L-ornithine C5H13N2O2
D-gluconate C6H11O7
acetate C2H3O2
nitrate NO3
nitrite NO2
ammonium H4N
L-tyrosine C9H11NO3
glycerol C3H8O3
cytidine C9H13N3O5
L-arginine C6H15N4O2
a nucleoside
citrate C6H5O7
L-aspartate C4H6NO4
L-glutamine C5H10N2O3
thiamin C12H17N4OS
L-lysine C6H15N2O2
L-phenylalanine C9H11NO2
chloride Cl
deoxyadenosine C10H13N5O3
L-histidine C6H9N3O2
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Species name
CPD-4422[e]
FE-3[e]
CPD-1106[e]
CPDCWI-18[e]
-3-4-DIHYDROXYBENZOATE[e]
THR[e]
L-LACTATE[e]
ETOH[e]
FORMATE[e]
BETAINE[e]
FE-2[e]
PRO[e]
ALPHA-GLUCOSE[e]
-4-AMINO-BUTYRATE[e]
CO-2[e]
SPERMIDINE[e]
BENZOATE[e]
CPDCWI-7[e]
Amino-Acids-20[e]
CD-2[e]
WATER[e]
GLT[e]
GUANOSINE[e]
CPDCWI-6[e]
URACIL[e]
PHOSPHONATE[e]
ILE[e]
L-ALPHA-ALANINE[e]
Pi[e]
MO-2[e]
DEOXYCYTIDINE[e]
-2-KETOGLUTARATE[e]
PROTON[e]
CYS[e]
CPD-12541[e]
SUCROSE[e]
CPD-763[e]

Species id
chromate HO4Cr
Fe3+ Fe
2-aminoethylphosphonate C2H8NO3P
Ferric-protocatechuate
protocatechuate C7H5O4
L-threonine C4H9NO3
(S)-lactate C3H5O3
ethanol C2H6O
formate CHO2
glycine betaine C5H11NO2
Fe2+ Fe
L-proline C5H9NO2
alpha-D-glucose C6H12O6
4-aminobutyrate C4H9NO2
Co2+ Co
spermidine C7H22N3
benzoate C7H5O2
ferric-petrobactin
a standard alpha amino acid
Cd2+ Cd
H2O H2O
L-glutamate C5H8NO4
guanosine C10H13N5O5
ferric-bacillibactin
uracil C4H4N2O2
phosphonate HO3P
L-isoleucine C6H13NO2
L-alanine C3H7NO2
phosphate HO4P
Mo2+ Mo
deoxycytidine C9H13N3O4
2-oxoglutarate C5H4O5
H+ H
L-cysteine C3H7NO2S
N-acetyl-alpha-D-glucosamine C8H15NO6
sucrose C12H22O11
arsenite H2O3As

281

Species name
SUC[e]
XANTHINE[e]
CPD-10353[e]
GLYCEROL-3P[e]
XANTHOSINE[e]
LEU[e]
MN-2[e]
ADENOSINE[e]
K-[e]
MG-2[e]
TREHALOSE[e]
ASN[e]
OXALATE[e]
MET[e]
UREA[e]
CPD-9984[e]
SULFATE[e]
CELLOBIOSE[e]
PUTRESCINE[e]
Fructose[e]

Species id
succinate C4H4O4
xanthine C5H4N4O2
(R)-acetoin C4H8O2
sn-glycerol-3-phosphate C3H7O6P
xanthosine C10H12N4O6
L-leucine C6H13NO2
Mn2+ Mn
adenosine C10H13N5O4
K+ K
Mg2+ Mg
trehalose C12H22O11
L-asparagine C4H8N2O3
oxalate C2O4
L-methionine C5H11NO2S
urea CH4N2O
bacillibactin C39H42N6O18
sulfate O4S
cellobiose C12H22O11
putrescine C4H14N2
Fructose C6H12O6

VAL[e]

L-valine C5H11NO2

HOMO-SER[e]
NA-[e]
CPD-9985[e]
ZN-2[e]

L-homoserine C4H9NO3
Na+ Na
petrobactin C34H51N6O11
Zn2+ Zn

A8.2. Intracellular metabolites
Table S15. Metabolites in the cytosol space for B. anthracis. The name, id, and
formula for each species are provided.
Species name
-3-Ketopimeloyl-ACP-methyl-esters[c]
TRANS-D2-ENOYL-ACP[c]
Saturated-Fatty-Acyl-ACPs[c]
ITP[c]
-4-FUMARYL-ACETOACETATE[c]

Species id
a 3-oxo-pimelyl-[acp] methyl ester
a trans-delta2-enoyl-acyl-[acp]
a 2,3,4-saturated fatty acyl-[acp]
ITP C10H11N4O14P3
4-fumaryl-acetoacetate C8H6O6
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Species name
CPD-237[c]
OXALATE[c]
tRNA-pseudouridine-38-40[c]
PROPIONATE[c]
CPD-448[c]
R-3-hydroxy-cis-vaccenoyl-ACPs[c]
PROTEIN-LIPOYLLYSINE[c]
-3-HYDROXY-L-KYNURENINE[c]
L-1-phosphatidyl-inositols[c]
BCCP-dimers[c]
ILE-tRNAs[c]
CYTOSINE[c]
NITRITE[c]
Bromide[c]
CPD-1106[c]
Aldehydes[c]
THZ[c]
Enoylglutaryl-ACP-methyl-esters[c]
Oxo-glutarate-dehydro-suc-DH-lipoyl[c]
L-GLUTAMATE-5-P[c]
ThiI-L-cysteine[c]
H2CO3[c]
Cytochromes-C-Reduced[c]
Charged-TRP-tRNAs[c]
UMP[c]
CPD-4211[c]
GLYCERATE[c]
BUTYRIC-ACID[c]
D-HEXOSE-6-PHOSPHATE[c]
Pyruvate-dehydrogenase-acetylDHlipoyl[c]
CPD0-2113[c]
IDP[c]
SUC-COA[c]
PAPS[c]

Species id
indole-3-acetamide C10H10N2O
oxalate C2O4
a tRNA pseudouridine38-40
propionate C3H5O2
beta-D-glucose 1-phosphate C6H11O9P
a {R}-3-hydroxy-cis-vaccenoyl-[acp]
a [glycine-cleavage complex H protein] N6{lipoyl}lysine
3-hydroxy-L-kynurenine C10H12N2O4
an L-1-phosphatidyl-inositol
a biotinylated [BCCP dimer]
tRNAile
cytosine C4H5N3O
nitrite NO2
a bromide
2-aminoethylphosphonate C2H8NO3P
an aldehyde
4-methyl-5-{beta-hydroxyethyl}thiazole
C6H9NOS
an enoylglutaryl-[acp] methyl ester
a [2-oxoglutarate dehydrogenase E2 protein]
N6-{S-succinyldihydrolipoyl}lysine
L-glutamate-5-phosphate C5H8NO7P
a [ThiI sulfur-carrier protein]-L-cysteine
carbonic acid CH2O3
a reduced cytochrome c
L-tryptophanyl-tRNAtrp
uridine-5'-phosphate C9H11N2O9P
dimethylallyl diphosphate C5H9O7P2
D-glycerate C3H5O4
n-butanoate C4H7O2
D-hexose 6-phosphate C6H11O9P
a [pyruvate dehydrogenase E2 protein] N6{S-acetyldihydrolipoyl}lysine
1-octadecanoyl-sn-glycerol 3-phosphate
C21H41O7P
IDP C10H11N4O11P2
succinyl-CoA C25H35N7O19P3S
phosphoadenosine-5'-phosphosulfate
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Species name

Species id
C10H11N5O13P2S

L-CYSTEATE[c]
L-LACTATE[c]
cis-delta5-lignoceroyl-ACPs[c]
PYRIDOXINE[c]
NA-[c]
Charged-PHE-tRNAs[c]
PHOSPHO-ENOL-PYRUVATE[c]
OXALACETIC-ACID[c]

{R}-cysteate C3H6NO5S
{S}-lactate C3H5O3
a cis-delta5-C24 1-[acp]
pyridoxine C8H11NO3
Na+ Na
L-phenylalanyl-tRNAphe
phosphoenolpyruvate C3H2O6P
oxaloacetate C4H2O5
5'-phosphoribosyl-4-{Nsuccinocarboxamide}-5-aminoimidazole
C13H15N4O12P
4,5-dihydroxy-2,3-pentanedione C5H8O4
guanosine C10H13N5O5
streptothricin F C19H37N8O8
D-glyceraldehyde C3H6O3
a cis-delta11-3-oxo-C30 1-[acp]
{1R,6R}-6-hydroxy-2-succinylcyclohexa2,4-diene-1-carboxylate C11H10O6
trans-hexadec-2-enoyl-CoA
C37H60N7O17P3S
Nbeta-acetylstreptothricin F C21H38N8O9
a {R}-3-hydroxybehenoyl-[acp]
a protein-L-methionine-{R}-S-oxide
urea-1-carboxylate C2H3N2O3
7-carboxy-7-deazaguanine C7H5N4O3
L-valine C5H11NO2
4-guanidinobutyramide C5H13N4O
a 3-hydroxyglutaryl-[acp] methyl ester
2-succinyl-5-enolpyruvyl-6-hydroxy-3cyclohexene-1-carboxylate C14H13O9
triacontanal C30H60O
precorrin-2 C42H41N4O16
a cis-delta7-3-hydroxyC26 1-[acp]
a ubiquinol
1,4-dihydroxy-2-naphthoyl-CoA
C32H38N7O19P3S
an octanoylated protein lipoyl-domain
UDP-N-acetylglucosamine-enolpyruvate

P-RIBOSYL-4-SUCCCARBAMINOIMIDAZOLE[c]
DIHYDROXYPENTANEDIONE[c]
GUANOSINE[c]
CPD-9011[c]
GLYCERALD[c]
cis-delta11-3-oxo-melissoyl-ACPs[c]
CPD-9923[c]
CPD0-2117[c]
CPD-9012[c]
R-3-hydroxybehenoyl-ACPs[c]
Protein-L-methionine-R-S-oxides[c]
CPD-578[c]
CPD-13043[c]
VAL[c]
-4-GUANIDO-BUTYRAMIDE[c]
-3-Hydroxyglutaryl-ACP-methyl-ester[c]
CPD-9924[c]
CPD-7888[c]
DIHYDROSIROHYDROCHLORIN[c]
cis-delta7-3-hydroxycerotoyl-ACPs[c]
Ubiquinols[c]
CPD-9925[c]
Octanoylated-domains[c]
UDP-ACETYL-CARBOXYVINYL-
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Species name
GLUCOSAMINE[c]
CPD-444[c]
Primary-Alcohols[c]
N-ACETYL-D-MANNOSAMINE[c]
CPD-3708[c]
GLY-tRNAs[c]
Protein-3-phospho-L-histidines[c]
CPD-8624[c]
CPD-12261[c]
ACETYL-GLU[c]
CPD-3709[c]
CPD-9718[c]
Charged-VAL-tRNAs[c]
Acceptor[c]
CPD-8625[c]
PPI[c]
DIHYDRONEOPTERIN-P3[c]
Butanoyl-ACPs[c]
Nucleoside-Triphosphates[c]
cis-delta19-3-hydroxyC38-ACPs[c]
-5-P-RIBOSYL-NFORMYLGLYCINEAMIDE[c]
Oxidized-flavodoxins[c]
-2-Hexadecenoyl-ACPs[c]
ANTHRANILATE[c]
P-HYDROXY-PHENYLPYRUVATE[c]
CPD66-45[c]
D-SERINE[c]
HOMO-SER[c]
SER-tRNAs[c]
DIHYDROXY-BUTANONE-P[c]
GLUCONATE[c]

Species id
C20H26N3O19P2
S-methyl-5-thio-alpha-D-ribose 1-phosphate
C6H11O7PS
a primary alcohol
N-acetyl-beta-D-mannosamine C8H15NO6
guanosine 3'-monophosphate
C10H12N5O8P
tRNAgly
a protein-Npi-phospho-L-histidine
peptidylproline {omega = 180}
a peptidoglycan with D,D cross-links
{meso-diaminopimelate containing}
C203H318N28O87P2
N-acetyl-L-glutamate C7H9NO5
guanosine 2',3'-cyclic monophosphate
C10H11N5O7P
menaquinone-7 C46H64O2
L-valyl-tRNAval
an oxidized electron acceptor
peptidylproline {omega = 0}
diphosphate HO7P2
7,8-dihydroneopterin triphosphate
C9H12N5O13P3
a butyryl-[acp]
a nucleoside triphosphate
a cis-delta19-3-hydroxyC38 1-[acp]
5'-phosphoribosyl-N-formylglycineamide
C8H13N2O9P
an oxidized flavodoxin C17H19N4O9P
a trans hexadecenoyl-[acp]
anthranilate C7H6NO2
4-hydroxyphenylpyruvate C9H7O4
dipalmitoyl-L-1-phosphatidyl-inositol
C41H78O13P
D-serine C3H7NO3
L-homoserine C4H9NO3
tRNAser
1-deoxy-L-glycero-tetrulose 4-phosphate
C4H7O6P
D-gluconate C6H11O7
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Species name
MET-tRNAs[c]
CPD-7880[c]
PALMITATE[c]
MALONATE-S-ALD[c]
D-GLT[c]
CPD-7881[c]
Hexanoyl-ACPs[c]
Monocarboxylic-Acid-Amides[c]
PHE[c]
-10-FORMYL-THF[c]
Apo-AsbD-Proteins[c]
CPD-7882[c]
FAD[c]
CPD0-2224[c]
ISOBUTYRYL-COA[c]
-3-oxo-decanoyl-ACPs[c]
Protein-Histidines[c]
CPD-7883[c]
R-3-hydroxyhexanoyl-ACPs[c]
CPD-7845[c]
Beta-3-hydroxybutyryl-ACPs[c]
CPD-7884[c]
DTDP-DEOH-DEOXY-GLUCOSE[c]
-5-DEHYDROGLUCONATE[c]
Nucleosides[c]
Palmitoleoyl-ACPs[c]
COPROPORPHYRINOGEN-III[c]
D-ALA-D-ALA[c]
CPD-7885[c]
AMINO-HYDROXYMETHYL-METHYLPYR-P[c]
OXYGEN-MOLECULE[c]
-5-FORMYL-THF[c]
R-3-hydroxystearoyl-ACPs[c]
NADPH[c]
CPD-7886[c]

Species id
tRNAmet
dodecanal C12H24O
palmitate C16H31O2
malonate semialdehyde C3H3O3
D-glutamate C5H8NO4
dotriacontanal C32H64O
a hexanoyl-[acp]
a monocarboxylic-acid-amide
L-phenylalanine C9H11NO2
10-formyl-tetrahydrofolate C20H21N7O7
an apo-AsbD protein
eicosanal C20H40O
FAD C27H31N9O15P2
{S}-3-hydroxyoctanoyl-CoA
C29H46N7O18P3S
isobutyryl-CoA C25H38N7O17P3S
a 3-oxo-decanoyl-[acp]
a [protein]-L-histidine
hexacosanal C26H52O
an {R}-3-hydroxyhexanoyl-[acp]
1-docosanol C22H46O
an {R}-3-hydroxybutanoyl-[acp]
octacosanal C28H56O
dTDP-4-dehydro-6-deoxy-alpha-D-glucose
C16H22N2O15P2
5-dehydro-D-gluconate C6H9O7
a nucleoside
a palmitoleoyl-[acp]
coproporphyrinogen III C36H40N4O8
D-alanyl-D-alanine C6H12N2O3
tetracosanal C24H48O
4-amino-2-methyl-5phosphomethylpyrimidine C6H8N3O4P
oxygen O2
5-formyl-tetrahydrofolate C20H21N7O7
a {R}-3-hydroxystearoyl-[acp]
NADPH C21H26N7O17P3
tetradecanal C14H28O
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Species name
SIROHEME[c]
FUM[c]
HEME-O[c]
CPD-8999[c]
Cis-Delta5-dodecenoyl-ACPs[c]
GLUCOSAMINE-1P[c]
CPD-7887[c]
-2-PG[c]
SO3[c]
Protein-L-methionine[c]
LL-DIAMINOPIMELATE[c]
Monocarboxylates[c]
AGMATHINE[c]
CPD-3706[c]
CPD0-2330[c]
PYRUVATE[c]
Decanoyl-ACPs[c]
CPD-3707[c]
N-acetyl-D-glucosamine[c]
Pi[c]
CPD-3746[c]
N2-SUCCINYLGLUTAMATE[c]
CPD-9717[c]
CPD0-1699[c]
Charged-LEU-tRNAs[c]
FADH2[c]
CHORISMATE[c]
SHIKIMATE-5P[c]
L-BETA-ASPARTYL-P[c]
ACETYL-COA[c]
CPD-62[c]
SHIKIMATE[c]
HOMO-CYS[c]

Species id
siroheme C42H36N4O16Fe
fumarate C4H2O4
heme o C49H56N4O5Fe
5-{methylthio}-2,3-dioxopentyl phosphate
C6H9O6PS
a cis-delta5-dodecenoyl-[acp]
D-glucosamine 1-phosphate C6H13NO8P
tetratriacontanal C34H68O
2-phospho-D-glycerate C3H4O7P
sulfite O3S
a [protein]-L-methionine
L,L-diaminopimelate C7H14N2O4
a monocarboxylate
agmatine C5H16N4
3'-adenosine monophosphate
C10H12N5O7P
phosphatidylglycerol (dihexadec-9-enoyl, nC16 1) C38H70O10P
pyruvate C3H3O3
a decanoyl-[acp]
adenosine 2'3'-cyclic monophosphate
C10H11N5O6P
N-acetyl-D-glucosamine C8H15NO6
phosphate HO4P
methanesulfonate CH3O3S
N2-succinylglutamate C9H10NO7
ubiquinone-7 C44H66O4
6-carboxy-5,6,7,8-tetrahydropterin
C7H8N5O3
L-leucyl-tRNAleu
FADH2 C27H33N9O15P2
chorismate C10H8O6
shikimate-3-phosphate C7H8O8P
L-aspartyl-4-phosphate C4H6NO7P
acetyl-CoA C23H34N7O17P3S
2,3-dihydroxybenzoyl-AMP
C17H17N5O10P
shikimate C7H9O5
L-homocysteine C4H9NO2S
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Species name
N2-SUCCINYLORNITHINE[c]
TARTRONATE-S-ALD[c]
ASN-tRNAs[c]
DUTP[c]
Donor-H2[c]
CPD-7671[c]
IMIDAZOLE-ACETOL-P[c]
PYRIDOXAL-PHOSPHATE[c]
CPD-20[c]
Secondary-Alcohols[c]
CL-[c]
FRUCTOSE-6P[c]
XANTHINE[c]
CPD-12824[c]
CPD-12117[c]
LAUROYLCOA-CPD[c]
FMN[c]
CPD-201[c]
UDP-GALACTOSE[c]
ARG-tRNAs[c]
Charged-ARG-tRNAs[c]
FORMYL-L-METHIONYL-PEPTIDE[c]
THIAMINE[c]
TETRA-H-BIOPTERIN[c]
COBINAMIDE[c]
BETAINE[c]
UDP-MANNACA[c]
ACETYL-P[c]
CPD-12822[c]
D-SEDOHEPTULOSE-7-P[c]
CPD-6321[c]
UTP[c]
THIAMINE-P[c]
CHLORAMPHENICOL-3-ACETATE[c]

Species id
N2-succinyl-L-ornithine C9H15N2O5
tartronate semialdehyde C3H3O4
tRNAasn
dUTP C9H11N2O14P3
a reduced electron acceptor
methanethiol CH4S
imidazole acetol-phosphate C6H7N2O5P
pyridoxal 5'-phosphate C8H8NO6P
3-hydroxy-5- oxohexanoyl-CoA
C27H40N7O19P3S
a secondary alcohol
chloride Cl
D-fructose-6-phosphate C6H11O9P
xanthine C5H4N4O2
cardiolipin {tetrahexadecanoyl, n-C16 0}
C73H140O17P2
demethylmenaquinol-7 C45H64O2
lauroyl-CoA C33H54N7O17P3S
FMN C17H18N4O9P
4-hydroxybenzoyl-CoA
C28H36N7O18P3S
UDP-D-galactose C15H22N2O17P2
tRNAarg
L-arginyl-tRNAarg
formyl-L-methionyl peptide
thiamin C12H17N4OS
tetrahydrobiopterin C9H15N5O3
cobinamide C48H72N11O8Co
glycine betaine C5H11NO2
UDP-N-acetyl-beta-D-mannosaminouronate
C17H22N3O18P2
acetylphosphate C2H3O5P
phosphatidylglycerol {dioctadecanoyl, nC18 0} C42H82O10P
D-sedoheptulose-7-phosphate C7H13O10P
[procollagen] trans 4-hyroxy-L-proline
UTP C9H11N2O15P3
thiamin phosphate C12H16N4O4PS
chloramphenicol 3-acetate

288

Species name

Species id
C13H14N2O6Cl2

MALONYL-COA[c]
R-3-hydroxyarachidoyl-ACPs[c]
CPD-10815[c]

malonyl-CoA C24H33N7O19P3S
a {R}-3-hydroxyarachidoyl-[acp]
methylphosphate CH3O4P
S-adenosyl-L-homocysteine
C14H20N6O5S
a 3,4-DHB-AsbD protein
beta-D-fructofuranose C6H12O6
a reduced flavodoxin C17H21N4O9P
phosphoribulosylformimino-AICAR-P
C15H21N5O15P2
dUDP C9H11N2O11P2
ethanol C2H6O
beta-D-glucose-6-phosphate C6H11O9P
L-histidyl-tRNAhis
phosphatidylglycerophosphate
{dioctadecanoyl, n-C18 0} C42H81O13P2
a 3-oxo-glutaryl-[acp] methyl ester
{2S}-2-isopropyl-3-oxosuccinate C7H8O5
dipicolinate C7H3NO4
L-glutaminyl-tRNAgln
beta-maltose C12H22O11
a cis-delta7-C26 1-[acp]
1,2-dipalmitoyl-phosphatidylglycerolphosphate C38H73O13P2
5-hydroxytryptophol C10H11NO2
L-histidinol-phosphate C6H11N3O4P
spermidine C7H22N3
a protein-L-methionine-{S}-S-oxide
{S}-dihydroorotate C5H5N2O4

ADENOSYL-HOMO-CYS[c]
-34-DHB-AsbD-Proteins[c]
BETA-D-FRUCTOSE[c]
Reduced-flavodoxins[c]
PHOSPHORIBULOSYL-FORMIMINOAICAR-P[c]
DUDP[c]
ETOH[c]
GLC-6-P[c]
Charged-HIS-tRNAs[c]
CPD-12820[c]
-3-Ketoglutaryl-ACP-methyl-ester[c]
CPD-7100[c]
CPD-4841[c]
Charged-GLN-tRNAs[c]
MALTOSE[c]
cis-delta7-cerotoyl-ACPs[c]
CPD-12821[c]
CPD-11671[c]
L-HISTIDINOL-P[c]
SPERMIDINE[c]
Protein-L-Methionine-S-Oxides[c]
DI-H-OROTATE[c]
Cyclic-2-3-RibonucleosideMonophosphates[c]
Charged-ASP-tRNAs[c]
-2-ACETO-2-HYDROXY-BUTYRATE[c]
CPDN-384[c]
CPD-245[c]
cis-delta15-3-oxo-gheddoyl-ACPs[c]
LYS[c]
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a nucleoside 2',3'-cyclic phosphate
L-aspartyl-tRNAasp
2-aceto-2-hydroxy-butanoate C6H9O4
2-hydroxychromene-2-carboxylate
C10H7O4
3-carboxy-cis,cis-muconate C7H3O6
a cis-delta15-3-oxo-C34 1-[acp]
L-lysine C6H15N2O2

Species name
CPD-246[c]
CPDN-385[c]
CPD0-2108[c]
-2-METHYL-BUTYRYL-COA[c]
NADH[c]
cis-delta21-3-hydroxyC40-ACPs[c]
HISTIDINAL[c]
CARBAMYUL-L-ASPARTATE[c]
UDP[c]
Primary-Amines[c]
METHYLENE-THF[c]
DIHYDROPTERIN-CH2OH-PP[c]
O-SUCCINYL-L-HOMOSERINE[c]
PALMITYL-COA[c]
CPD-763[c]
CPD-1136[c]
DETHIOBIOTIN[c]
CIS-ACONITATE[c]
L-GLUTAMATE-GAMMASEMIALDEHYDE[c]
SUCC-S-ALD[c]
CPD-8742[c]
Cytochromes-C-Oxidized[c]
Pyruvate-dehydrogenase-dihydrolipoate[c]
HOMOGENTISATE[c]
CPD-371[c]
-2K-4CH3-PENTANOATE[c]
N3-ACETYLGENTAMICIN-C[c]
-4-AMINO-4-DEOXYCHORISMATE[c]
N-ACETYL-GLUTAMYL-P[c]
CPD-12258[c]
Trans-D3-cis-D7-tetradecenoyl-ACPs[c]
B-KETOACYL-ACP[c]

Species id
{2Z}-5-oxohex-2-enedioate C6H4O5
trans-O-hydroxybenzylidenepyruvate
C10H7O4
trans-oct-2-enoyl-CoA C29H44N7O17P3S
I
NADH C21H27N7O14P2
a cis-delta21-3-hydroxyC40 1-[acp]
histidinal C6H10N3O
N-carbamoyl-L-aspartate C5H6N2O5
UDP C9H11N2O12P2
a primary amine
5,10-methylenetetrahydrofolate
C20H21N7O6
6-hydroxymethyl-dihydropterin diphosphate
C7H8N5O8P2
O-succinyl-L-homoserine C8H12NO6
palmitoyl-CoA C37H62N7O17P3S
arsenite H2O3As
cis-2-methylaconitate C7H5O6
dethiobiotin C10H17N2O3
cis-aconitate C6H3O6
L-glutamate gamma-semialdehyde
C5H9NO3
succinate semialdehyde C4H5O3
{3E}-2-oxohex-3-enedioate C6H4O5
an oxidized cytochrome c
a [pyruvate dehydrogenase E2 protein] N6{dihydrolipoyl}lysine
homogentisate C8H7O4
octanal C8H16O
4-methyl-2-oxopentanoate C6H9O3
N3'-acetylgentamicin C
4-amino-4-deoxychorismate C10H10NO5
N-acetylglutamyl-phosphate C7H9NO8P
UDP-N-acetylmuramoyl-L-alanyl-gammaD-glutamyl-L-lysyl-D-alanine
C37H57N8O25P2
a trans-delta3-cis-delta7-tetradecenoyl-[acp]
a 3-oxoacyl-[acp]
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Species name
CANAVANINOSUCCINATE[c]
Protein-L-glutamine[c]
CPD-8260[c]
cis-delta17-3-hydroxyC36-ACPs[c]
UDP-AAGMDIAMINOHEPTANEDIOATE[c]
Stearoyl-ACPs[c]
-2-KETO-3-METHYL-VALERATE[c]
CPD-11740[c]
LEU[c]
-3-DEHYDRO-SHIKIMATE[c]
CH33ADO[c]
DAMP[c]
-4-CYTIDINE-5-DIPHOSPHO-2-C[c]
CPD-335[c]
BIOPTERIN[c]
-4-IMIDAZOLONE-5-PROPIONATE[c]
PHOSPHORIBOSYL-FORMIMINOAICAR-P[c]
L-CANALINE[c]
DIOH-ISOVALERATE[c]
LYS-tRNAs[c]
CO-2[c]
NADP[c]
CPD-11020[c]
L-methionyl-tRNAfmet[c]
CPD0-2107[c]
BIOTIN[c]
CPD-7879[c]
L-ORNITHINE[c]
CPD0-2106[c]
N-5-PHOSPHORIBOSYLANTHRANILATE[c]
-3-oxo-cis-D9-hexadecenoyl-ACPs[c]

Species id
canavaninosuccinate C9H15N4O7
a [protein]-L-glutamine
1,2-dipalmitoyl-phosphatidylglycerol
C38H74O10P
a cis-delta17-3-hydroxyC36 1-[acp]
UDP-N-acetylmuramoyl-L-alanyl-Dglutamyl-meso-2,6-diaminopimelate
C35H51N7O26P2
a stearoyl-[acp]
2-keto-3-methyl-valerate C6H9O3
carboxyphosphinopyruvate C4H2O7P
L-leucine C6H13NO2
3-dehydroshikimate C7H7O5
5'-deoxyadenosine C10H13N5O3
dAMP C10H12N5O6P
4-{cytidine 5'-diphospho}-2-C-methyl-Derythritol C14H23N3O14P2
{R}-3-hydroxybutanoate C4H7O3
dihydrobiopterin C9H13N5O3
4-imidazolone-5-propionate C6H6N2O3
1-{5-phosphoribosyl}-5-[{5phosphoribosylamino}methylideneamino]i
midazole-4-carboxamide C15H21N5O15P2
L-canaline C4H10N2O3
2,3-dihydroxy-3-methylbutanoate C5H9O4
tRNAlys
Co2+ Co
NADP+ C21H25N7O17P3
5-chloro-4-hydroxy-2-oxopentanoate
C5H6O4Cl
L-methionyl-tRNAfmet
{S}-3-hydroxydodecanoyl-CoA
C33H54N7O18P3S
biotin C10H15N2O3S
docosanal C22H44O
L-ornithine C5H13N2O2
3-oxooctanoyl-CoA C29H44N7O18P3S
N-{5'-phosphoribosyl}-anthranilate
C12H13NO9P
a 3-oxo-cis-delta9-hexadecenoyl-[acp]
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Species name
CPD-377[c]
PROTOPORPHYRINOGEN[c]
CPD-10284[c]
MO-2[c]
CPD0-2105[c]
PHOSPHATIDYL-MYO-INOSITOL-45BISPHOSPHA[c]
CPD0-1423[c]
HOP-2229-ENE[c]
THYMIDINE[c]

CPD-12295[c]

ACETALD[c]
GENTAMICIN-C[c]
CPD-1083[c]
UDP-MANNAC[c]
N-6-AMINOHEXANOYL-6AMINOHEXANOATE[c]
CPD0-1422[c]
BENZOATE[c]
-3-SULFINOALANINE[c]
UREA[c]
P3I[c]
CPD-9955[c]
-3-hydroxypimeloyl-ACP-methyl-esters[c]
XYLULOSE-5-PHOSPHATE[c]
TRP-tRNAs[c]
RIBOSE[c]
HS[c]
NIACINAMIDE[c]
-1-4-alpha-D-Glucan[c]
CPD-1086[c]
-4-MALEYL-ACETOACETATE[c]
ACET[c]

Species id
2-keto-D-gluconate C6H9O7
protoporphyrinogen IX C34H38N4O4
3-oxo-myristoyl-CoA C35H56N7O18P3S
Mo2+ Mo
3-oxododecanoyl-CoA C33H52N7O18P3S
a 1-phosphatidyl-1D-myo-inositol 4,5bisphosphate
distearoyl phosphatidate C39H75O8P
hop-22{29}-ene C30H50
thymidine C10H14N2O5
N-acetylmuramoyl-L-alanyl-Disoglutaminyl-N-{beta-D-asparaginyl}-Llysyl-D-alanyl-D-alaninediphosphoundecaprenyl-Nacetylglucosamine C98H161N11O27P2
acetaldehyde C2H4O
gentamicin-C
{E}-2-methylcrotonoyl-CoA
C26H38N7O17P3S
UDP-N-acetyl-D-mannosamine
C17H25N3O17P2
6-aminohexanoate linear dimer
C12H24N2O3
dipalmitoyl phosphatidate C35H67O8P
benzoate C7H5O2
3-sulfinoalanine C3H6NO4S
urea CH4N2O
PPPi O10P3
ubiquinol-7 C44H68O4
a 3-hydroxypimelyl-[acp] methyl ester
D-xylulose-5-phosphate C5H9O8P
tRNAtrp
D-ribose C5H10O5
hydrogen sulfide H2S
nicotinamide C6H6N2O
a 1,4-alpha-D-glucan
5-amino-6-{5-phospho-Dribitylamino}uracil C9H15N4O9P
4-maleyl-acetoacetate C8H6O6
acetate C2H3O2
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Species name
PHE-tRNAs[c]
-1-PALMITOYLGLYCEROL-3PHOSPHATE[c]

Species id
tRNAphe
1-palmitoylglycerol 3-phosphate
C19H37O7P
6,7-dimethyl-8-{1-D-ribityl}lumazine
C13H17N4O6
{S}-3-hydroxy-stearoyl-CoA
C39H66N7O18P3S
an unsulfurated sulfur acceptor
hydroxymethylbilane C40H38N4O17
aniline C6H7N
N-succinyl-L,L-2,6-diaminopimelate
C11H16N2O7
1-hexacosanol C26H54O
tRNAgln
beta-alanine C3H7NO2
7,8-dihydro-D-neopterin C9H13N5O4
2-methylthio-N-6-isopentyl adenosine-37
tRNA
a trans tetradec-2-enoyl-[acp]
arsenate HO4As
a glycerophosphodiester
1-octacosanol C28H58O
L-cystathionine C7H14N2O4S
S-adenosyl-L-methionine C15H23N6O5S
AMP C10H12N5O7P
4alpha-hydroxy-tetrahydrobiopterin
C9H15N5O4
D-proline C5H9NO2
hexanoyl-CoA C27H42N7O17P3S
Cd2+ Cd
K+ K

DIMETHYL-D-RIBITYL-LUMAZINE[c]
CPD0-2253[c]
Unsulfurated-Sulfur-Acceptors[c]
HYDROXYMETHYLBILANE[c]
ANILINE[c]
N-SUCCINYLLL-2-6DIAMINOPIMELATE[c]
CPD-7871[c]
GLN-tRNAs[c]
B-ALANINE[c]
DIHYDRO-NEO-PTERIN[c]
-2-METHYLTHIO-N-6-ISOPENTYLADENOSINE-37-[c]
Tetradec-2-enoyl-ACPs[c]
ARSENATE[c]
Glycerophosphodiesters[c]
CPD-7872[c]
L-CYSTATHIONINE[c]
S-ADENOSYLMETHIONINE[c]
AMP[c]
CPD-5881[c]
D-PROLINE[c]
HEXANOYL-COA[c]
CD-2[c]
K-[c]
-7-AMINOMETHYL-7DEAZAGUANINE[c]
ASP-tRNAs[c]
CPD-7874[c]
-3-oxo-stearoyl-ACPs[c]
-7-CYANO-7-DEAZAGUANINE[c]

preQ1 C7H10N5O
tRNAasp
1-tetracosanol C24H50O
a 3-oxo-stearoyl-[acp]
preQ0 C7H5N5O
guanylyl molybdenum cofactor
C20H22N10O15P2S2Mo
adenine C5H5N5

CPD-582[c]
ADENINE[c]
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Species name
DIHYDROXYACETONE[c]
CPD-8123[c]
CPD-7875[c]
ADP-D-GLUCOSE[c]
CPD-10353[c]
CPD-7876[c]
SEC-tRNAs[c]
Protein-phospho-L-histidines[c]
CPD-507[c]
Trans-D3-cis-D9-hexadecenoyl-ACPs[c]
DTDP-DEOH-DEOXY-MANNOSE[c]
DEOXYXYLULOSE-5P[c]
TYLOSIN[c]
Charged-ILE-tRNAs[c]
COPROPORPHYRINOGEN-I[c]
CPD-7877[c]
SUCROSE[c]
N1-ACETYLSPERMINE[c]
CHLORAMPHENICOL[c]
GLYCOCHOLIC-ACID[c]
PROPANOL[c]
-3-SULFINYL-PYRUVATE[c]
CYS-tRNAs[c]
-3-oxo-petroselinoyl-ACPs[c]
SUCROSE-6P[c]
GLUTATHIONE[c]
CPD-8989[c]
Oxo-glutarate-dehydrogenase-lipoyl[c]
TRP[c]
UDP-GLUCURONATE[c]
THIAMINE-PYROPHOSPHATE[c]
CPD-19[c]
trans-D2-cis-D17-C36-ACPs[c]
BUTANOL[c]
ETHANAMINE[c]

Species id
dihydroxyacetone C3H6O3
molybdenum cofactor
C10H10N5O8PS2Mo
1-tetradecanol C14H30O
ADP-alpha-D-glucose C16H23N5O15P2
{R}-acetoin C4H8O2
1-tetratriacontanol C34H70O
tRNAsec
a protein N-phospho-L-histidine
6-phospho-beta-D-glucosyl-{1,4}-Dglucose C12H21O14P
a trans-delta3-cis-delta9-hexadecenoyl-[acp]
dTDP-4-dehydro-6-deoxy-beta-L-mannose
C16H22N2O15P2
1-deoxy-D-xylulose 5-phosphate C5H9O7P
tylosin C47H79NO16
L-isoleucyl-tRNAile
coproporphyrinogen I C36H40N4O8
1-triacontanol C30H62O
sucrose C12H22O11
N1-acetylspermine C12H31N4O
chloramphenicol C11H12N2O5Cl2
glycocholate C26H42NO6
n-propanol C3H8O
3-sulfinyl-pyruvate C3H2O5S
tRNAcys
a 3-oxo-petroslinoyl-[acp]
sucrose-6-phosphate C12H21O14P
glutathione C10H16N3O6S
L-methionine-{S}-S-oxide C5H11NO3S
a [2-oxoglutarate dehydrogenase E2 protein]
N6-{lipoyl}lysine
L-tryptophan C11H12N2O2
UDP-D-glucuronate C15H19N2O18P2
thiamin diphosphate C12H16N4O7P2S
3-hydroxy-5-oxohexanoate C6H9O4
a trans-delta2-cis-delta17-C36 2-[acp]
n-butanol C4H10O
ethylamine C2H8N
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Species name
XANTHOSINE[c]
Pyruvate-dehydrogenase-lipoate[c]
DEOXY-RIBOSE-1P[c]
SIROHYDROCHLORIN[c]
CPD-11997[c]
-3-5-ADP[c]
CPD-884[c]
HYDROXY-METHYL-BUTENYL-DIP[c]
CPD-11994[c]
DELTA1-PIPERIDEINE-2-6DICARBOXYLATE[c]
DEOXY-RIBOSE-5P[c]
CPD-195[c]
-2-PHOSPHO-4-CYTIDINE-5DIPHOSPHO-2-C-MET[c]
CPD-196[c]
-7-8-DIHYDROPTEROATE[c]
O-SUCCINYLBENZOATE[c]
DEOXYCYTIDINE[c]
S-3-HYDROXYBUTANOYL-COA[c]
UDP-N-ACETYLMURAMATE[c]
trans-delta2-behenoyl-ACPs[c]
BCAA-dehydrogenase-2MP-DH-lipoyl[c]
CPD-602[c]
CPD-12818[c]
trans-D2-cis-D15-gheddoyl-ACPs[c]
D-GLUCOSAMINE-6-P[c]
-4DIMETHYLAMINOPHENYLAZOBENZE
NE[c]

Species id
xanthosine C10H12N4O6
a [pyruvate dehydrogenase E2 protein] N6{lipoyl}lysine
deoxyribose-1-phosphate C5H9O7P
sirohydrochlorin C42H38N4O16
N-acetylmuramoyl-pentapeptide-diphosphodecaprenol C82H131N7O23P2
adenosine 3',5'-bisphosphate
C10H11N5O10P2
6-aminohexanoate C6H13NO2
1-hydroxy-2-methyl-2-{E}-butenyl 4diphosphate C5H9O8P2
omega, mono-trans, poly-cis-decaprenyl
phosphate C50H81O4P
{S}-2,3,4,5-tetrahydrodipicolinate
C7H7NO4
2-deoxy-D-ribose-5-phosphate C5H9O7P
octanoate C8H15O2
2-phospho-4-{cytidine 5'-diphospho}-2-Cmethyl-D-erythritol C14H22N3O17P3
octanoyl-CoA C29H46N7O17P3S
7,8-dihydropteroate C14H13N6O3
o-succinylbenzoate C11H8O5
deoxycytidine C9H13N3O4
{S}-3-hydroxybutanoyl-CoA
C25H38N7O18P3S
UDP-N-acetylmuramate C20H28N3O19P2
a trans-docos-2-enoyl-[acp]
an [apo BCAA dehydrogenase E2 protein]
N6-{S-[2methylpropanoyl]dihydrolipoyl}lysine
5-amino-6-{5-phospho-Dribosylamino}uracil C9H13N4O9P
phosphatidylethanolamine {dioctadecanoyl,
n-C18 0} C41H82NO8P
a trans-delta2-cis-delta15-C34 2-[acp]
D-glucosamine-6-phosphate C6H13NO8P
4-dimethylaminophenylazobenzene
C14H15N3
a [lipoamide acyltransferase] N6-{S-[3methylbutanoyl]dihydrolipoyl}lysine

BCAA-dehydrogenase-3MB-DH-lipoyl[c]
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Species name
CPD-12819[c]
Kanamycins[c]
GLYCEROPHOSPHOGLYCEROL[c]
-2-METHYL-3-HYDROXY-BUTYRYLCOA[c]
-3-hydroxy-cis-D9-hexaecenoyl-ACPs[c]
CPD-12816[c]
METHACRYLYL-COA[c]
BCAA-dehydrogenase-2MB-DH-lipoyl[c]
DGMP[c]
-3HYDROHYDROXYPHOSPHORYLPYRU
VATE[c]
PANTETHEINE-P[c]

Species id
1,2-dipalmitoyl-phosphatidyl-ethanolamine
C37H74NO8P
a kanamycin
glycerophosphoglycerol C6H14O8P
2-methyl-3-hydroxybutyryl-CoA
C26H40N7O18P3S
a 3-hydroxy cis delta9-hexadecenoyl-[acp]
phosphatidylserine {dioctadecanoyl, n-C18
0} C42H81NO10P
methylacrylyl-CoA C25H36N7O17P3S
[lipoamide acyltransferase] N6-{S-[2methylbutanoyl]dihydrolipoyl}lysine
dGMP C10H12N5O7P

CPD-12817[c]
DIHYDROFOLATE[c]
RIBOFLAVIN[c]
-3-oxo-behenoyl-ACPs[c]
-4-PHOSPHONOOXY-THREONINE[c]
-2-KETOGLUTARATE[c]
CPD-12814[c]
CPD-12815[c]
Glycogens[c]
CARBAMOYL-P[c]
L-glutamyl-tRNAGln[c]
PORPHOBILINOGEN[c]
D-6-P-GLUCONO-DELTA-LACTONE[c]
D-Hexoses[c]
-3-ENOLPYRUVYL-SHIKIMATE-5P[c]
CADAVERINE[c]
Hex-2-enoyl-ACPs[c]
Pimeloyl-ACPs[c]
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phosphinopyruvate C3H3O5P
4'-phosphopantetheine C11H21N2O7PS
1,2-dipalmitoyl-phosphatidylserine
C38H73NO10P
7,8-dihydrofolate monoglutamate
C19H19N7O6
riboflavin C17H19N4O6
a 3-oxo-behenoyl-[acp]
4-phospho-hydroxy-L-threonine
C4H8NO7P
2-oxoglutarate C5H4O5
CDP-1,2-dioctadecanoylglycerol
C48H87N3O15P2
CDP-1,2-dipalmitoylglycerol
C44H79N3O15P2
a glycogen C24H42O21
carbamoyl-phosphate CH2NO5P
L-glutamyl-tRNAGln
porphobilinogen C10H13N2O4
6-phospho-D-glucono-1,5-lactone
C6H9O9P
a D-hexose C6H12O6
5-enolpyruvyl-shikimate-3-phosphate
C10H9O10P
cadaverine C5H16N2
a trans hex-2-enoyl-[acp]
a pimelyl-[acp]

Species name
CO-A[c]
CPD-10490[c]
cis-delta19-C38-ACPs[c]
-2-3-DIHYDROXYBENZOATE[c]

Species id
coenzyme A C21H32N7O16P3S
N-ethylglycine C4H9NO2
a cis-delta19-C38 1-[acp]
2,3-dihydroxybenzoate C7H5O4
{R}-2,3-dihydroxy-3-methylbutanoate
C5H9O4
a trans-delta2-cis-delta7-C26 2-[acp]
D-myo-inositol 1,2-cyclic phosphate
C6H10O8P
a reduced glutaredoxin
an oxidized glutaredoxin
L-methionyl-tRNAmet

CPD-13357[c]
trans-D2-cis-D7-cerotoyl-ACPs[c]
CPD-1121[c]
Red-Glutaredoxins[c]
Ox-Glutaredoxins[c]
Charged-MET-tRNAs[c]
PYRROLINE-HYDROXYCARBOXYLATE[c]
Charged-SER-tRNAs[c]
tRNA-with-7-aminomethyl-7deazaguanine[c]
ACETYLSERINE[c]
CPD-9038[c]
cis-delta11-3-hydroxymelissoyl-ACPs[c]
AMINOMETHYLDIHYDROLIPOYLGCVH[c]
OH-ACYL-ACP[c]
PHOSPHORIBOSYL-CARBOXYAMINOIMIDAZOLE[c]
UROCANATE[c]
ERYTHROSE-4P[c]
GAP[c]
DIHYDROXYNAPHTHOATE[c]
DIAMINONONANOATE[c]
-3-P-HYDROXYPYRUVATE[c]
-3-KETOBUTYRATE[c]
THZ-P[c]
FUCULOSE-1P[c]
XANTHOSINE-5-PHOSPHATE[c]
N-ACETYL-AAA-SEMIALDEHYDE[c]
ThiI-S-sulfanylcysteine[c]

pyrroline-hydroxy-carboxylate C5H6NO3
L-seryl-tRNAser
7-aminomethyl-7-deazaguanine at position
34 of a tRNA containing GUN anticodon
O-acetyl-L-serine C5H9NO4
precorrin-1 C41H38N4O16
a cis-delta11-3-hydroxyC30 1-[acp]
a [glycine-cleavage complex H protein] N6{aminomethyldihydrolipoyl}lysine
a {3R}-3-hydroxyacyl-[acp]
5-amino-1-{5-phospho-Dribosyl}imidazole-4-carboxylate
C9H11N3O9P
urocanate C6H5N2O2
D-erythrose-4-phosphate C4H7O7P
D-glyceraldehyde-3-phosphate C3H5O6P
1,4-dihydroxy-2-naphthoate C11H7O4
7,8-diaminopelargonate C9H21N2O2
3-phospho-hydroxypyruvate C3H2O7P
acetoacetate C4H5O3
4-methyl-5-{2-phosphonooxyethyl}thiazole
C6H8NO4PS
L-fuculose-1-phosphate C6H11O8P
XMP C10H11N4O9P
N2-acetyl-alpha-aminoadipate semialdehyde
C8H12NO4
a [ThiI sulfur-carrier protein]-S-
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Species name

Species id
sulfanylcysteine

SUC[c]
Sulfurated-Sulfur-Acceptors[c]
VAL-tRNAs[c]
HIS[c]

succinate C4H4O4
S-sulfanyl-[acceptor]
tRNAval
L-histidine C6H9N3O2
N-acetyl-L-glutamate 5-semialdehyde
C7H10NO4
L-alanyl-tRNAala
H+ H
a trans-delta2-decenoyl-[acp]
dATP C10H12N5O12P3
FMNH2 C17H21N4O9P
a cis-delta9-C28 1-[acp]
a kanamycin-3-phosphate
D-aspartate C4H6NO4
an alcohol
N-acetyl-D-glucosamine-6-phosphate
C8H14NO9P
GMP C10H12N5O8P
6-hydroxymethyl-7,8-dihydropterin
C7H9N5O2
inosine C10H12N4O5
myristoyl-CoA C35H58N7O17P3S
superoxide O2
3-sulfopyruvate C3H2O6S
a 3-oxo-octanoyl-[acp]
stearoyl-CoA C39H66N7O17P3S
a cis-delta19-3-oxo-C38 1-[acp]
{S}-malate C4H4O5
a delta4-hexadecenoyl-[acp]
pyridoxal C8H9NO3
3-hydroxyanthranilate C7H6NO3
a monoamine
a trans dodec-2-enoyl-[acp]
an oxidized ferredoxin
2,5-didehydro-D-gluconate C6H7O7
5'-deoxy-5'-fluoroadenosine
C10H12N5O3F
1-dotriacontanol C32H66O

CPD-469[c]
Charged-ALA-tRNAs[c]
PROTON[c]
Trans-D2-decenoyl-ACPs[c]
DATP[c]
FMNH2[c]
cis-delta9-montanoyl-ACPs[c]
Kanamycin-3-phosphates[c]
CPD-302[c]
Alcohols[c]
N-ACETYL-D-GLUCOSAMINE-6-P[c]
GMP[c]
AMINO-OH-HYDROXYMETHYLDIHYDROPTERIDINE[c]
INOSINE[c]
TETRADECANOYL-COA[c]
SUPER-OXIDE[c]
CPD-380[c]
-3-Oxo-octanoyl-ACPs[c]
STEAROYL-COA[c]
cis-delta19-3-oxo-C38-ACPs[c]
MAL[c]
Delta4-hexadecenoyl-ACPs[c]
PYRIDOXAL[c]
-3-HYDROXY-ANTHRANILATE[c]
Monoamines[c]
Dodec-2-enoyl-ACPs[c]
Oxidized-ferredoxins[c]
-25-DIDEHYDRO-D-GLUCONATE[c]
CPD-5923[c]
CPD-7868[c]
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Species name
GUANOSINE-5DP-3DP[c]
CPD0-2171[c]
ATP[c]
cis-vaccen-2-enoyl-ACPs[c]
INDOLE-ACETATE-AUXIN[c]
PRO-tRNAs[c]
MANNOSE-1P[c]
CPD-7869[c]
GLYCOLALDEHYDE[c]
Phospholipid-Cyclopropane-Fatty-Acids[c]
DADP[c]
-3OH-4P-OH-ALPHAKETOBUTYRATE[c]
ACETYL-ETCETERAGLUCOSAMINYLDIPHOSPHOUND[c]
CPD-12287[c]
STEARIC-ACID[c]
PROTOPORPHYRIN-IX[c]
Dipeptides-With-Proline-Carboxy[c]
CPDCWI-18[c]
FRUCTOSE-16-DIPHOSPHATE[c]
APS[c]
L-PHOSPHATIDATE[c]
NITRATE[c]
NAD[c]
Carboxybiotin-BCCP[c]
CPD-11444[c]
GLYCOLLATE[c]
-3b-hydroxy-D5-steroids[c]
CPD-9421[c]
DTDP-RHAMNOSE[c]
MYO-INOSITOL[c]
DEOXYURIDINE[c]
-5-PHOSPHORIBOSYL-NFORMYLGLYCINEAMIDINE[c]
Charged-THR-tRNAs[c]

Species id
ppGpp C10H12N5O17P4
{S}-3-hydroxytetradecanoyl-CoA
C35H58N7O18P3S
ATP C10H12N5O13P3
a cis-vaccen-2-enoyl-[acp]
indole-3-acetate C10H8NO2
tRNApro
alpha-D-mannose 1-phosphate C6H11O9P
1-eicosanol C20H42O
glycolaldehyde C2H4O2
a phospholipid cyclopropane fatty acid
dADP C10H12N5O9P2
2-oxo-3-hydroxy-4-phosphobutanoate
C4H4O8P
prenyl-P-P-GlcNAc-ManNAc
C71H116N2O17P2
hydrogen bromide Br
stearate C18H35O2
protoporphyrin IX C34H32N4O4
a dipeptide with proline at carboxy terminal
Ferric-protocatechuate
fructose-1,6-bisphosphate C6H10O12P2
adenosine 5'-phosphosulfate
C10H12N5O10PS
a 1,2-diacyl-sn-glycerol-3-phosphate
nitrate NO3
NAD+ C21H26N7O14P2
a carboxylated-biotinylated [BCCP dimer]
uroporphyrinogen-I C40H44N4O16
glycolate C2H3O3
a 3beta-hydroxy-delta5-steroid
2-methyl-trans-aconitate C7H5O6
dTDP-alpha-L-rhamnose
C16H24N2O15P2
myo-inositol C6H12O6
deoxyuridine C9H12N2O5
5-phosphoribosyl-N-formylglycineamidine
C8H15N3O8P
L-threonyl-tRNAthr
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Species name
DIACYLGLYCEROL[c]
LACTALD[c]
Pimeloyl-ACP-methyl-esters[c]
trans-D2-cis-D19-C38-ACPs[c]
-3-P-SERINE[c]
-1-2DIPALMITOYLPHOSPHATIDYLCHOLI
NE[c]
NIACINE[c]
CPD-7046[c]
L-PANTOATE[c]
OXIDIZED-GLUTATHIONE[c]
GLYCEROL-3P[c]
cis-delta21-3-oxo-C40-ACPs[c]
CPD-9984[c]
Charged-TYR-tRNAs[c]
CPD-466[c]
MET[c]
CPDCWI-13[c]
ADP[c]
CPD-9985[c]
-5-METHYLTHIOADENOSINE[c]
CANAVANINE[c]
GERANYL-PP[c]
C1[c]
D-MYO-INOSITOL-1MONOPHOSPHATE[c]
CPD-12673[c]
INDOLE-3-GLYCEROL-P[c]
CPD-1301[c]
cis-delta17-3-oxo-C36-ACPs[c]
trans-D2-cis-D9-montanoyl-ACPs[c]
CPD-11480[c]
CPD0-881[c]

Species id
a 1,2-diacylglycerol
L-lactaldehyde C3H6O2
a pimelyl-[acp] methyl ester
a trans-delta2-cis-delta19-C38 2-[acp]
3-phospho-L-serine C3H6NO6P
1,2-dipalmitoyl-phosphatidylcholine
C40H80NO8P
nicotinate C6H4NO2
S2- S
{R}-pantoate C6H11O4
glutathione disulfide C20H30N6O12S2
sn-glycerol-3-phosphate C3H7O6P
a cis-delta21-3-oxo-C40 1-[acp]
bacillibactin C39H42N6O18
L-tyrosyl-tRNAtyr
{S}-3-amino-2-methylpropanoate
C4H9NO2
L-methionine C5H11NO2S
stearoylcardiolipin C81H158O17P2
ADP C10H12N5O10P2
petrobactin C34H51N6O11
S-methyl-5'-thioadenosine C11H15N5O3S
L-canavanine C5H13N4O3
geranyl diphosphate C10H17O7P2
UDP-N-acetylmuramoyl-L-alanyl-Dglutamyl-meso-2,6-diaminopimelyl-Dalanyl-D-alanine C41H61N9O28P2
1D-myo-inositol -monophosphate
C6H11O9P
5-chloro-5-deoxy-D-ribonate C5H8O5Cl
{1S,2R}-1-C-{indol-3-yl}glycerol 3phosphate C11H12NO6P
tetrahydropteroyl tri-L-glutamate
C29H37N9O12
a cis-delta17-3-oxo-C36 1-[acp]
a trans-delta2-cis-delta9-C28 2-[acp]
N8,N'8-citryl-bis{spermidine}
C20H45N6O5
N-acetyl-beta-muramate 6-phosphate
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Species name

Species id
C11H17NO11P

-2-3-DIHYDRODIPICOLINATE[c]
PHOSPHORYL-CHOLINE[c]
CPD-12708[c]

{S}-2,3-dihydrodipicolinate C7H5NO4
phosphoryl-choline C5H13NO4P
fluoroacetaldehyde C2H3OF
5-methyltetrahydropteroyltri-L-glutamate
C30H39N9O12
7-keto-8-aminopelargonate C9H17NO3
UDP-N-acetylmuramoyl-L-alanyl-gammaD-glutamyl-L-lysyl-D-alanyl-D-alanine
C40H62N9O26P2
trans-delta2-decenoyl-CoA
C31H48N7O17P3S
phosphonoacetaldehyde C2H4O4P
pyridoxine-5'-phosphate C8H10NO6P

CPD-1302[c]
-8-AMINO-7-OXONONANOATE[c]
C3[c]
T2-DECENOYL-COA[c]
CPD-551[c]
PYRIDOXINE-5P[c]
-5-HYDROXYINDOLEACETALDEHYDE[c]
R-4-PHOSPHOPANTOTHENOYL-LCYSTEINE[c]
CPD-11481[c]
CPD0-882[c]
GLYCEROL[c]
CPD-12709[c]
-3-DEOXY-D-ARABINOHEPTULOSONATE-7-P[c]
C4[c]
-2-HYDROXY-3-KETO-5METHYLTHIO-1-PHOSPHOP[c]
-3-oxo-D5-steroids[c]
LIPOYL-AMP[c]
Charged-LYS-tRNAs[c]
PRO[c]
CPD-12706[c]
PROCOLLAGEN-L-PROLINE[c]
C5[c]

5-hydroxyindole acetaldehyde C10H9NO2
R-4'-phosphopantothenoyl-L-cysteine
C12H20N2O9PS
N1-{3,4-dihydroxybenzoyl}-N8,N'8-citrylbis{spermidine} C27H48N6O8
1,6-anhydro-N-acetyl-beta-muramate
C11H16NO7
glycerol C3H8O3
fluoroacetate C2H2O2F
3-deoxy-D-arabino-heptulosonate-7phosphate C7H10O10P
N-acetylmuramoyl-L-alanyl-gamma-Dglutamyl-L-lysyl- D-alanyl-D-alaninediphosphoundecaprenol
C86H140N7O21P2
2-hydroxy-5-{methylthio}-3-oxopent-1-enyl
phosphate C6H8O6PS
a 3-oxo-delta5-steroid
lipoyl-adenylate C18H25N5O8PS2
L-lysyl-tRNAlys
L-proline C5H9NO2
5-fluoro-5-deoxy-D-ribose-1-phosphate
C5H8O7FP
[procollagen]-L-proline
N-acetylmuramoyl-L-alanyl-D-glutamylmeso-2,6-diaminopimelyl-D-alanyl-Dalanine-diphosphoundecaprenol
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Species name

Species id
C87H139N7O23P2

CPDCWI-16[c]

storageiron
UDP-N-acetylmuramyl-L-Ala
C23H33N4O20P2
a peptidoglycan with cleaved N-acetylglucosamine
4-guanidinobutyrate C5H11N3O2
N-acetylmuramoyl-L-alanyl-D-glutamylmeso-2,6-diaminopimelyl-D-alanyl-Dalanine-diphosphoundecaprenyl-Nacetylglucosamine C95H152N8O28P2
indole acetaldehyde C10H9NO

CPD0-1456[c]
Peptidoglycan-With-Cleaved-Nac[c]
CPD-592[c]
C6[c]
INDOLE-ACETALDEHYDE[c]
N-6-ISOPENTYL-ADENOSINE-37TRNA[c]
DEOXYGUANOSINE[c]
Glutaryl-ACP-methyl-esters[c]
CPD-618[c]
CPD0-1082[c]
METHIONYL-PEPTIDE[c]
BIOMASS-CCO-CYTOSOL[c]
CPD1G-567[c]
CPDCWI-14[c]
-4-P-PANTOTHENATE[c]
-3-OXOADIPATE-ENOL-LACTONE[c]
-23-DIPHOSPHOGLYCERATE[c]
SER[c]
ALA-tRNAs[c]
CPD-1771[c]
ACETYL-DGLUCOSAMINYLDIPHOSPHOUNDECAPRE[c]
CPD0-1081[c]
L-ASPARTATE-SEMIALDEHYDE[c]
Beta-hydroxydecanoyl-ACPs[c]
cis-delta9-3-oxo-montanoyl-ACPs[c]
CPD-7867[c]
CPD-10774[c]

N-6-isopentyl adenosine-37 tRNA
deoxyguanosine C10H13N5O4
a glutaryl-[acp] methyl ester
{2R,3S}-2-methylisocitrate C7H7O7
L-Ala-gamma-D-Glu-DAP-D-Ala
C18H30N5O9
methionyl peptide
biomass
arachidoyl-CoA C41H70N7O17P3S
1,2-distearoyl-sn-glycerol C39H76O5
D-4'-phosphopantothenate C9H15NO8P
3-oxoadipate enol lactone C6H5O4
2,3-diphosphoglycerate C3H3O10P2
L-serine C3H7NO3
tRNAala
N-acetyl-L,L-2,6-diaminopimelate
C9H15N2O5
N-acetyl-alpha-D-glucosaminyl-diphosphoditrans,octacis-undecaprenol
C63H103NO12P2
N-acetyl-beta-D-glucosamine{anhydrous}N-acetylmuramate C19H30N2O12
L-aspartate-semialdehyde C4H7NO3
an {R}-3-hydroxydecanoyl-[acp]
a cis-delta9-3-oxo-C28 1-[acp]
1-dodecanol C12H26O
(2R,4S)-2-methyl-2,3,3,4tetrahydroxytetrahydrofuran C5H10O5
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Species name
PHOSPHONATE[c]
L-KYNURENINE[c]
CPD0-2244[c]
CPD0-1080[c]
CPD-3724[c]
S-ADENOSYLMETHIONINAMINE[c]
AMINO-RIBOSYLAMINO-1H-3H-PYRDIONE[c]
CPD-3725[c]
URACIL[c]
BCAA-dehydrogenase-lipoyl[c]
b-Keto-cis-D5-dodecenoyl-ACPs[c]
-4-AMINO-BUTYRATE[c]
DIHYDROLIPOYL-GCVH[c]
ALPHA-GLC-6-P[c]
tRNA-uridine-38-40[c]
THREO-DS-ISO-CITRATE[c]
CPD-7222[c]
CPD-10773[c]
cis-delta9-3-hydroxymontanoyl-ACPs[c]
-3-oxo-cis-D7-tetradecenoyl-ACPs[c]
RH[c]
PANTOTHENATE[c]
ACETYL-ACP[c]
-2-C-METHYL-D-ERYTHRITOL-4PHOSPHATE[c]
Petrosel-2-enoyl-ACPs[c]
Aliphatic-N-Acetyl-Diamines[c]
BCCP-monomers[c]
PROTOHEME[c]
CARBON-DIOXIDE[c]
INDOLE-PYRUVATE[c]
ACRYLAMIDE[c]

Species id
phosphonate HO3P
kynurenine C10H12N2O3
{S}-3-hydroxydecanoyl-CoA
C31H50N7O18P3S
GlcNAc-1,6-anhMurNAc-L-Ala-gamma-DGlu-DAP-D-Ala C37H58N7O20
uridine 3'-monophosphate C9H11N2O9P
S-adenosyl-L-methioninamine
C14H24N6O3S
5-amino-6-{D-ribitylamino}uracil
C9H16N4O6
uridine 2'3'-cyclic monophosphate
C9H10N2O8P
uracil C4H4N2O2
an [apo BCAA dehydrogenase E2 protein]
N6-{lipoyl}lysine
a 3-oxo-cis-delta5-dodecenoyl-[acp]
4-aminobutyrate C4H9NO2
a [glycine-cleavage complex H protein] N6{dihydrolipoyl}lysine
alpha-D-glucose 6-phosphate C6H11O9P
a tRNA uridine38-40
D-threo-isocitrate C6H5O7
2-trans-dodecenoyl-CoA
C33H52N7O17P3S
{2R,4S}-2-methyl-2,4dihydroxydihydrofuran-3-one C5H8O4
a cis-delta9-3-hydroxyC28 1-[acp]
a 3-oxo-cis-delta7-tetradecenoyl-[acp]
an organic molecule
{R}-pantothenate C9H16NO5
an acetyl-[acp]
2-C-methyl-D-erythritol-4-phosphate
C5H11O7P
a petrosel-2-enoyl-[acp]
an aliphatic N-acetyl-diamine
a [biotin-carboxyl-carrier protein monomer]
protoheme IX C34H30N4O4Fe
CO2 CO2
indole-3-pyruvate C11H8NO3
acrylamide C3H5NO
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Species name
CPD-7224[c]
-2-METHYL-ACETO-ACETYL-COA[c]
GLT-tRNAs[c]
TREHALOSE-6P[c]
-2-KETO-ISOVALERATE[c]
GLUTAMATE-1-SEMIALDEHYDE[c]
Reduced-ferredoxins[c]
CPD-2961[c]
PROPIONYL-COA[c]
DCMP[c]
CPD0-1110[c]
Charged-ASN-tRNAs[c]
CA-2[c]
HCO3[c]
ADENOSYLCOBINAMIDE[c]
-2C-METH-D-ERYTHRITOLCYCLODIPHOSPHATE[c]
PHOSPHORIBOSYL-FORMAMIDOCARBOXAMIDE[c]
CPD-650[c]
DGTP[c]
LIPOIC-ACID[c]
TYR[c]
Phospholipid-Olefinic-Fatty-Acids[c]
Palmitoyl-ACPs[c]
-4-HYDROXY-L-PROLINE[c]
CH3-MALONATE-S-ALD[c]
CPD-690[c]
CPD-12454[c]
Cis-Delta7-tetradecenoyl-ACPs[c]
CPD-7652[c]
GLC[c]
OH-HEXANOYL-COA[c]

Species id
N-acetyl-L-citrulline C8H14N3O4
2-methylacetoacetyl-CoA
C26H38N7O18P3S
tRNAGlu
trehalose 6-phosphate C12H21O14P
2-oxoisovalerate C5H7O3
glutamate-1-semialdehyde C5H9NO3
a reduced ferredoxin
6-phospho-D-gluconate C6H10O10P
propanoyl-CoA C24H36N7O17P3S
dCMP C9H12N3O7P
beta-D-ribopyranose C5H10O5
L-asparaginyl-tRNAasn
Ca2+ Ca
bicarbonate CHO3
adenosylcobinamide C58H84N16O11Co
2-C-methyl-D-erythritol-2,4cyclodiphosphate C5H10O9P2
phosphoribosyl-formamido-carboxamide
C10H13N4O9P
{R}-3-hydroxybutanoyl-CoA
C25H38N7O18P3S
dGTP C10H12N5O13P3
{R}-lipoate C8H13O2S2
L-tyrosine C9H11NO3
a phospholipid olefinic fatty acid
a palmitoyl-[acp]
trans-4-hydroxy-L-proline C5H9NO3
{S}-methylmalonate-semialdehyde
C4H5O3
adenosyl-cobyrinate a,c-diamide
C55H68N11O15Co
malonyl-CoA methyl ester
C25H36N7O19P3S
a cis-delta7-tetradecenoyl-[acp]
4-{beta-D-ribofuranosyl}aminobenzene-5'phosphate C11H14NO7P
beta-D-glucose C6H12O6
S}-3-hydroxyhexanoyl-CoA
C27H42N7O18P3S
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Species name
Amino-Acids-20[c]
Enoylpimeloyl-ACP-methyl-esters[c]
N-FORMIMINO-L-GLUTAMATE[c]
PRECURSOR-Z[c]
b-Hydroxy-cis-D5-dodecenoyl-ACPs[c]
NICOTINATE-NUCLEOTIDE[c]
UDP-GLUCOSE[c]
Oxo-glutarate-dehydrogenase-DH-lipoyl[c]
-3-Prime-RibonucleosideMonophosphates[c]
SQUALENE[c]
CPD-11654[c]
-3-oxo-palmitoyl-ACPs[c]
PHOSPHORIBOSYL-ATP[c]
ISOVALERYL-COA[c]
AMINO-HYDROXYMETHYLMETHYLPYRIMIDINE-PP[c]
DIHYDROXY-ACETONEPHOSPHATE[c]
QUINOLINATE[c]

Species id
a standard alpha amino acid
an enoylpimelyl-[acp] methyl ester
N-formimino-L-glutamate C6H9N2O4
cyclic pyranopterin monophosphate
C10H11N5O7P
a 3-hydroxy cis delta5-dodecenoyl-[acp]
nicotinate D-ribonucleotide C11H12NO9P
UDP-D-glucose C15H22N2O17P2
a [2-oxoglutarate dehydrogenase E2 protein]
N6-{dihydrolipoyl}lysine
a nucleoside 3'-phosphate
squalene C30H50
{5R}-5,6-dihydro-5-{thymidin-7yl}thymidine {in DNA}
a 3-oxo-palmitoyl-[acp]
phosphoribosyl-ATP C15H19N5O20P4
isovaleryl-CoA C26H40N7O17P3S
4-amino-2-methyl-5diphosphomethylpyrimidine C6H8N3O7P2
dihydroxyacetone phosphate C3H5O6P
quinolinate C7H3NO4
7,8-dihydroneopterin 3'-phosphate
C9H12N5O7P
GTP C10H12N5O14P3
cob{I}yrinate a,c-diamide
C45H56N6O12Co

DIHYDRONEOPTERIN-P[c]
GTP[c]
CPD-694[c]
-1-CARBOXYVINYLCARBOXYPHOSPHONATE[c]
CYS[c]
R-3-hydroxymyristoyl-ACPs[c]
-3-oxo-cis-vaccenoyl-ACPs[c]
R-3-Hydroxypalmitoyl-ACPs[c]
OROTIDINE-5-PHOSPHATE[c]
TMP[c]
DGDP[c]
cis-delta15-gheddoyl-ACPs[c]
CPD-12175[c]
CPD-7695[c]

carboxyphosphonoenolpyruvate C4H2O7P
L-cysteine C3H7NO2S
an {3R}-3-hydroxymyristoyl-[acp]
a 3-oxo-cis-vaccenoyl-[acp]
an {R}-3-hydroxypalmitoyl-[acp]
orotidine-5'-phosphate C10H10N2O11P
dTMP C10H13N2O8P
dGDP C10H12N5O10P2
a cis-delta15-C34 1-[acp]
{S}-3-hydroxy-isobutyrate C4H7O3
N-acetylmuramoyl-L-alanyl-D-glutamyl-Llysyl-D-alanyl-D-alanine-
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Species name

N3-Acetal-deoxystreptamine-antib[c]
BCCP-biotin-monomers[c]
CPD-9646[c]
cis-delta15-3-hydroxygheddoyl-ACPs[c]
-3-HYDROXY-3-METHYL-GLUTARYLCOA[c]
HISTIDINOL[c]
INOSITOL-1-4-5-TRISPHOSPHATE[c]
Peptidoglycans[c]
CPD-12173[c]

Species id
diphosphoundecaprenyl-Nacetylglucosamine C94H153N8O26P2
an N3'-acetyl-2-deoxystreptamine antibiotic
a biotinylated [BCCP monomer]
ditrans,octacis-undecaprenyl phosphate
C55H89O4P
a cis-delta15-3-hydroxyC34 1-[acp]
{S}-3-hydroxy-3-methylglutaryl-CoA
C27H39N7O20P3S
histidinol C6H12N3O
D-myo-inositol {1,4,5}-trisphosphate
C6H9O15P3
a peptidoglycan
{S}-3-hydroxy-isobutyryl-CoA
C25H38N7O18P3S

L-DELTA1-PYRROLINE-5CARBOXYLATE[c]
IMINOASPARTATE[c]

{S}-1-pyrroline-5-carboxylate C5H6NO2
alpha-iminosuccinate C4H3NO4
1,2-dihydroxy-5-{methylthio}pent-1-en-3one C6H9O3S
3-oxohexanoyl-CoA C27H40N7O18P3S
a myristoyl-[acp]
a {R}-3-hydroxylignoceroyl-[acp]
putrescine C4H14N2
glyoxylate C2HO3
orotate C5H3N2O4
{2Z,4E}-5-hydroxyhexa-2,4-dienedioate
C6H4O5
2-amino-3-oxobutanoate C4H6NO3
CMP C9H12N3O8P
a carboxylate
Mn2+ Mn
GDP C10H12N5O11P2
tRNAthr
fructose-1-phosphate C6H11O9P
2-oxo-4-methylthiobutanoate C5H7O3S
cob{I}alamin C62H88N13O14PCo
L-glutamine C5H10N2O3
citrate C6H5O7
an {R}-3-hydroxyoctanoyl-[acp]

CPD-85[c]
K-HEXANOYL-COA[c]
Myristoyl-ACPs[c]
R-3-hydroxylignoceroyl-ACPs[c]
PUTRESCINE[c]
GLYOX[c]
OROTATE[c]
CPD-8720[c]
AMINO-OXOBUT[c]
CMP[c]
Carboxylates[c]
MN-2[c]
GDP[c]
THR-tRNAs[c]
FRU1P[c]
CPD-479[c]
COB-I-ALAMIN[c]
GLN[c]
CIT[c]
-3-Hydroxy-octanoyl-ACPs[c]
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Species name
-2-ALPHA-HYDROXYETHYL-THPP[c]
CROTONYL-COA[c]
TYR-tRNAs[c]
cis-delta5-3-hydroxylignoceroyl-ACPs[c]
Charged-CYS-tRNAs[c]
Alkanesulfonates[c]
ADENOSYLCOBALAMIN[c]
-3-oxo-arachidoyl-ACPs[c]
ZN-2[c]
-2-DEHYDROPANTOATE[c]
Crotonyl-ACPs[c]
CPD0-2123[c]
ASN[c]
DEOXYINOSINE[c]
GDP-TP[c]
CPD-10226[c]
cis-delta5-3-oxo-lignoceroyl-ACPs[c]
-5-AMINO-LEVULINATE[c]
DIPEPTIDES[c]
cis-delta7-3-oxo-cerotoyl-ACPs[c]
CPD-12279[c]
SPERMINE[c]
L-ALPHA-ALANINE[c]
CPD-10227[c]
CPD0-2121[c]
GERANYLGERANYL-PP[c]
GLC-1-P[c]
D-LACTATE[c]
L-CITRULLINE[c]
-5-PHOSPHO-RIBOSYLGLYCINEAMIDE[c]
CPD-316[c]
DELTA3-ISOPENTENYL-PP[c]
FORMALDEHYDE[c]
CPD0-2120[c]

Species id
2-{alpha-hydroxyethyl}thiamine
diphosphate C14H20N4O8P2S
crotonyl-CoA C25H36N7O17P3S
tRNAtyr
a cis-delta5-3-hydroxyC24 1-[acp]
L-cysteinyl-tRNAcys
an alkanesulfonate
coenzyme B12 C72H100N18O17PCo
a 3-oxo-arachidoyl-[acp]
Zn2+ Zn
2-dehydropantoate C6H9O4
a crotonyl-[acp]
3-oxodecanoyl-CoA C31H48N7O18P3S
L-asparagine C4H8N2O3
deoxyinosine C10H12N4O4
pppGpp C10H12N5O20P5
3-amino-3-deoxy-D-fructose 6-phosphate
C6H13NO8P
a cis-delta5-3-oxo-C24 1-[acp]
5-amino-levulinate C5H9NO3
a dipeptide
a cis-delta7-3-oxo-C26 1-[acp]
2-iminoacetate C2H2NO2
spermine C10H30N4
L-alanine C3H7NO2
1-deoxy-1-imino-D-erythrose 4-phosphate
C4H9NO6P
trans-hex-2-enoyl-CoA C27H40N7O17P3S
all-trans-geranyl-geranyl diphosphate
C20H33O7P2
alpha-D-glucose 1-phosphate C6H11O9P
{R}-lactate C3H5O3
L-citrulline C6H13N3O3
5-phospho-ribosyl-glycineamide
C7H14N2O8P
reduced riboflavin C17H22N4O6
isopentenyl diphosphate C5H9O7P2
formaldehyde CH2O
trans-tetradec-2-enoyl-CoA
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Species name

Species id
C35H56N7O17P3S

CPD-10267[c]
CPDCWI-7[c]
GLT[c]
Nucleoside-Diphosphates[c]

decanoyl-CoA C31H50N7O17P3S
ferric-petrobactin
L-glutamate C5H8NO4
a nucleoside diphosphate
5,10-methenyltetrahydrofolate
C20H20N7O6
D-erythro-imidazole-glycerol-phosphate
C6H9N2O6P
N-citryl-spermidine C13H25N3O6
L-2,4-diaminobutanoate C4H11N2O2
D-mannose 6-phosphate C6H11O9P
ferric-bacillibactin
1-{o-carboxyphenylamino}-1'deoxyribulose-5'-phosphate C12H13NO9P
carbon monoxide CO
sarcosine C3H7NO2
uridine C9H12N2O6
IMP C10H11N4O8P
deoxyadenosine C10H13N5O3
5-methylthioribulose-1-phosphate
C6H11O7PS
methanol CH4O
N1-acetylspermidine C9H23N3O
N1-{3,4-dihydroxybenzoyl}-N8-citrylspermidine C20H28N3O9
O-phospho-L-homoserine C4H8NO6P
trans-2,3-stearoyl-CoA C39H64N7O17P3S
L-arginino-succinate C10H17N4O6
N-acetylputrescine C6H14N2O
3,4-dihydroxybenzoate-adenylate
C17H17N5O10P
an organic hydroperoxide
S-methyl-L-methionine C6H14NO2S
Mg2+ Mg
hydrogen peroxide H2O2
N-formylkynurenine C11H14N2O4
a peptidoglycan dimer {mesodiaminopimelate containing}
C135H214N16O49P2

-5-10-METHENYL-THF[c]
D-ERYTHRO-IMIDAZOLE-GLYCEROLP[c]
CPD-11479[c]
CPD-470[c]
MANNOSE-6P[c]
CPDCWI-6[c]
CARBOXYPHENYLAMINODEOXYRIBULOSE-P[c]
CARBON-MONOXIDE[c]
SARCOSINE[c]
URIDINE[c]
IMP[c]
DEOXYADENOSINE[c]
CPD-1063[c]
METOH[c]
CPD-568[c]
CPD-11477[c]
O-PHOSPHO-L-HOMOSERINE[c]
CPD-10262[c]
L-ARGININO-SUCCINATE[c]
CPD-569[c]
CPD-11474[c]
Alkyl-Hydro-Peroxides[c]
CPD-397[c]
MG-2[c]
HYDROGEN-PEROXIDE[c]
N-FORMYLKYNURENINE[c]
CPD-12231[c]
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Species name
Charged-GLY-tRNAs[c]
-6-PYRUVOYL-5678TETRAHYDROPTERIN[c]
CPD-10260[c]
-2-Oxo-carboxylates[c]
BUTYRYL-COA[c]
GLY[c]
ACP[c]
UROPORPHYRINOGEN-III[c]
PHOSPHATIDYLCHOLINE[c]
DEPHOSPHO-COA[c]
Trans-D3-cis-D5-dodecenoyl-ACPs[c]
CHOLATE[c]
D-CYSTEINE[c]
CPD-9451[c]
CPD0-2232[c]
-3-4-DIHYDROXYBENZOATE[c]
GUANINE[c]
POLYRIBITOL-PHOSPHATE[c]
Deoxystreptamine-Antib[c]
METHYL-GLYOXAL[c]
Octanoyl-ACPs[c]
DEHYDROQUINATE[c]
Dodecanoyl-ACPs[c]
DIHYDRO-DIOH-BENZOATE[c]
CPD0-2230[c]
-3-hydroxy-cis-D7-tetraecenoyl-ACPs[c]
-2-OXOBUTANOATE[c]
CPD-560[c]
UDP-N-ACETYL-D-GLUCOSAMINE[c]
N-ALPHA-ACETYLORNITHINE[c]

CPD-12302[c]

Species id
glycyl-tRNAgly
6-pyruvoyl tetrahydropterin C9H11N5O3
3-oxo-stearoyl-CoA C39H64N7O18P3S
a 2-oxo carboxylate
butanoyl-CoA C25H38N7O17P3S
glycine C2H5NO2
a holo-[acp]
uroporphyrinogen-III C40H36N4O16
a phosphatidylcholine
dephospho-CoA C21H33N7O13P2S
a trans-delta3-cis-delta5-dodecenoyl-[acp]
cholate C24H39O5
D-cysteine C3H7NO2S
2-isopropylmaleate C7H8O4
{S}-3-Hydroxyhexadecanoyl-CoA
C37H62N7O18P3S
protocatechuate C7H5O4
guanine C5H5N5O
poly{ribitol phosphate}
a 2-deoxystreptamine antibiotic
methylglyoxal C3H4O2
an octanoyl-[acp]
3-dehydroquinate C7H9O6
a dodecanoyl-[acp]
2,3-dihydroxy-2,3-dihydrobenzoate
C7H7O4
Phosphatidylglycerophosphate {dihexadec9-enoyl, n-C16 1} C38H69O13P2
a 3-hydroxy cis delta7-tetradecenoyl-[acp]
2-oxobutanoate C4H5O3
S-methyl-5-thio-D-ribose C6H12O4S
UDP-alpha-N-acetyl-D-glucosamine
C17H25N3O17P2
N-acetyl-L-ornithine C7H14N2O3
N-acetylmuramoyl-L-alanyl-Disoglutaminyl-N-{beta-D-asparatyl}-Llysyl-D-alanyl-D-alaninediphosphoundecaprenyl-Nacetylglucosamine C98H159N10O28P2
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Species name
Aliphatic-Alpha-Omega-Diamines[c]
FARNESYL-PP[c]
-3-oxo-dodecanoyl-ACPs[c]
PROPIONYL-P[c]
CYTIDINE[c]
CPD66-34[c]
CPD-12303[c]
Charged-PRO-tRNAs[c]
CPD-10766[c]
N2ACETYL-ALPHA-NP[c]
Orthophosphoric-Monoesters[c]
FORMATE[c]
cis-delta17-C36-ACPs[c]
Lipoylated-domains[c]
HYPOXANTHINE[c]
-1-L-MYO-INOSITOL-1-P[c]
N-formyl-L-methionyl-tRNAfmet[c]
AICAR[c]
CPD0-1108[c]
CPD-3711[c]
ADENOSINE[c]
CPD-564[c]
Light[c]
DTDP-D-GLUCOSE[c]
SULFATE[c]
UNDECAPRENYL-DIPHOSPHATE[c]
CPD-822[c]
HOPAN-22-OL[c]
trans-D2-cis-D5-lignoceroyl-ACPs[c]
CPD0-1148[c]

Species id
an aliphatic alpha,omega-diamine
{2E,6E}-farnesyl diphosphate
C15H25O7P2
a 3-oxo-dodecanoyl-[acp]
propionyl-P C3H5O5P
cytidine C9H13N3O5
1,2-dipalmitoylglycerol C35H68O5
N-acetylmuramoyl-L-alanyl-gamma-Dglutamyl-L-lysyl- D-alanyldiphosphoundecaprenol
C83H135N6O20P2
L-prolyl-tRNApro
7,8-H2pterin-6-yl-methyl-4-{beta-Dribofuranosyl}aminobenzene 5'-phosphate
C18H19N6O8P
N2acetyl-alpha-aminoadipyl-deltaphosphate C8H11NO8P
a phosphate monoester
formate CHO2
a cis-delta17-C36 1-[acp]
a lipoylated protein lipoyl-domain
hypoxanthine C5H4N4O
1D-myo-inositol {3}-monophosphate
C6H11O9P
N-formyl-L-methionyl-tRNAfmet
aminoimidazole carboxamide ribonucleotide
C9H13N4O8P
beta-D-ribofuranose C5H10O5
cytidine-3'-monophosphate C9H12N3O8P
adenosine C10H13N5O4
S-ribosyl-L-homocysteine C9H17NO6S
hnu
dTDP-alpha-D-glucose C16H24N2O16P2
sulfate O4S
di-trans,octa-cis-undecaprenyl diphosphate
C55H89O7P2
N2-succinyl-L-glutamate 5-semialdehyde
C9H11NO6
hopan-22-ol C30H52O
a trans-delta2-cis-delta5-C24 2-[acp]
N,N'-dimethyl-p-phenylenediamine
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Species name

Species id
C8H12N2

-1-KETO-2-METHYLVALERATE[c]
Sulfur-Acceptors[c]
BUTANAL[c]
apo-ACP[c]
L-ASPARTATE[c]
PHENYL-PYRUVATE[c]
CPD-13228[c]

2,3-dihydroxy-3-methylvalerate C6H11O4
a sulfur acceptor
butanal C4H8O
an apo-[acp]
L-aspartate C4H6NO4
keto-phenylpyruvate C9H7O3
trans-2-pentenal C5H8O
cytidine 2',3'-cyclic monophosphate
C9H11N3O7P
a 3-oxo-hexanoyl-[acp]
acetoacetyl-CoA C25H36N7O18P3S
tertiary butyl hydroperoxide C4H10O2
H2O H2O
5-amino-1-{5-phospho-D-ribosyl}imidazole
C8H13N3O7P
maltotetraose C24H42O21
trans-2-pentenol C5H10O
a carboxylic ester
a holo-AsbD protein
a ubiquinone
macrocin C46H77NO16
tetrahydrofolate C19H21N7O6
a malonyl-[acp]
formamide CH3NO
an acetoacetyl-[acp]
2-carboxy-5-oxo-2,5-dihydrofuran-2-acetate
C7H4O6
dCTP C9H12N3O13P3
glutathionylspermidine C17H36N6O5S
a trans oct-2-enoyl-[acp]
UDP-N-acetylmuramoyl-L-alanyl-Dglutamate C28H39N5O23P2
tRNAhis
dTTP C10H13N2O14P3
L-glutamyl-tRNAGlu
3-oxo-palmitoyl-CoA C37H60N7O18P3S
meso-diaminopimelate C7H14N2O4
D-alanine C3H7NO2

CPD-3713[c]
-3-oxo-hexanoyl-ACPs[c]
ACETOACETYL-COA[c]
BUTYL-HYDROPEROXIDE[c]
WATER[c]
-5-PHOSPHORIBOSYL-5AMINOIMIDAZOLE[c]
MALTOTETRAOSE[c]
CPD-13229[c]
Carboxylic-esters[c]
Holo-AsbD-Proteins[c]
Ubiquinones[c]
MACROCIN[c]
THF[c]
MALONYL-ACP[c]
FORMAMIDE[c]
Acetoacetyl-ACPs[c]
CPD-7737[c]
DCTP[c]
GLUTATHIONYLSPERMIDINE[c]
-2-Octenoyl-ACPs[c]
UDP-AA-GLUTAMATE[c]
HIS-tRNAs[c]
TTP[c]
Charged-GLT-tRNAs[c]
-3-OXOPALMITOYL-COA[c]
MESO-DIAMINOPIMELATE[c]
D-ALANINE[c]
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Species name
-2-ETHYLHEXAN-1-OL[c]
CU-2[c]
Ceramides[c]
CPD-1243[c]
R-3-hydroxydodecanoyl-ACPs[c]
FRU[c]
FE-3[c]
-2-D-THREO-HYDROXY-3-CARBOXYISOCAPROATE[c]
NITRIC-OXIDE[c]
CPD-6972[c]
tRNAs-containing-epoxy-quenosine[c]
CPD-10434[c]
-4-hydroxybenzoate[c]
FE-2[c]
ISOCHORISMATE[c]
DIACYLGLYCEROLPYROPHOSPHATE[c]
Sphingomyelins[c]
LONG-CHAIN-KETONE[c]
CTP[c]
RIBULOSE-5P[c]

Species id
2-ethylhexan-1-ol C8H18O
Cu2+ Cu
a ceramide
isomaltose C12H22O11
a {R}-3-hydroxydodecanoyl-[acp]
D-fructose C6H12O6
Fe3+ Fe
{2R,3S}-3-isopropylmalate C7H10O5
nitric oxide NO
4-{2'-carboxyphenyl}-4-oxobutyryl-CoA
C32H39N7O20P3S
epoxyqueuosine at position 34 of a tRNA
containing GUN anticodon
ethanesulfonate C2H5O3S
4-hydroxybenzoate C7H5O3
Fe2+ Fe
isochorismate C10H8O6
a 1,2-diacyl-sn-glycerol 3-diphosphate
a sphingomyelin
a ketone
CTP C9H12N3O14P3
D-ribulose-5-phosphate C5H9O8P
1-{5-phospho-D-ribosyl}-AMP
C15H19N5O14P2
O-D-Alanyl-poly{ribitol phosphate}
{2S,3S}-2-methylcitrate C7H7O7
L-2-acetamido-6-oxoheptanedioate
C9H11NO6
chromate HO4Cr
butanoyl phosphate C4H7O5P
biliverdin-IX-alpha C33H32N4O6
dCDP C9H12N3O10P2
hydroxylamine H3NO
acrylate C3H3O2
ammonium H4N
acetylmaltose C14H24O12
4-acetamidobutanal C6H11NO2

PHOSPHORIBOSYL-AMP[c]
CPD-70[c]
CPD-622[c]
N-ACETYL-L-2-AMINO-6-OXOPIMELATE[c]
CPD-4422[c]
BUTYRYL-P[c]
BILIVERDINE[c]
DCDP[c]
HYDROXYLAMINE[c]
ACRYLATE[c]
AMMONIUM[c]
ACETYLMALTOSE[c]
CPD-30[c]
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Species name
ALL-TRANS-HEPTAPRENYLDIPHOSPHATE[c]
TDP[c]
RIBOSE-5P[c]
G3P[c]
-2-ACETO-LACTATE[c]
trans-delta2-arachidoyl-ACPs[c]
R-3-hydroxypetroselinoyl-ACPs[c]
PYRIDOXAMINE-5P[c]
DIAMINO-OHPHOSPHORIBOSYLAMINO-PYR[c]
trans-delta2-lignoceroyl-ACPs[c]
DUMP[c]
-5-METHYL-THF[c]
Protein-N5-methyl-L-glutamine[c]
DPG[c]
ALPHA-GLUCOSE[c]
CPD-12125[c]
RIBOSE-1P[c]
N-ACETYL-D-GLUCOSAMINE-1-P[c]
S-ADENOSYL-4-METHYLTHIO-2OXOBUTANOATE[c]
Octadec-2-enoyl-ACPs[c]
L-seryl-SEC-tRNAs[c]
GLC-D-LACTONE[c]
CPD-35[c]
CPD-13337[c]
CPD-665[c]
-5-P-BETA-D-RIBOSYL-AMINE[c]
-3-oxo-myristoyl-ACPs[c]
ADENYLOSUCC[c]
THR[c]
BCAA-dehydrogenase-DH-lipoyl[c]
CPD-233[c]
P-AMINO-BENZOATE[c]

Species id
all-trans-heptaprenyl diphosphate
C35H57O7P2
dTDP C10H13N2O11P2
D-ribose-5-phosphate C5H9O8P
3-phospho-D-glycerate C3H4O7P
{S}-2-acetolactate C5H7O4
a trans-eicos-2-enoyl-[acp]
a {R}-3-hydroxypetroselinoyl-[acp]
pyridoxamine 5'-phosphate C8H12N2O5P
2,5-diamino-6-{5-phospho-Dribosylamino}pyrimidin-4{3H}-one
C9H14N5O8P
a trans-tetracos-2-enoyl-[acp]
dUMP C9H11N2O8P
5-methyl-tetrahydrofolate C20H23N7O6
a [protein]-N5-methyl-L-glutamine
1,3-bisphospho-D-glycerate C3H4O10P2
alpha-D-glucose C6H12O6
menaquinol-7 C46H66O2
alpha-D-ribose-1-phosphate C5H9O8P
N-acetyl-alpha-D-glucosamine 1-phosphate
C8H14NO9P
S-adenosyl-4-methylthio-2-oxobutanoate
C15H19N5O6S
a trans-octadec-2-enoyl-[acp]
L-seryl-tRNAsec
D-glucono-1,5-lactone C6H10O6
4-acetamidobutanoate C6H10NO3
4-oxalocrotonate C6H4O5
propanal C3H6O
5-phospho-beta-D-ribosyl-amine
C5H11NO7P
a 3-oxo-myristoyl-[acp]
adenylo-succinate C14H14N5O11P
L-threonine C4H9NO3
an [apo BCAA dehydrogenase E2 protein]
N6-{dihydrolipoyl}lysine
{3S}-3,6-diaminohexanoate C6H15N2O2
4-aminobenzoate C7H6NO2
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Species name
CPD-11643[c]
Red-Thioredoxin[c]
CDP[c]
METHYLAMINE[c]

Species id
thymidylyl-{3'-5'}-thymidylate {in DNA}
a reduced thioredoxin
CDP C9H12N3O11P2
methylamine CH6N
nicotinate adenine dinucleotide
C21H24N6O15P2

DEAMIDO-NAD[c]
Guanine34-in-tRNA-with-GUNanticodon[c]
CPD-667[c]
Ox-Thioredoxin[c]
LEU-tRNAs[c]
ARG[c]
CPD-10194[c]
AMMONIA[c]
PREPHENATE[c]
-3-CARBOXY-3-HYDROXYISOCAPROATE[c]
O-UREIDOHOMOSERINE[c]
ILE[c]

guanine at position 34 of a bacterial tRNA
O-acetyl-L-homoserine C6H11NO4
an oxidized thioredoxin
tRNAleu
L-arginine C6H15N4O2
acetylcadaverine C7H17N2O
ammonia H3N
prephenate C10H8O6
{2S}-2-isopropylmalate C7H10O5
O-ureidohomoserine C5H11N3O4
L-isoleucine C6H13NO2
5-phospho-alpha-D-ribose 1-diphosphate
C5H8O14P3

PRPP[c]
L-ERYTHRO-4-HYDROXYGLUTAMATE[c]

L-erythro-4-hydroxy-glutamate C5H8NO5

A8.3. Reactions
Table S16. Reaction of the model for B. anthracis. The name and the locus
associated with each reaction are provided.
Name
{OHACYL-COADEHYDROG-RXN-CPD02232-NAD--3OXOPALMITOYL-COANADH-PROTON.46.
1.1.1.145-RXN

Reaction
+1*CPD02232[c]+1*NAD[c]->+1*NADH[c]+1*PROTO
N[c]+1*-3OXOPALMITOYL-COA[c]
+1*NAD[c]+1*-3bhydroxy-D5-steroids[c]<->+1*NADH[c]+1*PROTO
N[c]+1*-3-oxo-D5steroids[c]
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Locus

GCWI-5129 GCWI-5442

GCWI-3255

Name
1.1.1.215-RXN

1.14.11.2-RXN

1.18.1.2-RXN

1.2.1.2-RXN

1.2.1.25-RXN

1.2.4.4-RXN

1.4.3.19-RXN

1.5.1.20-RXN

Reaction
+1*GLUCONATE[c]+1*N
ADP[c]<-->+1*CPD377[c]+1*NADPH[c]+1*PR
OTON[c]
+1*OXYGENMOLECULE[c]+1*PROCO
LLAGEN-LPROLINE[c]+1*-2KETOGLUTARATE[c]->+1*CARBONDIOXIDE[c]+1*CPD6321[c]+1*SUC[c]
+1*NADP[c]+1*PROTON[
c]+2*Reducedferredoxins[c]<->+1*NADPH[c]+2*Oxidize
d-ferredoxins[c]
+1*FORMATE[c]+1*NAD[
c]-->+1*CARBONDIOXIDE[c]+1*NADH[c]
+1*COA[c]+1*NAD[c]+1*-2KETO-ISOVALERATE[c]->+1*CARBONDIOXIDE[c]+1*ISOBUTY
RYL-COA[c]+1*NADH[c]
+1*BCAA-dehydrogenaselipoyl[c]+1*-2-KETOISOVALERATE[c]->+1*BCAA-dehydrogenase2MP-DHlipoyl[c]+1*CARBONDIOXIDE[c]
+1*GLY[c]+1*OXYGENMOLECULE[c]+1*WATE
R[c]<->+1*AMMONIA[c]+1*GL
YOX[c]+1*HYDROGENPEROXIDE[c]+1*PROTON
[c]
+1*METHYLENETHF[c]+1*NADH[c]+1*PR
OTON[c]->+1*NAD[c]+1*-5METHYL-THF[c]
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Locus
GCWI-5026

GCWI-4369

GCWI-795 GCWI-3606

GCWI-4298

GCWI-4298 GCWI-4299

GCWI-954 GCWI-2885

GCWI-4388

Name

1.8.4.12-RXN

1.8.4.8-RXN

1PFRUCTPHOSN-RXN

1TRANSKETO-RXN

2-DEHYDROPANTOATEREDUCT-RXN

2ISOPROPYLMALATESYN
-RXN

2-METHYLCITRATEDEHYDRATASE-RXN
2-METHYLCITRATESYNTHASE-RXN
2-OXOGLUTARATESYNTHASE-RXN

Reaction
+1*Protein-L-methionine-RS-oxides[c]+1*RedThioredoxin[c]-->+1*OxThioredoxin[c]+1*ProteinLmethionine[c]+1*WATER[c
]
+1*PAPS[c]+1*RedThioredoxin[c]-->+1*OxThioredoxin[c]+2*PROTON
[c]+1*SO3[c]+1*-3-5ADP[c]
+1*ATP[c]+1*FRU1P[c]->+1*ADP[c]+1*FRUCTOS
E-16DIPHOSPHATE[c]+1*PRO
TON[c]
+1*D-SEDOHEPTULOSE7-P[c]+1*GAP[c]<->+1*RIBOSE5P[c]+1*XYLULOSE-5PHOSPHATE[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-2DEHYDROPANTOATE[c]->+1*LPANTOATE[c]+1*NADP[c
]
+1*ACETYLCOA[c]+1*WATER[c]+1*2-KETOISOVALERATE[c]->+1*COA[c]+1*PROTON[c]+1*-3CARBOXY-3-HYDROXYISOCAPROATE[c]
+1*CPD-622[c]-->+1*CPD1136[c]+1*WATER[c]
+1*OXALACETICACID[c]+1*PROPIONYLCOA[c]+1*WATER[c]->+1*CO-A[c]+1*CPD622[c]+1*PROTON[c]
+1*CO-A[c]+2*Oxidizedferredoxins[c]+1*-2-
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Locus

GCWI-1959

GCWI-1582

GCWI-3799

GCWI-3420 GCWI-3707

GCWI-1993 GCWI-4004

GCWI-1563

GCWI-2433

GCWI-4721

GCWI-3857

Name

2.1.1.79-RXN

2.3.1.157-RXN

2.3.1.168-RXN

2.3.1.179-RXN

2.3.1.180-RXN

2.3.1.89-RXN

Reaction
KETOGLUTARATE[c]->+1*CARBONDIOXIDE[c]+1*PROTON[c
]+2*Reducedferredoxins[c]+1*SUCCOA[c]
+1*Phospholipid-OlefinicFatty-Acids[c]+1*SADENOSYLMETHIONIN
E[c]-->+1*ADENOSYLHOMOCYS[c]+1*PROTON[c]+1*
Phospholipid-CyclopropaneFatty-Acids[c]
+1*ACETYLCOA[c]+1*GLUCOSAMIN
E-1P[c]-->+1*COA[c]+1*N-ACETYL-DGLUCOSAMINE-1P[c]+1*PROTON[c]
+1*BCAA-dehydrogenase2MP-DH-lipoyl[c]+1*COA[c]-->+1*BCAAdehydrogenase-DHlipoyl[c]+1*ISOBUTYRYL
-COA[c]
+1*MALONYLACP[c]+1*PalmitoleoylACPs[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxo-cisvaccenoyl-ACPs[c]
+1*ACETYLCOA[c]+1*MALONYLACP[c]-->+1*AcetoacetylACPs[c]+1*CARBONDIOXIDE[c]+1*CO-A[c]
+1*ACETYLCOA[c]+1*DELTA1PIPERIDEINE-2-6DICARBOXYLATE[c]+1*
WATER[c]-->+1*COA[c]+1*N-ACETYL-L-2AMINO-6-OXOPIMELATE[c]
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Locus

GCWI-3446

GCWI-234

GCWI-4297

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

GCWI-4123

Name

2.4.1.129-RXN

2.5.1.19-RXN

2.5.1.64-RXN

2.6.1.22-RXN

2.6.1.37-RXN

2.7.1.148-RXN

2.7.13.3-RXN

2.7.3.9-RXN

2.7.4.22-RXN

Reaction
+1*CPD7695[c]+1*Peptidoglycans[c
]->+1*Peptidoglycans[c]+1*
UNDECAPRENYLDIPHOSPHATE[c]
+1*PHOSPHO-ENOLPYRUVATE[c]+1*SHIKIM
ATE-5P[c]-->+1*Pi[c]+1*3-ENOLPYRUVYLSHIKIMATE-5P[c]
+1*ISOCHORISMATE[c]+
1*PROTON[c]+1*-2KETOGLUTARATE[c]->+1*CARBONDIOXIDE[c]+1*CPD9924[c]
+1*CPD-466[c]+1*-2KETOGLUTARATE[c]<->+1*CH3-MALONATE-SALD[c]+1*GLT[c]
+1*CPD1106[c]+1*PYRUVATE[c]->+1*CPD-551[c]+1*LALPHA-ALANINE[c]
+1*ATP[c]+1*-4CYTIDINE-5DIPHOSPHO-2-C[c]->+1*ADP[c]+1*PROTON[c
]+1*-2-PHOSPHO-4CYTIDINE-5DIPHOSPHO-2-C-MET[c]
+1*ATP[c]+1*ProteinHistidines[c]<->+1*ADP[c]+1*PROTON[c
]+1*Protein-phospho-Lhistidines[c]
+1*PHOSPHO-ENOLPYRUVATE[c]+1*ProteinHistidines[c]<->+1*PYRUVATE[c]+1*Pro
tein-3-phospho-Lhistidines[c]
+1*ATP[c]+1*UMP[c]->+1*ADP[c]+1*UDP[c]
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Locus

GCWI-2429

GCWI-2984

GCWI-4979

GCWI-531

GCWI-1492

GCWI-230

GCWI-1619 GCWI-783

GCWI-4190

GCWI-1914 GCWI-3909

Name

2.7.7.60-RXN

2.7.8.23-RXN

2.8.1.6-RXN

2OXOGLUTARATEDEHRXN

2OXOGLUTDECARBRXN

2PGADEHYDRAT-RXN

2TRANSKETO-RXN

Reaction
+1*CTP[c]+1*PROTON[c]
+1*-2-C-METHYL-DERYTHRITOL-4PHOSPHATE[c]->+1*PPI[c]+1*-4CYTIDINE-5DIPHOSPHO-2-C[c]
+1*PROTON[c]+1*-1CARBOXYVINYLCARBOXYPHOSPHONAT
E[c]<-->+1*CARBONDIOXIDE[c]+1*-3HYDROHYDROXYPHOS
PHORYLPYRUVATE[c]
+1*DETHIOBIOTIN[c]+2*
SADENOSYLMETHIONIN
E[c]+1*Sulfurated-SulfurAcceptors[c]->+1*BIOTIN[c]+2*CH33A
DO[c]+2*MET[c]+1*PROT
ON[c]+1*UnsulfuratedSulfur-Acceptors[c]
+1*COA[c]+1*NAD[c]+1*-2KETOGLUTARATE[c]->+1*CARBONDIOXIDE[c]+1*NADH[c]+
1*SUC-COA[c]
+1*Oxo-glutaratedehydrogenaselipoyl[c]+2*PROTON[c]+1
*-2KETOGLUTARATE[c]->+1*CARBONDIOXIDE[c]+1*Oxoglutarate-dehydro-suc-DHlipoyl[c]
+1*-2-PG[c]<->+1*PHOSPHO-ENOLPYRUVATE[c]+1*WATER
[c]
+1*ERYTHROSE4P[c]+1*XYLULOSE-5PHOSPHATE[c]<->+1*FRUCTOSE-
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Locus

GCWI-275

GCWI-2434

GCWI-4255

GCWI-1429

GCWI-1429

GCWI-5234

GCWI-3420 GCWI-3707

Name

3-CH3-2OXOBUTANOATE-OHCH3-XFER-RXN

3-DEHYDROQUINATEDEHYDRATASE-RXN

3-DEHYDROQUINATESYNTHASE-RXN

3-HYDROXBUTYRYLCOA-DEHYDRATASERXN

3-HYDROXYKYNURENINASE-RXN

3-HYDROXYBUTYRATEDEHYDROGENASE-RXN
3HYDROXYDECANOYLACP-DEHYDR-RXN
3HYDROXYDECANOYLACP-DEHYDR-RXNBETAHYDROXYDECANOYLACPS--TRANS-D2DECENOYL-ACPSWATER.56.

Reaction
6P[c]+1*GAP[c]
+1*METHYLENETHF[c]+1*WATER[c]+1*2-KETOISOVALERATE[c]->+1*THF[c]+1*-2DEHYDROPANTOATE[c]
+1*DEHYDROQUINATE[
c]-->+1*WATER[c]+1*-3DEHYDROSHIKIMATE[c]
+1*-3-DEOXY-DARABINOHEPTULOSONATE-7P[c]->+1*DEHYDROQUINATE
[c]+1*Pi[c]
+1*CPD-650[c]->+1*CROTONYLCOA[c]+1*WATER[c]
+1*WATER[c]+1*-3HYDROXY-LKYNURENINE[c]-->+1*LALPHAALANINE[c]+1*PROTON[
c]+1*-3-HYDROXYANTHRANILATE[c]
+1*CPD335[c]+1*NAD[c]<->+1*NADH[c]+1*PROTO
N[c]+1*-3KETOBUTYRATE[c]
+1*OH-ACYL-ACP[c]->+1*TRANS-D2-ENOYLACP[c]+1*WATER[c]
+1*Beta-hydroxydecanoylACPs[c]-->+1*Trans-D2decenoylACPs[c]+1*WATER[c]
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Locus

GCWI-1701

GCWI-4335

GCWI-1679

GCWI-2439 GCWI-1106
GCWI-2616 GCWI-3561
GCWI-4652 GCWI-2616
GCWI-1478 GCWI-2037
GCWI-4490

GCWI-2808

GCWI-4173

GCWI-5366 GCWI-2941

GCWI-5366 GCWI-2941

Name
3HYDROXYISOBUTYRAT
E-DEHYDROGENASERXN
3HYDROXYISOBUTYRYL
-COA-HYDROLASE-RXN

3ISOPROPYLMALDEHYD
ROG-RXN

3-ISOPROPYLMALISOMRXN

Reaction
+1*CPD12175[c]+1*NAD[c]->+1*CH3-MALONATE-SALD[c]+1*NADH[c]+1*PR
OTON[c]
+1*CPD12173[c]+1*WATER[c]->+1*CO-A[c]+1*CPD12175[c]+1*PROTON[c]
+1*NAD[c]+1*-2-DTHREO-HYDROXY-3CARBOXYISOCAPROATE[c]->+1*CPD7100[c]+1*NADH[c]+1*PR
OTON[c]
+1*-3-CARBOXY-3HYDROXYISOCAPROATE[c]->+1*CPD9451[c]+1*WATER[c]

3-OXOACYL-ACPREDUCT-RXN

+1*B-KETOACYLACP[c]+1*NADPH[c]+1*P
ROTON[c]->+1*NADP[c]+1*OHACYL-ACP[c]

3-OXOACYL-ACPREDUCT-RXN-R-3HYDROXYARACHIDOYL
-ACPS-NADP--3-OXOARACHIDOYL-ACPSNADPH-PROTON.68.

+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-arachidoylACPs[c]->+1*NADP[c]+1*R-3hydroxyarachidoyl-ACPs[c]

3-OXOACYL-ACPSYNTH-BASE-RXN
3-OXOACYL-ACPSYNTH-RXN

+1*ACETYLACP[c]+1*MALONYLACP[c]->+1*ACP[c]+1*Acetoacetyl
-ACPs[c]+1*CARBONDIOXIDE[c]
+1*MALONYLACP[c]+1*Saturated-Fatty-
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Locus

GCWI-4184 GCWI-4185

GCWI-2439

GCWI-1564

GCWI-1565 GCWI-1566
GCWI-375 GCWI-2066
GCWI-3377 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-4754 GCWI-375
GCWI-3377 GCWI-4754
GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935
GCWI-375 GCWI-2066
GCWI-3377 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-4754 GCWI-375
GCWI-3377 GCWI-4754
GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935
GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350
GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

Name

3-OXOACYL-ACPSYNTH-RXNPALMITOYL-ACPSMALONYL-ACP--3-OXOSTEAROYL-ACPSCARBON-DIOXIDEACP.67.
3-SULFINOALANINEAMINOTRANSFERASERXN

3.1.2.23-RXN

3.1.4.10-RXN
3.1.4.10-RXN-CPD66-45-CPD66-34-CPD-1121.28.

3.1.4.11-RXN

3.2.1.10-RXN

3.2.1.17-RXN

Reaction
Acyl-ACPs[c]->+1*ACP[c]+1*BKETOACYLACP[c]+1*CARBONDIOXIDE[c]
+1*MALONYLACP[c]+1*PalmitoylACPs[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxostearoyl-ACPs[c]
+1*-2KETOGLUTARATE[c]+1*
-3SULFINOALANINE[c]<->+1*GLT[c]+1*-3SULFINYL-PYRUVATE[c]
+1*CPD201[c]+1*WATER[c]<->+1*COA[c]+1*PROTON[c]+1*-4hydroxybenzoate[c]
+1*L-1-phosphatidylinositols[c]<-->+1*CPD1121[c]+1*DIACYLGLYC
EROL[c]
+1*CPD66-34[c]+1*CPD1121[c]<-->+1*CPD6645[c]
+1*PHOSPHATIDYLMYO-INOSITOL-45BISPHOSPHA[c]+1*WAT
ER[c]->+1*DIACYLGLYCEROL[
c]+1*INOSITOL-1-4-5TRISPHOSPHATE[c]+1*P
ROTON[c]
+1*CPD1243[c]+1*WATER[c]<->+2*ALPHA-GLUCOSE[c]
+1*Peptidoglycans[c]+1*W
ATER[c]<-->+1*N-acetylDglucosamine[c]+1*Peptidogl
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Locus

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

GCWI-1706 GCWI-2940

GCWI-3639 GCWI-4643

GCWI-3839

GCWI-3839

GCWI-880

GCWI-4156

GCWI-3485

Name

3.4.13.5-RXN

3.4.13.9-RXN

3.4.17.14-RXN

3.5.1.88-RXN

3.6.3.12-RXN

3.6.3.27-RXN

3.6.3.4-RXN

325-BISPHOSPHATENUCLEOTIDASE-RXN
3PGAREARR-RXN

Reaction
ycan-With-Cleaved-Nac[c]
+1*DIPEPTIDES[c]+1*WA
TER[c]<-->+1*AminoAcids-20[c]+1*AminoAcids-20[c]
+1*Dipeptides-WithProlineCarboxy[c]+1*WATER[c]<
-->+1*Amino-Acids20[c]+1*PRO[c]
+1*C3[c]+1*WATER[c]<->+1*CPD-12258[c]+1*DALANINE[c]
+1*FORMYL-LMETHIONYLPEPTIDE[c]+1*WATER[c]
<->+1*FORMATE[c]+1*ME
THIONYLPEPTIDE[c]+1*PROTON[c
]
+1*ATP[c]+1*K[e]+1*WATER[c]->+1*ADP[c]+1*K[c]+1*PROTON[c]+1*Pi[c]
+1*ATP[c]+1*Pi[e]+1*WA
TER[c]->+1*ADP[c]+1*PROTON[c
]+2*Pi[c]
+1*ATP[c]+1*CU2[c]+1*WATER[c]->+1*ADP[c]+1*CU2[e]+1*PROTON[c]+1*Pi[c
]
+1*WATER[c]+1*-3-5ADP[c]->+1*AMP[c]+1*Pi[c]
+1*G3P[c]<-->+1*-2-PG[c]
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Locus

GCWI-2562

GCWI-3960 GCWI-4334
GCWI-4741
GCWI-1443 GCWI-1631
GCWI-2057 GCWI-2169
GCWI-2592 GCWI-2624
GCWI-2625 GCWI-4642
GCWI-4972 GCWI-5130
GCWI-5489 GCWI-193
GCWI-4218

GCWI-3951 GCWI-4116

GCWI-961 GCWI-962
GCWI-4405 GCWI-4404
GCWI-4403 GCWI-4402
GCWI-920 GCWI-919
GCWI-918
GCWI-3810

GCWI-4734
GCWI-1868 GCWI-2175
GCWI-3826 GCWI-4078
GCWI-4480 GCWI-5091
GCWI-2556 GCWI-5235

Name

4CARBOXYMUCONOLAC
TONEDECARBOXYLASE-RXN

4HYDROXYPHENYLPYRU
VATE-DIOXYGENASERXN

4.1.1.74-RXN

4.2.1.58-RXN

4.2.1.59-RXN

4.2.1.61-RXN

4.2.3.12-RXN

4.3.1.17-RXN

5-FORMYL-THF-CYCLOLIGASE-RXN
5-METHYLTHIORIBOSEKINASE-RXN

Reaction
+1*CPD7737[c]+1*PROTON[c]->+1*CARBONDIOXIDE[c]+1*-3OXOADIPATE-ENOLLACTONE[c]
+1*OXYGENMOLECULE[c]+1*PHYDROXYPHENYLPYRUVATE[c]->+1*CARBONDIOXIDE[c]+1*HOMOGE
NTISATE[c]
+1*INDOLEPYRUVATE[c]+1*PROTO
N[c]<-->+1*CARBONDIOXIDE[c]+1*INDOLEACETALDEHYDE[c]
+1*Beta-3-hydroxybutyrylACPs[c]-->+1*CrotonylACPs[c]+1*WATER[c]
+1*-3-Hydroxy-octanoylACPs[c]->+1*WATER[c]+1*-2Octenoyl-ACPs[c]
+1*R-3-HydroxypalmitoylACPs[c]->+1*WATER[c]+1*-2Hexadecenoyl-ACPs[c]
+1*DIHYDRONEOPTERI
N-P3[c]<->+1*P3I[c]+1*PROTON[c]
+1*-6-PYRUVOYL-5678TETRAHYDROPTERIN[c]
+1*SER[c]->+1*AMMONIA[c]+1*PR
OTON[c]+1*PYRUVATE[c
]
+1*ADP[c]+1*Pi[c]+1*-510-METHENYL-THF[c]->+1*ATP[c]+1*-5FORMYL-THF[c]
+1*ATP[c]+1*CPD-560[c]->+1*ADP[c]+1*CPD-
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Locus
GCWI-3526

GCWI-2047 GCWI-2879

GCWI-427

GCWI-2554

GCWI-2941 GCWI-5366

GCWI-2941 GCWI-5366

GCWI-2941 GCWI-5366

GCWI-1510

GCWI-4278 GCWI-3306
GCWI-4279 GCWI-3307

GCWI-4398
GCWI-552 GCWI-4175

Name
5.3.1.23-RXN
5.4.2.10-RXN
5.4.99.17-RXN
5.5.1.2-RXN

6-PHOSPHO-BETAGLUCOSIDASE-RXN

6.1.1.13-RXN

6.3.4.16-RXN

6.3.5.7-RXN

6PFRUCTPHOS-RXN

6PGLUCONOLACT-RXN

Reaction
444[c]+1*PROTON[c]
+1*CPD-444[c]-->+1*CPD1063[c]
+1*D-GLUCOSAMINE-6P[c]->+1*GLUCOSAMINE1P[c]
+1*SQUALENE[c]<->+1*HOP-2229-ENE[c]
+1*CPD245[c]+1*PROTON[c]->+1*CPD-7737[c]
+1*CPD507[c]+1*WATER[c]<->+1*ALPHA-GLC-6P[c]+1*ALPHAGLUCOSE[c]
+1*ATP[c]+1*DALANINE[c]+1*POLYRIB
ITOL-PHOSPHATE[c]<->+1*AMP[c]+1*CPD70[c]+1*PPI[c]+1*PROTO
N[c]
+1*AMMONIA[c]+2*ATP[
c]+1*CARBONDIOXIDE[c]+1*WATER[c]
->+2*ADP[c]+1*CARBAM
OYLP[c]+2*PROTON[c]+1*Pi[c
]
+1*ATP[c]+1*GLN[c]+1*L
-glutamyl-tRNAGln[c]->+1*ADP[c]+1*ChargedGLNtRNAs[c]+1*GLT[c]+1*Pi[
c]
+1*ATP[c]+1*FRUCTOSE6P[c]->+1*ADP[c]+1*FRUCTOS
E-16DIPHOSPHATE[c]+1*PRO
TON[c]
+1*D-6-P-GLUCONODELTA-
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Locus
GCWI-553 GCWI-4174
GCWI-359
GCWI-3590
GCWI-498

GCWI-5306

GCWI-1537 GCWI-1539

GCWI-3970 GCWI-3971

GCWI-526 GCWI-527
GCWI-528

GCWI-4726

GCWI-3421

Name

ABC-24-RXN

ABC-25-RXN

ABC-26-RXN

ABC-34-RXN

ACETALD-DEHYDROGRXN

ACETATE--COA-LIGASERXN
ACETATEKIN-RXN
ACETOACETATE--COALIGASE-RXN

Reaction
LACTONE[c]+1*WATER[
c]-->+1*CPD2961[c]+1*PROTON[c]
+1*ATP[c]+1*SPERMIDIN
E[e]+1*WATER[c]<->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*SPERMIDINE
[c]
+1*ATP[c]+1*PUTRESCIN
E[e]+1*WATER[c]->+1*ADP[c]+1*PROTON[c
]+1*PUTRESCINE[c]+1*Pi
[c]

+1*ATP[c]+1*PRO[e]+1*
WATER[c]->+1*ADP[c]+1*PRO[c]+1*
PROTON[c]+1*Pi[c]

+1*ATP[c]+1*GLYCEROL
-3P[e]+1*WATER[c]->+1*ADP[c]+1*GLYCERO
L3P[c]+1*PROTON[c]+1*Pi[
c]
+1*ACETYLCOA[c]+1*NADH[c]+1*PR
OTON[c]->+1*ACETALD[c]+1*COA[c]+1*NAD[c]
+1*ACET[c]+1*ATP[c]+1*
CO-A[c]-->+1*ACETYLCOA[c]+1*AMP[c]+1*PPI[
c]
+1*ACETYLP[c]+1*ADP[c]->+1*ACET[c]+1*ATP[c]
+1*ATP[c]+1*CO-A[c]+1*3-KETOBUTYRATE[c]--
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Locus

GCWI-1452 GCWI-1453
GCWI-1454 GCWI-1455

GCWI-1452 GCWI-1453
GCWI-1454 GCWI-1455
GCWI-2838 GCWI-2837
GCWI-2371 GCWI-2370
GCWI-2839 GCWI-573
GCWI-847 GCWI-574
GCWI-1070 GCWI-2039
GCWI-2040 GCWI-575
GCWI-4291 GCWI-4290
GCWI-4289 GCWI-2043
GCWI-2042 GCWI-2041
GCWI-1072 GCWI-1071
GCWI-846 GCWI-845
GCWI-844 GCWI-843
GCWI-773 GCWI-774
GCWI-775 GCWI-776

GCWI-2379 GCWI-3587
GCWI-2881 GCWI-1451
GCWI-4498
GCWI-2618 GCWI-4792
GCWI-4775
GCWI-4767
GCWI-2618

Name

ACETOLACTATEDECARBOXYLASE-RXN

ACETOLACTREDUCTOIS
OM-RXN
ACETOLACTREDUCTOIS
OM-RXN-CPD-13357NADP--2-ACETOLACTATE-NADPHPROTON.45.
ACETOLACTSYN-RXN

ACETOOHBUTREDUCTO
ISOM-RXN

ACETOOHBUTSYN-RXN

ACETYL-COAACETYLTRANSFER-RXN
ACETYL-COACARBOXYLTRANSFERRXN

Reaction
>+1*ACETOACETYLCOA[c]+1*AMP[c]+1*PPI[
c]
+1*PROTON[c]+1*-2ACETO-LACTATE[c]->+1*CARBONDIOXIDE[c]+1*CPD10353[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-2-ACETOLACTATE[c]-->+1*DIOHISOVALERATE[c]+1*NA
DP[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-2-ACETOLACTATE[c]-->+1*CPD13357[c]+1*NADP[c]
+1*PROTON[c]+2*PYRU
VATE[c]-->+1*CARBONDIOXIDE[c]+1*-2ACETO-LACTATE[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-2-ACETO-2HYDROXYBUTYRATE[c]->+1*NADP[c]+1*-1KETO-2METHYLVALERATE[c]
+1*PROTON[c]+1*PYRU
VATE[c]+1*-2OXOBUTANOATE[c]->+1*CARBONDIOXIDE[c]+1*-2ACETO-2-HYDROXYBUTYRATE[c]
+2*ACETYL-COA[c]<->+1*ACETOACETYLCOA[c]+1*CO-A[c]
+1*ACETYLCOA[c]+1*ATP[c]+1*HCO
3[c]->+1*ADP[c]+1*MALONY
LCOA[c]+1*PROTON[c]+1*
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Locus

GCWI-1082

GCWI-1562 GCWI-1964

GCWI-1562 GCWI-1964

GCWI-1963 GCWI-1560
GCWI-1561 GCWI-1962
GCWI-1081

GCWI-1562 GCWI-1964

GCWI-1963 GCWI-1560
GCWI-1561 GCWI-1962
GCWI-1081

GCWI-3656 GCWI-4164
GCWI-5128 GCWI-5443
GCWI-4320 GCWI-2613
GCWI-2614 GCWI-4321
GCWI-4727 GCWI-4728

Name

ACETYLGLUTKIN-RXN

ACETYLHOMOSER-CYSRXN
ACETYLORNDEACETRXN

ACETYLORNTRANSAMRXN
ACID-PHOSPHATASERXN
ACID-PHOSPHATASERXN-CPD-10815-WATER-PI-METOH.26.
ACONITATEDEHYDRRXN
ACONITATEHYDR-RXN

ACSERLY-RXN

ADCLY-RXN

ADENINE-DEAMINASERXN

Reaction
Pi[c]
+1*ACETYLGLU[c]+1*ATP[c]->+1*ADP[c]+1*NACETYL-GLUTAMYLP[c]
+1*CPD-667[c]+1*HS[c]->+1*ACET[c]+1*HOMOCYS[c]+1*PROTON[c]
+1*N-ALPHAACETYLORNITHINE[c]+1
*WATER[c]->+1*ACET[c]+1*LORNITHINE[c]
+1*CPD-469[c]+1*GLT[c]->+1*N-ALPHAACETYLORNITHINE[c]+1
*-2-KETOGLUTARATE[c]
+1*OrthophosphoricMonoesters[c]+1*WATER[
c]->+1*Alcohols[c]+1*Pi[c]
+1*METOH[c]+1*Pi[c]->+1*CPD10815[c]+1*WATER[c]
+1*CIT[c]-->+1*CISACONITATE[c]+1*WATE
R[c]
+1*CISACONITATE[c]+1*WATE
R[c]-->+1*THREO-DSISO-CITRATE[c]
+1*ACETYLSERINE[c]+1
*HS[c]->+1*ACET[c]+1*CYS[c]+1
*PROTON[c]
+1*-4-AMINO-4DEOXYCHORISMATE[c]>+1*PROTON[c]+1*PYRU
VATE[c]+1*P-AMINOBENZOATE[c]
+1*ADENINE[c]+1*WATE
R[c]->+1*AMMONIA[c]+1*HY
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Locus

GCWI-4270

GCWI-5507

GCWI-688 GCWI-2386

GCWI-4269

GCWI-4638

GCWI-4638
GCWI-3646

GCWI-3646

GCWI-4500 GCWI-255
GCWI-1946

GCWI-258

GCWI-3058

Name
ADENOSYLHOMOCYSTE
INE-NUCLEOSIDASERXN
ADENPHOSPHOR-RXN
ADENPRIBOSYLTRANRXN
ADENYL-KIN-RXN
ADENYLOSUCCINATESYNTHASE-RXN
ADENYLYLSULFKINRXN

ADPREDUCT-RXN

AGMATIN-RXN

AICARSYN-RXN

AICARTRANSFORMRXN

AIRCARBOXY-RXN

Reaction
POXANTHINE[c]
+1*ADENOSYL-HOMOCYS[c]+1*WATER[c]->+1*ADENINE[c]+1*CPD564[c]
+1*ADENOSINE[c]+1*Pi[c
]->+1*ADENINE[c]+1*RIB
OSE-1P[c]
+1*ADENINE[c]+1*PRPP[
c]-->+1*AMP[c]+1*PPI[c]
+1*AMP[c]+1*ATP[c]<->+2*ADP[c]
+1*GTP[c]+1*IMP[c]+1*LASPARTATE[c]->+1*ADENYLOSUCC[c]+
1*GDP[c]+2*PROTON[c]+
1*Pi[c]
+1*APS[c]+1*ATP[c]->+1*ADP[c]+1*PAPS[c]+1
*PROTON[c]
+1*ADP[c]+1*RedThioredoxin[c]->+1*DADP[c]+1*OxThioredoxin[c]+1*WATER[
c]
+1*AGMATHINE[c]+1*W
ATER[c]->+1*PUTRESCINE[c]+1*U
REA[c]
+1*P-RIBOSYL-4SUCCCARBAMINOIMIDAZOLE[c]->+1*AICAR[c]+1*FUM[c]
+1*AICAR[c]+1*-10FORMYL-THF[c]->+1*PHOSPHORIBOSYLFORMAMIDOCARBOXAMIDE[c]+1*TH
F[c]
+1*CARBONDIOXIDE[c]+1*-5PHOSPHORIBOSYL-5AMINOIMIDAZOLE[c]->+1*PHOSPHORIBOSYL-
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Locus

GCWI-2913 GCWI-2630
GCWI-4501
GCWI-4228 GCWI-1624
GCWI-4228
GCWI-4533
GCWI-321

GCWI-5572

GCWI-1584
GCWI-1519 GCWI-1521
GCWI-1521 GCWI-1519
GCWI-1522

GCWI-5468

GCWI-498

GCWI-506

GCWI-496 GCWI-497

Name

AIRS-RXN

AKBLIG-RXN

ALANINE--TRNALIGASE-RXN

ALANINEDEHYDROGENASE-RXN

ALARACECAT-RXN

Reaction
CARBOXYAMINOIMIDAZOLE[c]+2*
PROTON[c]
+1*ATP[c]+1*-5PHOSPHORIBOSYL-NFORMYLGLYCINEAMIDI
NE[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*-5PHOSPHORIBOSYL-5AMINOIMIDAZOLE[c]
+1*AMINOOXOBUT[c]+1*COA[c]+1*PROTON[c]->+1*ACETYLCOA[c]+1*GLY[c]
+1*ALAtRNAs[c]+1*ATP[c]+1*LALPHAALANINE[c]+1*PROTON[
c]->+1*AMP[c]+1*ChargedALA-tRNAs[c]+1*PPI[c]
+1*L-ALPHAALANINE[c]+1*NAD[c]+1
*WATER[c]<->+1*AMMONIA[c]+1*NA
DH[c]+2*PROTON[c]+1*P
YRUVATE[c]
+1*L-ALPHAALANINE[c]-->+1*DALANINE[c]

ALCOHOL-DEHYDROGGENERIC-RXN

+1*NAD[c]+1*PrimaryAlcohols[c]<->+1*Aldehydes[c]+1*NAD
H[c]+1*PROTON[c]

ALCOHOL-DEHYDROGGENERIC-RXN-2ETHYLHEXAN-1-OLNAD--CPD-371-NADHPROTON.43.

+1*CPD371[c]+1*NADH[c]+1*PR
OTON[c]<->+1*NAD[c]+1*-2ETHYLHEXAN-1-OL[c]

ALCOHOL-DEHYDROG-

+1*CPD-
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Locus

GCWI-504

GCWI-823

GCWI-3653 GCWI-4515

GCWI-798 GCWI-4753

GCWI-439 GCWI-2178
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878

Name
GENERIC-RXN-CPD13229-NAD--CPD-13228NADH-PROTON.37.

Reaction
13228[c]+1*NADH[c]+1*P
ROTON[c]<-->+1*CPD13229[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7845-NAD--CPD-7879NADH-PROTON.35.

+1*CPD7879[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7845[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7867-NAD--CPD-7880NADH-PROTON.35.

+1*CPD7880[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7867[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7868-NAD--CPD-7881NADH-PROTON.35.

+1*CPD7881[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7868[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7869-NAD--CPD-7882NADH-PROTON.35.

+1*CPD7882[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7869[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7871-NAD--CPD-7883NADH-PROTON.35.

+1*CPD7883[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7871[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7872-NAD--CPD-7884NADH-PROTON.35.

+1*CPD7884[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7872[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7874-NAD--CPD-7885NADH-PROTON.35.

+1*CPD7885[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7874[c]+1*NAD[c]
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Locus
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423

Name

Reaction

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7875-NAD--CPD-7886NADH-PROTON.35.

+1*CPD7886[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7875[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7876-NAD--CPD-7887NADH-PROTON.35.

+1*CPD7887[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7876[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXN-CPD7877-NAD--CPD-7888NADH-PROTON.35.

+1*CPD7888[c]+1*NADH[c]+1*PR
OTON[c]<-->+1*CPD7877[c]+1*NAD[c]

ALCOHOL-DEHYDROGGENERIC-RXNPROPANOL-NAD--CPD665-NADH-PROTON.34.

+1*CPD665[c]+1*NADH[c]+1*PR
OTON[c]<->+1*NAD[c]+1*PROPAN
OL[c]

ALCOHOL-DEHYDROGRXN

+1*ACETALD[c]+1*NAD
H[c]+1*PROTON[c]->+1*ETOH[c]+1*NAD[c]

ALKANALMONOOXYGENASEFMN-LINKED-RXN

ALKAPHOSPHA-RXN
ALKAPHOSPHA-RXNCPD-10815-WATER-METOH-PI.26.

+1*Aldehydes[c]+1*FMNH
2[c]+1*OXYGENMOLECULE[c]<->+1*Carboxylates[c]+1*FM
N[c]+1*Light[c]+2*PROTO
N[c]+1*WATER[c]
+1*OrthophosphoricMonoesters[c]+1*WATER[
c]->+1*Alcohols[c]+1*Pi[c]
+1*METOH[c]+1*Pi[c]->+1*CPD10815[c]+1*WATER[c]
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Locus
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-4498 GCWI-2357
GCWI-2357 GCWI-4498
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-2049 GCWI-2121
GCWI-3424

GCWI-3029 GCWI-4475

GCWI-3029 GCWI-4475

Name

AMIDASE-RXN

AMINOGLYCOSIDE-N3ACETYLTRANSFERASERXN
AMINOGLYCOSIDE-N3ACETYLTRANSFERASERXN-GENTAMICIN-CACETYL-COA--N3ACETYLGENTAMICIN-CCO-A.52.
AMPDEPHOSPHORYLATIONRXN
AMPSYN-RXN

ANTHRANSYN-RXN

ARGDECARBOX-RXN

ARGINASE-RXN

ARGININE--TRNALIGASE-RXN

ARGSUCCINLYA-RXN
ARGSUCCINSYN-RXN

Reaction
+1*Monocarboxylic-AcidAmides[c]+1*WATER[c]<>+1*AMMONIA[c]+1*Mo
nocarboxylates[c]+1*PROT
ON[c]
+1*ACETYLCOA[c]+1*Deoxystreptami
ne-Antib[c]<-->+1*COA[c]+1*N3-Acetaldeoxystreptamine-antib[c]
+1*CO-A[c]+1*N3ACETYLGENTAMICINC[c]<-->+1*ACETYLCOA[c]+1*GENTAMICINC[c]
+1*AMP[c]+1*WATER[c]>+1*ADENOSINE[c]+1*Pi
[c]
+1*ADENYLOSUCC[c]->+1*AMP[c]+1*FUM[c]
+1*CHORISMATE[c]+1*G
LN[c]->+1*ANTHRANILATE[c]+
1*GLT[c]+1*PROTON[c]+
1*PYRUVATE[c]
+1*ARG[c]+1*PROTON[c]
->+1*AGMATHINE[c]+1*C
ARBON-DIOXIDE[c]
+1*ARG[c]+1*WATER[c]<
-->+1*LORNITHINE[c]+1*UREA[c
]
+1*ARG[c]+1*ARGtRNAs[c]+1*ATP[c]+1*PR
OTON[c]->+1*AMP[c]+1*ChargedARG-tRNAs[c]+1*PPI[c]
+1*L-ARGININOSUCCINATE[c]<->+1*ARG[c]+1*FUM[c]
+1*ATP[c]+1*L-
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Locus

GCWI-2029 GCWI-2171

GCWI-2962

GCWI-2962

GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241
GCWI-498

GCWI-1409

GCWI-4106

GCWI-356

GCWI-2267 GCWI-5463

GCWI-3582 GCWI-4759
GCWI-4760

Name

ARYLFORMAMIDASERXN

ASNSYNA-RXN

ASNSYNB-RXN

ASPAMINOTRANS-RXN

ASPARAGHYD-RXN

ASPARAGINE--TRNALIGASE-RXN

ASPARTASE-RXN

ASPARTATE--TRNALIGASE-RXN

Reaction
ASPARTATE[c]+1*LCITRULLINE[c]<->+1*AMP[c]+1*LARGININOSUCCINATE[c]+1*PPI[c]+
1*PROTON[c]
+1*NFORMYLKYNURENINE[c
]+1*WATER[c]->+1*FORMATE[c]+1*LKYNURENINE[c]+3*PRO
TON[c]
+1*AMMONIA[c]+1*ATP[
c]+1*L-ASPARTATE[c]->+1*AMP[c]+1*ASN[c]+1
*PPI[c]
+1*ATP[c]+1*GLN[c]+1*L
ASPARTATE[c]+1*WATE
R[c]->+1*AMP[c]+1*ASN[c]+1
*GLT[c]+1*PPI[c]+1*PRO
TON[c]
+1*L-ASPARTATE[c]+1*2-KETOGLUTARATE[c]<>+1*GLT[c]+1*OXALACE
TIC-ACID[c]
+1*ASN[c]+1*WATER[c]->+1*AMMONIA[c]+1*LASPARTATE[c]+1*PROT
ON[c]
+1*ASN[c]+1*ASNtRNAs[c]+1*ATP[c]+1*PR
OTON[c]->+1*AMP[c]+1*ChargedASN-tRNAs[c]+1*PPI[c]
+1*L-ASPARTATE[c]->+1*AMMONIA[c]+1*FU
M[c]+1*PROTON[c]
+1*ASPtRNAs[c]+1*ATP[c]+1*LASPARTATE[c]+1*PROT
ON[c]->+1*AMP[c]+1*Charged-
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Locus

GCWI-2807

GCWI-1922

GCWI-1328 GCWI-1874
GCWI-2341 GCWI-1922

GCWI-1706 GCWI-2940

GCWI-1658 GCWI-3156

GCWI-4686

GCWI-813 GCWI-1916
GCWI-3155

GCWI-2277 GCWI-4528

Name
ASPARTATERACEMASE-RXN
ASPARTATESEMIALDEHYDEDEHYDROGENASE-RXN

ASPARTATEKIN-RXN

ASPCARBTRANS-RXN

ASPDECARBOX-RXN

ATPPHOSPHORIBOSYLT
RANS-RXN

Reaction
ASP-tRNAs[c]+1*PPI[c]
+1*L-ASPARTATE[c]<->+1*CPD-302[c]
+1*L-BETA-ASPARTYLP[c]+1*NADPH[c]+1*PRO
TON[c]-->+1*LASPARTATESEMIALDEHYDE[c]+1*N
ADP[c]+1*Pi[c]
+1*ATP[c]+1*LASPARTATE[c]->+1*ADP[c]+1*L-BETAASPARTYL-P[c]
+1*CARBAMOYLP[c]+1*L-ASPARTATE[c]->+1*CARBAMYUL-LASPARTATE[c]+1*PROT
ON[c]+1*Pi[c]
+1*LASPARTATE[c]+1*PROT
ON[c]-->+1*BALANINE[c]+1*CARBONDIOXIDE[c]
+1*ATP[c]+1*PRPP[c]->+1*PHOSPHORIBOSYLATP[c]+1*PPI[c]

Locus
GCWI-2313 GCWI-2701
GCWI-4879

GCWI-2511 GCWI-3885

GCWI-1925 GCWI-3884

GCWI-3973

GCWI-1703

GCWI-1567 GCWI-1568

ATPSYN-RXN

+1*ATP[c]+3*PROTON[c]
+1*WATER[c]<->+1*ADP[c]+4*PROTON[e
]+1*Pi[c]

GCWI-1159 GCWI-3410
GCWI-4891 GCWI-5412
GCWI-1813 GCWI-5408
GCWI-5407 GCWI-5406
GCWI-5405 GCWI-5404
GCWI-3278 GCWI-5411
GCWI-5410 GCWI-5409

AZOBENZENEREDUCTASE-RXN

+1*ANILINE[c]+1*CPD01148[c]+2*NADP[c]<->+2*NADPH[c]+2*PROTO
N[c]+1*-4DIMETHYLAMINOPHEN
YLAZOBENZENE[c]

GCWI-2017 GCWI-2331
GCWI-2367 GCWI-5511

BETAPHOSPHOGLUCOMUTAS
E-RXN

+1*CPD-448[c]<->+1*GLC-6-P[c]

BIOTIN-CARBOXYLRXN

+1*ATP[c]+1*BCCPdimers[c]+1*HCO3[c]->+1*ADP[c]+1*Carboxybio
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GCWI-2613 GCWI-4320

Name

BIOTINLIG-RXN

BISPHOSPHOGLYCERAT
E-MUTASE-RXN
BRANCHEDCHAINAMINOTRANSFE
RILEU-RXN
BRANCHEDCHAINAMINOTRANSFE
RLEU-RXN
BRANCHEDCHAINAMINOTRANSFE
RVAL-RXN
BTUR2-RXN

BUTYRATE-KINASERXN
CARBODEHYDRAT-RXN
CARBOXYLESTERASERXN

CARBPSYN-RXN

Reaction
tinBCCP[c]+1*PROTON[c]+1
*Pi[c]
+1*ATP[c]+1*BCCPmonomers[c]+1*BIOTIN[c]
-->+1*AMP[c]+1*BCCPbiotinmonomers[c]+1*PPI[c]
+1*DPG[c]<->+1*PROTON[c]+1*-23DIPHOSPHOGLYCERATE
[c]
+1*ILE[c]+1*-2KETOGLUTARATE[c]<->+1*GLT[c]+1*-2-KETO3-METHYLVALERATE[c]
+1*GLT[c]+1*-2K-4CH3PENTANOATE[c]->+1*LEU[c]+1*-2KETOGLUTARATE[c]
+1*VAL[c]+1*-2KETOGLUTARATE[c]<->+1*GLT[c]+1*-2-KETOISOVALERATE[c]
+1*ATP[c]+1*COBINAMI
DE[c]<->+1*ADENOSYLCOBINA
MIDE[c]+1*P3I[c]
+1*ADP[c]+1*BUTYRYLP[c]->+1*ATP[c]+1*BUTYRICACID[c]
+1*H2CO3[c]<->+1*CARBONDIOXIDE[c]+1*WATER[c]
+1*Carboxylicesters[c]+1*WATER[c]<->+1*Alcohols[c]+1*Carbox
ylates[c]+1*PROTON[c]
+2*ATP[c]+1*GLN[c]+1*H
CO3[c]+1*WATER[c]->+2*ADP[c]+1*CARBAM
OYLP[c]+1*GLT[c]+2*PROTO
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Locus

GCWI-1699

GCWI-2556 GCWI-5235

GCWI-1559 GCWI-1961

GCWI-1559 GCWI-1961

GCWI-1559 GCWI-1961

GCWI-1640

GCWI-4301

GCWI-4918

GCWI-2779 GCWI-5207

GCWI-3970 GCWI-3971

Name
CARDIOLIPSYN-RXNCPD-8260--CPD-12824GLYCEROL.29.
CATAL-RXN

CDPDIGLYSYN-RXNCTP-CPD0-1422-PROTON-CPD-12815-PPI.36.
CDPDIGLYSYN-RXNCTP-CPD0-1423-PROTON-CPD-12814-PPI.36.
CDPKIN-RXN

CDPREDUCT-RXN

CHLORAMPHENICOL-OACETYLTRANSFERASERXN

CHOLOYLGLYCINEHYDROLASE-RXN
CHORISMATESYNTHASE-RXN
CHORISMATEMUT-RXN

CITSYN-RXN

Reaction
N[c]+1*Pi[c]
+2*CPD-8260[c]<->+1*CPD12824[c]+1*GLYCEROL[c]
+2*HYDROGENPEROXIDE[c]->+1*OXYGENMOLECULE[c]+2*WATE
R[c]
+1*CPD01422[c]+1*CTP[c]+1*PRO
TON[c]-->+1*CPD12815[c]+1*PPI[c]
+1*CPD01423[c]+1*CTP[c]+1*PRO
TON[c]-->+1*CPD12814[c]+1*PPI[c]
+1*ATP[c]+1*CDP[c]->+1*ADP[c]+1*CTP[c]
+1*CDP[c]+1*RedThioredoxin[c]->+1*DCDP[c]+1*OxThioredoxin[c]+1*WATER[
c]
+1*ACETYLCOA[c]+1*CHLORAMPH
ENICOL[c]<->+1*CHLORAMPHENICO
L-3-ACETATE[c]+1*COA[c]
+1*GLYCOCHOLICACID[c]+1*WATER[c]->+1*CHOLATE[c]+1*GLY
[c]
+1*-3-ENOLPYRUVYLSHIKIMATE-5P[c]->+1*CHORISMATE[c]+1*
Pi[c]
+1*CHORISMATE[c]->+1*PREPHENATE[c]
+1*ACETYLCOA[c]+1*OXALACETICACID[c]+1*WATER[c]->+1*CIT[c]+1*COA[c]+1*PROTON[c]
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Locus

GCWI-829 GCWI-1366

GCWI-1061 GCWI-1330
GCWI-3056 GCWI-3180

GCWI-3906

GCWI-3906
GCWI-1677
GCWI-1521 GCWI-1519
GCWI-1522

GCWI-2489

GCWI-3303 GCWI-3846

GCWI-1678 GCWI-2987
GCWI-2988

GCWI-2432 GCWI-4721

Name
CMPKI-RXN
COBALADENOSYLTRAN
S-RXN

CTPSYN-RXN

CYCPHOSDIESTER-RXN

CYCPHOSDIESTER-RXNCPD-3707-WATER--CPD3706-PROTON.32.
CYCPHOSDIESTER-RXNCPD-3709-WATER--CPD3708-PROTON.32.
CYCPHOSDIESTER-RXNCPD-3713-WATER--CPD3711-PROTON.32.
CYCPHOSDIESTER-RXNCPD-3725-WATER--CPD3724-PROTON.32.

CYSPH-RXN

CYSTATHIONINE-BETALYASE-RXN

Reaction
+1*ATP[c]+1*CMP[c]->+1*ADP[c]+1*CDP[c]
+1*ATP[c]+1*COB-IALAMIN[c]<->+1*ADENOSYLCOBAL
AMIN[c]+1*P3I[c]
+1*ATP[c]+1*GLN[c]+1*U
TP[c]+1*WATER[c]->+1*ADP[c]+1*CTP[c]+1*
GLT[c]+2*PROTON[c]+1*
Pi[c]
+1*Cyclic-2-3RibonucleosideMonophosphates[c]+1*WA
TER[c]->+1*PROTON[c]+1*-3Prime-RibonucleosideMonophosphates[c]
+1*CPD3707[c]+1*WATER[c]->+1*CPD3706[c]+1*PROTON[c]
+1*CPD3709[c]+1*WATER[c]->+1*CPD3708[c]+1*PROTON[c]
+1*CPD3713[c]+1*WATER[c]->+1*CPD3711[c]+1*PROTON[c]
+1*CPD3725[c]+1*WATER[c]->+1*CPD3724[c]+1*PROTON[c]
+1*CYS[c]+1*OPHOSPHO-LHOMOSERINE[c]-->+1*LCYSTATHIONINE[c]+1*Pi
[c]
+1*LCYSTATHIONINE[c]+1*
WATER[c]->+1*AMMONIA[c]+1*HO
MOCYS[c]+1*PROTON[c]+1*
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Locus
GCWI-1659
GCWI-1640

GCWI-5437

GCWI-4263

GCWI-4263

GCWI-4263

GCWI-4263

GCWI-4263

GCWI-4389

GCWI-5029 GCWI-4390
GCWI-4499

Name

CYSTEINE--TRNALIGASE-RXN

CYTIDEAM-RXN

CYTIDEAM2-RXN

CYTIDINEKIN-RXN

CYTIKIN-RXN
D-ALANINEAMINOTRANSFERASERXN
D-PPENTOMUT-RXN
DADPKIN-RXN

DAHPSYN-RXN

DALADALALIG-RXN

DAPASYN-RXN

Reaction
PYRUVATE[c]
+1*ATP[c]+1*CYS[c]+1*C
YStRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedCYS-tRNAs[c]+1*PPI[c]
+1*DEOXYCYTIDINE[c]+
1*WATER[c]->+1*AMMONIA[c]+1*DE
OXYURIDINE[c]
+1*CYTIDINE[c]+1*WAT
ER[c]->+1*AMMONIA[c]+1*URI
DINE[c]
+1*CYTIDINE[c]+1*GTP[
c]->+1*CMP[c]+1*GDP[c]+1*
PROTON[c]
+1*ATP[c]+1*CYTIDINE[
c]->+1*ADP[c]+1*CMP[c]+1*
PROTON[c]
+1*D-ALANINE[c]+1*-2KETOGLUTARATE[c]<->+1*DGLT[c]+1*PYRUVATE[c]
+1*DEOXY-RIBOSE1P[c]<-->+1*DEOXYRIBOSE-5P[c]
+1*ATP[c]+1*DADP[c]->+1*ADP[c]+1*DATP[c]
+1*ERYTHROSE4P[c]+1*PHOSPHO-ENOLPYRUVATE[c]+1*WATER
[c]-->+1*Pi[c]+1*-3DEOXY-D-ARABINOHEPTULOSONATE-7-P[c]
+1*ATP[c]+2*DALANINE[c]->+1*ADP[c]+1*D-ALA-DALA[c]+1*PROTON[c]+1*
Pi[c]
+1*SADENOSYLMETHIONIN
E[c]+1*-8-AMINO-7-
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Locus

GCWI-279

GCWI-2004 GCWI-3664
GCWI-4431
GCWI-2004 GCWI-3664
GCWI-4431

GCWI-4507

GCWI-4507

GCWI-2346 GCWI-5332

GCWI-4229
GCWI-1677

GCWI-2988

GCWI-431 GCWI-2677

GCWI-4260

Name

DCDPKIN-RXN

DCYSDESULF-RXN

DEOXYADENPHOSPHOR
-RXN
DEOXYGUANOSINEKINASE-RXN
DEOXYGUANPHOSPHOR
-RXN

DEOXYINOPHOSPHORRXN

DEOXYRIBOSE-P-ALDRXN
DEPHOSPHOCOAKINRXN

DETHIOBIOTIN-SYNRXN

DGDPKIN-RXN

Reaction
OXONONANOATE[c]->+1*DIAMINONONANO
ATE[c]+1*S-ADENOSYL4-METHYLTHIO-2OXOBUTANOATE[c]
+1*ATP[c]+1*DCDP[c]->+1*ADP[c]+1*DCTP[c]
+1*DCYSTEINE[c]+1*WATER[
c]<->+1*AMMONIA[c]+1*HS[
c]+1*PROTON[c]+1*PYR
UVATE[c]
+1*DEOXYADENOSINE[c
]+1*Pi[c]<->+1*ADENINE[c]+1*DEO
XY-RIBOSE-1P[c]
+1*ATP[c]+1*DEOXYGU
ANOSINE[c]->+1*ADP[c]+1*DGMP[c]+
1*PROTON[c]
+1*DEOXYGUANOSINE[
c]+1*Pi[c]<-->+1*DEOXYRIBOSE1P[c]+1*GUANINE[c]
+1*DEOXYINOSINE[c]+1
*Pi[c]<-->+1*DEOXYRIBOSE1P[c]+1*HYPOXANTHINE
[c]
+1*DEOXY-RIBOSE5P[c]->+1*ACETALD[c]+1*GAP
[c]
+1*ATP[c]+1*DEPHOSPH
O-COA[c]->+1*ADP[c]+1*COA[c]+1*PROTON[c]
+1*ATP[c]+1*CARBONDIOXIDE[c]+1*DIAMINO
NONANOATE[c]->+1*ADP[c]+1*DETHIOBI
OTIN[c]+3*PROTON[c]+1
*Pi[c]
+1*ATP[c]+1*DGDP[c]--
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Locus

GCWI-1677

GCWI-3244

GCWI-1624 GCWI-4228

GCWI-199 GCWI-200

GCWI-1624 GCWI-4228

GCWI-1624 GCWI-4228

GCWI-2001

GCWI-4711

GCWI-4259

GCWI-1677

Name

DHBAMPLIG-RXN

DHBDEHYD-RXN

DHSHIKIMATEDEHYDRO-RXN

DIACYLGLYKIN-RXN

DIACYLGLYKIN-RXNATP-CPD66-34--CPD01422-ADP-PROTON.35.

DIAMACTRANS-RXN

DIAMACTRANS-RXNCADAVERINE-ACETYLCOA--CPD-10194-CO-APROTON.45.
DIAMINOPIMDECARBRXN
DIAMINOPIMEPIM-RXN

Reaction
>+1*ADP[c]+1*DGTP[c]
+1*ATP[c]+1*PROTON[c]
+1*-2-3DIHYDROXYBENZOATE
[c]<-->+1*CPD62[c]+1*PPI[c]
+1*DIHYDRO-DIOHBENZOATE[c]+1*NAD[c]>+1*NADH[c]+1*PROTO
N[c]+1*-2-3DIHYDROXYBENZOATE
[c]
+1*-3-DEHYDROSHIKIMATE[c]->+1*WATER[c]+1*-3-4DIHYDROXYBENZOATE
[c]
+1*ATP[c]+1*DIACYLGL
YCEROL[c]<->+1*ADP[c]+1*LPHOSPHATIDATE[c]+1*P
ROTON[c]
+1*ATP[c]+1*CPD6634[c]<->+1*ADP[c]+1*CPD01422[c]+1*PROTON[c]
+1*ACETYLCOA[c]+1*Aliphatic-AlphaOmega-Diamines[c]<->+1*Aliphatic-N-AcetylDiamines[c]+1*COA[c]+1*PROTON[c]
+1*CO-A[c]+1*CPD10194[c]+1*PROTON[c]<->+1*ACETYLCOA[c]+1*CADAVERINE[
c]
+1*MESODIAMINOPIMELATE[c]+1
*PROTON[c]->+1*CARBONDIOXIDE[c]+1*LYS[c]
+1*LLDIAMINOPIMELATE[c]--
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Locus

GCWI-2450

GCWI-2448

GCWI-2090

GCWI-4432

GCWI-4432

GCWI-2127 GCWI-5196

GCWI-2127 GCWI-5196

GCWI-1581

GCWI-5059

Name

DIHYDRODIPICSYNRXN

DIHYDROFOLATEREDU
CT-RXN

DIHYDROFOLATESYNT
H-RXN

DIHYDRONEOPTERINMONO-P-DEPHOS-RXN

DIHYDROOROT-RXN

DIHYDROXYISOVALDE
HYDRAT-RXN
DIHYDROXYISOVALDE
HYDRAT-RXN-CPD13357--2-KETOISOVALERATEWATER.36.
DIHYDROXYMETVALDE
HYDRAT-RXN
DIMETHUROPORDEHYD
ROG-RXN

Reaction
>+1*MESODIAMINOPIMELATE[c]
+1*L-ASPARTATESEMIALDEHYDE[c]+1*P
YRUVATE[c]->+1*PROTON[c]+2*WAT
ER[c]+1*-2-3DIHYDRODIPICOLINATE
[c]
+1*DIHYDROFOLATE[c]
+1*NADPH[c]+1*PROTO
N[c]->+1*NADP[c]+1*THF[c]
+1*ATP[c]+1*GLT[c]+1*7-8DIHYDROPTEROATE[c]->+1*ADP[c]+1*DIHYDRO
FOLATE[c]+1*PROTON[c]
+1*Pi[c]
+1*DIHYDRONEOPTERI
N-P[c]+1*WATER[c]->+1*DIHYDRO-NEOPTERIN[c]+1*Pi[c]
+1*CARBAMYUL-LASPARTATE[c]+1*PROT
ON[c]-->+1*DI-HOROTATE[c]+1*WATER[
c]
+1*DIOHISOVALERATE[c]->+1*WATER[c]+1*-2KETO-ISOVALERATE[c]
+1*CPD-13357[c]->+1*WATER[c]+1*-2KETO-ISOVALERATE[c]
+1*-1-KETO-2METHYLVALERATE[c]->+1*WATER[c]+1*-2KETO-3-METHYLVALERATE[c]
+1*DIHYDROSIROHYDR
OCHLORIN[c]+1*NAD[c]-
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Locus

GCWI-2882 GCWI-3883

GCWI-853 GCWI-2329

GCWI-4584

GCWI-3029 GCWI-4475

GCWI-3972 GCWI-4969

GCWI-1965

GCWI-1965

GCWI-1965

GCWI-1589 GCWI-2239

Name

DIOHBUTANONEPSYNRXN

DSERDEAM-RXN

DTDPDEHYDRHAMEPIM
-RXN

DTDPDEHYRHAMREDU
CT-RXN

DTDPGLUCDEHYDRATRXN

DTDPGLUCOSEPP-RXN
DTDPKIN-RXN
DTMPKI-RXN
DUDPKIN-RXN
DURIDKI-RXN

DUTP-PYROP-RXN

Reaction
>+1*NADH[c]+2*PROTO
N[c]+1*SIROHYDROCHL
ORIN[c]
+1*RIBULOSE-5P[c]->+1*DIHYDROXYBUTANONEP[c]+1*FORMATE[c]+1*P
ROTON[c]
+1*D-SERINE[c]->+1*AMMONIA[c]+1*PR
OTON[c]+1*PYRUVATE[c
]
+1*DTDP-DEOH-DEOXYGLUCOSE[c]-->+1*DTDPDEOH-DEOXYMANNOSE[c]
+1*DTDP-DEOH-DEOXYMANNOSE[c]+1*NADPH[
c]+1*PROTON[c]->+1*DTDPRHAMNOSE[c]+1*NADP[
c]
+1*DTDP-D-GLUCOSE[c]->+1*DTDP-DEOHDEOXYGLUCOSE[c]+1*WATER[c
]
+1*GLC-1P[c]+1*PROTON[c]+1*TT
P[c]<-->+1*DTDP-DGLUCOSE[c]+1*PPI[c]
+1*ATP[c]+1*TDP[c]->+1*ADP[c]+1*TTP[c]
+1*ATP[c]+1*TMP[c]->+1*ADP[c]+1*TDP[c]
+1*ATP[c]+1*DUDP[c]->+1*ADP[c]+1*DUTP[c]
+1*ATP[c]+1*DEOXYURI
DINE[c]->+1*ADP[c]+1*DUMP[c]+
1*PROTON[c]
+1*DUTP[c]+1*WATER[c]
->+1*DUMP[c]+1*PPI[c]+1
*PROTON[c]
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Locus

GCWI-4252

GCWI-1902

GCWI-1390

GCWI-1392

GCWI-1391

GCWI-1389
GCWI-1677
GCWI-215
GCWI-1677
GCWI-5429

GCWI-4053

Name

DXPREDISOM-RXN

DXS-RXN
ENOYL-ACP-REDUCTNADPH-RXNPALMITOYL-ACPSNADP--NADPH-2HEXADECENOYL-ACPSPROTON.54.
ENOYL-COA-HYDRATRXN-CPD0-2107--CPD7222-WATER.26.
ENOYL-COA-HYDRATRXN-CPD0-2171--CPD02120-WATER.27.
ENOYL-COA-HYDRATRXN-CPD0-2224--CPD02108-WATER.27.
ENOYL-COA-HYDRATRXN-CPD0-2232--CPD02117-WATER.27.
ENOYL-COA-HYDRATRXN-CPD0-2244--T2DECENOYL-COAWATER.33.
ENOYL-COA-HYDRATRXN-CPD0-2253--CPD10262-WATER.27.
ENOYL-COA-HYDRATRXN-OH-HEXANOYLCOA--CPD0-2121WATER.33.
ENZRXN-161-RXN

Reaction
+1*DEOXYXYLULOSE5P[c]+1*NADPH[c]+1*PR
OTON[c]->+1*NADP[c]+1*-2-CMETHYL-DERYTHRITOL-4PHOSPHATE[c]
+1*GAP[c]+1*PROTON[c]
+1*PYRUVATE[c]->+1*CARBONDIOXIDE[c]+1*DEOXYX
YLULOSE-5P[c]

Locus

GCWI-3399 GCWI-3905

GCWI-4313

+1*NADPH[c]+1*PROTO
N[c]+1*-2-HexadecenoylACPs[c]->+1*NADP[c]+1*Palmitoyl
-ACPs[c]

GCWI-1393

+1*CPD7222[c]+1*WATER[c]->+1*CPD0-2107[c]
+1*CPD02120[c]+1*WATER[c]->+1*CPD0-2171[c]
+1*CPD02108[c]+1*WATER[c]->+1*CPD0-2224[c]
+1*CPD02117[c]+1*WATER[c]->+1*CPD0-2232[c]

GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439
GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439
GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439
GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439

+1*T2-DECENOYLCOA[c]+1*WATER[c]->+1*CPD0-2244[c]

GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439

+1*CPD10262[c]+1*WATER[c]->+1*CPD0-2253[c]
+1*CPD02121[c]+1*WATER[c]->+1*OH-HEXANOYLCOA[c]
+1*BUTANOL[c]+1*NAD[
c]<->+1*BUTANAL[c]+1*NA
DH[c]+1*PROTON[c]

GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439
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GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439
GCWI-2357 GCWI-4498
GCWI-379 GCWI-878
GCWI-1005 GCWI-1195
GCWI-2654 GCWI-2708

Name

F16ALDOLASE-RXN

F16BDEPHOS-RXN

FABAUNSATDEHYDRRXN
FADSYN-RXN

FGAMSYN-RXN

FLAVONADPREDUCTRXN

FMNREDUCT-RXN

FORMAMIDASE-RXN

FORMATETHFLIG-RXN

Reaction

+1*FRUCTOSE-16DIPHOSPHATE[c]<->+1*DIHYDROXYACETONEPHOSPHATE[c]+1*GAP[c]
+1*FRUCTOSE-16DIPHOSPHATE[c]+1*WA
TER[c]-->+1*FRUCTOSE6P[c]+1*Pi[c]
+1*Beta-hydroxydecanoylACPs[c]-->+1*Trans-D2decenoylACPs[c]+1*WATER[c]
+1*ATP[c]+1*FMN[c]+2*P
ROTON[c]->+1*FAD[c]+1*PPI[c]
+1*ATP[c]+1*GLN[c]+1*
WATER[c]+1*-5-PRIBOSYL-NFORMYLGLYCINEAMID
E[c]->+1*ADP[c]+1*GLT[c]+1*
PROTON[c]+1*Pi[c]+1*-5PHOSPHORIBOSYL-NFORMYLGLYCINEAMIDI
NE[c]
+1*NADP[c]+1*Reducedflavodoxins[c]<->+1*NADPH[c]+1*Oxidize
dflavodoxins[c]+1*PROTON
[c]
+1*FMN[c]+1*NADH[c]+2
*PROTON[c]->+1*FMNH2[c]+1*NAD[c]
+1*FORMAMIDE[c]+1*W
ATER[c]<->+1*AMMONIA[c]+1*FO
RMATE[c]+1*PROTON[c]
+1*ATP[c]+1*FORMATE[
c]+1*THF[c]->+1*ADP[c]+1*Pi[c]+1*10-FORMYL-THF[c]
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Locus
GCWI-3152 GCWI-3423
GCWI-3425 GCWI-3545
GCWI-3011 GCWI-2580
GCWI-5434

GCWI-5083 GCWI-5432

GCWI-2941 GCWI-5366

GCWI-3893

GCWI-502 GCWI-501
GCWI-500

GCWI-5050 GCWI-558

GCWI-1778 GCWI-3373
GCWI-5277
GCWI-4083

GCWI-2205

Name
FORMIMINOGLUTAMAS
E-RXN

FPPSYN-RXN

FRUCTOKINASE-RXN

FUCPALDOL-RXN

FUMARYLACETOACETA
SE-RXN

FUMHYDR-RXN

GABATRANSAM-RXN

GAPOXNPHOSPHN-RXN

GART-RXN

Reaction
+1*N-FORMIMINO-LGLUTAMATE[c]+1*WAT
ER[c]->+1*FORMAMIDE[c]+1*
GLT[c]
+1*DELTA3ISOPENTENYLPP[c]+1*GERANYL-PP[c]->+1*FARNESYLPP[c]+1*PPI[c]
+1*ATP[c]+1*BETA-DFRUCTOSE[c]->+1*ADP[c]+1*FRUCTOS
E-6P[c]+1*PROTON[c]
+1*FUCULOSE-1P[c]<->+1*DIHYDROXYACETONEPHOSPHATE[c]+1*LACT
ALD[c]
+1*WATER[c]+1*-4FUMARYLACETOACETATE[c]->+1*FUM[c]+1*PROTON[
c]+1*-3KETOBUTYRATE[c]
+1*MAL[c]<->+1*FUM[c]+1*WATER[c
]
+1*-2KETOGLUTARATE[c]+1*
-4-AMINOBUTYRATE[c]->+1*GLT[c]+1*SUCC-SALD[c]
+1*GAP[c]+1*NAD[c]+1*
Pi[c]<->+1*DPG[c]+1*NADH[c]+
1*PROTON[c]
+1*-10-FORMYLTHF[c]+1*-5-PHOSPHORIBOSYLGLYCINEAMIDE[c]->+1*PROTON[c]+1*THF[c
]+1*-5-P-RIBOSYL-NFORMYLGLYCINEAMID
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Locus

GCWI-3677

GCWI-4314

GCWI-974

GCWI-554

GCWI-428 GCWI-1323

GCWI-631 GCWI-1886

GCWI-531

GCWI-4710 GCWI-5238

GCWI-505

Name

GARTRANSFORMYL2RXN

GCVMULTI-RXN

GCVP-RXN

GCVT-RXN

GDPKIN-RXN

GDPREDUCT-RXN

GLU6PDEHYDROG-RXN
GLUC1PADENYLTRANSRXN

Reaction
E[c]
+1*ATP[c]+1*FORMATE[
c]+1*-5-PHOSPHORIBOSYLGLYCINEAMIDE[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*-5-PRIBOSYL-NFORMYLGLYCINEAMID
E[c]
+1*GLY[c]+1*NAD[c]+1*
THF[c]->+1*AMMONIA[c]+1*CA
RBONDIOXIDE[c]+1*METHYLE
NETHF[c]+1*NADH[c]+1*PR
OTON[c]
+1*GLY[c]+1*PROTEINLIPOYLLYSINE[c]->+1*AMINOMETHYLDIH
YDROLIPOYLGCVH[c]+1*CARBONDIOXIDE[c]
+1*AMINOMETHYLDIHY
DROLIPOYLGCVH[c]+1*THF[c]->+1*AMMONIA[c]+1*DIH
YDROLIPOYLGCVH[c]+1*METHYLENE
-THF[c]
+1*ATP[c]+1*GDP[c]->+1*ADP[c]+1*GTP[c]
+1*GDP[c]+1*RedThioredoxin[c]->+1*DGDP[c]+1*OxThioredoxin[c]+1*WATER[
c]
+1*GLC-6P[c]+1*NADP[c]-->+1*D6-P-GLUCONO-DELTALACTONE[c]+1*NADPH[c
]+1*PROTON[c]
+1*ATP[c]+1*GLC-1P[c]+1*PROTON[c]<--
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Locus

GCWI-505

GCWI-4362

GCWI-4362 GCWI-4360
GCWI-4361

GCWI-4362

GCWI-1677
GCWI-1519 GCWI-1521
GCWI-1521 GCWI-1519
GCWI-1522

GCWI-975

GCWI-4989

Name

GLUC1PURIDYLTRANSRXN

GLUCOKIN-RXN

GLUCONOKIN-RXN

GLUCOSAMINE-6-PDEAMIN-RXN

GLURS-RXN

GLUTAMATEDEHYDROGENASE-RXN

GLUTAMATE-NACETYLTRANSFERASERXN

GLUTAMATESYN-RXN

GLUTAMIDOTRANSRXN

Reaction
>+1*ADP-DGLUCOSE[c]+1*PPI[c]
+1*GLC-1P[c]+1*PROTON[c]+1*UT
P[c]<-->+1*PPI[c]+1*UDPGLUCOSE[c]
+1*ALPHAGLUCOSE[c]+1*ATP[c]->+1*ADP[c]+1*ALPHAGLC-6-P[c]+1*PROTON[c]
+1*ATP[c]+1*GLUCONA
TE[c]->+1*ADP[c]+1*CPD2961[c]+1*PROTON[c]
+1*D-GLUCOSAMINE-6P[c]+1*WATER[c]->+1*AMMONIA[c]+1*FR
UCTOSE6P[c]+1*PROTON[c]
+1*ATP[c]+1*GLT[c]+1*G
LTtRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedGLT-tRNAs[c]+1*PPI[c]
+1*GLT[c]+1*NAD[c]+1*
WATER[c]->+1*AMMONIA[c]+1*NA
DH[c]+2*PROTON[c]+1*2-KETOGLUTARATE[c]
+1*GLT[c]+1*N-ALPHAACETYLORNITHINE[c]->+1*ACETYLGLU[c]+1*LORNITHINE[c]
+1*GLN[c]+1*NADPH[c]+
1*PROTON[c]+1*-2KETOGLUTARATE[c]->+2*GLT[c]+1*NADP[c]
+1*GLN[c]+1*PHOSPHOR
IBULOSYL-FORMIMINOAICAR-P[c]->+1*AICAR[c]+1*DERYTHRO-IMIDAZOLEGLYCEROLP[c]+1*GLT[c]+1*PROTO
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Locus

GCWI-5042

GCWI-4396

GCWI-364 GCWI-365
GCWI-3416

GCWI-4196

GCWI-277

GCWI-1653

GCWI-4271

GCWI-719

GCWI-1571 GCWI-1573

Name

GLUTAMIN-RXN

GLUTAMINESYN-RXN

GLUTATHIONEPEROXIDASE-RXN

GLUTKIN-RXN
GLUTRACE-RXN

GLUTRNAREDUCT-RXN

GLUTSEMIALDEHYDRO
G-RXN

GLY3KIN-RXN

GLYCEROL-KIN-RXN

GLYCERONE-KINASERXN

Reaction
N[c]
+1*GLN[c]+1*WATER[c]>+1*AMMONIA[c]+1*GL
T[c]+1*PROTON[c]
+1*AMMONIA[c]+1*ATP[
c]+1*GLT[c]->+1*ADP[c]+1*GLN[c]+1*
Pi[c]
+2*GLUTATHIONE[c]+1*
HYDROGENPEROXIDE[c]->+1*OXIDIZEDGLUTATHIONE[c]+2*WA
TER[c]
+1*ATP[c]+1*GLT[c]->+1*ADP[c]+1*LGLUTAMATE-5-P[c]
+1*GLT[c]-->+1*D-GLT[c]
+1*Charged-GLTtRNAs[c]+1*NADPH[c]->+1*GLTtRNAs[c]+1*GLUTAMAT
E-1SEMIALDEHYDE[c]+1*N
ADP[c]
+1*L-GLUTAMATE-5P[c]+1*NADPH[c]+1*PRO
TON[c]-->+1*LGLUTAMATE-GAMMASEMIALDEHYDE[c]+1*N
ADP[c]+1*Pi[c]
+1*ATP[c]+1*GLYCERAT
E[c]->+1*ADP[c]+1*G3P[c]+1*
PROTON[c]
+1*ATP[c]+1*GLYCEROL
[c]->+1*ADP[c]+1*GLYCERO
L-3P[c]+1*PROTON[c]
+1*ATP[c]+1*DIHYDROX
YACETONE[c]<->+1*ADP[c]+1*DIHYDRO
XY-ACETONEPHOSPHATE[c]+1*PROT
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Locus

GCWI-719 GCWI-692
GCWI-3172

GCWI-3785

GCWI-2217

GCWI-3022
GCWI-1064 GCWI-4611

GCWI-4593

GCWI-3021

GCWI-1216

GCWI-1164

Name

GLYCINE--TRNALIGASE-RXN
GLYCOGEN-BRANCHRXN
GLYCOGENSYN-RXN

GLYCOLALDDEHYDROG-RXN
GLYCOPHOSPHORYLRXN
GLYCPDIESTER-RXN

GLYCPDIESTER-RXNGLYCEROPHOSPHOGLY
CEROL-WATER-GLYCEROL-GLYCEROL3P-PROTON.58.
GLYMALTOPHOSPHORY
L-RXN
GLYOHMETRANS-RXN

GLYRIBONUCSYN-RXN

GMKALT-RXN

Reaction
ON[c]
+1*ATP[c]+1*GLY[c]+1*G
LYtRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedGLY-tRNAs[c]+1*PPI[c]
+1*-1-4-alpha-D-Glucan[c]->+1*Glycogens[c]
+1*ADP-D-GLUCOSE[c]->+1*ADP[c]+1*-1-4-alphaD-Glucan[c]
+1*GLYCOLALDEHYDE[
c]+1*NAD[c]+1*WATER[c
]->+1*GLYCOLLATE[c]+1*
NADH[c]+2*PROTON[c]
+1*Glycogens[c]+1*Pi[c]->+1*GLC-1-P[c]
+1*Glycerophosphodiesters[
c]+1*WATER[c]<->+1*Alcohols[c]+1*GLYC
EROL3P[c]+1*PROTON[c]
+1*GLYCEROL[c]+1*GL
YCEROL3P[c]+1*PROTON[c]<->+1*GLYCEROPHOSPHO
GLYCEROL[c]+1*WATER
[c]
+1*Glycogens[c]+1*Pi[c]<->+1*GLC-1P[c]+1*MALTOTETRAOS
E[c]
+1*SER[c]+1*THF[c]->+1*GLY[c]+1*METHYL
ENE-THF[c]+1*WATER[c]
+1*ATP[c]+1*GLY[c]+1*5-P-BETA-D-RIBOSYLAMINE[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*-5-PHOSPHORIBOSYLGLYCINEAMIDE[c]
+1*ATP[c]+1*DGMP[c]<->+1*ADP[c]+1*DGDP[c]
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Locus

GCWI-5037

GCWI-4990
GCWI-4987

GCWI-4986
GCWI-5472 GCWI-4306
GCWI-797 GCWI-3539
GCWI-2726

GCWI-5472 GCWI-4306
GCWI-797 GCWI-3539
GCWI-2726

GCWI-4986

GCWI-5415

GCWI-507

GCWI-3955

Name
GMP-REDUCT-RXN

GMP-SYN-GLUT-RXN

GMP-SYN-NH3-RXN

GPPSYN-RXN

GSAAMINOTRANS-RXN

GSPSYN-RXN

GTP-CYCLOHYDRO-IRXN

GTP-CYCLOHYDRO-IIRXN

GTPPYPHOSKIN-RXN
GUANIDINOBUTANAMI
DE-NH3-RXN

Reaction
+1*GMP[c]+1*NADPH[c]+
1*PROTON[c]->+1*AMMONIA[c]+1*IMP
[c]+1*NADP[c]
+1*ATP[c]+1*GLN[c]+1*
WATER[c]+1*XANTHOSI
NE-5-PHOSPHATE[c]->+1*AMP[c]+1*GLT[c]+1*
GMP[c]+1*PPI[c]+2*PROT
ON[c]
+1*AMMONIA[c]+1*ATP[
c]+1*XANTHOSINE-5PHOSPHATE[c]->+1*AMP[c]+1*GMP[c]+1
*PPI[c]+1*PROTON[c]
+1*CPD4211[c]+1*DELTA3ISOPENTENYL-PP[c]->+1*GERANYLPP[c]+1*PPI[c]
+1*GLUTAMATE-1SEMIALDEHYDE[c]->+1*-5-AMINOLEVULINATE[c]
+1*ATP[c]+1*GLUTATHI
ONE[c]+1*SPERMIDINE[c
]->+1*ADP[c]+1*GLUTATH
IONYLSPERMIDINE[c]+1
*PROTON[c]+1*Pi[c]
+1*GTP[c]+1*WATER[c]->+1*DIHYDRONEOPTERI
NP3[c]+1*FORMATE[c]+1*
PROTON[c]
+1*GTP[c]+3*WATER[c]->+1*DIAMINO-OHPHOSPHORIBOSYLAMIN
OPYR[c]+1*FORMATE[c]+1
*PPI[c]+2*PROTON[c]
+1*ATP[c]+1*GTP[c]->+1*AMP[c]+1*GDP-TP[c]
+1*WATER[c]+1*-4GUANIDO-
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Locus
GCWI-5557

GCWI-470

GCWI-470

GCWI-4314

GCWI-720 GCWI-4588

GCWI-2964

GCWI-1673

GCWI-4252

GCWI-4532
GCWI-2029 GCWI-2171

Name

GUANPRIBOSYLTRANRXN
GUANYL-KIN-RXN
H2NEOPTERINALDOLRXN

H2NEOPTERINP3PYROP
HOSPHOHYDRO-RXN

H2PTERIDINEPYROPHOS
PHOKIN-RXN

H2PTEROATESYNTHRXN

HEME-OXYGENASEDECYCLIZING-RXN

HEMEOSYN-RXN
HEMN-RXN

Reaction
BUTYRAMIDE[c]<->+1*AMMONIA[c]+1*CP
D-592[c]+1*PROTON[c]
+1*GUANINE[c]+1*PRPP[
c]-->+1*GMP[c]+1*PPI[c]
+1*ATP[c]+1*GMP[c]<->+1*ADP[c]+1*GDP[c]
+1*DIHYDRO-NEOPTERIN[c]-->+1*AMINOOH-HYDROXYMETHYLDIHYDROPTERIDINE[c]+
1*GLYCOLALDEHYDE[c]
+1*DIHYDRONEOPTERI
N-P3[c]+1*WATER[c]->+1*DIHYDRONEOPTERI
NP[c]+1*PPI[c]+1*PROTON
[c]
+1*AMINO-OHHYDROXYMETHYLDIHYDROPTERIDINE[c]+
1*ATP[c]->+1*AMP[c]+1*DIHYDRO
PTERIN-CH2OHPP[c]+1*PROTON[c]
+1*DIHYDROPTERINCH2OH-PP[c]+1*PAMINO-BENZOATE[c]->+1*PPI[c]+1*-7-8DIHYDROPTEROATE[c]
+3*DonorH2[c]+3*OXYGENMOLECULE[c]+1*PROTO
HEME[c]+2*PROTON[c]<>+3*Acceptor[c]+1*BILIV
ERDINE[c]+1*CARBONMONOXIDE[c]+1*FE2[c]+3*WATER[c]
+1*FARNESYLPP[c]+1*PROTOHEME[c]+
1*WATER[c]<->+1*HEME-O[c]+1*PPI[c]
+1*COPROPORPHYRINO
GEN-III[c]+2*S-
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Locus

GCWI-251 GCWI-4941
GCWI-1727
GCWI-3955

GCWI-260

GCWI-3029 GCWI-4475

GCWI-261

GCWI-259

GCWI-4669

GCWI-4089
GCWI-1089 GCWI-4447

Name

HEXOKINASE-RXN

HISTALDEHYD-RXN

HISTAMINOTRANS-RXN

HISTCYCLOHYD-RXN

HISTIDINE--TRNALIGASE-RXN

HISTIDINE-AMMONIALYASE-RXN

HISTIDPHOS-RXN

HISTOLDEHYD-RXN

HISTPRATPHYD-RXN

Reaction
ADENOSYLMETHIONIN
E[c]-->+2*CARBONDIOXIDE[c]+2*CH33ADO
[c]+2*MET[c]+1*PROTOP
ORPHYRINOGEN[c]
+1*ATP[c]+1*DHexoses[c]<->+1*ADP[c]+1*DHEXOSE-6PHOSPHATE[c]+1*PROT
ON[c]
+1*HISTIDINAL[c]+1*NA
D[c]+1*WATER[c]->+1*HIS[c]+1*NADH[c]+2
*PROTON[c]
+1*GLT[c]+1*IMIDAZOL
E-ACETOL-P[c]-->+1*LHISTIDINOL-P[c]+1*-2KETOGLUTARATE[c]
+1*PHOSPHORIBOSYLAMP[c]+1*WATER[c]->+1*PHOSPHORIBOSYLFORMIMINO-AICAR-P[c]
+1*ATP[c]+1*HIS[c]+1*HI
StRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedHIS-tRNAs[c]+1*PPI[c]
+1*HIS[c]->+1*AMMONIA[c]+1*PR
OTON[c]+1*UROCANATE
[c]
+1*L-HISTIDINOLP[c]+1*WATER[c]->+1*HISTIDINOL[c]+1*Pi
[c]
+1*HISTIDINOL[c]+1*NA
D[c]->+1*HISTIDINAL[c]+1*N
ADH[c]+1*PROTON[c]
+1*PHOSPHORIBOSYLATP[c]+1*WATER[c]->+1*PHOSPHORIBOSYLAMP[c]+1*PPI[c]+1*PROT
ON[c]
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Locus

GCWI-4396

GCWI-1569

GCWI-1680 GCWI-2986

GCWI-1574

GCWI-3369 GCWI-4529

GCWI-3680

GCWI-1576

GCWI-1569

GCWI-1575

Name
HOLO-ACP-SYNTH-RXN

HOMOCYSMET-RXN

HOMOCYSMETB12-RXN

HOMOCYSTEINE-SMETHYLTRANSFERASERXN

HOMOGENTISATE-12DIOXYGENASE-RXN

HOMOSERINE-OACETYLTRANSFERASERXN

HOMOSERKIN-RXN

HOMSUCTRAN-RXN

HYDROXYLAMINEREDUCTASE-RXN
HYDROXYMETHYLGLU
TARYL-COA-LYASERXN

Reaction
+1*CO-A[c]+1*apoACP[c]-->+1*ACP[c]+1*3-5-ADP[c]
+1*CPD1302[c]+1*HOMO-CYS[c]->+1*CPD1301[c]+1*MET[c]
+1*HOMO-CYS[c]+1*-5METHYL-THF[c]->+1*MET[c]+1*THF[c]
+1*HOMO-CYS[c]+1*SADENOSYLMETHIONIN
E[c]-->+1*ADENOSYLHOMOCYS[c]+1*MET[c]+1*PRO
TON[c]
+1*HOMOGENTISATE[c]
+1*OXYGENMOLECULE[c]<->+1*PROTON[c]+1*-4MALEYLACETOACETATE[c]
+1*ACETYLCOA[c]+1*HOMO-SER[c]->+1*CO-A[c]+1*CPD667[c]
+1*ATP[c]+1*HOMOSER[c]-->+1*ADP[c]+1*OPHOSPHO-LHOMOSERINE[c]+1*PRO
TON[c]
+1*HOMOSER[c]+1*SUC-COA[c]->+1*CO-A[c]+1*OSUCCINYL-LHOMOSERINE[c]
+1*FADH2[c]+1*HYDRO
XYLAMINE[c]->+1*AMMONIA[c]+1*FA
D[c]+1*WATER[c]
+1*-3-HYDROXY-3METHYL-GLUTARYLCOA[c]-->+1*ACETYLCOA[c]+1*-3KETOBUTYRATE[c]
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Locus
GCWI-437 GCWI-2455

GCWI-4144

GCWI-4387

GCWI-4388

GCWI-429

GCWI-4859

GCWI-2074

GCWI-5506

GCWI-3482

GCWI-2615

Name

HYDROXYPYRROLINED
EH-RXN

HYPOXANPRIBOSYLTR
AN-RXN

IGPSYN-RXN

IMIDAZOLONEPROPION
ASE-RXN

IMIDPHOSDEHYD-RXN

IMP-DEHYDROG-RXN

IMPCYCLOHYDROLASERXN
INOPHOSPHOR-RXN
INORGPYROPHOSPHATRXN
IPPISOM-RXN

Reaction
+1*NAD[c]+1*PYRROLIN
E-HYDROXYCARBOXYLATE[c]+2*W
ATER[c]<-->+1*LERYTHRO-4-HYDROXYGLUTAMATE[c]+1*NAD
H[c]+1*PROTON[c]
+1*HYPOXANTHINE[c]+
1*PRPP[c]->+1*IMP[c]+1*PPI[c]
+1*CARBOXYPHENYLA
MINODEOXYRIBULOSEP[c]+1*PROTON[c]->+1*CARBONDIOXIDE[c]+1*INDOLE3-GLYCEROLP[c]+1*WATER[c]
+1*PROTON[c]+1*WATE
R[c]+1*-4IMIDAZOLONE-5PROPIONATE[c]-->+1*NFORMIMINO-LGLUTAMATE[c]
+1*D-ERYTHROIMIDAZOLE-GLYCEROLP[c]-->+1*IMIDAZOLEACETOLP[c]+1*WATER[c]
+1*IMP[c]+1*NAD[c]+1*
WATER[c]->+1*NADH[c]+1*PROTO
N[c]+1*XANTHOSINE-5PHOSPHATE[c]
+1*PHOSPHORIBOSYLFORMAMIDOCARBOXAMIDE[c]<->+1*IMP[c]+1*WATER[c]
+1*INOSINE[c]+1*Pi[c]->+1*HYPOXANTHINE[c]
+1*RIBOSE-1P[c]
+1*PPI[c]+1*WATER[c]->+1*PROTON[c]+2*Pi[c]
+1*DELTA3ISOPENTENYL-PP[c]<--
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Locus

GCWI-516

GCWI-251 GCWI-4941
GCWI-1727

GCWI-1412

GCWI-3678

GCWI-1570

GCWI-192

GCWI-506
GCWI-4228 GCWI-1624
GCWI-4228
GCWI-2876 GCWI-5260
GCWI-1661

Name

ISOCHORMAT-RXN

ISOCHORSYN-RXN
ISOCIT-CLEAV-RXN

ISOCITDEH-RXN

ISOLEUCINE--TRNALIGASE-RXN

ISOVALERYLCOADHLIPOAMIDE-RXN

KANAMYCIN-KINASERXN
KETOACYLCOATHIOLRXN-BUTYRYL-COAACETYL-COA--KHEXANOYL-COA-COA.44.
KETOACYLCOATHIOLRXN-CPD-10267ACETYL-COA--CPD02105-CO-A.37.
KETOACYLCOATHIOL-

Reaction
>+1*CPD-4211[c]
+1*ISOCHORISMATE[c]+
1*WATER[c]->+1*DIHYDRO-DIOHBENZOATE[c]+1*PYRUV
ATE[c]
+1*CHORISMATE[c]->+1*ISOCHORISMATE[c]
+1*THREO-DS-ISOCITRATE[c]->+1*GLYOX[c]+1*SUC[c]
+1*NADP[c]+1*THREODS-ISO-CITRATE[c]->+1*CARBONDIOXIDE[c]+1*NADPH[c]
+1*-2KETOGLUTARATE[c]
+1*ATP[c]+1*ILE[c]+1*IL
EtRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedILE-tRNAs[c]+1*PPI[c]
+1*BCAA-dehydrogenase3MB-DH-lipoyl[c]+1*COA[c]-->+1*BCAAdehydrogenase-DHlipoyl[c]+1*ISOVALERYLCOA[c]
+1*ATP[c]+1*Kanamycins[
c]<->+1*ADP[c]+1*Kanamycin
-3phosphates[c]+1*PROTON[
c]
+1*CO-A[c]+1*KHEXANOYL-COA[c]->+1*ACETYLCOA[c]+1*BUTYRYLCOA[c]

Locus
GCWI-201 GCWI-517
GCWI-1532 GCWI-1754
GCWI-2992 GCWI-3182
GCWI-3183 GCWI-3311
GCWI-4391 GCWI-2350
GCWI-2451
GCWI-4980 GCWI-2449
GCWI-1306

GCWI-4720

GCWI-2273 GCWI-3979

GCWI-4297

GCWI-3134 GCWI-4827

GCWI-5128

+1*CO-A[c]+1*CPD02105[c]-->+1*ACETYLCOA[c]+1*CPD-10267[c]

GCWI-5128

+1*CO-A[c]+1*CPD0-

GCWI-5128
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Name
RXN-CPD-196-ACETYLCOA--CPD0-2123-COA.35.
KETOACYLCOATHIOLRXN-HEXANOYL-COAACETYL-COA--CPD02106-CO-A.40.
KETOACYLCOATHIOLRXN-LAUROYLCOACPD-ACETYL-COA--CPD10284-CO-A.42.
KETOACYLCOATHIOLRXN-PALMITYL-COAACETYL-COA--CPD10260-CO-A.40.
KETOACYLCOATHIOLRXN-TETRADECANOYLCOA-ACETYL-COA--3OXOPALMITOYL-COACO-A.54.

KETOISOCAPROATERXN

KYNURENINASE-RXN

L-ASPARTATE-OXIDRXN

L-GLN-FRUCT-6-PAMINOTRANS-RXN

Reaction
2123[c]-->+1*ACETYLCOA[c]+1*CPD-196[c]
+1*CO-A[c]+1*CPD02106[c]-->+1*ACETYLCOA[c]+1*HEXANOYLCOA[c]
+1*CO-A[c]+1*CPD10284[c]-->+1*ACETYLCOA[c]+1*LAUROYLCO
A-CPD[c]
+1*CO-A[c]+1*CPD10260[c]-->+1*ACETYLCOA[c]+1*PALMITYLCOA[c]
+1*CO-A[c]+1*-3OXOPALMITOYLCOA[c]-->+1*ACETYLCOA[c]+1*TETRADECAN
OYL-COA[c]
+1*BCAA-dehydrogenaselipoyl[c]+1*-2K-4CH3PENTANOATE[c]->+1*BCAA-dehydrogenase3MB-DHlipoyl[c]+1*CARBONDIOXIDE[c]
+1*LKYNURENINE[c]+1*WAT
ER[c]->+1*ANTHRANILATE[c]+
1*L-ALPHAALANINE[c]+1*PROTON[
c]
+1*LASPARTATE[c]+1*OXYG
EN-MOLECULE[c]->+1*HYDROGENPEROXIDE[c]+1*IMINOA
SPARTATE[c]+1*PROTO
N[c]
+1*FRUCTOSE6P[c]+1*GLN[c]-->+1*DGLUCOSAMINE-6P[c]+1*GLT[c]
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Locus

GCWI-5128

GCWI-5128

GCWI-5128

GCWI-5128

GCWI-4298 GCWI-4299

GCWI-2808

GCWI-4557

GCWI-361

Name
L-LACTATEDEHYDROGENASE-RXN
LLACTDEHYDROGFMNRXN
LACTALDDEHYDROGRXN

LEUCINE--TRNALIGASE-RXN

LEUCINEDEHYDROGENASE-RXN

LUMAZINESYN-RXN

LYSDECARBOX-RXN

LYSINE--TRNA-LIGASERXN
LYSINE-23AMINOMUTASE-RXN
MACROCIN-OMETHYLTRANSFERASE-

Reaction
+1*LLACTATE[c]+1*NAD[c]<>+1*NADH[c]+1*PROTO
N[c]+1*PYRUVATE[c]
+1*CPD-9718[c]+1*LLACTATE[c]-->+1*CPD12125[c]+1*PYRUVATE[c]
+1*LACTALD[c]+1*NAD[
c]+1*WATER[c]<-->+1*LLACTATE[c]+1*NADH[c]
+2*PROTON[c]
+1*ATP[c]+1*LEU[c]+1*L
EUtRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedLEU-tRNAs[c]+1*PPI[c]
+1*LEU[c]+1*NAD[c]+1*
WATER[c]<->+1*AMMONIA[c]+1*NA
DH[c]+2*PROTON[c]+1*2K-4CH3PENTANOATE[c]
+1*AMINORIBOSYLAMINO-1H-3HPYRDIONE[c]+1*DIHYDROX
Y-BUTANONE-P[c]->+1*DIMETHYL-DRIBITYLLUMAZINE[c]+1*PROTO
N[c]+1*Pi[c]+2*WATER[c]
+1*LYS[c]+1*PROTON[c]>+1*CADAVERINE[c]+1*
CARBON-DIOXIDE[c]
+1*ATP[c]+1*LYS[c]+1*L
YStRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedLYS-tRNAs[c]+1*PPI[c]
+1*LYS[c]-->+1*CPD233[c]
+1*MACROCIN[c]+1*SADENOSYLMETHIONIN
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Locus
GCWI-2031 GCWI-4991
GCWI-5121

GCWI-2379 GCWI-3587
GCWI-2881 GCWI-1451

GCWI-4866

GCWI-4302

GCWI-4253

GCWI-214 GCWI-4106

GCWI-264

GCWI-2389
GCWI-1383

Name
RXN

MALATE-DEH-RXN
MALATEDEHYDROGENASEACCEPTOR-RXN-MALCPD-9717-OXALACETIC-ACIDCPD-9955.39.
MALIC-NAD-RXN

MALIC-NADP-RXN

MALONYL-COA-ACPTRANSACYL-RXN

MALSYN-RXN

MALTACETYLTRANRXN

MBCOA-DHLIPOAMIDERXN
METHENYLTHFCYCLOH
YDRO-RXN

Reaction
E[c]<-->+1*ADENOSYLHOMOCYS[c]+1*PROTON[c]+1*
TYLOSIN[c]
+1*MAL[c]+1*NAD[c]<->+1*NADH[c]+1*OXALA
CETICACID[c]+1*PROTON[c]
+1*CPD9717[c]+1*MAL[c]->+1*CPD9955[c]+1*OXALACETICACID[c]
+1*MAL[c]+1*NAD[c]->+1*CARBONDIOXIDE[c]+1*NADH[c]+
1*PYRUVATE[c]
+1*MAL[c]+1*NADP[c]->+1*CARBONDIOXIDE[c]+1*NADPH[c]
+1*PYRUVATE[c]
+1*ACP[c]+1*MALONYLCOA[c]+1*PROTON[c]<->+1*COA[c]+1*MALONYLACP[c]
+1*ACETYLCOA[c]+1*GLYOX[c]+1*
WATER[c]-->+1*COA[c]+1*MAL[c]+1*PROTO
N[c]
+1*ACETYLCOA[c]+1*MALTOSE[c]<>+1*ACETYLMALTOSE[c
]+1*CO-A[c]
+1*BCAA-dehydrogenase2MB-DH-lipoyl[c]+1*COA[c]-->+1*BCAAdehydrogenase-DHlipoyl[c]+1*-2-METHYLBUTYRYL-COA[c]
+1*WATER[c]+1*-5-10METHENYL-THF[c]<--
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Locus

GCWI-4719 GCWI-786
GCWI-1917 GCWI-3163
GCWI-4719 GCWI-4730
GCWI-786 GCWI-1917
GCWI-3163 GCWI-4719
GCWI-4730 GCWI-3002

GCWI-786 GCWI-1917
GCWI-3163 GCWI-4730
GCWI-786 GCWI-1917
GCWI-3163 GCWI-4719
GCWI-4730

GCWI-3936

GCWI-1305

GCWI-3394

GCWI-4297

GCWI-4317

Name

METHGLYSYN-RXN

METHIONINE--TRNALIGASE-RXN

METHIONINE-GAMMALYASE-RXN

METHIONYL-TRNAFORMYLTRANSFERASERXN

METHYLACETOACETYL
COATHIOL-RXN

METHYLACYLYLCOAHYDROXY-RXN
METHYLENETHFDEHYD
ROG-NADP-RXN
METHYLISOCITRATELYASE-RXN
METHYLTHIOADENOSI
NE-NUCLEOSIDASERXN
METHYLVALERATE-

Reaction
>+1*PROTON[c]+1*-10FORMYL-THF[c]
+1*DIHYDROXYACETONEPHOSPHATE[c]<->+1*METHYLGLYOXAL[c]+1*Pi[c]
+1*ATP[c]+1*MET[c]+1*
METtRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedMET-tRNAs[c]+1*PPI[c]
+1*MET[c]+1*WATER[c]>+1*AMMONIA[c]+1*CP
D7671[c]+1*PROTON[c]+1*
-2-OXOBUTANOATE[c]
+1*L-methionyltRNAfmet[c]+1*-10FORMYL-THF[c]<->+1*N-formyl-L-methionyltRNAfmet[c]+1*THF[c]
+1*CO-A[c]+1*-2METHYL-ACETOACETYL-COA[c]->+1*ACETYLCOA[c]+1*PROPIONYLCOA[c]
+1*METHACRYLYLCOA[c]+1*WATER[c]->+1*CPD-12173[c]
+1*METHYLENETHF[c]+1*NADP[c]->+1*NADPH[c]+1*-5-10METHENYL-THF[c]
+1*CPD-618[c]->+1*PYRUVATE[c]+1*SU
C[c]
+1*WATER[c]+1*-5METHYLTHIOADENOSI
NE[c]->+1*ADENINE[c]+1*CPD560[c]
+1*BCAA-dehydrogenase-
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Locus

GCWI-1695

GCWI-223 GCWI-5154

GCWI-4785

GCWI-3950

GCWI-3656 GCWI-4164
GCWI-5128 GCWI-5443
GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439
GCWI-4317

GCWI-2434

GCWI-2913

GCWI-2827 GCWI-4113

Name
RXN

MMUM-RXN
MYO-INOSITOL-1OR-4MONOPHOSPHATASERXN
NACETYLDIAMINOPIMEL
ATE-DEACETYLASERXN
NACETYLGLUTPREDUCTRXN

N-ACETYLTRANSFERRXN

NACGLCTRANS-RXN

NAD-KIN-RXN

NAD-SYNTH-GLN-RXN

NAD-SYNTH-NH3-RXN

Reaction
lipoyl[c]+1*-2-KETO-3METHYL-VALERATE[c]->+1*BCAA-dehydrogenase2MB-DHlipoyl[c]+1*CARBONDIOXIDE[c]
+1*CPD-397[c]+1*HOMOCYS[c]->+2*MET[c]+1*PROTON[
c]
+1*WATER[c]+1*-1-LMYO-INOSITOL-1-P[c]->+1*MYOINOSITOL[c]+1*Pi[c]
+1*CPD1771[c]+1*WATER[c]->+1*ACET[c]+1*LLDIAMINOPIMELATE[c]
+1*NADPH[c]+1*NACETYL-GLUTAMYLP[c]+1*PROTON[c]->+1*CPD469[c]+1*NADP[c]+1*Pi[c]
+1*ACETYLCOA[c]+1*GLT[c]->+1*ACETYLGLU[c]+1*COA[c]+1*PROTON[c]
+1*C5[c]+1*UDP-NACETYL-DGLUCOSAMINE[c]<->+1*C6[c]+1*PROTON[c]
+1*UDP[c]
+1*ATP[c]+1*NAD[c]->+1*ADP[c]+1*NADP[c]+
1*PROTON[c]
+1*ATP[c]+1*DEAMIDONAD[c]+1*GLN[c]+1*WA
TER[c]->+1*AMP[c]+1*GLT[c]+1*
NAD[c]+1*PPI[c]+1*PROT
ON[c]
+1*AMMONIA[c]+1*ATP[
c]+1*DEAMIDO-NAD[c]->+1*AMP[c]+1*NAD[c]+1
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Locus
GCWI-4297

GCWI-4388

GCWI-4102

GCWI-4122

GCWI-4272

GCWI-1049

GCWI-3994 GCWI-4386

GCWI-1374 GCWI-4772

GCWI-2102

GCWI-2102

Name

NADH-DEHYDROG-ARXN

NADPHDEHYDROGENASEFLAVIN-RXN

NAG1P-URIDYLTRANSRXN

NAG6PDEACET-RXN

NAPHTHOATE-SYN-RXN

NICONUCADENYLYLTR
AN-RXN

NICOTINAMID-RXN

NICOTINATEPRIBOSYLT
RANS-RXN

NITRIC-OXIDESYNTHASE-RXN

Reaction
*PPI[c]
+1*CPD9718[c]+1*NADH[c]+1*PR
OTON[c]-->+1*CPD12125[c]+1*NAD[c]
+1*CPD316[c]+1*NADP[c]<->+1*NADPH[c]+2*PROTO
N[c]+1*RIBOFLAVIN[c]
+1*N-ACETYL-DGLUCOSAMINE-1P[c]+1*PROTON[c]+1*UT
P[c]<-->+1*PPI[c]+1*UDPN-ACETYL-DGLUCOSAMINE[c]
+1*N-ACETYL-DGLUCOSAMINE-6P[c]+1*WATER[c]->+1*ACET[c]+1*DGLUCOSAMINE-6-P[c]
+1*CPD6972[c]+1*PROTON[c]->+1*CPD9925[c]+1*WATER[c]
+1*ATP[c]+1*NICOTINAT
ENUCLEOTIDE[c]+1*PROT
ON[c]-->+1*DEAMIDONAD[c]+1*PPI[c]
+1*NIACINAMIDE[c]+1*
WATER[c]->+1*AMMONIA[c]+1*NIA
CINE[c]+1*PROTON[c]
+1*NIACINE[c]+1*PROT
ON[c]+1*PRPP[c]->+1*NICOTINATENUCLEOTIDE[c]+1*PPI[c]
+2*ARG[c]+3*NADPH[c]+
4*OXYGENMOLECULE[c]+1*PROTO
N[c]-->+2*LCITRULLINE[c]+3*NADP[
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Locus
GCWI-5390 GCWI-5391
GCWI-5393 GCWI-5394
GCWI-5395 GCWI-5396
GCWI-5397 GCWI-5398
GCWI-5399 GCWI-5400
GCWI-2138 GCWI-2211
GCWI-3525
GCWI-1778 GCWI-3373

GCWI-234

GCWI-4197

GCWI-4977

GCWI-4461

GCWI-2029 GCWI-2171

GCWI-802 GCWI-4815

GCWI-5547

Name

NUCLEOSIDETRIPHOSPHATASE-RXN
OACETYLHOMOSERINETHIOL-LYASE-RXN
OSUCCHOMOSERLYASERXN
OSUCCINYLBENZOATECOA-LIG-RXN
OSUCCINYLBENZOATECOA-SYN-RXN
OHACYL-COADEHYDROG-RXN-CPD02107-NAD--CPD0-2105NADH-PROTON.37.
OHACYL-COADEHYDROG-RXN-CPD02171-NAD--CPD-10284NADH-PROTON.37.
OHACYL-COADEHYDROG-RXN-CPD02224-NAD--CPD0-2106NADH-PROTON.37.
OHACYL-COADEHYDROG-RXN-CPD02244-NAD--CPD0-2123NADH-PROTON.37.
OHACYL-COA-

Reaction
c]+2*NITRICOXIDE[c]+4*WATER[c]
+1*NucleosideTriphosphates[c]+1*WATE
R[c]-->+1*NucleosideDiphosphates[c]+1*PROTO
N[c]+1*Pi[c]
+1*CPD-667[c]+1*CPD7671[c]->+1*ACET[c]+1*MET[c]+
1*PROTON[c]
+1*CYS[c]+1*OSUCCINYL-LHOMOSERINE[c]-->+1*LCYSTATHIONINE[c]+1*P
ROTON[c]+1*SUC[c]
+1*ATP[c]+1*COA[c]+1*OSUCCINYLBENZOATE[c]
-->+1*AMP[c]+1*CPD6972[c]+1*PPI[c]
+1*CPD-9923[c]-->+1*OSUCCINYLBENZOATE[c]
+1*WATER[c]
+1*CPD02107[c]+1*NAD[c]->+1*CPD02105[c]+1*NADH[c]+1*PR
OTON[c]
+1*CPD02171[c]+1*NAD[c]->+1*CPD10284[c]+1*NADH[c]+1*P
ROTON[c]
+1*CPD02224[c]+1*NAD[c]->+1*CPD02106[c]+1*NADH[c]+1*PR
OTON[c]
+1*CPD02244[c]+1*NAD[c]->+1*CPD02123[c]+1*NADH[c]+1*PR
OTON[c]
+1*CPD0-
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Locus

GCWI-4608

GCWI-5507

GCWI-4389

GCWI-4976

GCWI-4979

GCWI-5129 GCWI-5442

GCWI-5129 GCWI-5442

GCWI-5129 GCWI-5442

GCWI-5129 GCWI-5442

GCWI-5129 GCWI-5442

Name
DEHYDROG-RXN-CPD02253-NAD--CPD-10260NADH-PROTON.37.
OHACYL-COADEHYDROG-RXN-OHHEXANOYL-COA-NAD-K-HEXANOYL-COANADH-PROTON.48.
OHMETHYLBILANESYNRXN

ORNCARBAMTRANSFER
-RXN

ORNITHINE--OXO-ACIDAMINOTRANSFERASERXN
ORNITHINECYCLODEAMINASERXN
ORNITHINE-GLUAMINOTRANSFORASERXN
OROPRIBTRANS-RXN

OROTPDECARB-RXN

P-PANTOCYSDECARBRXN

Reaction
2253[c]+1*NAD[c]->+1*CPD10260[c]+1*NADH[c]+1*P
ROTON[c]
+1*NAD[c]+1*OHHEXANOYL-COA[c]->+1*K-HEXANOYLCOA[c]+1*NADH[c]+1*PR
OTON[c]
+4*PORPHOBILINOGEN[
c]+1*WATER[c]->+4*AMMONIA[c]+1*HY
DROXYMETHYLBILANE
[c]+4*PROTON[c]
+1*CARBAMOYLP[c]+1*LORNITHINE[c]<-->+1*LCITRULLINE[c]+1*PROT
ON[c]+1*Pi[c]
+1*L-ORNITHINE[c]+1*2-Oxo-carboxylates[c]<->+1*Amino-Acids20[c]+1*L-GLUTAMATEGAMMASEMIALDEHYDE[c]
+1*L-ORNITHINE[c]->+1*AMMONIUM[c]+1*P
RO[c]
+1*L-ORNITHINE[c]+1*2-KETOGLUTARATE[c]<->+1*GLT[c]+1*LGLUTAMATE-GAMMASEMIALDEHYDE[c]
+1*OROTATE[c]+1*PRPP[
c]-->+1*OROTIDINE-5PHOSPHATE[c]+1*PPI[c]
+1*OROTIDINE-5PHOSPHATE[c]+1*PROT
ON[c]-->+1*CARBONDIOXIDE[c]+1*UMP[c]
+1*PROTON[c]+1*R-4PHOSPHOPANTOTHENO
YL-L-CYSTEINE[c]->+1*CARBONDIOXIDE[c]+1*PANTETH
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Locus

GCWI-5129 GCWI-5442

GCWI-4591

GCWI-4268

GCWI-1325

GCWI-1112

GCWI-1325

GCWI-3966

GCWI-3967

GCWI-3953

Name

P-PANTOCYSLIG-RXN

PABASYN-RXN

PANTEPADENYLYLTRA
N-RXN

PANTOATE-BETAALANINE-LIG-RXN

PANTOTHENATE-KINRXN

PEPCARBOXYKIN-RXN

PEPDEPHOS-RXN

PEPSYNTH-RXN

PEPTIDYLPROLYLISOMERASE-RXN

Reaction
EINE-P[c]
+1*CTP[c]+1*CYS[c]+1*4-P-PANTOTHENATE[c]->+1*CMP[c]+1*PPI[c]+1*P
ROTON[c]+1*R-4PHOSPHOPANTOTHENO
YL-L-CYSTEINE[c]
+1*CHORISMATE[c]+1*G
LN[c]-->+1*GLT[c]+1*-4AMINO-4DEOXYCHORISMATE[c]
+1*ATP[c]+1*PANTETHE
INE-P[c]+1*PROTON[c]->+1*DEPHOSPHOCOA[c]+1*PPI[c]
+1*ATP[c]+1*BALANINE[c]+1*LPANTOATE[c]->+1*AMP[c]+1*PANTOT
HENATE[c]+1*PPI[c]+1*P
ROTON[c]
+1*ATP[c]+1*PANTOTHE
NATE[c]->+1*ADP[c]+1*PROTON[c
]+1*-4-PPANTOTHENATE[c]
+1*ATP[c]+1*OXALACET
IC-ACID[c]->+1*ADP[c]+1*CARBONDIOXIDE[c]+1*PHOSPHO
-ENOL-PYRUVATE[c]
+1*ADP[c]+1*PHOSPHOENOLPYRUVATE[c]+1*PROTO
N[c]->+1*ATP[c]+1*PYRUVAT
E[c]
+1*ATP[c]+1*PYRUVATE
[c]+1*WATER[c]->+1*AMP[c]+1*PHOSPHO
-ENOLPYRUVATE[c]+2*PROTO
N[c]+1*Pi[c]
+1*CPD-8624[c]<->+1*CPD-8625[c]
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Locus

GCWI-3953

GCWI-195 GCWI-256
GCWI-257 GCWI-1410

GCWI-4073

GCWI-1702

GCWI-253 GCWI-2942

GCWI-4890

GCWI-3375 GCWI-4725

GCWI-3139

GCWI-4204 GCWI-1229
GCWI-1338 GCWI-2422

Name
PGLUCISOM-RXN
PGLYCDEHYDROG-RXN
PGPPHOSPHA-RXN-CPD12820-WATER--CPD12822-PI.30.
PGPPHOSPHA-RXN-CPD12821-WATER--CPD8260-PI.29.
PGPPHOSPHA-RXNCPD0-2230-WATER-CPD0-2330-PI.30.
PHENYLALANINE-TRNA-LIGASE-RXN

PHENYLALANINE-4MONOOXYGENASE-RXN

PHOSACETYLTRANSRXN
PHOSGLYPHOS-RXN
PHOSMANMUT-RXN
PHOSNACMURPENTATR
ANS-RXN
PHOSPHAGLYPSYNRXN-CPD-12814GLYCEROL-3P--CMPCPD-12820-PROTON.44.
PHOSPHAGLYPSYNRXN-CPD-12815GLYCEROL-3P--CMPCPD-12821-PROTON.44.

Reaction
+1*GLC-6-P[c]<->+1*FRUCTOSE-6P[c]
+1*G3P[c]+1*NAD[c]->+1*NADH[c]+1*PROTO
N[c]+1*-3-PHYDROXYPYRUVATE[c]
+1*CPD12820[c]+1*WATER[c]->+1*CPD-12822[c]+1*Pi[c]
+1*CPD12821[c]+1*WATER[c]->+1*CPD-8260[c]+1*Pi[c]
+1*CPD02230[c]+1*WATER[c]->+1*CPD0-2330[c]+1*Pi[c]
+1*ATP[c]+1*PHE[c]+1*P
HEtRNAs[c]+1*PROTON[c]->+1*AMP[c]+1*ChargedPHE-tRNAs[c]+1*PPI[c]
+1*OXYGENMOLECULE[c]+1*PHE[c]
+1*TETRA-HBIOPTERIN[c]-->+1*CPD5881[c]+1*TYR[c]
+1*ACETYLCOA[c]+1*Pi[c]->+1*ACETYL-P[c]+1*COA[c]
+1*ATP[c]+1*G3P[c]<->+1*ADP[c]+1*DPG[c]
+1*MANNOSE-6P[c]->+1*MANNOSE-1P[c]
+1*C1[c]+1*CPD-9646[c]->+1*C5[c]+1*UMP[c]
+1*CPD12814[c]+1*GLYCEROL3P[c]<->+1*CMP[c]+1*CPD12820[c]+1*PROTON[c]
+1*CPD12815[c]+1*GLYCEROL3P[c]->+1*CMP[c]+1*CPD12821[c]+1*PROTON[c]
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Locus
GCWI-5020
GCWI-3317

GCWI-4687 GCWI-4688

GCWI-4484

GCWI-5487
GCWI-5237
GCWI-5043
GCWI-3997

GCWI-3865

GCWI-3865

Name
PHOSPHASERDECARBRXN-CPD-12816PROTON--CPD-12818CARBON-DIOXIDE.43.
PHOSPHASERDECARBRXN-CPD-12817PROTON--CPD-12819CARBON-DIOXIDE.43.
PHOSPHASERSYN-RXNCPD-12814-SER--CMPCPD-12816-PROTON.36.
PHOSPHASERSYN-RXNCPD-12815-SER--CMPCPD-12817-PROTON.36.
PHOSPHATEBUTYRYLTRANSFERAS
E-RXN
PHOSPHOGLUCMUTRXN

PHOSPHOLIPASE-C-RXN

PHOSPHOLIPASE-CRXN-1-2DIPALMITOYLPHOSPHA
TIDYLCHOLINE-WATER-PHOSPHORYLCHOLINE-CPD66-34PROTON.77.
PHOSPHONOACETALDE
HYDE-HYDROLASE-RXN

PNKIN-RXN

Reaction
+1*CPD12816[c]+1*PROTON[c]->+1*CARBONDIOXIDE[c]+1*CPD12818[c]
+1*CPD12817[c]+1*PROTON[c]->+1*CARBONDIOXIDE[c]+1*CPD12819[c]
+1*CPD12814[c]+1*SER[c]->+1*CMP[c]+1*CPD12816[c]+1*PROTON[c]
+1*CPD12815[c]+1*SER[c]->+1*CMP[c]+1*CPD12817[c]+1*PROTON[c]
+1*BUTYRYLCOA[c]+1*Pi[c]->+1*BUTYRYLP[c]+1*CO-A[c]
+1*GLC-1-P[c]<->+1*ALPHA-GLC-6-P[c]
+1*PHOSPHATIDYLCHO
LINE[c]+1*WATER[c]->+1*DIACYLGLYCEROL[
c]+1*PHOSPHORYLCHOLINE[c]+1*PROTON[
c]
+1*WATER[c]+1*-1-2DIPALMITOYLPHOSPHA
TIDYLCHOLINE[c]->+1*CPD6634[c]+1*PHOSPHORYLCHOLINE[c]+1*PROTON[
c]
+1*CPD551[c]+1*WATER[c]->+1*ACETALD[c]+1*PRO
TON[c]+1*Pi[c]
+1*ATP[c]+1*PYRIDOXI
NE[c]->+1*ADP[c]+1*PROTON[c
]+1*PYRIDOXINE-5P[c]
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Locus

GCWI-4466

GCWI-4466

GCWI-1158 GCWI-1578

GCWI-1158 GCWI-1578

GCWI-4303
GCWI-5043

GCWI-880

GCWI-880

GCWI-1491

GCWI-5515

Name

PORPHOBILSYNTH-RXN

PPENTOMUT-RXN
PPGPPSYN-RXN

PRAISOM-RXN

PREPHENATEDEHYDRA
T-RXN

PREPHENATEDEHYDRO
G-RXN

PRIBFAICARPISOM-RXN

PRODISULFREDUCT-ARXN

PROLINE--TRNALIGASE-RXN
PROLINE-RACEMASE-

Reaction
+2*-5-AMINOLEVULINATE[c]->+1*PORPHOBILINOGEN
[c]+1*PROTON[c]+2*WA
TER[c]
+1*RIBOSE-1P[c]->+1*RIBOSE-5P[c]
+1*GUANOSINE-5DP3DP[c]+1*WATER[c]->+1*GDP[c]+1*PPI[c]+1*P
ROTON[c]
+1*N-5PHOSPHORIBOSYLANTHRANILATE[c]->+1*CARBOXYPHENYL
AMINODEOXYRIBULOSE-P[c]
+1*PREPHENATE[c]+1*P
ROTON[c]->+1*CARBONDIOXIDE[c]+1*PHENYLPYRUVATE[c]+1*WATER
[c]
+1*NAD[c]+1*PREPHENA
TE[c]-->+1*CARBONDIOXIDE[c]+1*NADH[c]+
1*P-HYDROXYPHENYLPYRUVATE[c]
+1*PHOSPHORIBOSYLFORMIMINO-AICAR-P[c]>+1*PHOSPHORIBULOS
YL-FORMIMINO-AICARP[c]
+2*GLUTATHIONE[c]+1*
Ox-Glutaredoxins[c]<->+1*OXIDIZEDGLUTATHIONE[c]+1*Red
-Glutaredoxins[c]
+1*ATP[c]+1*PRO[c]+1*P
ROTON[c]+1*PROtRNAs[c]->+1*AMP[c]+1*ChargedPRO-tRNAs[c]+1*PPI[c]
+1*PRO[c]-->+1*D-
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Locus

GCWI-4589

GCWI-4229
GCWI-4532

GCWI-1413

GCWI-4561

GCWI-2985

GCWI-1572

GCWI-603 GCWI-3903

GCWI-1111 GCWI-2884

Name
RXN
PROTOHEMEFERROCHE
LAT-RXN

PROTOPORGENOXI-RXN

PRPPAMIDOTRANS-RXN

PRPPSYN-RXN

PRTRANS-RXN

PSERTRANSAM-RXN

PSERTRANSAMPYRRXN

PYRIDOXKIN-RXN

PYRIMSYN3-RXN

Reaction
PROLINE[c]
+1*FE2[c]+1*PROTOPORPHYRI
N-IX[c]->+1*PROTOHEME[c]+2*P
ROTON[c]
+3*OXYGENMOLECULE[c]+1*PROTO
PORPHYRINOGEN[c]->+3*HYDROGENPEROXIDE[c]+1*PROTOP
ORPHYRIN-IX[c]
+1*GLN[c]+1*PRPP[c]+1*
WATER[c]->+1*GLT[c]+1*PPI[c]+1*5-P-BETA-D-RIBOSYLAMINE[c]
+1*ATP[c]+1*RIBOSE5P[c]->+1*AMP[c]+1*PROTON[
c]+1*PRPP[c]
+1*ANTHRANILATE[c]+1
*PRPP[c]-->+1*N-5PHOSPHORIBOSYLANTHRANILATE[c]+1*PP
I[c]
+1*GLT[c]+1*-3-PHYDROXYPYRUVATE[c]
-->+1*-2KETOGLUTARATE[c]+1*
-3-P-SERINE[c]
+1*GLT[c]+1*-3OH-4POH-ALPHAKETOBUTYRATE[c]->+1*-2KETOGLUTARATE[c]+1*
-4-PHOSPHONOOXYTHREONINE[c]
+1*ATP[c]+1*PYRIDOXA
L[c]->+1*ADP[c]+1*PROTON[c
]+1*PYRIDOXALPHOSPHATE[c]
+1*AMINOHYDROXYMETHYL-
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Locus

GCWI-1255 GCWI-1329

GCWI-1256 GCWI-2497

GCWI-503

GCWI-235

GCWI-1410 GCWI-1411

GCWI-3318

GCWI-3318

GCWI-5515

GCWI-958 GCWI-5515

Name

PYRROLINECARBDEHY
DROG-RXN

PYRUFLAVREDUCTRXN

PYRUVATECARBOXYLASE-RXN

PYRUVDEH-RXN

PYRUVFORMLY-RXN

QUINOLINATE-SYNTHARXN

QUINOPRIBOTRANSRXN

Reaction
METHYL-PYRP[c]+1*ATP[c]->+1*ADP[c]+1*AMINOHYDROXYMETHYLMETHYLPYRIMIDINEPP[c]
+1*L-DELTA1PYRROLINE-5CARBOXYLATE[c]+1*NA
D[c]+2*WATER[c]->+1*GLT[c]+1*NADH[c]+
1*PROTON[c]
+1*CO-A[c]+1*Oxidizedferredoxins[c]+1*PYRUVA
TE[c]-->+1*ACETYLCOA[c]+1*CARBONDIOXIDE[c]+1*PROTON[c
]+1*Reduced-ferredoxins[c]
+1*ATP[c]+1*HCO3[c]+1*
PYRUVATE[c]->+1*ADP[c]+1*OXALACE
TICACID[c]+1*PROTON[c]+1
*Pi[c]
+1*COA[c]+1*NAD[c]+1*PYRU
VATE[c]-->+1*ACETYLCOA[c]+1*CARBONDIOXIDE[c]+1*NADH[c]
+1*COA[c]+1*PYRUVATE[c]->+1*ACETYLCOA[c]+1*FORMATE[c]
+1*DIHYDROXYACETONEPHOSPHATE[c]+1*IMINO
ASPARTATE[c]->+1*Pi[c]+1*QUINOLINA
TE[c]+2*WATER[c]
+2*PROTON[c]+1*PRPP[c
]+1*QUINOLINATE[c]->+1*CARBONDIOXIDE[c]+1*NICOTIN
ATENUCLEOTIDE[c]+1*PPI[c]
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Locus

GCWI-516

GCWI-3858

GCWI-4091

GCWI-4113

GCWI-702

GCWI-4555

GCWI-4556

Name

R101-RXN

R11-RXN

R145-RXN

R147-RXN

R15-RXN

R222-RXN

R223-RXN

R311-RXN

R344-RXN

R4-RXN

R4-RXN-BUTANOL-NAD-

Reaction
+1*GLT[c]+1*LASPARTATESEMIALDEHYDE[c]->+1*CPD-470[c]+1*-2KETOGLUTARATE[c]
+1*ACET[c]+1*BUTYRYL
-COA[c]-->+1*ACETYLCOA[c]+1*BUTYRICACID[c]
+1*CPD-1063[c]->+1*CPD8999[c]+1*WATER[c]
+1*CPD85[c]+1*OXYGENMOLECULE[c]->+1*CPD479[c]+1*FORMATE[c]+1
*PROTON[c]
+1*CPD479[c]+1*GLT[c]<->+1*MET[c]+1*-2KETOGLUTARATE[c]
+1*CPD371[c]+1*NAD[c]+1*WAT
ER[c]<-->+1*CPD195[c]+1*NADH[c]+2*PR
OTON[c]
+1*ATP[c]+1*COA[c]+1*CPD-195[c]->+1*AMP[c]+1*CPD196[c]+1*PPI[c]
+1*ACRYLAMIDE[c]+1*
WATER[c]<->+1*ACRYLATE[c]+1*A
MMONIA[c]+1*PROTON[
c]
+1*ATP[c]+1*CPD694[c]<-->+1*CPD690[c]+1*P3I[c]
+1*Alkyl-HydroPeroxides[c]+1*NADH[c]+
1*PROTON[c]->+1*Alcohols[c]+1*NAD[c
]+1*WATER[c]
+1*BUTYL-
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Locus

GCWI-3308

GCWI-2385 GCWI-2384

GCWI-4180

GCWI-4181

GCWI-5024

GCWI-2379 GCWI-2379
GCWI-3587 GCWI-2881
GCWI-1451
GCWI-2036 GCWI-2087
GCWI-3657 GCWI-3659

GCWI-2029 GCWI-2171

GCWI-1640

GCWI-550 GCWI-551

GCWI-550 GCWI-551

Name
WATER--BUTYLHYDROPEROXIDENADH-PROTON.51.

R8-RXN

R82-RXN

R83-RXN

RIB5PISOM-RXN

RIBOFLAVIN-SYN-RXN

RIBOFLAVINKIN-RXN

RIBOFLAVINSYNDEAMRXN

RIBOFLAVINSYNREDUC
-RXN
RIBOKIN-RXN
RIBOPHOSPHAT-RXN

Reaction
HYDROPEROXIDE[c]+1*
NADH[c]+1*PROTON[c]->+1*BUTANOL[c]+1*NA
D[c]+1*WATER[c]
+1*ACETYLCOA[c]+1*CPD-19[c]->+1*ACET[c]+1*CPD20[c]
+1*CPD-8999[c]->+1*PROTON[c]+1*-2HYDROXY-3-KETO-5METHYLTHIO-1PHOSPHOP[c]
+1*WATER[c]+1*-2HYDROXY-3-KETO-5METHYLTHIO-1PHOSPHOP[c]-->+1*CPD85[c]+1*Pi[c]
+1*RIBOSE-5P[c]<->+1*RIBULOSE-5P[c]
+2*DIMETHYL-DRIBITYLLUMAZINE[c]+1*PROTO
N[c]-->+1*AMINORIBOSYLAMINO-1H-3HPYRDIONE[c]+1*RIBOFLAVI
N[c]
+1*ATP[c]+1*RIBOFLAVI
N[c]->+1*ADP[c]+1*FMN[c]+1
*PROTON[c]
+1*DIAMINO-OHPHOSPHORIBOSYLAMIN
O-PYR[c]+1*WATER[c]->+1*AMMONIA[c]+1*CP
D-602[c]
+1*CPD602[c]+1*NADPH[c]+1*PR
OTON[c]-->+1*CPD1086[c]+1*NADP[c]
+1*ATP[c]+1*RIBOSE[c]->+1*ADP[c]+1*PROTON[c
]+1*RIBOSE-5P[c]
+1*CPD-
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Locus

GCWI-2384

GCWI-4178

GCWI-4179

GCWI-2843 GCWI-5417

GCWI-4251

GCWI-3893

GCWI-4250

GCWI-4250

GCWI-869

Name

RIBOSYLHOMOCYSTEIN
ASE-RXN
RIBULP3EPIM-RXN

RXN-0

RXN-10

RXN-10009

RXN-10015
RXN-10017

RXN-10642

RXN-10654

Reaction
1086[c]+1*WATER[c]->+1*AMINORIBOSYLAMINO-1H-3HPYR-DIONE[c]+1*Pi[c]
+1*CPD-564[c]->+1*DIHYDROXYPENTA
NEDIONE[c]+1*HOMOCYS[c]
+1*RIBULOSE-5P[c]<->+1*XYLULOSE-5PHOSPHATE[c]
+1*ACETYLCOA[c]+1*PUTRESCINE[c
]<-->+1*CO-A[c]+1*CPD569[c]+2*PROTON[c]
+1*ATP[c]+1*LASPARTATE[c]+1*OUREIDOHOMOSERINE[c]
<->+1*AMP[c]+1*CANAVA
NINOSUCCINATE[c]+1*P
PI[c]+1*PROTON[c]
+1*CPD7652[c]+1*DIHYDROPTE
RIN-CH2OH-PP[c]<->+1*CPD10766[c]+1*PPI[c]+2*PRO
TON[c]
+1*DIHYDROXYPENTAN
EDIONE[c]-->+1*CPD10773[c]
+1*CPD10773[c]+1*WATER[c]->+1*CPD-10774[c]
+1*CPD-11444[c]<->+4*CARBONDIOXIDE[c]+1*COPROPO
RPHYRINOGENI[c]+4*PROTON[c]
+1*Cis-Delta5-dodecenoylACPs[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxo-cisD7-tetradecenoyl-ACPs[c]
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Locus

GCWI-4916

GCWI-3944

GCWI-2733 GCWI-3297

GCWI-4760

GCWI-259

GCWI-1254

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

Name

RXN-10655

RXN-10657

RXN-10658

RXN-10659

RXN-10661

RXN-10674

RXN-10675

RXN-10676

RXN-10677

Reaction
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-cis-D7tetradecenoyl-ACPs[c]->+1*NADP[c]+1*-3hydroxy-cis-D7tetraecenoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D3-cis-D7tetradecenoyl-ACPs[c]->+1*Cis-Delta7tetradecenoylACPs[c]+1*NADP[c]
+1*Cis-Delta7tetradecenoylACPs[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxo-cisD9-hexadecenoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-cis-D9hexadecenoyl-ACPs[c]->+1*NADP[c]+1*-3hydroxy-cis-D9hexaecenoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D3-cis-D9hexadecenoyl-ACPs[c]->+1*NADP[c]+1*Palmitole
oyl-ACPs[c]
+1*Apo-AsbDProteins[c]+1*CO-A[c]->+1*Holo-AsbDProteins[c]+1*-3-5-ADP[c]
+1*ATP[c]+1*PROTON[c]
+1*-3-4DIHYDROXYBENZOATE
[c]-->+1*CPD11474[c]+1*PPI[c]
+1*CPD-11474[c]+1*HoloAsbD-Proteins[c]->+1*AMP[c]+1*PROTON[
c]+1*-34-DHB-AsbDProteins[c]
+1*CPD-11479[c]+1*-34-
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Locus
GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935

GCWI-1393

GCWI-2090

GCWI-2087

GCWI-2089

Name

RXN-10678

RXN-10679

RXN-10680

RXN-10681

RXN-10682

RXN-10781

RXN-10814

RXN-10827
RXN-11028

Reaction
DHB-AsbD-Proteins[c]->+1*CPD11477[c]+1*Holo-AsbDProteins[c]+1*PROTON[c]
+1*ATP[c]+1*CPD11477[c]+1*SPERMIDINE[
c]-->+1*AMP[c]+1*CPD11481[c]+1*PPI[c]+1*PRO
TON[c]
+1*CPD-11481[c]+1*-34DHB-AsbD-Proteins[c]->+1*CPD-9985[c]+1*HoloAsbDProteins[c]+1*PROTON[c]
+1*ATP[c]+1*CIT[c]+1*SP
ERMIDINE[c]->+1*AMP[c]+1*CPD11479[c]+1*PPI[c]+1*PRO
TON[c]
+1*ATP[c]+1*CPD11479[c]+1*SPERMIDINE[
c]-->+1*AMP[c]+1*CPD11480[c]+1*PPI[c]+1*PRO
TON[c]
+1*CPD-11480[c]+1*-34DHB-AsbD-Proteins[c]->+1*CPD11481[c]+1*Holo-AsbDProteins[c]+1*PROTON[c]
+1*NADH[c]+1*PROTON[
c]+1*-5HYDROXYINDOLEACETALDEHYDE[c]<->+1*CPD11671[c]+1*NAD[c]
+1*PHE[c]+1*-2KETOGLUTARATE[c]<->+1*GLT[c]+1*PHENYLPYRUVATE[c]
+1*-1-CARBOXYVINYLCARBOXYPHOSPHONAT
E[c]<-->+1*CPD-11740[c]
+1*C1[c]+1*CPD11994[c]<-->+1*CPD11997[c]+1*UMP[c]
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Locus

GCWI-2086

GCWI-2089

GCWI-2085

GCWI-2086

GCWI-2089

GCWI-2357 GCWI-4498

GCWI-1706 GCWI-2940

GCWI-2434
GCWI-3997

Name
RXN-11051

RXN-11213

RXN-11277

RXN-11302

RXN-11322

RXN-11329

RXN-11338

RXN-11347

RXN-11458

Reaction
+1*CPD11654[c]+2*PROTON[c]<->+1*CPD-11643[c]
+1*CH3-MALONATE-SALD[c]+1*COA[c]+1*NAD[c]+1*WATE
R[c]->+1*HCO3[c]+1*NADH[c]
+1*PROPIONYLCOA[c]+1*PROTON[c]
+1*DIACYLGLYCEROLPYROPHOSPHATE[c]+1*
WATER[c]<-->+1*LPHOSPHATIDATE[c]+1*P
ROTON[c]+1*Pi[c]
+1*CPD12231[c]+2*WATER[c]->+1*CPD-12261[c]+2*DALANINE[c]+1*UNDECA
PRENYLDIPHOSPHATE[c]
+1*GAP[c]+1*GLN[c]+1*
RIBOSE-5P[c]->+1*GLT[c]+1*PROTON[c
]+1*PYRIDOXALPHOSPHATE[c]+1*Pi[c]+3
*WATER[c]
+1*CPD12287[c]+1*HYDROGENPEROXIDE[c]+1*PROTON
[c]+1*RH[c]<->+1*Bromide[c]+2*WATE
R[c]
+1*AMMONIUM[c]+1*AT
P[c]+1*CPD-12302[c]<->+1*AMP[c]+1*CPD12295[c]+1*PPI[c]+1*PRO
TON[c]
+1*CPD-12258[c]+1*CPD9646[c]<-->+1*CPD12303[c]+1*UMP[c]
+3*DELTA3ISOPENTENYLPP[c]+1*GERANYLGERA
NYL-PP[c]<-->+1*ALL-
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Locus
GCWI-4341

GCWI-2437 GCWI-2577

GCWI-1456 GCWI-2398
GCWI-2572 GCWI-4885
GCWI-5119

GCWI-3999

GCWI-194

GCWI-3181

GCWI-1922

GCWI-3997

GCWI-1674 GCWI-1676

Name

RXN-11475

RXN-11476

RXN-11478

RXN-11479

RXN-11480

RXN-11482

RXN-11483
RXN-11484

Reaction
TRANS-HEPTAPRENYLDIPHOSPHATE[c]+3*PPI[
c]
+1*MALONYLCOA[c]+1*SADENOSYLMETHIONIN
E[c]-->+1*ADENOSYLHOMO-CYS[c]+1*CPD12454[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-KetoglutarylACP-methyl-ester[c]->+1*NADP[c]+1*-3Hydroxyglutaryl-ACPmethyl-ester[c]
+1*Enoylglutaryl-ACPmethylesters[c]+1*NADPH[c]+1*
PROTON[c]-->+1*GlutarylACP-methylesters[c]+1*NADP[c]
+1*Glutaryl-ACP-methylesters[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3Ketopimeloyl-ACP-methylesters[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-KetopimeloylACP-methyl-esters[c]->+1*NADP[c]+1*-3hydroxypimeloyl-ACPmethyl-esters[c]
+1*Enoylpimeloyl-ACPmethylesters[c]+1*NADPH[c]+1*
PROTON[c]->+1*NADP[c]+1*PimeloylACP-methyl-esters[c]
+1*Pimeloyl-ACP-methylesters[c]+1*WATER[c]->+1*METOH[c]+1*PROT
ON[c]+1*Pimeloyl-ACPs[c]
+1*L-ALPHA-
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Locus

GCWI-4256

GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935

GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935

GCWI-1393

GCWI-4257
GCWI-4258

Name

RXN-11503

RXN-11662

RXN-11667

RXN-11717

RXN-11737

RXN-11743

RXN-11746

RXN-11752

RXN-11847

RXN-12093

Reaction
ALANINE[c]+1*PROTON[
c]+1*Pimeloyl-ACPs[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-8AMINO-7OXONONANOATE[c]
+1*ATP[c]+1*FRU[c]<->+1*ADP[c]+1*FRUCTOS
E-6P[c]+1*PROTON[c]
+1*ACETOACETYLCOA[c]+1*NADH[c]+1*PR
OTON[c]->+1*NAD[c]+1*S-3HYDROXYBUTANOYLCOA[c]
+1*S-3HYDROXYBUTANOYLCOA[c]->+1*CROTONYLCOA[c]+1*WATER[c]
+1*CPD-12673[c]<->+1*CPD11020[c]+1*WATER[c]
+1*L-CYSTEATE[c]+1*-2KETOGLUTARATE[c]<->+1*CPD380[c]+1*GLT[c]
+1*CPD-5923[c]+1*Pi[c]->+1*ADENINE[c]+1*CPD12706[c]
+1*CPD12708[c]+1*NAD[c]+1*W
ATER[c]-->+1*CPD12709[c]+1*NADH[c]+2*P
ROTON[c]
+1*ACETYLCOA[c]+1*CPD-9011[c]<->+1*CO-A[c]+1*CPD9012[c]+1*PROTON[c]
+1*CPD-12117[c]+1*SADENOSYLMETHIONIN
E[c]-->+1*ADENOSYLHOMO-CYS[c]+1*CPD12125[c]+1*PROTON[c]
+1*AMMONIA[c]+1*ATP[
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Locus

GCWI-974

GCWI-5129 GCWI-5129
GCWI-5442

GCWI-2616 GCWI-2439
GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-1965

GCWI-1706 GCWI-2940

GCWI-1624 GCWI-4228

GCWI-2379 GCWI-3587
GCWI-2881 GCWI-1451

GCWI-3200

GCWI-1675

GCWI-1509

Name

RXN-12121

RXN-12352

RXN-12354
RXN-12444

RXN-12448

RXN-12508

RXN-12583

RXN-12588

Reaction
c]+1*CPD-13043[c]->+1*ADP[c]+1*Pi[c]+1*W
ATER[c]+1*-7-CYANO-7DEAZAGUANINE[c]
+2*HYDROGENPEROXIDE[c]<->+1*OXYGENMOLECULE[c]+2*WATE
R[c]
+1*OXYGENMOLECULE[c]+2*Ubiquin
ols[c]->+2*Ubiquinones[c]+2*WA
TER[c]
+1*CPD-13337[c]<->+1*CPD-8742[c]
+1*FMN[c]+1*NADPH[c]+
2*PROTON[c]->+1*FMNH2[c]+1*NADP[
c]
+1*NAD[c]+1*SecondaryAlcohols[c]<-->+1*LONGCHAINKETONE[c]+1*NADH[c]+
1*PROTON[c]
+1*Pyruvatedehydrogenaselipoate[c]+1*-2-ALPHAHYDROXYETHYLTHPP[c]-->+1*PyruvatedehydrogenaseacetylDHlipoyl[c]+1*THIA
MINEPYROPHOSPHATE[c]
+1*PROTON[c]+1*PYRU
VATE[c]+1*THIAMINEPYROPHOSPHATE[c]->+1*CARBONDIOXIDE[c]+1*-2ALPHAHYDROXYETHYLTHPP[c]
+1*CYS[c]+1*PROTON[c]
+1*Sulfur-Acceptors[c]<--
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Locus

GCWI-1061 GCWI-1330
GCWI-3056 GCWI-3180
GCWI-5324 GCWI-4920
GCWI-4121 GCWI-2051
GCWI-5323 GCWI-4919
GCWI-2050
GCWI-5476
GCWI-1778 GCWI-3373
GCWI-2357 GCWI-379
GCWI-878 GCWI-1005
GCWI-1195 GCWI-2654
GCWI-2708 GCWI-3152
GCWI-3423 GCWI-3425
GCWI-3545 GCWI-4498

GCWI-4114 GCWI-4115

GCWI-4114 GCWI-4115

GCWI-4558

Name

RXN-12614

RXN-1381-PALMITYLCOA-GLYCEROL-3P--1PALMITOYLGLYCEROL3-PHOSPHATE-CO-A.63.
RXN-1381-STEAROYLCOA-GLYCEROL-3P-CPD0-2113-CO-A.41.
RXN-1623-STEAROYLCOA-CPD0-2113--CPD01423-CO-A.39.
RXN-22

RXN-2901

RXN-34

RXN-37

RXN-3962

Reaction
>+1*L-ALPHAALANINE[c]+1*SulfuratedSulfur-Acceptors[c]
+1*GLY[c]+1*OXYGENMOLECULE[c]<->+1*CPD12279[c]+1*HYDROGENPEROXIDE[c]+1*PROTON
[c]
+1*GLYCEROL3P[c]+1*PALMITYLCOA[c]-->+1*CO-A[c]+1*1PALMITOYLGLYCEROL3-PHOSPHATE[c]
+1*GLYCEROL3P[c]+1*STEAROYLCOA[c]-->+1*COA[c]+1*CPD0-2113[c]
+1*CPD02113[c]+1*STEAROYLCOA[c]-->+1*COA[c]+1*CPD0-1423[c]
+1*CANAVANINOSUCCI
NATE[c]<->+1*CANAVANINE[c]+1*
FUM[c]
+1*B-ALANINE[c]+1*-2KETOGLUTARATE[c]<->+1*GLT[c]+1*MALONA
TE-S-ALD[c]
+1*CANAVANINE[c]+1*
WATER[c]<-->+1*LCANALINE[c]+1*PROTO
N[c]+1*UREA[c]
+1*CPD30[c]+1*NAD[c]+1*WATE
R[c]<-->+1*CPD35[c]+1*NADH[c]+2*PRO
TON[c]
+1*N-6AMINOHEXANOYL-6AMINOHEXANOATE[c]+
1*WATER[c]<-->+2*CPD884[c]
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Locus

GCWI-954 GCWI-2885

GCWI-2538 GCWI-3637
GCWI-3937

GCWI-2538 GCWI-3637
GCWI-3937

GCWI-408 GCWI-2332

GCWI-3582 GCWI-4759

GCWI-531

GCWI-356

GCWI-2379 GCWI-3587
GCWI-2881 GCWI-1451

GCWI-3340

Name

RXN-4822

RXN-4961

RXN-5041

RXN-5061

RXN-5076

RXN-5183

RXN-5901
RXN-6182
RXN-7101

RXN-721
RXN-7607

Reaction
+1*GLT[c]+1*N-ACETYLL-2-AMINO-6-OXOPIMELATE[c]-->+1*CPD1771[c]+1*-2KETOGLUTARATE[c]
+1*SQUALENE[c]+1*WA
TER[c]<-->+1*HOPAN-22OL[c]
+1*NAD[c]+1*-2-3DIHYDRODIPICOLINATE
[c]-->+1*CPD4841[c]+1*NADH[c]+1*PR
OTON[c]
+1*METHYLENETHF[c]+2*PROTON[c]+2*
Reduced-ferredoxins[c]->+2*Oxidizedferredoxins[c]+1*-5METHYL-THF[c]
+1*PROTON[e]+1*XANT
HINE[e]->+1*PROTON[c]+1*XANT
HINE[c]
+1*N2ACETYL-ALPHANP[c]+1*NADPH[c]+1*PR
OTON[c]<->+1*NADP[c]+1*NACETYL-AAASEMIALDEHYDE[c]+1*Pi
[c]
+1*ACETOACETYLCOA[c]+1*NADPH[c]+1*P
ROTON[c]-->+1*CPD650[c]+1*NADP[c]
+1*FRUCTOSE-6P[c]<->+1*ALPHA-GLC-6-P[c]
+2*BCCP-biotinmonomers[c]-->+1*BCCPdimers[c]
+1*CPD-667[c]+1*CYS[c]->+1*ACET[c]+1*LCYSTATHIONINE[c]+1*P
ROTON[c]
+1*IMP[c]+1*WATER[c]->+1*INOSINE[c]+1*Pi[c]
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Locus

GCWI-3590

GCWI-3886 GCWI-3887

GCWI-4388

GCWI-1728

GCWI-4272

GCWI-5442 GCWI-1482
GCWI-5020

GCWI-4389
GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179

Name

RXN-7609

RXN-7716

RXN-7719

RXN-7800

RXN-7908
RXN-7913
RXN-7933

RXN-7958

RXN-821

RXN-8340
RXN-8391

Reaction
+1*GMP[c]+1*WATER[c]>+1*GUANOSINE[c]+1*Pi
[c]
+1*NAD[c]+1*Oxoglutarate-dehydrogenaseDH-lipoyl[c]->+1*NADH[c]+1*Oxoglutarate-dehydrogenaselipoyl[c]+1*PROTON[c]
+1*BCAA-dehydrogenaseDH-lipoyl[c]+1*NAD[c]->+1*BCAA-dehydrogenaselipoyl[c]+1*NADH[c]+1*P
ROTON[c]
+1*CPD7100[c]+1*PROTON[c]->+1*CARBONDIOXIDE[c]+1*-2K-4CH3PENTANOATE[c]
+1*CPD-5881[c]->+1*BIOPTERIN[c]+1*W
ATER[c]
+1*ATP[c]+1*DCMP[c]->+1*ADP[c]+1*DCDP[c]
+1*CPD7224[c]+1*WATER[c]->+1*ACET[c]+1*LCITRULLINE[c]
+1*ATP[c]+1*PROPIONA
TE[c]<->+1*ADP[c]+1*PROPION
YL-P[c]
+1*FAD[c]+1*PRO[c]->+1*FADH2[c]+1*LDELTA1-PYRROLINE-5CARBOXYLATE[c]+1*PR
OTON[c]
+1*GTP[c]<->+1*PPI[c]+1*PRECURSO
R-Z[c]
+1*Delta4-hexadecenoylACPs[c]+1*MALONYLACP[c]--
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Locus
GCWI-4241
GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241

GCWI-1429 GCWI-2826
GCWI-4112 GCWI-4300

GCWI-2826 GCWI-4112
GCWI-4300

GCWI-4485
GCWI-1659
GCWI-688 GCWI-2386

GCWI-4767

GCWI-5131

GCWI-405 GCWI-4849
GCWI-3599 GCWI-2233
GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

Name

RXN-8529

RXN-8629

RXN-8631

RXN-8654

RXN-8668

RXN-8669

RXN-8672

RXN-8673

Reaction
>+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxopetroselinoyl-ACPs[c]
+1*CPD-8720[c]->+1*CPD-246[c]
+1*DIHYDROLIPOYLGCVH[c]+1*NAD[c]->+1*NADH[c]+1*PROTEI
NLIPOYLLYSINE[c]+1*PR
OTON[c]
+1*FRU1P[c]<->+1*DIHYDROXYACETONEPHOSPHATE[c]+1*GLYC
ERALD[c]
+1*ATP[c]+1*LIPOICACID[c]+1*PROTON[c]->+1*LIPOYLAMP[c]+1*PPI[c]
+1*Protein-L-Methionine-SOxides[c]+1*RedThioredoxin[c]-->+1*OxThioredoxin[c]+1*ProteinLmethionine[c]+1*WATER[c
]
+1*CPD-8989[c]+1*RedThioredoxin[c]->+1*MET[c]+1*OxThioredoxin[c]+1*WATER[
c]
+1*DALANINE[c]+1*OXYGEN
MOLECULE[c]+1*WATE
R[c]<->+1*AMMONIA[c]+1*HY
DROGENPEROXIDE[c]+1*PROTON
[c]+1*PYRUVATE[c]
+1*OXYGENMOLECULE[c]+1*SARCO
SINE[c]+1*WATER[c]<->+1*GLYOX[c]+1*HYDR
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Locus

GCWI-3434 GCWI-5476

GCWI-4362 GCWI-2826
GCWI-4112 GCWI-4300

GCWI-2580 GCWI-5434

GCWI-1272 GCWI-4343
GCWI-5486

GCWI-5539 GCWI-1959

GCWI-1959 GCWI-5539

GCWI-954 GCWI-2885

GCWI-954 GCWI-2885

Name

RXN-8674

RXN-8675

RXN-8975

RXN-8976

RXN-8979

RXN-8991

RXN-8999

RXN-9190

Reaction
OGENPEROXIDE[c]+1*METHY
LAMINE[c]
+1*CPD10490[c]+1*OXYGENMOLECULE[c]+1*WATE
R[c]<->+1*ETHANAMINE[c]+1*
GLYOX[c]+1*HYDROGE
N-PEROXIDE[c]
+1*CPD-9038[c]+1*SADENOSYLMETHIONIN
E[c]-->+1*ADENOSYLHOMOCYS[c]+1*DIHYDROSIRO
HYDROCHLORIN[c]
+1*C3[c]+1*CPD9646[c]<->+1*C4[c]+1*UMP[c]
+1*C4[c]+1*UDP-NACETYL-DGLUCOSAMINE[c]<->+1*CPD7695[c]+1*PROTON[c]+1*
UDP[c]
+1*CPD-622[c]<->+1*CPD9421[c]+1*WATER[c]
+1*CPD9451[c]+1*WATER[c]->+1*-2-D-THREOHYDROXY-3-CARBOXYISOCAPROATE[c]
+8*DELTA3ISOPENTENYLPP[c]+1*FARNESYLPP[c]->+8*PPI[c]+1*UNDECAP
RENYL-DIPHOSPHATE[c]
+1*ALL-TRANSHEPTAPRENYLDIPHOSPHATE[c]+1*DIH
YDROXYNAPHTHOATE[
c]+1*PROTON[c]->+1*CARBON-
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Locus

GCWI-954 GCWI-2885

GCWI-1587 GCWI-2241

GCWI-3997

GCWI-3994 GCWI-4386

GCWI-2433

GCWI-1565 GCWI-1566

GCWI-3907

GCWI-3201

Name

RXN-9310

RXN-9311

RXN-9374

RXN-9386

RXN-9514

RXN-9516

Reaction
DIOXIDE[c]+1*CPD12117[c]+1*PPI[c]
+1*CPD-9924[c]->+1*CPD9923[c]+1*PYRUVATE[c]
+1*CPD9925[c]+1*WATER[c]->+1*COA[c]+1*DIHYDROXYNAP
HTHOATE[c]+1*PROTON
[c]
+6*ATP[c]+3*GLY[c]+3*T
HR[c]+3*-2-3DIHYDROXYBENZOATE
[c]-->+6*AMP[c]+1*CPD9984[c]+6*PPI[c]+3*PROT
ON[c]+3*WATER[c]
+1*ATP[c]+1*GLNtRNAs[c]+1*GLT[c]->+1*AMP[c]+1*LglutamyltRNAGln[c]+1*PPI[c]
+1*AcetoacetylACPs[c]+1*NADPH[c]+1*
PROTON[c]-->+1*Beta-3hydroxybutyrylACPs[c]+1*NADP[c]
+1*ButanoylACPs[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxohexanoyl-ACPs[c]

Locus

GCWI-4978

GCWI-277

GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

RXN-9518

+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-hexanoylACPs[c]->+1*NADP[c]+1*R-3hydroxyhexanoyl-ACPs[c]

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427 GCWI-3427
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-375 GCWI-3377
GCWI-4754 GCWI-375
GCWI-2066 GCWI-3377
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-4754

RXN-9520

+1*R-3-hydroxyhexanoylACPs[c]-->+1*Hex-2-

GCWI-2941 GCWI-5366
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Name

RXN-9521

RXN-9523

RXN-9524

RXN-9526

RXN-9527

Reaction
enoylACPs[c]+1*WATER[c]
+1*Hex-2-enoylACPs[c]+1*NADPH[c]+1*
PROTON[c]->+1*HexanoylACPs[c]+1*NADP[c]
+1*HexanoylACPs[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-Oxooctanoyl-ACPs[c]

+1*NADPH[c]+1*PROTO
N[c]+1*-3-Oxo-octanoylACPs[c]->+1*NADP[c]+1*-3Hydroxy-octanoyl-ACPs[c]

+1*NADPH[c]+1*PROTO
N[c]+1*-2-OctenoylACPs[c]->+1*NADP[c]+1*OctanoylACPs[c]
+1*MALONYLACP[c]+1*OctanoylACPs[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxodecanoyl-ACPs[c]

Locus

GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350
GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427 GCWI-3427
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-375 GCWI-3377
GCWI-4754 GCWI-375
GCWI-2066 GCWI-3377
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-4754
GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

RXN-9528

+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-decanoylACPs[c]-->+1*BetahydroxydecanoylACPs[c]+1*NADP[c]

GCWI-3427 GCWI-3427
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-375 GCWI-3377
GCWI-4754 GCWI-375
GCWI-2066 GCWI-3377
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-4754

RXN-9530

+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D2-decenoylACPs[c]-->+1*Decanoyl-

GCWI-1393
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Name

RXN-9531

RXN-9532

RXN-9533

RXN-9534

RXN-9535

Reaction
ACPs[c]+1*NADP[c]
+1*DecanoylACPs[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxododecanoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-dodecanoylACPs[c]->+1*NADP[c]+1*R-3hydroxydodecanoylACPs[c]
+1*R-3hydroxydodecanoylACPs[c]-->+1*Dodec-2enoylACPs[c]+1*WATER[c]
+1*Dodec-2-enoylACPs[c]+1*NADPH[c]+1*
PROTON[c]->+1*DodecanoylACPs[c]+1*NADP[c]
+1*DodecanoylACPs[c]+1*MALONYLACP[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxomyristoyl-ACPs[c]

Locus

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350
GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-375
GCWI-3377 GCWI-4754
GCWI-375 GCWI-2066
GCWI-3377 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-4754
GCWI-2941 GCWI-5366

GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

RXN-9536

+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-myristoylACPs[c]->+1*NADP[c]+1*R-3hydroxymyristoyl-ACPs[c]

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427 GCWI-3427
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-375 GCWI-3377
GCWI-4754 GCWI-375
GCWI-2066 GCWI-3377
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-4754

RXN-9537

+1*R-3-hydroxymyristoylACPs[c]-->+1*Tetradec-2enoylACPs[c]+1*WATER[c]

GCWI-2941 GCWI-5366
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Name
RXN-9538

RXN-9539

RXN-9540

RXN-9548

RXN-9549

RXN-9552

RXN-9553

RXN-9556

Reaction
+1*NADPH[c]+1*PROTO
N[c]+1*Tetradec-2-enoylACPs[c]-->+1*MyristoylACPs[c]+1*NADP[c]
+1*MALONYLACP[c]+1*MyristoylACPs[c]->+1*ACP[c]+1*CARBONDIOXIDE[c]+1*-3-oxopalmitoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-palmitoylACPs[c]->+1*NADP[c]+1*R-3Hydroxypalmitoyl-ACPs[c]

Locus
GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350
GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-375
GCWI-3377 GCWI-4754
GCWI-375 GCWI-2066
GCWI-3377 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-4754

+1*StearoylACPs[c]+1*WATER[c]->+1*ACP[c]+1*STEARICACID[c]
+1*PalmitoylACPs[c]+1*WATER[c]<->+1*ACP[c]+1*PALMITA
TE[c]+1*PROTON[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxopetroselinoyl-ACPs[c]->+1*NADP[c]+1*R-3hydroxypetroselinoylACPs[c]
+1*R-3hydroxypetroselinoylACPs[c]-->+1*Petrosel-2enoylACPs[c]+1*WATER[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-cisvaccenoyl-ACPs[c]->+1*NADP[c]+1*R-3-
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GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427 GCWI-3427
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-375 GCWI-3377
GCWI-4754 GCWI-375
GCWI-2066 GCWI-3377
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-4754
GCWI-2941 GCWI-5366
GCWI-3427 GCWI-3427
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-375 GCWI-3377

Name

RXN-9557

RXN-9583

RXN-9598

Reaction
hydroxy-cis-vaccenoylACPs[c]
+1*R-3-hydroxy-cisvaccenoyl-ACPs[c]->+1*WATER[c]+1*cisvaccen-2-enoyl-ACPs[c]
+1*CPD10226[c]+1*RIBOSE5P[c]<-->+1*CPD10227[c]+1*DSEDOHEPTULOSE-7-P[c]
+1*Monoamines[c]+1*OX
YGENMOLECULE[c]+1*WATE
R[c]<->+1*Aldehydes[c]+1*HYD
ROGENPEROXIDE[c]+1*PrimaryAmines[c]

RXN-9615

+1*AMMONIUM[e]->+1*AMMONIUM[c]

RXN-9633

+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-stearoylACPs[c]->+1*NADP[c]+1*R-3hydroxystearoyl-ACPs[c]

RXN-9634

RXN-9655

RXN-9657

+1*R-3-hydroxystearoylACPs[c]-->+1*Octadec-2enoylACPs[c]+1*WATER[c]
+1*Beta-hydroxydecanoylACPs[c]-->+1*Trans-D2decenoylACPs[c]+1*WATER[c]
+1*CrotonylACPs[c]+1*NADH[c]+1*P
ROTON[c]-->+1*Butanoyl-
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Locus
GCWI-4754 GCWI-375
GCWI-2066 GCWI-3377
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-4754
GCWI-2941 GCWI-5366

GCWI-3420 GCWI-3707

GCWI-2032 GCWI-2123

GCWI-1331 GCWI-1740
GCWI-1878 GCWI-2399
GCWI-4535
GCWI-2066 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-3427 GCWI-2066
GCWI-3588 GCWI-3869
GCWI-3935 GCWI-375
GCWI-3377 GCWI-4754
GCWI-375 GCWI-2066
GCWI-3377 GCWI-3588
GCWI-3869 GCWI-3935
GCWI-4754
GCWI-2941 GCWI-5366

GCWI-2941 GCWI-5366

Name

RXN-969

RXN-9770

RXN-9772

RXN-9787

RXN-982

RXN-9929

RXN-9939

RXN-9952

RXN-9987

Reaction
ACPs[c]+1*NAD[c]
+1*GLYCOLLATE[c]+1*O
XYGEN-MOLECULE[c]->+1*GLYOX[c]+1*HYDR
OGEN-PEROXIDE[c]
+1*CPD3746[c]+1*NADH[c]+1*O
XYGEN-MOLECULE[c]->+1*FORMALDEHYDE[c]
+1*NAD[c]+1*SO3[c]+1*
WATER[c]
+1*FUM[c]+1*LASPARTATE[c]->+1*IMINOASPARTATE[
c]+1*PROTON[c]+1*SUC[
c]
+1*CYS[c]+1*ThiI-Lcysteine[c]<-->+1*LALPHAALANINE[c]+1*ThiI-Ssulfanylcysteine[c]
+1*ARSENATE[c]+1*PRO
TON[c]+1*RedGlutaredoxins[c]<->+1*CPD-763[c]+1*OxGlutaredoxins[c]+1*WATE
R[c]
+1*DI-HOROTATE[c]+1*FUM[c]->+1*OROTATE[c]+1*SUC
[c]
+1*ACETYLCOA[c]+1*SPERMINE[c]<
-->+1*CO-A[c]+1*N1ACETYLSPERMINE[c]+1*
PROTON[c]
+1*CPD2961[c]+1*NADP[c]->+1*CARBONDIOXIDE[c]+1*NADPH[c]
+1*RIBULOSE-5P[c]
+1*UDP-N-ACETYL-DGLUCOSAMINE[c]+1*WA
TER[c]<-->+1*NACETYL-D-
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Locus

GCWI-1462 GCWI-3554
GCWI-1463

GCWI-2951

GCWI-4557

GCWI-4523 GCWI-4778
GCWI-5102 GCWI-4558

GCWI-3210

GCWI-3968

GCWI-5196 GCWI-2127

GCWI-367 GCWI-367
GCWI-3419

GCWI-5298 GCWI-5367

Name

RXN0-1061

RXN0-1132

RXN0-1133

RXN0-1147

RXN0-12

RXN0-1241

RXN0-1321

RXN0-1342

Reaction
MANNOSAMINE[c]+1*PR
OTON[c]+1*UDP[c]
+1*ATP[c]+1*WATER[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]
+1*NAD[c]+1*Pyruvatedehydrogenasedihydrolipoate[c]->+1*NADH[c]+1*PROTO
N[c]+1*Pyruvatedehydrogenase-lipoate[c]
+1*CO-A[c]+1*PyruvatedehydrogenaseacetylDHlipoyl[c]->+1*ACETYLCOA[c]+1*Pyruvatedehydrogenasedihydrolipoate[c]
+1*Oxo-glutaratedehydrogenase-DHlipoyl[c]+1*PROTON[c]+1
*SUC-COA[c]<-->+1*COA[c]+1*Oxo-glutaratedehydro-suc-DH-lipoyl[c]
+1*ZN-2[e]-->+1*ZN-2[c]
+1*Protein-Lglutamine[c]+1*SADENOSYLMETHIONIN
E[c]<-->+1*ADENOSYLHOMOCYS[c]+1*PROTON[c]+1*
Protein-N5-methyl-Lglutamine[c]
+1*Guanine34-in-tRNAwith-GUN-anticodon[c]+1*7-AMINOMETHYL-7DEAZAGUANINE[c]->+1*GUANINE[c]+1*tRN
A-with-7-aminomethyl-7deazaguanine[c]
+1*SADENOSYLMETHIONIN
E[c]+1*tRNA-with-7-
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Locus

GCWI-4608

GCWI-2826 GCWI-4112
GCWI-4300

GCWI-2827

GCWI-1429 GCWI-1428

GCWI-2475 GCWI-1740
GCWI-1878 GCWI-2399
GCWI-4535

GCWI-5427

GCWI-4542

GCWI-4543

Name

RXN0-1461

RXN0-1483

RXN0-16

RXN0-2142

RXN0-2145

RXN0-2161

RXN0-262

RXN0-280

Reaction
aminomethyl-7deazaguanine[c]->+1*ADENINE[c]+1*MET
[c]+2*PROTON[c]+1*tRN
As-containing-epoxyquenosine[c]
+1*COPROPORPHYRINO
GEN-III[c]+1*OXYGENMOLECULE[c]+2*PROTO
N[c]-->+2*CARBONDIOXIDE[c]+1*PROTOPO
RPHYRINOGEN[c]+2*WA
TER[c]
+4*FE-2[c]+1*OXYGENMOLECULE[c]+4*PROTO
N[c]-->+4*FE3[c]+2*WATER[c]
+1*MN2[e]+1*PROTON[e]->+1*MN2[c]+1*PROTON[c]
+1*NADPH[c]+1*PROTO
N[c]+1*b-Keto-cis-D5dodecenoyl-ACPs[c]->+1*NADP[c]+1*bHydroxy-cis-D5dodecenoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*Trans-D3-cis-D5dodecenoyl-ACPs[c]->+1*Cis-Delta5dodecenoylACPs[c]+1*NADP[c]
+1*ATP[c]+1*PROTON[c]
+1*SECtRNAs[c]+1*SER[c]<->+1*AMP[c]+1*L-serylSEC-tRNAs[c]+1*PPI[c]
+1*CPD8123[c]+1*GTP[c]+1*PRO
TON[c]-->+1*CPD582[c]+1*PPI[c]
+1*Alkanesulfonates[c]+1*
FMNH2[c]+1*OXYGENMOLECULE[c]--
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Locus

GCWI-1089 GCWI-4447

GCWI-5170
GCWI-1990 GCWI-1740
GCWI-1878 GCWI-2399
GCWI-4535
GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

GCWI-196

GCWI-4887

GCWI-2951

Name

RXN0-280-CPD-10434FMNH2-OXYGENMOLECULE--ACETALDSO3-FMN-WATERPROTON.62.
RXN0-280-CPD-3746FMNH2-OXYGENMOLECULE-FORMALDEHYDE-SO3FMN-WATERPROTON.66.

RXN0-302

RXN0-366

RXN0-4022

RXN0-4621

RXN0-4641

RXN0-5055

Reaction
>+1*Aldehydes[c]+1*FMN[
c]+2*PROTON[c]+1*SO3[c
]+1*WATER[c]
+1*CPD10434[c]+1*FMNH2[c]+1*
OXYGEN-MOLECULE[c]>+1*ACETALD[c]+1*FM
N[c]+2*PROTON[c]+1*SO
3[c]+1*WATER[c]
+1*CPD3746[c]+1*FMNH2[c]+1*O
XYGEN-MOLECULE[c]->+1*FMN[c]+1*FORMAL
DEHYDE[c]+2*PROTON[c
]+1*SO3[c]+1*WATER[c]
+1*-2-PHOSPHO-4CYTIDINE-5DIPHOSPHO-2-C-MET[c]->+1*CMP[c]+1*-2CMETH-D-ERYTHRITOLCYCLODIPHOSPHATE[c]
+1*GUANOSINE[c]+1*W
ATER[c]->+1*GUANINE[c]+1*RIB
OSE[c]
+2*NADPH[c]+3*PROTO
N[c]+1*-7-CYANO-7DEAZAGUANINE[c]->+2*NADP[c]+1*-7AMINOMETHYL-7DEAZAGUANINE[c]
+1*ATP[c]+1*CPD0882[c]+1*WATER[c]->+1*ADP[c]+1*CPD0881[c]+1*PROTON[c]
+1*CPD0881[c]+1*WATER[c]->+1*D-LACTATE[c]+1*NACETYL-DGLUCOSAMINE-6-P[c]
+1*ACETYLCOA[c]+1*CarboxybiotinBCCP[c]-->+1*BCCPdimers[c]+1*MALONYL-
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Locus

GCWI-2951

GCWI-2951

GCWI-276

GCWI-5211 GCWI-2933
GCWI-2480

GCWI-1512

GCWI-2536

GCWI-1041

GCWI-4320 GCWI-2613
GCWI-2614 GCWI-4321
GCWI-4727 GCWI-4728

Name

RXN0-5063

RXN0-5114

RXN0-5199

RXN0-5219
RXN0-5223-CPD-12822ATP--CPD-12820-ADPPROTON.36.
RXN0-5223-CPD-8260ATP--CPD-12821-ADPPROTON.35.
RXN0-5223-CPD0-2330ATP--CPD0-2230-ADPPROTON.36.
RXN0-5224

RXN0-5225

Reaction
COA[c]
+1*N-6-ISOPENTYLADENOSINE-37TRNA[c]+2*SADENOSYLMETHIONIN
E[c]+1*Sulfurated-SulfurAcceptors[c]<->+1*ADENOSYL-HOMOCYS[c]+1*CH33ADO[c]+1
*MET[c]+1*PROTON[c]+1
*Unsulfurated-SulfurAcceptors[c]+1*-2METHYLTHIO-N-6ISOPENTYLADENOSINE-37-[c]
+1*WATER[c]+1*-3-PSERINE[c]->+1*Pi[c]+1*SER[c]
+1*GUANOSINE[c]+1*Pi[
c]->+1*GUANINE[c]+1*RIB
OSE-1P[c]
+1*AMMONIA[c]+1*PRO
TON[c]<->+1*AMMONIUM[c]
+1*ATP[c]+1*CPD12822[c]->+1*ADP[c]+1*CPD12820[c]+1*PROTON[c]
+1*ATP[c]+1*CPD8260[c]->+1*ADP[c]+1*CPD12821[c]+1*PROTON[c]
+1*ATP[c]+1*CPD02330[c]->+1*ADP[c]+1*CPD02230[c]+1*PROTON[c]
+1*HCO3[c]+1*PROTON[
c]<-->+1*CARBONDIOXIDE[c]+1*WATER[c]
+1*CPD01080[c]+1*WATER[c]<->+1*CPD01081[c]+1*CPD0-1082[c]
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Locus

GCWI-3856

GCWI-4228 GCWI-1624
GCWI-4228

GCWI-529

GCWI-529

GCWI-529

GCWI-4918
GCWI-3727 GCWI-4017
GCWI-336 GCWI-1087
GCWI-1109 GCWI-1656
GCWI-1931 GCWI-1932
GCWI-2520 GCWI-2594

Name

RXN0-5240

RXN0-5289

RXN0-5292
RXN0-5304
RXN0-5305
RXN0-5330
RXN0-5330-CPD-9717NADH-PROTON--CPD9955-NAD.35.
RXN0-5405

RXN0-5408

RXN0-5468

RXN0-5507

Reaction

+1*DALANINE[c]+1*PYRIDOX
AL-PHOSPHATE[c]<->+1*PYRIDOXAMINE5P[c]+1*PYRUVATE[c]
+1*GLYCERATE[c]+1*N
AD[c]<->+1*NADH[c]+1*PROTO
N[c]+1*TARTRONATE-SALD[c]
+1*DCMP[c]+1*WATER[c
]->+1*DEOXYCYTIDINE[c]
+1*Pi[c]
+1*CPD0-1110[c]->+1*CPD0-1108[c]
+1*CPD0-1108[c]<->+1*RIBOSE[c]
+1*NADH[c]+1*PROTON[
c]+1*Ubiquinones[c]->+1*NAD[c]+1*Ubiquinols
[c]
+1*CPD9717[c]+1*NADH[c]+1*PR
OTON[c]-->+1*CPD9955[c]+1*NAD[c]
+2*C6[c]-->+1*CPD12231[c]+1*PROTON[c]+1
*UNDECAPRENYLDIPHOSPHATE[c]
+1*D-MYO-INOSITOL-1MONOPHOSPHATE[c]+1*
WATER[c]<-->+1*MYOINOSITOL[c]+1*Pi[c]
+1*Alkyl-HydroPeroxides[c]+1*RedThioredoxin[c]->+1*Alcohols[c]+1*OxThioredoxin[c]+1*WATER[
c]
+1*DIHYDRONEOPTERI
N-P3[c]+1*WATER[c]->+1*ACETALD[c]+1*CPD
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Locus
GCWI-3666 GCWI-3700
GCWI-5334
GCWI-439 GCWI-2178
GCWI-5415

GCWI-2436

GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241
GCWI-870

GCWI-5395 GCWI-5397
GCWI-5398 GCWI-5399
GCWI-5400
GCWI-5395 GCWI-5397
GCWI-5398 GCWI-5399
GCWI-5400
GCWI-1615

GCWI-4102

GCWI-4769

GCWI-1510

Name

RXN0-6377
RXN0-6491-CPD-9717-DIH-OROTATE--CPD-9955OROTATE.40.
RXN0-6554-DI-HOROTATE-CPD-9718-OROTATE-CPD-12125.41.

RXN0-6575

RXN0-723

RXN0-724

RXN0-745

RXN0-746

RXN0-882

Reaction
01699[c]+1*P3I[c]+2*PROT
ON[c]
+3*NADH[c]+1*NITRITE[
c]+5*PROTON[c]->+1*AMMONIUM[c]+3*N
AD[c]+2*WATER[c]
+1*CPD-9717[c]+1*DI-HOROTATE[c]-->+1*CPD9955[c]+1*OROTATE[c]
+1*CPD-9718[c]+1*DI-HOROTATE[c]-->+1*CPD12125[c]+1*OROTATE[c]
+1*CPD01699[c]+1*PROTON[c]+1*
SADENOSYLMETHIONIN
E[c]->+1*AMMONIA[c]+1*CH
33ADO[c]+1*CPD13043[c]+1*MET[c]
+1*CTP[c]+1*Reducedflavodoxins[c]->+1*DCTP[c]+1*Oxidizedflavodoxins[c]+1*WATER[
c]
+1*Reducedflavodoxins[c]+1*UTP[c]->+1*DUTP[c]+1*Oxidizedflavodoxins[c]+1*WATER[
c]
+1*ATP[c]+1*Reducedflavodoxins[c]->+1*DATP[c]+1*Oxidizedflavodoxins[c]+1*WATER[
c]
+1*GTP[c]+1*Reducedflavodoxins[c]->+1*DGTP[c]+1*Oxidizedflavodoxins[c]+1*WATER[
c]
+1*PROTON[c]+2*Reduce
d-ferredoxins[c]+1*-2CMETH-D-ERYTHRITOLCYCLODIPHOSPHATE[c]

396

Locus

GCWI-1585 GCWI-2242
GCWI-2243
GCWI-3969
GCWI-3969

GCWI-1511

GCWI-3636

GCWI-3636

GCWI-3636

GCWI-3636

GCWI-4412

Name

RXN0-949

RXN1G-1053

RXN1G-1130

RXN1G-163

RXN1G-171

RXN1G-240

RXN1G-285

Reaction
-->+1*HYDROXYMETHYL-BUTENYLDIP[c]+2*Oxidizedferredoxins[c]+1*WATER[c
]
+2*CPD7046[c]+1*Octanoylateddomains[c]+2*SADENOSYLMETHIONIN
E[c]->+2*CH33ADO[c]+1*Lipo
ylateddomains[c]+2*MET[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta19-3-oxoC38-ACPs[c]<->+1*NADP[c]+1*cisdelta19-3-hydroxyC38ACPs[c]
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D19C38-ACPs[c]<->+1*NAD[c]+1*cisdelta19-C38-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta11-3-oxomelissoyl-ACPs[c]<->+1*NADP[c]+1*cisdelta11-3-hydroxymelissoylACPs[c]
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D5lignoceroyl-ACPs[c]<->+1*NAD[c]+1*cis-delta5lignoceroyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta9-3-oxomontanoyl-ACPs[c]<->+1*NADP[c]+1*cisdelta9-3-hydroxymontanoylACPs[c]
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D9montanoyl-ACPs[c]<->+1*NAD[c]+1*cis-delta9-
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Locus

GCWI-5093

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

Name

RXN1G-287

RXN1G-320

RXN1G-358

RXN1G-364

RXN1G-37

RXN1G-396

RXN1G-460

RXN1G-469

RXN1G-479

Reaction
montanoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta21-3-oxoC40-ACPs[c]<->+1*NADP[c]+1*cisdelta21-3-hydroxyC40ACPs[c]
+1*R-3-hydroxyarachidoylACPs[c]->+1*WATER[c]+1*transdelta2-arachidoyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta15-3-oxogheddoyl-ACPs[c]<->+1*NADP[c]+1*cisdelta15-3-hydroxygheddoylACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta7-3-oxocerotoyl-ACPs[c]<->+1*NADP[c]+1*cisdelta7-3-hydroxycerotoylACPs[c]
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D7cerotoyl-ACPs[c]<->+1*NAD[c]+1*cis-delta7cerotoyl-ACPs[c]
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D15gheddoyl-ACPs[c]<->+1*NAD[c]+1*cisdelta15-gheddoyl-ACPs[c]
+1*CPD1G567[c]+1*MALONYLACP[c]-->+1*CARBONDIOXIDE[c]+1*COA[c]+1*-3-oxo-behenoylACPs[c]
+1*NADP[c]+1*R-3hydroxybehenoyl-ACPs[c]->+1*NADPH[c]+1*PROTO
N[c]+1*-3-oxo-behenoylACPs[c]
+1*R-3-hydroxybehenoyl-
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Locus

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-2941 GCWI-5366

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

GCWI-1393

GCWI-3257 GCWI-1940
GCWI-1349 GCWI-1350

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427
GCWI-2941 GCWI-5366

Name

RXN1G-517

RXN1G-72

RXN1G-881

RXN1G-962

RXN490-3641

RXN66-3

RXNCWI-10

Reaction
ACPs[c]->+1*WATER[c]+1*transdelta2-behenoyl-ACPs[c]
+1*R-3-hydroxylignoceroylACPs[c]->+1*WATER[c]+1*transdelta2-lignoceroyl-ACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta5-3-oxolignoceroyl-ACPs[c]<->+1*NADP[c]+1*cisdelta5-3hydroxylignoceroylACPs[c]
+1*NADPH[c]+1*PROTO
N[c]+1*cis-delta17-3-oxoC36-ACPs[c]<->+1*NADP[c]+1*cisdelta17-3-hydroxyC36ACPs[c]
+1*NADH[c]+1*PROTON[
c]+1*trans-D2-cis-D17C36-ACPs[c]<->+1*NAD[c]+1*cisdelta17-C36-ACPs[c]
+1*OXYGENMOLECULE[c]+1*PRO[c]
+1*-2KETOGLUTARATE[c]->+1*CARBONDIOXIDE[c]+1*SUC[c]+1*
-4-HYDROXY-LPROLINE[c]
+1*ACETALD[c]+1*NAD[
c]+1*WATER[c]->+1*ACET[c]+1*NADH[c]
+2*PROTON[c]
+1*CPDCWI7[c]+1*FMNH2[c]+1*OXY
GEN-MOLECULE[c]->+1*CIT[c]+1*FE2[c]+1*FMN[c]+2*SPERM
IDINE[c]+2*-3-4DIHYDROXYBENZOATE
[c]
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Locus

GCWI-2941 GCWI-5366

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-3935 GCWI-3869
GCWI-3588 GCWI-2066
GCWI-3427

GCWI-1393

GCWI-4369

GCWI-2379 GCWI-2379
GCWI-3587 GCWI-2881
GCWI-1451

Name
RXNCWI-100
RXNCWI-104

RXNCWI-105

RXNCWI-106

RXNCWI-107

RXNCWI-108

RXNCWI-109

RXNCWI-110
RXNCWI-111

RXNCWI-112

Reaction
+1*FE-3[c]->+1*CPDCWI-16[c]
+1*FE-3[e]+3*-3-4DIHYDROXYBENZOATE
[e]-->+1*CPDCWI18[e]+6*PROTON[e]
+1*ATP[c]+1*CPDCWI18[e]+1*WATER[c]->+1*ADP[c]+1*CPDCWI18[c]+1*Pi[c]
+1*CPDCWI18[c]+6*PROTON[c]->+1*FE-3[c]+3*-3-4DIHYDROXYBENZOATE
[c]
+1*ACET[c]+1*PROTON[
c]<->+1*ACET[e]+1*PROTON
[e]
+1*ATP[c]+1*CPD10353[c]+1*WATER[c]->+1*ADP[c]+1*CPD10353[e]+1*PROTON[c]+1
*Pi[c]

+1*L-ALPHAALANINE[e]+1*PROTON[
e]-->+1*L-ALPHAALANINE[c]+1*PROTON[
c]

+1*CPD-763[c]<->+1*CPD-763[e]
+1*PROTON[e]+1*SUC[e]
<->+1*PROTON[c]+1*SUC[c
]
+1*ATP[c]+1*MN2[e]+1*WATER[c]->+1*ADP[c]+1*MN-
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Locus

GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893

Name

Reaction
2[c]+1*PROTON[c]+1*Pi[c
]

RXNCWI-113

+1*PROTON[e]+1*TYR[e]
->+1*PROTON[c]+1*TYR[c
]

RXNCWI-114

+1*ASN[e]+1*PROTON[e]
->+1*ASN[c]+1*PROTON[c
]

RXNCWI-115

+1*ATP[c]+1*GLN[e]+1*
WATER[c]->+1*ADP[c]+1*GLN[c]+1*
PROTON[c]+1*Pi[c]

RXNCWI-13

RXNCWI-14

+1*PALMITYLCOA[c]+1*-1PALMITOYLGLYCEROL3-PHOSPHATE[c]->+1*CO-A[c]+1*CPD01422[c]
+1*CPD12125[c]+2*CytochromesCOxidized[c]+1*PROTON[c]
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Locus

GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-573 GCWI-847
GCWI-574 GCWI-1070
GCWI-2039 GCWI-2040
GCWI-575 GCWI-4291
GCWI-4290 GCWI-4289
GCWI-2043 GCWI-2042
GCWI-2041 GCWI-1072
GCWI-1071 GCWI-846
GCWI-845 GCWI-844
GCWI-843

GCWI-408 GCWI-2332

GCWI-1684

Name

RXNCWI-15

RXNCWI-16

RXNCWI-17

RXNCWI-21

RXNCWI-22

RXNCWI-23

RXNCWI-24

RXNCWI-25

Reaction
-->+1*CPD9718[c]+2*Cytochromes-CReduced[c]+3*PROTON[e]
+2*Cytochromes-CReduced[c]+0.5*OXYGENMOLECULE[c]+6*PROTO
N[c]-->+2*Cytochromes-COxidized[c]+4*PROTON[e]
+1*WATER[c]
+1*CPD12125[c]+1*NITRATE[c]+
2*PROTON[c]-->+1*CPD9718[c]+1*NITRITE[c]+2*
PROTON[e]+1*WATER[c]
+1*CPD9718[c]+1*GLYCEROL3P[c]-->+1*CPD12125[c]+1*DIHYDROXYACETONEPHOSPHATE[c]
+1*CPD12125[c]+0.5*OXYGENMOLECULE[c]+2*PROTO
N[c]-->+1*CPD9718[c]+2*PROTON[e]+1*
WATER[c]
+1*NADH[c]+2*NITRICOXIDE[c]+2*OXYGENMOLECULE[c]->+1*NAD[c]+2*NITRATE[
c]+1*PROTON[c]
+1*NADPH[c]+2*NITRICOXIDE[c]+2*OXYGENMOLECULE[c]->+1*NADP[c]+2*NITRAT
E[c]+1*PROTON[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-2-3DIHYDRODIPICOLINATE
[c]-->+1*DELTA1PIPERIDEINE-2-6DICARBOXYLATE[c]+1*
NADP[c]
+1*NADH[c]+1*PROTON[
c]+1*-2-3-
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Locus

GCWI-4085 GCWI-4086
GCWI-4087 GCWI-4088

GCWI-2225 GCWI-2223
GCWI-2224 GCWI-2226

GCWI-1217

GCWI-5324 GCWI-4920
GCWI-4121 GCWI-2051
GCWI-5323 GCWI-4919
GCWI-2050

GCWI-1609

GCWI-1609

GCWI-1694

GCWI-1694

Name

RXNCWI-26

RXNCWI-27

RXNCWI-29

RXNCWI-30

RXNCWI-31

RXNCWI-32

RXNCWI-33

RXNCWI-35

Reaction
DIHYDRODIPICOLINATE
[c]-->+1*DELTA1PIPERIDEINE-2-6DICARBOXYLATE[c]+1*
NAD[c]
+1*GLC[c]+1*NADP[c]->+1*GLC-DLACTONE[c]+1*NADPH[c
]+1*PROTON[c]
+1*GLC[c]+1*NAD[c]->+1*GLC-DLACTONE[c]+1*NADH[c]
+1*PROTON[c]
+1*DIHYDROXYACETONEPHOSPHATE[c]+1*NADH
[c]+1*PROTON[c]->+1*GLYCEROL3P[c]+1*NAD[c]
+1*L-ASPARTATESEMIALDEHYDE[c]+1*N
ADPH[c]+1*PROTON[c]->+1*HOMOSER[c]+1*NADP[c]
+1*L-ASPARTATESEMIALDEHYDE[c]+1*N
ADH[c]+1*PROTON[c]->+1*HOMOSER[c]+1*NAD[c]
+1*HYDROXY-METHYLBUTENYLDIP[c]+1*NADPH[c]+1*P
ROTON[c]-->+1*DELTA3ISOPENTENYLPP[c]+1*NADP[c]+1*WAT
ER[c]
+1*HYDROXY-METHYLBUTENYLDIP[c]+1*NADH[c]+1*PR
OTON[c]-->+1*DELTA3ISOPENTENYLPP[c]+1*NAD[c]+1*WATE
R[c]
+1*L-DELTA1PYRROLINE-5-
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Locus

GCWI-4843

GCWI-4843

GCWI-1667

GCWI-2072 GCWI-2675
GCWI-5505

GCWI-2072 GCWI-2675
GCWI-5505

GCWI-4421

GCWI-4421

GCWI-399 GCWI-3023
GCWI-3161 GCWI-4277

Name

RXNCWI-36

RXNCWI-38

RXNCWI-39

Reaction
CARBOXYLATE[c]+1*NA
DPH[c]+2*PROTON[c]->+1*NADP[c]+1*PRO[c]
+1*L-DELTA1PYRROLINE-5CARBOXYLATE[c]+1*NA
DP[c]+2*WATER[c]->+1*GLT[c]+1*NADPH[c]
+1*PROTON[c]
+1*HYDROXY-METHYLBUTENYLDIP[c]+1*NADPH[c]+1*P
ROTON[c]-->+1*CPD4211[c]+1*NADP[c]+1*W
ATER[c]
+1*HYDROXY-METHYLBUTENYLDIP[c]+1*NADH[c]+1*PR
OTON[c]-->+1*CPD4211[c]+1*NAD[c]+1*WA
TER[c]

RXNCWI-41

+1*PROTON[e]+1*TRP[e]>+1*PROTON[c]+1*TRP[c
]

RXNCWI-42

+1*PROTON[e]+1*VAL[e]
->+1*PROTON[c]+1*VAL[
c]
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Locus

GCWI-516

GCWI-4421

GCWI-4421

GCWI-3872 GCWI-3873
GCWI-4677 GCWI-3160
GCWI-2162 GCWI-2019
GCWI-1602 GCWI-1023
GCWI-893 GCWI-5138
GCWI-3501 GCWI-3313
GCWI-3227 GCWI-3159
GCWI-3026 GCWI-1063
GCWI-1037 GCWI-896
GCWI-833 GCWI-799
GCWI-687 GCWI-3147
GCWI-3146 GCWI-907
GCWI-3872 GCWI-3873
GCWI-4677 GCWI-3160
GCWI-2162 GCWI-2019
GCWI-1602 GCWI-1023
GCWI-893 GCWI-5138
GCWI-3501 GCWI-3313
GCWI-3227 GCWI-3159
GCWI-3026 GCWI-1063
GCWI-1037 GCWI-896
GCWI-833 GCWI-799
GCWI-687 GCWI-3147
GCWI-3146 GCWI-907

Name
RXNCWI-43
RXNCWI-44

Reaction
+1*CA-2[e]+1*CIT[e]->+1*CA-2[c]+1*CIT[c]
+1*ATP[c]+1*CA2[c]+1*WATER[c]->+1*ADP[c]+1*CA2[e]+1*Pi[c]

RXNCWI-45

+1*LASPARTATE[e]+1*PROT
ON[e]-->+1*LASPARTATE[c]+1*PROT
ON[c]

RXNCWI-46

+1*PHE[e]+1*PROTON[e]>+1*PHE[c]+1*PROTON[c
]

RXNCWI-47

RXNCWI-48

RXNCWI-49
RXNCWI-50

+1*ATP[c]+1*COA[c]+1*STEARICACID[c]->+1*AMP[c]+1*PPI[c]+1*
STEAROYL-COA[c]
+2*CPD12822[c]+2*PROTON[c]<->+1*CPDCWI13[c]+1*GLYCEROL[c]
+1*ATP[c]+1*CPDCWI14[c]<->+1*ADP[c]+1*CPD01423[c]+1*PROTON[c]
+1*ATP[c]+1*COA[c]+1*PALMITATE[c]--
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Locus
GCWI-785

GCWI-3872 GCWI-3873
GCWI-4677 GCWI-3160
GCWI-2162 GCWI-2019
GCWI-1602 GCWI-1023
GCWI-893 GCWI-5138
GCWI-3501 GCWI-3313
GCWI-3227 GCWI-3159
GCWI-3026 GCWI-1063
GCWI-1037 GCWI-896
GCWI-833 GCWI-799
GCWI-687 GCWI-3147
GCWI-3146 GCWI-907
GCWI-3872 GCWI-3873
GCWI-4677 GCWI-3160
GCWI-2162 GCWI-2019
GCWI-1602 GCWI-1023
GCWI-893 GCWI-5138
GCWI-3501 GCWI-3313
GCWI-3227 GCWI-3159
GCWI-3026 GCWI-1063
GCWI-1037 GCWI-896
GCWI-833 GCWI-799
GCWI-687 GCWI-3147
GCWI-3146 GCWI-907
GCWI-2036 GCWI-2087
GCWI-3657 GCWI-1090
GCWI-1274 GCWI-4654

GCWI-4432
GCWI-2036 GCWI-2087
GCWI-3657 GCWI-1090

Name

RXNCWI-53

Reaction
>+1*AMP[c]+1*PALMITY
L-COA[c]+1*PPI[c]
+1*ATP[c]+1*FE3[e]+1*WATER[c]->+1*ADP[c]+1*FE3[c]+1*PROTON[c]+1*Pi[c
]

Locus
GCWI-1274 GCWI-4654

RXNCWI-54

+1*ATP[c]+1*CYS[e]+1*
WATER[c]->+1*ADP[c]+1*CYS[c]+1*
PROTON[c]+1*Pi[c]

GCWI-573 GCWI-847
GCWI-574 GCWI-1070
GCWI-2039 GCWI-575
GCWI-2040 GCWI-4291
GCWI-4290 GCWI-4289
GCWI-2043 GCWI-2042
GCWI-2041 GCWI-1072
GCWI-1071 GCWI-846
GCWI-845 GCWI-844
GCWI-843

RXNCWI-57

+1*DGMP[c]+1*WATER[c
]->+1*DEOXYGUANOSINE
[c]+1*Pi[c]

GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241

RXNCWI-58

+1*GUANOSINE[c]<->+1*GUANOSINE[e]

RXNCWI-59

+1*XANTHOSINE[c]<->+1*XANTHOSINE[e]

RXNCWI-60

+1*INOSINE[c]<->+1*INOSINE[e]

RXNCWI-61

+1*ADENOSINE[c]<->+1*ADENOSINE[e]

RXNCWI-62

+1*ARG[e]+1*ATP[c]+1*
WATER[c]->+1*ADP[c]+1*ARG[c]+1*
PROTON[c]+1*Pi[c]
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GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400
GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400
GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400
GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400
GCWI-573 GCWI-847
GCWI-574 GCWI-1070
GCWI-2039 GCWI-2040
GCWI-575 GCWI-4291
GCWI-4290 GCWI-4289
GCWI-2043 GCWI-2042
GCWI-2041 GCWI-1072
GCWI-1071 GCWI-846

Name

Reaction

RXNCWI-63

+1*ARG[e]+1*PROTON[e]
->+1*ARG[c]+1*PROTON[
c]

RXNCWI-64

+1*ATP[c]+1*LEU[e]+1*
WATER[c]->+1*ADP[c]+1*LEU[c]+1*
PROTON[c]+1*Pi[c]

RXNCWI-65

+1*LEU[e]+1*PROTON[e]
->+1*LEU[c]+1*PROTON[c
]

RXNCWI-66

+1*ATP[c]+1*HIS[e]+1*W
ATER[c]->+1*ADP[c]+1*HIS[c]+1*
PROTON[c]+1*Pi[c]
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Locus
GCWI-845 GCWI-844
GCWI-843
GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-573 GCWI-847
GCWI-574 GCWI-1070
GCWI-2039 GCWI-2040
GCWI-575 GCWI-4291
GCWI-4290 GCWI-4289
GCWI-2043 GCWI-2042
GCWI-2041 GCWI-1072
GCWI-1071 GCWI-846
GCWI-845 GCWI-844
GCWI-843
GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-573 GCWI-847
GCWI-574 GCWI-1070
GCWI-2039 GCWI-2040
GCWI-575 GCWI-4291
GCWI-4290 GCWI-4289
GCWI-2043 GCWI-2042
GCWI-2041 GCWI-1072
GCWI-1071 GCWI-846
GCWI-845 GCWI-844
GCWI-843

Name

Reaction

RXNCWI-67

+1*HIS[e]+1*PROTON[e]>+1*HIS[c]+1*PROTON[c]

RXNCWI-68

+1*MET[e]+1*PROTON[e]
->+1*MET[c]+1*PROTON[
c]

RXNCWI-69

+1*ATP[c]+1*MET[e]+1*
WATER[c]->+1*ADP[c]+1*MET[c]+1*
PROTON[c]+1*Pi[c]

RXNCWI-7

RXNCWI-70

RXNCWI-72

Locus
GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-573 GCWI-847
GCWI-574 GCWI-1070
GCWI-2039 GCWI-2040
GCWI-575 GCWI-4291
GCWI-4290 GCWI-4289
GCWI-2043 GCWI-2042
GCWI-2041 GCWI-1072
GCWI-1071 GCWI-846
GCWI-845 GCWI-844
GCWI-843

+1*CPD-9984[e]+1*FE3[e]-->+1*CPDCWI6[e]+6*PROTON[e]
+1*ATP[c]+1*THIAMINE[
e]+1*WATER[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*THIAMINE[c]
+1*PROTON[e]+1*THIAM
INE[e]->+1*PROTON[c]+1*THIA
MINE[c]
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GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833

Name

RXNCWI-73

RXNCWI-74

RXNCWI-75
RXNCWI-76
RXNCWI-77

RXNCWI-78

RXNCWI-79

RXNCWI-8

RXNCWI-81

RXNCWI-82
RXNCWI-83

Reaction

+1*ATP[c]+1*DEOXYAD
ENOSINE[c]->+1*ADP[c]+1*DAMP[c]+
1*PROTON[c]
+1*DEOXYADENOSINE[c
]<->+1*DEOXYADENOSINE
[e]
+1*DAMP[c]+1*WATER[c
]->+1*DEOXYADENOSINE
[c]+1*Pi[c]
+1*ATP[c]+1*DAMP[c]->+1*ADP[c]+1*DADP[c]
+1*TMP[c]+1*WATER[c]>+1*Pi[c]+1*THYMIDINE
[c]
+1*CMP[c]+1*WATER[c]>+1*CYTIDINE[c]+1*Pi[c]
+1*ITP[c]+1*URIDINE[c]>+1*IDP[c]+1*PROTON[c]
+1*UMP[c]
+1*CPD-9985[e]+1*FE3[e]-->+1*CPDCWI7[e]+5*PROTON[e]
+1*CYTIDINE[c]+1*ITP[c]
->+1*CMP[c]+1*IDP[c]+1*
PROTON[c]
+1*CYTOSINE[c]+1*RIBO
SE-1P[c]->+1*CYTIDINE[c]+1*Pi[c]
+1*CYTIDINE[e]->+1*CYTIDINE[c]
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Locus
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-199 GCWI-200
GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400
GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241
GCWI-321
GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241
GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241
GCWI-3037 GCWI-3096
GCWI-4507

GCWI-4507

GCWI-2003 GCWI-4227
GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810

Name

Reaction

RXNCWI-85

+1*ATP[c]+1*DEOXYCY
TIDINE[c]->+1*ADP[c]+1*DCMP[c]

GCWI-199 GCWI-200

RXNCWI-86

+1*DEOXYCYTIDINE[c]<
->+1*DEOXYCYTIDINE[e]

GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400

RXNCWI-87

+1*ATP[c]+1*IDP[c]->+1*ADP[c]+1*ITP[c]

GCWI-1677

RXNCWI-88

RXNCWI-89

RXNCWI-9

RXNCWI-90

RXNCWI-91

RXNCWI-92
RXNCWI-93

+1*ILE[e]+1*PROTON[e]->+1*ILE[c]+1*PROTON[c]

+1*FAD[c]+1*PALMITYL
-COA[c]-->+1*CPD02117[c]+1*FADH2[c]
+1*CPDCWI6[c]+3*PROTON[c]+9*WA
TER[c]-->+1*FE3[c]+3*GLY[c]+3*THR[c]+
3*-2-3DIHYDROXYBENZOATE
[c]
+1*FAD[c]+1*TETRADEC
ANOYL-COA[c]->+1*CPD02120[c]+1*FADH2[c]
+1*FAD[c]+1*LAUROYL
COA-CPD[c]-->+1*CPD7222[c]+1*FADH2[c]
+1*CPD10267[c]+1*FAD[c]->+1*FADH2[c]+1*T2DECENOYL-COA[c]
+1*CPD-196[c]+1*FAD[c]->+1*CPD0-
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Locus
GCWI-538 GCWI-400

GCWI-5138 GCWI-3501
GCWI-3313 GCWI-3227
GCWI-3159 GCWI-3026
GCWI-1063 GCWI-1037
GCWI-896 GCWI-833
GCWI-799 GCWI-687
GCWI-3147 GCWI-3146
GCWI-907 GCWI-3872
GCWI-3873 GCWI-4677
GCWI-3160 GCWI-2162
GCWI-2019 GCWI-1602
GCWI-1023 GCWI-893
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-3817 GCWI-3818
GCWI-3816 GCWI-3815
GCWI-3814

GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440

Name

RXNCWI-94

RXNCWI-95

RXNCWI-96

RXNCWI-99

RXNI-3-MAL-CPD-9718-OXALACETIC-ACIDCPD-12125.40.
RXNN-386

RXNN-404

RXNQT-4191

S-ADENMETSYN-RXN

SAICARSYN-RXN

Reaction
2108[c]+1*FADH2[c]
+1*FAD[c]+1*HEXANOY
L-COA[c]-->+1*CPD02121[c]+1*FADH2[c]
+1*BUTYRYLCOA[c]+1*FAD[c]->+1*CROTONYLCOA[c]+1*FADH2[c]
+1*FAD[c]+1*STEAROYL
-COA[c]-->+1*CPD10262[c]+1*FADH2[c]
+1*NADPH[c]+1*Octadec2-enoylACPs[c]+1*PROTON[c]->+1*NADP[c]+1*StearoylACPs[c]
+1*CPD9718[c]+1*MAL[c]->+1*CPD12125[c]+1*OXALACETIC
-ACID[c]
+1*CPDN-384[c]<->+1*CPDN-385[c]
+1*CPD237[c]+1*WATER[c]<->+1*AMMONIA[c]+1*IND
OLE-ACETATEAUXIN[c]+1*PROTON[c]
+1*THIAMINEP[c]+1*WATER[c]->+1*Pi[c]+1*THIAMINE[c
]
+1*ATP[c]+1*MET[c]+1*
WATER[c]->+1*PPI[c]+1*Pi[c]+1*SADENOSYLMETHIONIN
E[c]
+1*ATP[c]+1*LASPARTATE[c]+1*PHOSP
HORIBOSYL-CARBOXYAMINOIMIDAZOLE[c]->+1*ADP[c]+1*PROTON[c
]+1*P-RIBOSYL-4SUCCCARBAMINOIMIDAZOLE[c]+1*
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Locus
GCWI-5441
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-2435 GCWI-2612
GCWI-5127 GCWI-5440
GCWI-5441
GCWI-1393

GCWI-3002 GCWI-3002
GCWI-786 GCWI-1917
GCWI-3163 GCWI-4719
GCWI-4730
GCWI-2027

GCWI-2029 GCWI-2171

GCWI-4638

GCWI-4889

GCWI-499

Name

SAMDECARB-RXN

SARCOX-RXN

SERINE--TRNA-LIGASERXN

SERINE-O-ACETTRANRXN

SHIKIMATE-5DEHYDROGENASE-RXN

SHIKIMATE-KINASERXN

SIROHEMEFERROCHELAT-RXN

SPERMACTRAN-RXN

SPERMIDINESYN-RXN

Reaction
Pi[c]
+1*PROTON[c]+1*SADENOSYLMETHIONIN
E[c]-->+1*CARBONDIOXIDE[c]+1*SADENOSYLMETHIONIN
AMINE[c]
+1*OXYGENMOLECULE[c]+1*SARCO
SINE[c]+1*WATER[c]->+1*FORMALDEHYDE[c]
+1*GLY[c]+1*HYDROGE
N-PEROXIDE[c]
+1*ATP[c]+1*PROTON[c]
+1*SER[c]+1*SERtRNAs[c]->+1*AMP[c]+1*ChargedSER-tRNAs[c]+1*PPI[c]
+1*ACETYLCOA[c]+1*SER[c]->+1*ACETYLSERINE[c]+
1*CO-A[c]
+1*NADP[c]+1*SHIKIMA
TE[c]<->+1*NADPH[c]+1*PROTO
N[c]+1*-3-DEHYDROSHIKIMATE[c]
+1*ATP[c]+1*SHIKIMAT
E[c]->+1*ADP[c]+1*PROTON[c
]+1*SHIKIMATE-5P[c]
+1*FE2[c]+1*SIROHYDROCHL
ORIN[c]->+2*PROTON[c]+1*SIRO
HEME[c]
+1*ACETYLCOA[c]+1*SPERMIDINE[c
]<-->+1*CO-A[c]+1*CPD568[c]+1*PROTON[c]
+1*PUTRESCINE[c]+1*SADENOSYLMETHIONIN
AMINE[c]->+1*PROTON[c]+1*SPER
MIDINE[c]+1*-5-
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Locus

GCWI-4709 GCWI-5311

GCWI-2888 GCWI-2889

GCWI-196

GCWI-278

GCWI-4463

GCWI-4368

GCWI-1588

GCWI-5196 GCWI-2127

GCWI-5310 GCWI-5469

Name

SPHINGOMYELINPHOSPHODIESTERASERXN

SPONTPRO-RXN

SUCC-FUM-OXRED-RXN
SUCCCOASYN-RXN

SUCCDIAMINOPIMDESU
CC-RXN

SUCCGLUALDDEHYDRXN

SUCCINATESEMIALDEHYDEDEHYDROGENASE-RXN

SUCCORNTRANSAMRXN

SUCCSEMIALDDEHYDR
OG-RXN

Reaction
METHYLTHIOADENOSI
NE[c]
+1*Sphingomyelins[c]+1*
WATER[c]->+1*Ceramides[c]+1*PHO
SPHORYLCHOLINE[c]+1*PROTON[
c]
+1*L-GLUTAMATEGAMMASEMIALDEHYDE[c]<->+1*L-DELTA1PYRROLINE-5CARBOXYLATE[c]+1*PR
OTON[c]+1*WATER[c]
+1*FAD[c]+1*SUC[c]<->+1*FADH2[c]+1*FUM[c]
+1*ATP[c]+1*COA[c]+1*SUC[c]<->+1*ADP[c]+1*Pi[c]+1*SU
C-COA[c]
+1*N-SUCCINYLLL-2-6DIAMINOPIMELATE[c]+1
*WATER[c]<-->+1*LLDIAMINOPIMELATE[c]+1
*SUC[c]
+1*CPD822[c]+1*NAD[c]+1*WAT
ER[c]<-->+1*N2SUCCINYLGLUTAMATE[
c]+1*NADH[c]+2*PROTO
N[c]
+1*NAD[c]+1*SUCC-SALD[c]+1*WATER[c]->+1*NADH[c]+2*PROTO
N[c]+1*SUC[c]
+1*N2SUCCINYLORNITHINE[c]
+1*-2KETOGLUTARATE[c]<->+1*CPD822[c]+1*GLT[c]
+1*NADP[c]+1*SUCC-SALD[c]+1*WATER[c]->+1*NADPH[c]+2*PROTO
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Locus

GCWI-881

GCWI-4644
GCWI-3919 GCWI-3920

GCWI-4831

GCWI-2379 GCWI-3587
GCWI-2881 GCWI-1451

GCWI-533

GCWI-3055

GCWI-533

Name
SUCROSEPHOSPHATASE-RXN
SULFATEADENYLYLTRANS-RXN
SULFITE-REDUCT-RXN

SUPEROX-DISMUT-RXN

TEICHOICSYN2-RXN

THI-P-SYN-RXN

THIAMINPYROPHOSPHOKINASERXN
THIAZOLSYN3-RXN
THIOREDOXIN-REDUCTNADPH-RXN

Reaction
N[c]+1*SUC[c]
+1*SUCROSE6P[c]+1*WATER[c]<->+1*Pi[c]+1*SUCROSE[c]
+1*ATP[c]+1*PROTON[c]
+1*SULFATE[c]->+1*APS[c]+1*PPI[c]
+3*NADPH[c]+5*PROTO
N[c]+1*SO3[c]->+1*HS[c]+3*NADP[c]+3*
WATER[c]
+2*PROTON[c]+2*SUPER
-OXIDE[c]->+1*HYDROGENPEROXIDE[c]+1*OXYGE
N-MOLECULE[c]
+1*ACETYL-DGLUCOSAMINYLDIPHOS
PHOUNDECAPRE[c]+1*UDPMANNAC[c]->+1*ACETYLETCETERAGLUCOSAMINYLDIPHOS
PHOUND[c]+1*PROTON[c
]+1*UDP[c]
+1*AMINOHYDROXYMETHYLMETHYLPYRIMIDINEPP[c]+1*PROTON[c]+1*T
HZ-P[c]->+1*PPI[c]+1*THIAMINEP[c]
+1*ATP[c]+1*THIAMINE[
c]->+1*AMP[c]+1*PROTON[
c]+1*THIAMINEPYROPHOSPHATE[c]
+1*ATP[c]+1*THZ[c]->+1*ADP[c]+1*PROTON[c
]+1*THZ-P[c]
+1*NADPH[c]+1*OxThioredoxin[c]+1*PROTON
[c]-->+1*NADP[c]+1*RedThioredoxin[c]
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Locus

GCWI-975
GCWI-1583

GCWI-3232

GCWI-1630 GCWI-5548
GCWI-4408 GCWI-5030

GCWI-5521

GCWI-584

GCWI-3943

GCWI-583

GCWI-2822 GCWI-5257

Name
THREDEHYD-RXN

THREONINE--TRNALIGASE-RXN

THRESYN-RXN

THYKI-RXN

THYMIDYLATESYNRXN

TIGLYLCOA-HYDROXYRXN

TRANSHEXAPRENYLTRANSTR
ANSFERASE-RXN

TRANS-RXN-1

TRANS-RXN-104

TRANS-RXN-118
TRANS-RXN-125

Reaction
+1*THR[c]->+1*AMMONIA[c]+1*PR
OTON[c]+1*-2OXOBUTANOATE[c]
+1*ATP[c]+1*PROTON[c]
+1*THR[c]+1*THRtRNAs[c]->+1*AMP[c]+1*ChargedTHR-tRNAs[c]+1*PPI[c]
+1*O-PHOSPHO-LHOMOSERINE[c]+1*WAT
ER[c]->+1*Pi[c]+1*THR[c]
+1*ATP[c]+1*THYMIDIN
E[c]<->+1*ADP[c]+1*PROTON[c
]+1*TMP[c]
+1*DUMP[c]+1*METHYL
ENE-THF[c]->+1*DIHYDROFOLATE[c
]+1*TMP[c]
+1*CPD1083[c]+1*WATER[c]->+1*-2-METHYL-3HYDROXY-BUTYRYLCOA[c]
+4*DELTA3ISOPENTENYLPP[c]+1*FARNESYLPP[c]-->+1*ALL-TRANSHEPTAPRENYLDIPHOSPHATE[c]+4*PPI[
c]
+1*FORMATE[c]+1*PROT
ON[c]<->+1*FORMATE[e]+1*PRO
TON[e]
+1*LLACTATE[e]+1*PROTON[
e]<-->+1*LLACTATE[c]+1*PROTON[
c]
+1*NA-[e]+1*PRO[e]->+1*NA-[c]+1*PRO[c]
+1*L-ALPHA-
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Locus
GCWI-4278 GCWI-3306
GCWI-4279 GCWI-3307
GCWI-2540 GCWI-1966

GCWI-2466 GCWI-4704

GCWI-2073

GCWI-5429

GCWI-2328

GCWI-1106 GCWI-2616
GCWI-3561 GCWI-4652
GCWI-2439

GCWI-1674 GCWI-1676

GCWI-3601 GCWI-3808
GCWI-1474

GCWI-814 GCWI-1417
GCWI-5327
GCWI-1407 GCWI-3673
GCWI-842 GCWI-2461

Name

TRANS-RXN-139

Reaction
ALANINE[e]+1*NA-[e]->+1*L-ALPHAALANINE[c]+1*NA-[c]
+1*PROTON[e]+1*URACI
L[e]->+1*PROTON[c]+1*URAC
IL[c]
+1*NITRITE[e]->+1*NITRITE[c]
+1*CL-[e]-->+1*CL-[c]

TRANS-RXN-141

+1*MG-2[e]-->+1*MG-2[c]

TRANS-RXN-141A

+1*CO-2[e]-->+1*CO-2[c]

TRANS-RXN-143

+1*K-[e]-->+1*K-[c]

TRANS-RXN-132
TRANS-RXN-137

TRANS-RXN-144

TRANS-RXN-162

TRANS-RXN-23

TRANS-RXN-57

TRANS-RXN-58

+1*CA2[c]+1*PROTON[e]<->+1*CA2[e]+1*PROTON[c]
+1*GLT[e]+2*PROTON[e]
->+1*GLT[c]+2*PROTON[c
]
+1*PROTON[e]+1*-2KETOGLUTARATE[e]->+1*PROTON[c]+1*-2KETOGLUTARATE[c]
+1*PROTON[e]+1*-4AMINO-BUTYRATE[e]->+1*PROTON[c]+1*-4AMINO-BUTYRATE[c]
+1*LYS[e]+1*PROTON[e]>+1*LYS[c]+1*PROTON[c
]
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Locus
GCWI-2880 GCWI-3173
GCWI-3174 GCWI-5164
GCWI-5175 GCWI-5176
GCWI-3974
GCWI-1474
GCWI-5508
GCWI-3188 GCWI-4226
GCWI-2150 GCWI-1740
GCWI-1878 GCWI-2399
GCWI-4535
GCWI-3188 GCWI-4226
GCWI-331 GCWI-2704
GCWI-1740 GCWI-1878
GCWI-2399 GCWI-4535
GCWI-1476 GCWI-1553
GCWI-4120 GCWI-724
GCWI-5494 GCWI-5495
GCWI-1740 GCWI-1878
GCWI-2399 GCWI-4535
GCWI-627

GCWI-1592 GCWI-1593
GCWI-5315 GCWI-1552

GCWI-1126 GCWI-2574

GCWI-3805
GCWI-3102 GCWI-5138
GCWI-3501 GCWI-3313
GCWI-3227 GCWI-3159
GCWI-3026 GCWI-1063
GCWI-1037 GCWI-896
GCWI-833 GCWI-799

Name

Reaction

TRANS-RXN-8

+1*FE-2[e]-->+1*FE-2[c]

TRANS-RXN0-209

+1*GLUCONATE[e]+1*PR
OTON[e]->+1*GLUCONATE[c]+1*P
ROTON[c]

TRANS-RXN0-468

+1*Nucleosides[c]<->+1*Nucleosides[e]

TRANS-RXN0-470

TRANS-RXNCWI-1

TRANS-RXNCWI-10

TRANS-RXNCWI-11

TRANS-RXNCWI-11058

TRANS-RXNCWI-11074

+1*Pi[c]<-->+1*Pi[e]
+1*ATP[c]+1*CD2[e]+1*WATER[c]->+1*ADP[c]+1*CD2[c]+1*PROTON[c]+1*Pi[c
]
+1*CPD12125[c]+0.5*OXYGENMOLECULE[c]+4*PROTO
N[c]-->+1*CPD9718[c]+4*PROTON[e]+1*
WATER[c]
+1*CARBONDIOXIDE[e]<->+1*CARBONDIOXIDE[c]
+1*ATP[c]+1*CO2[e]+1*WATER[c]->+1*ADP[c]+1*CO2[c]+1*PROTON[c]+1*Pi[c
]
+1*ATP[c]+1*MO2[e]+1*WATER[c]->+1*ADP[c]+1*MO2[c]+1*PROTON[c]+1*Pi[c
]
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Locus
GCWI-687 GCWI-3147
GCWI-3146 GCWI-907
GCWI-3872 GCWI-3873
GCWI-4677 GCWI-3160
GCWI-2162 GCWI-2019
GCWI-1602 GCWI-1023
GCWI-893
GCWI-917 GCWI-4932
GCWI-916 GCWI-915
GCWI-1740 GCWI-1878
GCWI-2399 GCWI-4535
GCWI-366 GCWI-3417
GCWI-4964
GCWI-2002 GCWI-5335
GCWI-5174 GCWI-5173
GCWI-3020 GCWI-810
GCWI-538 GCWI-400
GCWI-1613

GCWI-618 GCWI-801

GCWI-5324 GCWI-4920
GCWI-4121 GCWI-2051
GCWI-5323 GCWI-4919
GCWI-2050

GCWI-329 GCWI-330

GCWI-402

Name
TRANS-RXNCWI-11079
TRANS-RXNCWI-11087

Reaction
+1*URACIL[e]+1*XANTH
INE[e]->+1*URACIL[c]+1*XANT
HINE[c]
+1*BENZOATE[e]->+1*BENZOATE[c]

TRANS-RXNCWI-11090

+1*ATP[c]+1*AminoAcids-20[e]+1*WATER[c]->+1*ADP[c]+1*AminoAcids20[c]+1*PROTON[c]+1*Pi[
c]

TRANS-RXNCWI-11105

+1*Amino-Acids20[e]+1*PROTON[e]->+1*Amino-Acids20[c]+1*PROTON[c]

TRANS-RXNCWI-11108

TRANS-RXNCWI-11113
TRANS-RXNCWI-11116

+1*CPD12541[e]+1*PHOSPHOENOL-PYRUVATE[c]<->+1*N-ACETYL-DGLUCOSAMINE-1P[c]+1*PYRUVATE[c]
+1*BETAINE[e]->+1*BETAINE[c]
+1*CIT[e]-->+1*CIT[c]

TRANS-RXNCWI-11128

+1*NA-[e]+1*PROTON[e]->+1*NA[c]+1*PROTON[c]

TRANS-RXNCWI-11133

+1*PHOSPHO-ENOL-
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Locus
GCWI-471 GCWI-897
GCWI-969 GCWI-4225
GCWI-4618 GCWI-5496
GCWI-570
GCWI-4291 GCWI-4290
GCWI-4289 GCWI-2043
GCWI-2042 GCWI-2041
GCWI-1072 GCWI-1071
GCWI-846 GCWI-845
GCWI-844 GCWI-843
GCWI-2040 GCWI-575
GCWI-1070 GCWI-2039
GCWI-574 GCWI-573
GCWI-847
GCWI-3872 GCWI-3873
GCWI-4677 GCWI-3160
GCWI-2162 GCWI-2019
GCWI-1602 GCWI-1023
GCWI-893 GCWI-5138
GCWI-3501 GCWI-3313
GCWI-3227 GCWI-3159
GCWI-3026 GCWI-1063
GCWI-1037 GCWI-896
GCWI-833 GCWI-799
GCWI-687 GCWI-3147
GCWI-3146 GCWI-907

GCWI-693

GCWI-760 GCWI-5339
GCWI-768
GCWI-2306 GCWI-1950
GCWI-1485 GCWI-1590
GCWI-1915 GCWI-3585
GCWI-4214 GCWI-1006
GCWI-911 GCWI-1768
GCWI-2301 GCWI-817
GCWI-892
GCWI-835

Name

TRANS-RXNCWI-11140
TRANS-RXNCWI-11143

TRANS-RXNCWI-11187

TRANS-RXNCWI-11200

TRANS-RXNCWI-11255
TRANS-RXNCWI-11258
TRANS-RXNCWI-11266
TRANS-RXNCWI-11281
TRANS-RXNCWI-11288

TRANS-RXNCWI-11297

TRANS-RXNCWI-11314

TRANS-RXNCWI-11353

Reaction
PYRUVATE[c]+1*TREHA
LOSE[e]->+1*PYRUVATE[c]+1*TR
EHALOSE-6P[c]
+1*PROTON[e]+1*SULFA
TE[e]->+1*PROTON[c]+1*SULF
ATE[c]
+1*GLYCEROL-3P[e]->+1*GLYCEROL-3P[c]
+1*PHOSPHO-ENOLPYRUVATE[c]+1*SUCRO
SE[e]<->+1*PYRUVATE[c]+1*SU
CROSE-6P[c]
+1*GLYCEROL[e]+1*PRO
TON[e]->+1*GLYCEROL[c]+1*PR
OTON[c]
+1*PROTON[e]+1*THR[c]
<->+1*PROTON[c]+1*THR[e
]
+1*HOMO-SER[c]->+1*HOMO-SER[e]
+1*Amino-Acids-20[e]->+1*Amino-Acids-20[c]
+1*NITRATE[e]->+1*NITRATE[c]
+1*ARG[e]+1*LORNITHINE[c]->+1*ARG[c]+1*LORNITHINE[e]
+1*FORMATE[c]+1*OXA
LATE[e]->+1*FORMATE[e]+1*OX
ALATE[c]
+1*ATP[c]+1*BETAINE[e]
+1*WATER[c]->+1*ADP[c]+1*BETAINE[
c]+1*PROTON[c]+1*Pi[c]
+1*PROTON[e]+1*SER[e]>+1*PROTON[c]+1*SER[c
]
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Locus

GCWI-858 GCWI-1092
GCWI-865

GCWI-1042

GCWI-1215

GCWI-3305 GCWI-3437
GCWI-1999 GCWI-2438
GCWI-1999 GCWI-2438
GCWI-2521 GCWI-2018
GCWI-2236
GCWI-2372

GCWI-2447 GCWI-2737
GCWI-2838 GCWI-2837
GCWI-2371 GCWI-2370
GCWI-2839
GCWI-3305 GCWI-3437
GCWI-2018 GCWI-2521

Name

TRANS-RXNCWI-11386

TRANS-RXNCWI-11389

TRANS-RXNCWI-11435

TRANS-RXNCWI-11456

TRANS-RXNCWI-11479

TRANS-RXNCWI-11519

TRANS-RXNCWI-11537

TRANS-RXNCWI-12

TRANS-RXNCWI-13

TRANS-RXNCWI-14
TRANS-RXNCWI-15
TRANS-RXNCWI-16

Reaction
+1*ATP[c]+1*PHOSPHON
ATE[e]+1*WATER[c]->+1*ADP[c]+1*PHOSPHO
NATE[c]+1*PROTON[c]+1
*Pi[c]
+1*Fructose[e]+1*PHOSPH
O-ENOL-PYRUVATE[c]->+1*FRU1P[c]+1*PYRUV
ATE[c]
+1*ALPHAGLUCOSE[e]+1*PROTON[
e]-->+1*ALPHAGLUCOSE[c]+1*PROTON[
c]
+1*CPD-4422[e]->+1*CPD-4422[c]
+1*ALPHAGLUCOSE[e]+1*PHOSPH
O-ENOL-PYRUVATE[c]->+1*ALPHA-GLC-6P[c]+1*PYRUVATE[c]
+1*ATP[c]+1*RIBOSE[e]+
1*WATER[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*RIBOSE[c]
+1*CELLOBIOSE[e]+1*P
HOSPHO-ENOLPYRUVATE[c]<->+1*CPD507[c]+1*PYRUVATE[c]
+1*-3-4DIHYDROXYBENZOATE
[c]-->+1*-3-4DIHYDROXYBENZOATE
[e]
+1*CPD9718[c]+1*FADH2[c]+2*P
ROTON[e]-->+1*CPD12125[c]+1*FAD[c]+2*PR
OTON[c]
+1*UREA[c]->+1*UREA[e]
+1*ARSENATE[c]<->+1*ARSENATE[e]
+1*ETOH[c]+1*PROTON[
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Locus
GCWI-3709 GCWI-3710
GCWI-3711 GCWI-3712

GCWI-3798

GCWI-4844

GCWI-5304

GCWI-5419

GCWI-3006 GCWI-3005
GCWI-3004 GCWI-873
GCWI-872 GCWI-871
GCWI-5312 GCWI-5313
GCWI-5314

Name

TRANS-RXNCWI-17
TRANS-RXNCWI-18

TRANS-RXNCWI-2
TRANS-RXNCWI-5
TRANS-RXNCWI-6
TRANS-RXNCWI-7

TRANS-RXNCWI-8

TRANS-RXNCWU-12494

TRANS-RXNCWU-12497

TRANSALDOL-RXN

TRE6PHYDRO-RXN
TRIOSEPISOMERIZATIO
N-RXN

Reaction
e]->+1*ETOH[e]+1*PROTON
[c]
+1*WATER[c]<->+1*WATER[e]
+1*OXYGENMOLECULE[e]<->+1*OXYGENMOLECULE[c]
+1*ATP[c]+1*WATER[c]+
1*ZN-2[e]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*ZN-2[c]
+1*CPD-9984[c]->+1*CPD-9984[e]
+1*CPD-9985[c]->+1*CPD-9985[e]
+1*ATP[c]+1*CPDCWI6[e]+1*WATER[c]->+1*ADP[c]+1*CPDCWI6[c]+1*Pi[c]
+1*ATP[c]+1*CPDCWI7[e]+1*WATER[c]->+1*ADP[c]+1*CPDCWI7[c]+1*Pi[c]
+1*ATP[c]+1*CPD1106[e]+1*WATER[c]->+1*ADP[c]+1*CPD1106[c]+1*PROTON[c]+1*
Pi[c]
+1*CPD1106[e]+1*PROTON[e]->+1*CPD1106[c]+1*PROTON[c]
+1*D-SEDOHEPTULOSE7-P[c]+1*GAP[c]<->+1*ERYTHROSE4P[c]+1*FRUCTOSE-6P[c]
+1*TREHALOSE6P[c]+1*WATER[c]<->+1*ALPHA-GLC-6P[c]+1*ALPHAGLUCOSE[c]
+1*GAP[c]<->+1*DIHYDROXY-
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Locus

GCWI-618 GCWI-801
GCWI-2092

GCWI-3818 GCWI-3817
GCWI-3816 GCWI-3815
GCWI-3814
GCWI-5203 GCWI-5202
GCWI-5201 GCWI-5200
GCWI-4657 GCWI-4656

GCWI-874 GCWI-3418

GCWI-836

GCWI-5236

Name

TRNA-PSEUDOURIDINESYNTHASE-I-RXN

TRYPSYN-RXN

TRYPTOPHAN--TRNALIGASE-RXN

TRYPTOPHAN-23DIOXYGENASE-RXN

TYROSINE--TRNALIGASE-RXN

TYROSINEAMINOTRANSFERASERXN

UDP-NACMUR-ALA-LIGRXN

UDP-NACMURALA-GLULIG-RXN
UDPNACMURALGLDAPAALI
G-RXN

Reaction
ACETONEPHOSPHATE[c]
+1*tRNA-uridine-3840[c]<-->+1*tRNApseudouridine-38-40[c]
+1*INDOLE-3GLYCEROLP[c]+1*SER[c]<->+1*GAP[c]+1*TRP[c]+1*
WATER[c]
+1*ATP[c]+1*PROTON[c]
+1*TRP[c]+1*TRPtRNAs[c]->+1*AMP[c]+1*ChargedTRP-tRNAs[c]+1*PPI[c]
+1*OXYGENMOLECULE[c]+2*PROTO
N[c]+1*TRP[c]-->+1*NFORMYLKYNURENINE[c
]
+1*ATP[c]+1*PROTON[c]
+1*TYR[c]+1*TYRtRNAs[c]->+1*AMP[c]+1*ChargedTYR-tRNAs[c]+1*PPI[c]
+1*TYR[c]+1*-2KETOGLUTARATE[c]<->+1*GLT[c]+1*PHYDROXYPHENYLPYRUVATE[c]
+1*ATP[c]+1*L-ALPHAALANINE[c]+1*UDP-NACETYLMURAMATE[c]->+1*ADP[c]+1*CPD01456[c]+1*PROTON[c]+1*
Pi[c]
+1*ATP[c]+1*CPD01456[c]+1*D-GLT[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*UDP-AAGLUTAMATE[c]
+1*ATP[c]+1*D-ALA-DALA[c]+1*UDP-AAGMDIAMINOHEPTANEDIOA
TE[c]--
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Locus

GCWI-1375 GCWI-332
GCWI-683 GCWI-3894

GCWI-1414 GCWI-1415

GCWI-1353 GCWI-3398

GCWI-2806

GCWI-4788 GCWI-5187

GCWI-1680 GCWI-2986

GCWI-4814

GCWI-3996

GCWI-433 GCWI-2276

Name

UDPNACMURALGLDAPLIGRXN

UDPGLCNACEPIM-RXN
UDPGLUCEPIM-RXN
UDPKIN-RXN

UDPMANNACADEHYDR
OG-RXN

UDPNACETYLGLUCOSA
MENOLPYRTRANS-RXN

UDPNACETYLMURAMA
TEDEHYDROG-RXN

UDPREDUCT-RXN

UGD-RXN

Reaction
>+1*ADP[c]+1*C1[c]+1*P
ROTON[c]+1*Pi[c]
+1*ATP[c]+1*MESODIAMINOPIMELATE[c]+1
*UDP-AAGLUTAMATE[c]->+1*ADP[c]+1*PROTON[c
]+1*Pi[c]+1*UDP-AAGMDIAMINOHEPTANEDIOA
TE[c]
+1*UDP-N-ACETYL-DGLUCOSAMINE[c]->+1*UDP-MANNAC[c]
+1*UDP-GALACTOSE[c]->+1*UDP-GLUCOSE[c]
+1*ATP[c]+1*UDP[c]->+1*ADP[c]+1*UTP[c]
+2*NAD[c]+1*UDPMANNAC[c]+1*WATER[c
]<->+2*NADH[c]+3*PROTO
N[c]+1*UDPMANNACA[c]
+1*PHOSPHO-ENOLPYRUVATE[c]+1*UDP-NACETYL-DGLUCOSAMINE[c]->+1*Pi[c]+1*UDPACETYLCARBOXYVINYLGLUCOSAMINE[c]
+1*NADPH[c]+1*PROTO
N[c]+1*UDP-ACETYLCARBOXYVINYLGLUCOSAMINE[c]->+1*NADP[c]+1*UDP-NACETYLMURAMATE[c]
+1*RedThioredoxin[c]+1*UDP[c]->+1*DUDP[c]+1*OxThioredoxin[c]+1*WATER[
c]
+2*NAD[c]+1*UDPGLUCOSE[c]+1*WATER[c
]<--
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Locus

GCWI-3998

GCWI-5298 GCWI-5367
GCWI-481 GCWI-5552
GCWI-5364
GCWI-1677

GCWI-5370

GCWI-5387 GCWI-5433

GCWI-3993 GCWI-5188

GCWI-1521 GCWI-1519
GCWI-1522

GCWI-5299

Name

UNDECAPRENYLDIPHOSPHATASE-RXN

URA-PHOSPH-RXN
URACILPRIBOSYLTRANS-RXN
UREA-CARBOXYLASERXN

URIDINEKIN-RXN

URKI-RXN

UROCANATEHYDRATASE-RXN

UROGENDECARBOXRXN

UROGENIIISYN-RXN
UROPORIIIMETHYLTRA
NSA-RXN

Reaction
>+2*NADH[c]+3*PROTO
N[c]+1*UDPGLUCURONATE[c]
+1*UNDECAPRENYLDIPHOSPHATE[c]+1*WA
TER[c]<-->+1*CPD9646[c]+1*PROTON[c]+1*
Pi[c]
+1*DEOXYURIDINE[c]+1
*Pi[c]<-->+1*DEOXYRIBOSE1P[c]+1*URACIL[c]
+1*PRPP[c]+1*URACIL[c]
-->+1*PPI[c]+1*UMP[c]
+1*ATP[c]+1*CARBONDIOXIDE[c]+1*UREA[c]+
1*WATER[c]->+1*ADP[c]+1*CPD578[c]+2*PROTON[c]+1*P
i[c]
+1*ATP[c]+1*URIDINE[c]
->+1*ADP[c]+1*PROTON[c
]+1*UMP[c]
+1*GTP[c]+1*URIDINE[c]
->+1*GDP[c]+1*PROTON[c
]+1*UMP[c]
+1*UROCANATE[c]+1*W
ATER[c]->+1*PROTON[c]+1*-4IMIDAZOLONE-5PROPIONATE[c]
+4*PROTON[c]+1*UROP
ORPHYRINOGEN-III[c]->+4*CARBONDIOXIDE[c]+1*COPROPO
RPHYRINOGEN-III[c]
+1*HYDROXYMETHYLB
ILANE[c]->+1*UROPORPHYRINOG
EN-III[c]+1*WATER[c]
+1*SADENOSYLMETHIONIN
E[c]+1*UROPORPHYRIN
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Locus

GCWI-488 GCWI-886
GCWI-1548 GCWI-2761

GCWI-1624 GCWI-4228
GCWI-3975 GCWI-5414

GCWI-3121

GCWI-3037 GCWI-3096
GCWI-4507
GCWI-3037 GCWI-3096
GCWI-4507

GCWI-3679

GCWI-1254

GCWI-4590

GCWI-1587 GCWI-2241

Name

VALINE--TRNA-LIGASERXN

XANPRIBOSYLTRANRXN
XANTHOSINEPHOSPHO
RY-RXN

XMPXAN-RXN

YIAE1-RXN

Reaction
OGEN-III[c]->+1*ADENOSYL-HOMOCYS[c]+1*CPD9038[c]+1*PROTON[c]
+1*ATP[c]+1*PROTON[c]
+1*VAL[c]+1*VALtRNAs[c]->+1*AMP[c]+1*ChargedVAL-tRNAs[c]+1*PPI[c]
+1*PRPP[c]+1*XANTHIN
E[c]->+1*PPI[c]+1*XANTHOSI
NE-5-PHOSPHATE[c]
+1*Pi[c]+1*XANTHOSINE
[c]-->+1*RIBOSE1P[c]+1*XANTHINE[c]
+1*WATER[c]+1*XANTH
OSINE-5-PHOSPHATE[c]>+1*Pi[c]+1*XANTHOSIN
E[c]
+1*NADPH[c]+1*PROTO
N[c]+1*-25-DIDEHYDROD-GLUCONATE[c]<->+1*NADP[c]+1*-5DEHYDROGLUCONATE[
c]

Locus

GCWI-4585

GCWI-1727

GCWI-1624 GCWI-4228
GCWI-2585 GCWI-2586
GCWI-2587 GCWI-3179
GCWI-4241

GCWI-5026

A8.4. Exchange fluxes
Table S17. List of exchange fluxes for nutrients and secretion for the model for
B. anthracis. The name, reaction, as well as lower and upper boundaries are
provides. The boundaries with the variable label refe to experimentally measured
fluxes which depend on the condition to be simulate.
Nutrients
Name

Rxn

ALPHA-GLUCOSEExchange-FLUX
ARG-Exchange-FLUX
CA-2-Exchange-FLUX
CL--Exchange-FLUX

+1*ALPHAGLUCOSE[e]<-->
+1*ARG[e]<-->
+1*CA-2[e]<-->
+1*CL-[e]<-->
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Lowboundary

Upperboundary

variable

variable

-1000
-1000
-1000

1000
1000
1000

CYS-Exchange-FLUX
FE-3-Exchange-FLUX
GLT-Exchange-FLUX
HIS-Exchange-FLUX
ILE-Exchange-FLUX
K--Exchange-FLUX
L-ASPARTATE-ExchangeFLUX
L-LACTATE-Exchange-FLUX
LEU-Exchange-FLUX
MET-Exchange-FLUX
MG-2-Exchange-FLUX
MN-2-Exchange-FLUX
NA--Exchange-FLUX
OXYGEN-MOLECULEExchange-FLUX
PHE-Exchange-FLUX
Pi-Exchange-FLUX
PRO-Exchange-FLUX
PROTON-Exchange-FLUX
SER-Exchange-FLUX
SULFATE-Exchange-FLUX
THIAMINE-Exchange-FLUX
THR-Exchange-FLUX
TRP-Exchange-FLUX
VAL-Exchange-FLUX
WATER-Exchange-FLUX

+1*CYS[e]<-->
+1*FE-3[e]<-->
+1*GLT[e]<-->
+1*HIS[e]<-->
+1*ILE[e]<-->
+1*K-[e]<-->
+1*L-ASPARTATE[e]<->
+1*L-LACTATE[e]<-->
+1*LEU[e]<-->
+1*MET[e]<-->
+1*MG-2[e]<-->
+1*MN-2[e]<-->
+1*NA-[e]<-->
+1*OXYGENMOLECULE[e]<-->
+1*PHE[e]<-->
+1*Pi[e]<-->
+1*PRO[e]<-->
+1*PROTON[e]<-->
+1*SER[e]<-->
+1*SULFATE[e]<-->
+1*THIAMINE[e]<-->
+1*THR[e]<-->
+1*TRP[e]<-->
+1*VAL[e]<-->
+1*WATER[e]<-->

-1000
variable
variable
-1000
-1000
-1000

1000
variable
variable
1000
1000
1000

-1000

1000

variable
-1000
-1000
-1000
-1000
-1000

variable
1000
1000
1000
1000
1000

variable

variable

-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000
-1000

1000
1000
1000
1000
1000
1000
1000
0
1000
1000
1000

Secretion
Name

Rxn

-3-4DIHYDROXYBENZOATEExchange-FLUX
ACET-Exchange-FLUX
BIOMASS-CCO-CYTOSOLExchange-FLUX

+1*-3-4DIHYDROXYBENZOAT
E[e]<-->
+1*ACET[e]<-->
+1*BIOMASS-CCOCYTOSOL[c]<-->
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Lowboundar
y

Upperboundary

variable

variable

0

1000

0

1000

CARBON-DIOXIDEExchange-FLUX
CPD-10353-Exchange-FLUX
CPD-10774-Exchange-FLUX
CPD-763-Exchange-FLUX
CPD-9984-Exchange-FLUX
CPD-9985-Exchange-FLUX
CPDCWI-16-Exchange-FLUX
ETOH-Exchange-FLUX
FORMATE-Exchange-FLUX
L-LACTATE-ExchangeFLUX
L-ORNITHINE-ExchangeFLUX
SPERMIDINE-ExchangeFLUX

+1*CARBONDIOXIDE[e]<-->
+1*CPD-10353[e]<-->
+1*CPD-10774[c]<-->
+1*CPD-763[e]<-->
+1*CPD-9984[e]<-->
+1*CPD-9985[e]<-->
+1*CPDCWI-16[c]<-->
+1*ETOH[e]<-->
+1*FORMATE[e]<-->

variable

variable

0
0
0
variable
variable
0
0
0

1000
1000
1000
variable
variable
1000
1000
1000

+1*L-LACTATE[e]<-->

variable

variable

+1*L-ORNITHINE[e]<->

0

1000

+1*SPERMIDINE[e]<-->

0

1000

A8.5.Biomass for iron-poor media phase I
Table S18. List of biomass’s reactants for B. anthracis model under iron-poor
conditions Phase I. The name, reaction, as well as lower and upper boundaries are
provides.
Metabolite
Protein

Glycine

0.55

L-Alanine

Species name
Charged-GLYtRNAs[c]
Charged-ALAtRNAs[c]
Charged-VALtRNAs[c]
Charged-LEUtRNAs[c]
Charged-ILEtRNAs[c]
Charged-SERtRNAs[c]
Charged-THRtRNAs[c]
Charged-PHEtRNAs[c]
Charged-TYR-

L-Valine
L-Leucine
L-Isoleucine
L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
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mmol/gDW
0.412078
0.433604
0.329047
0.375175
0.293682
0.182975
0.239866
0.162986
0.132234

Metabolite

Species name
tRNAs[c]
Charged-TRPtRNAs[c]
Charged-CYStRNAs[c]
Charged-METtRNAs[c]
Charged-LYStRNAs[c]
Charged-ARGtRNAs[c]
Charged-HIStRNAs[c]
Charged-ASPtRNAs[c]
Charged-ASNtRNAs[c]
Charged-GLNtRNAs[c]
Charged-GLTtRNAs[c]
Charged-PROtRNAs[c]
ATP[c]
GTP[c]
CTP[c]
UTP[c]
DATP[c]
DGTP[c]
DCTP[c]
TTP[c]
K-[c]
MG-2[c]
FE-3[c]
AMMONIUM[c]
SULFATE[c]
CA-2[c]
CO-A[c]
SPERMIDINE[c]
ACP[c]
L-ORNITHINE[c]

L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate

RNA
0.145

DNA
0.011

Ions
0.03185

Cofactors
0.01715

L-Proline
AMP (ATP)
GMP (GTP)
CMP (CTP)
UMP (UTP)
dAMP (dATP)
dGMP (dGTP)
dCMP (dCTP)
dTMP (dTTP)
K
Mg
Fe(+3)
NH4
SO4
Ca2+
coa
spermidine
ACP
L-Ornitine
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mmol/gDW

0.007688
0.010763
0.083031
0.264468
0.184512
0.087643
0.209114
0.209114
0.266005
0.266005
0.155298
43.610000
0.131137
0.089431
0.096310
0.010802
0.006413
0.005738
0.010802
0.700573
0.100903
0.003422
0.001285
0.000031
0.003179
0.000128
0.000020
0.000273
0.000046

Metabolite
NAD
NADP
NADPH
menaquinol 7

Lipids
0.025

Species name
NAD[c]
NADP[c]
NADPH[c]
CPD-12125[c]
-10-FORMYLTHF[c]
CPD-12824[c]
CPDCWI-13[c]
CPD-8260[c]
CPD-12822[c]

mmol/gDW
0.018220
0.001053
0.000237
0.000150

CPD-12819[c]

0.006196

CPD-12818[c]
CPD-12817[c]

0.000196
0.000415
0.000013
0.010908
0.000339
0.000572

octadecanoic/stearic/stearate
a peptidoglycan subunit

CPD-12816[c]
CPD66-34[c]
CPDCWI-14[c]
PALMITATE[c]
STEARICACID[c]
CPD-12261[c]

water

WATER[c]

39.200000

10-formyltetrahydrofolate
cardiolipin (tetrahexadecanoyl)
cardiolipin (stearoylcardiolipin)
1,2-dipalmitoyl-phosphatidylglycerol
phosphatidylglycerol (dioctadacanoyl)
1,2-dipalmitoylphosphatidylethanolamine
phosphatidylethanlamine
(dioctadecanoyl)
1,2-dipalmitoyl-phosphatidylserine
phosphatidylserine (dioctadecanoyl, nc18:0)
1,2-dipalmitoylglycerol
1,2-distearoyl-sn-glycerol
hexadecanoic/palmitic/palmitate

Cell wall
0.22

0.000207
0.000740
0.000023
0.005107
0.000162

0.000018
0.030270

Table S19. List of biomass’s products for B. anthracis model under iron-poor
conditions Phase I. The name, reaction, as well as lower and upper boundaries are
provides.

GAM

tRNAS recycling

name
ADP
H+
Pi
PPI
Biomass
Glycine
L-Alanine

Species name
ADP[c]
PROTON[c]
Pi[c]
PPI[c]
BIOMASS-CCO-CYTOSOL[c]
GLY-tRNAs[c]
ALA-tRNAs[c]

429

mmol/gDW
43.500000
43.500000
43.490000
0.458900
1.000000
0.412078
0.433604

name
L-Valine
L-Leucine
L-Isoleucine
L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate
L-Proline
apo-ACP

Species name
VAL-tRNAs[c]
LEU-tRNAs[c]
ILE-tRNAs[c]
SER-tRNAs[c]
THR-tRNAs[c]
PHE-tRNAs[c]
TYR-tRNAs[c]
TRP-tRNAs[c]
CYS-tRNAs[c]
MET-tRNAs[c]
LYS-tRNAs[c]
ARG-tRNAs[c]
HIS-tRNAs[c]
ASP-tRNAs[c]
ASN-tRNAs[c]
GLN-tRNAs[c]
GLT-tRNAs[c]
PRO-tRNAs[c]
apo-ACP[c]

mmol/gDW
0.329047
0.375175
0.293682
0.182975
0.239866
0.162986
0.132234
0.007688
0.010763
0.083031
0.264468
0.184512
0.087643
0.209114
0.209114
0.266005
0.266005
0.155298
0.000273109

A8.6. Biomass for iron-rich media phase I
Table S20. List of biomass’s reactants for B. anthracis model under iron-rich
conditions Phase I. The name, reaction, as well as lower and upper boundaries are
provides.
name
Protein

Glycine

0.55

L-Alanine

Species name
Charged-GLYtRNAs[c]
Charged-ALAtRNAs[c]
Charged-VALtRNAs[c]
Charged-LEUtRNAs[c]
Charged-ILEtRNAs[c]
Charged-SERtRNAs[c]

L-Valine
L-Leucine
L-Isoleucine
L-Serine

430

mmol/gDW
0.412078
0.433604
0.329047
0.375175
0.293682
0.182975

name

Species name
Charged-THRtRNAs[c]
Charged-PHEtRNAs[c]
Charged-TYRtRNAs[c]
Charged-TRPtRNAs[c]
Charged-CYStRNAs[c]
Charged-METtRNAs[c]
Charged-LYStRNAs[c]
Charged-ARGtRNAs[c]
Charged-HIStRNAs[c]
Charged-ASPtRNAs[c]
Charged-ASNtRNAs[c]
Charged-GLNtRNAs[c]
Charged-GLTtRNAs[c]
Charged-PROtRNAs[c]
ATP[c]
GTP[c]
CTP[c]
UTP[c]
DATP[c]
DGTP[c]
DCTP[c]
TTP[c]
K-[c]
MG-2[c]
FE-3[c]
AMMONIUM[c]
SULFATE[c]
CA-2[c]

L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate
L-Proline
RNA
0.145

DNA
0.011

Ions
0.03185

AMP (ATP)
GMP (GTP)
CMP (CTP)
UMP (UTP)
dAMP (dATP)
dGMP (dGTP)
dCMP (dCTP)
dTMP (dTTP)
K
Mg
Fe(+3)
NH4
SO4
Ca2+

431

mmol/gDW
0.239866
0.162986
0.132234
0.007688
0.010763
0.083031
0.264468
0.184512
0.087643
0.209114
0.209114
0.266005
0.266005
0.155298
26.610000
0.131137
0.089431
0.096310
0.010802
0.006413
0.005738
0.010802
0.700573
0.100903
0.003422
0.001285
0.000031
0.003179

Cofactors
0.01715

Lipids
0.025

Cell wall
0.22

name
coa
spermidine
ACP
L-Ornitine
NAD
NADP
NADPH
menaquinol 7
10-formyltetrahydrofolate
cardiolipin (tetrahexadecanoyl)
cardiolipin (stearoylcardiolipin)
1,2-dipalmitoylphosphatidylglycerol
phosphatidylglycerol
(dioctadacanoyl)
1,2-dipalmitoylphosphatidylethanolamine
phosphatidylethanlamine
(dioctadecanoyl)
1,2-dipalmitoylphosphatidylserine
phosphatidylserine
(dioctadecanoyl, n-c18:0)
1,2-dipalmitoylglycerol
1,2-distearoyl-sn-glycerol
hexadecanoic/palmitic/palmitate
octadecanoic/stearic/stearate
a peptidoglycan subunit

Species name
CO-A[c]
SPERMIDINE[c]
ACP[c]
L-ORNITHINE[c]
NAD[c]
NADP[c]
NADPH[c]
CPD-12125[c]
-10-FORMYL-THF[c]
CPD-12824[c]
CPDCWI-13[c]

water

WATER[c]

CPD-8260[c]
CPD-12822[c]
CPD-12819[c]
CPD-12818[c]
CPD-12817[c]
CPD-12816[c]
CPD66-34[c]
CPDCWI-14[c]
PALMITATE[c]
STEARIC-ACID[c]
CPD-12261[c]

mmol/gDW
0.000128
0.000020
0.000273
0.000046
0.018220
0.001053
0.000237
0.000150
0.000207
0.000740
0.000023
0.005107
0.000162
0.006196
0.000196
0.000415
0.000013
0.010908
0.000339
0.000572
0.000018
0.030270
22.190000

Table S21. List of biomass’s products for B. anthracis model under iron-rich
conditions Phase I. The name, reaction, as well as lower and upper boundaries are
provides.
GAM

name
ADP
H+
Pi
PPI

Species name
ADP[c]
PROTON[c]
Pi[c]
PPI[c]

432

mmol/gDW
26.500000
26.500000
26.490000
0.458900

name
Biomass
tRNAS recycling

Glycine
L-Alanine
L-Valine
L-Leucine
L-Isoleucine
L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate
L-Proline
apo-ACP

mmol/gDW
Species name
1.000000
BIOMASS-CCO-CYTOSOL[c]
GLY-tRNAs[c]
0.412078
ALA-tRNAs[c]
0.433604
VAL-tRNAs[c]
0.329047
LEU-tRNAs[c]
0.375175
ILE-tRNAs[c]
0.293682
SER-tRNAs[c]
0.182975
THR-tRNAs[c]
0.239866
PHE-tRNAs[c]
0.162986
TYR-tRNAs[c]
0.132234
TRP-tRNAs[c]
0.007688
CYS-tRNAs[c]
0.010763
MET-tRNAs[c]
0.083031
LYS-tRNAs[c]
0.264468
ARG-tRNAs[c]
0.184512
HIS-tRNAs[c]
0.087643
ASP-tRNAs[c]
0.209114
ASN-tRNAs[c]
0.209114
GLN-tRNAs[c]
0.266005
GLT-tRNAs[c]
0.266005
PRO-tRNAs[c]
0.155298
apo-ACP[c]
0.000273109

A8.7. Biomass for iron-poor media Phase II
Table S22. List of biomass’s reactants for B. anthracis model under iron-poor
conditions Phase II. The name, reaction, as well as lower and upper boundaries are
provides.
name
Protein

Glycine

0.55

L-Alanine

Species name
Charged-GLYtRNAs[c]
Charged-ALAtRNAs[c]
Charged-VALtRNAs[c]
Charged-LEUtRNAs[c]
Charged-ILEtRNAs[c]

L-Valine
L-Leucine
L-Isoleucine

433

mmol/gDW
0.412078
0.433604
0.329047
0.375175
0.293682

name

Species name
Charged-SERtRNAs[c]
Charged-THRtRNAs[c]
Charged-PHEtRNAs[c]
Charged-TYRtRNAs[c]
Charged-TRPtRNAs[c]
Charged-CYStRNAs[c]
Charged-METtRNAs[c]
Charged-LYStRNAs[c]
Charged-ARGtRNAs[c]
Charged-HIStRNAs[c]
Charged-ASPtRNAs[c]
Charged-ASNtRNAs[c]
Charged-GLNtRNAs[c]
Charged-GLTtRNAs[c]
Charged-PROtRNAs[c]
ATP[c]
GTP[c]
CTP[c]
UTP[c]
DATP[c]
DGTP[c]
DCTP[c]
TTP[c]
K-[c]
MG-2[c]
FE-3[c]
AMMONIUM[c]

L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate

RNA
0.145

DNA
0.011

Ions
0.03185

L-Proline
AMP (ATP)
GMP (GTP)
CMP (CTP)
UMP (UTP)
dAMP (dATP)
dGMP (dGTP)
dCMP (dCTP)
dTMP (dTTP)
K
Mg
Fe(+3)
NH4

434

mmol/gDW
0.182975
0.239866
0.162986
0.132234
0.007688
0.010763
0.083031
0.264468
0.184512
0.087643
0.209114
0.209114
0.266005
0.266005
0.155298
64.310000
0.131137
0.089431
0.096310
0.010802
0.006413
0.005738
0.010802
0.700573
0.100903
0.002030
0.001285

Cofactors
0.01715

Lipids
0.025

Cell wall
0.22

name
SO4
Ca2+
coa
spermidine
ACP
L-Ornitine
NAD
NADP
NADPH
menaquinol 7

Species name
SULFATE[c]
CA-2[c]
CO-A[c]
SPERMIDINE[c]
ACP[c]
L-ORNITHINE[c]
NAD[c]
NADP[c]
NADPH[c]
CPD-12125[c]
-10-FORMYLTHF[c]
CPD-12824[c]
CPDCWI-13[c]
CPD-8260[c]
CPD-12822[c]

mmol/gDW
0.000031
0.003179
0.000128
0.000020
0.000273
0.000046
0.018220
0.001053
0.000237
0.000150

CPD-12819[c]

0.006196

CPD-12818[c]
CPD-12817[c]

0.000196
0.000415
0.000013
0.010908
0.000339
0.000572

octadecanoic/stearic/stearate
a peptidoglycan subunit

CPD-12816[c]
CPD66-34[c]
CPDCWI-14[c]
PALMITATE[c]
STEARICACID[c]
CPD-12261[c]

water

WATER[c]

59.900000

10-formyltetrahydrofolate
cardiolipin (tetrahexadecanoyl)
cardiolipin (stearoylcardiolipin)
1,2-dipalmitoyl-phosphatidylglycerol
phosphatidylglycerol (dioctadacanoyl)
1,2-dipalmitoylphosphatidylethanolamine
phosphatidylethanlamine
(dioctadecanoyl)
1,2-dipalmitoyl-phosphatidylserine
phosphatidylserine (dioctadecanoyl, nc18:0)
1,2-dipalmitoylglycerol
1,2-distearoyl-sn-glycerol
hexadecanoic/palmitic/palmitate

0.000207
0.000740
0.000023
0.005107
0.000162

0.000018
0.030270

Table S23. List of biomass’s products for B. anthracis model under iron-poor
conditions Phase II. The name, reaction, as well as lower and upper boundaries are
provides.

GAM

name
ADP

Species name
ADP[c]

435

mmol/gDW
64.200000

tRNAS recycling

name
H+
Pi
PPI
Biomass
Glycine
L-Alanine
L-Valine
L-Leucine
L-Isoleucine
L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate
L-Proline
apo-ACP

Species name
mmol/gDW
PROTON[c]
64.200000
Pi[c]
64.190000
0.458900
PPI[c]
BIOMASS-CCO-CYTOSOL[c]
1.000000
GLY-tRNAs[c]
0.412078
ALA-tRNAs[c]
0.433604
VAL-tRNAs[c]
0.329047
LEU-tRNAs[c]
0.375175
ILE-tRNAs[c]
0.293682
SER-tRNAs[c]
0.182975
THR-tRNAs[c]
0.239866
PHE-tRNAs[c]
0.162986
TYR-tRNAs[c]
0.132234
TRP-tRNAs[c]
0.007688
CYS-tRNAs[c]
0.010763
MET-tRNAs[c]
0.083031
LYS-tRNAs[c]
0.264468
ARG-tRNAs[c]
0.184512
HIS-tRNAs[c]
0.087643
ASP-tRNAs[c]
0.209114
ASN-tRNAs[c]
0.209114
GLN-tRNAs[c]
0.266005
GLT-tRNAs[c]
0.266005
PRO-tRNAs[c]
0.155298
apo-ACP[c]
0.000273109

A8.8. Biomass for iron-rich media Phase II
Table S24. List of biomass’s reactants for B. anthracis model under iron-rich
conditions Phase II. The name, reaction, as well as lower and upper boundaries are
provides.
name
Protein

Glycine

0.55

L-Alanine

Species name
Charged-GLYtRNAs[c]
Charged-ALAtRNAs[c]

436

mmol/gD
W
0.412078
0.433604

name

Species name
Charged-VALtRNAs[c]
Charged-LEUtRNAs[c]
Charged-ILEtRNAs[c]
Charged-SERtRNAs[c]
Charged-THRtRNAs[c]
Charged-PHEtRNAs[c]
Charged-TYRtRNAs[c]
Charged-TRPtRNAs[c]
Charged-CYStRNAs[c]
Charged-METtRNAs[c]
Charged-LYStRNAs[c]
Charged-ARGtRNAs[c]
Charged-HIStRNAs[c]
Charged-ASPtRNAs[c]
Charged-ASNtRNAs[c]
Charged-GLNtRNAs[c]
Charged-GLTtRNAs[c]
Charged-PROtRNAs[c]
ATP[c]
GTP[c]
CTP[c]
UTP[c]
DATP[c]
DGTP[c]
DCTP[c]

L-Valine
L-Leucine
L-Isoleucine
L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate
L-Proline
RNA
0.145

DNA
0.011

AMP (ATP)
GMP (GTP)
CMP (CTP)
UMP (UTP)
dAMP (dATP)
dGMP (dGTP)
dCMP (dCTP)

437

mmol/gD
W
0.329047
0.375175
0.293682
0.182975
0.239866
0.162986
0.132234
0.007688
0.010763
0.083031
0.264468
0.184512
0.087643
0.209114
0.209114
0.266005
0.266005
0.155298
58.610000
0.131137
0.089431
0.096310
0.010802
0.006413
0.005738

Ions
0.03185

Cofactor
s
0.01715

name

Species name

dTMP (dTTP)
K
Mg
Fe(+3)
NH4
SO4
Ca2+

TTP[c]
K-[c]
MG-2[c]
FE-3[c]
AMMONIUM[c]
SULFATE[c]
CA-2[c]

mmol/gD
W
0.010802
0.700573
0.100903
0.003422
0.001285
0.000031
0.003179

coa

CO-A[c]

0.000128

spermidine
ACP
L-Ornitine
NAD
NADP
NADPH
menaquinol 7

SPERMIDINE[c]
ACP[c]
L-ORNITHINE[c]
NAD[c]
NADP[c]
NADPH[c]
CPD-12125[c]
-10-FORMYLTHF[c]
CPD-12824[c]
CPDCWI-13[c]
CPD-8260[c]
CPD-12822[c]

0.000020
0.000273
0.000046
0.018220
0.001053
0.000237
0.000150

CPD-12819[c]

0.006196

CPD-12818[c]

0.000196

CPD-12817[c]

0.000415

10-formyltetrahydrofolate
Lipids
0.025

Cell wall
0.22

0.000207

cardiolipin (tetrahexadecanoyl)
cardiolipin (stearoylcardiolipin)
1,2-dipalmitoyl-phosphatidylglycerol
phosphatidylglycerol (dioctadacanoyl)
1,2-dipalmitoylphosphatidylethanolamine
phosphatidylethanlamine
(dioctadecanoyl)
1,2-dipalmitoyl-phosphatidylserine
phosphatidylserine (dioctadecanoyl, nc18:0)
1,2-dipalmitoylglycerol
1,2-distearoyl-sn-glycerol
hexadecanoic/palmitic/palmitate
octadecanoic/stearic/stearate
a peptidoglycan subunit

CPD-12816[c]

0.000013

CPD66-34[c]
CPDCWI-14[c]
PALMITATE[c]
STEARIC-ACID[c]
CPD-12261[c]

0.010908
0.000339
0.000572
0.000018
0.030270

water

WATER[c]

54.200000

438

0.000740
0.000023
0.005107
0.000162

Table S25. List of biomass’s products for B. anthracis model under iron-rich
conditions Phase II. The name, reaction, as well as lower and upper boundaries are
provides.
GAM

tRNAS recycling

name
ADP
H+
Pi
PPI
Biomass
Glycine
L-Alanine
L-Valine
L-Leucine
L-Isoleucine
L-Serine
L-Threonine
L-Phenylalanine
L-Tyrosine
L-Tryptophan
L-Cysteine
L-Methionine
L-Lysine
L-Arginine
L-Histidine
L-Aspartate
L-Asparagine
L-Glutamine
L-Glutamate
L-Proline
apo-ACP

Species name
mmol/gDW
ADP[c]
58.500000
PROTON[c]
58.500000
Pi[c]
58.490000
PPI[c]
0.458900
BIOMASS-CCO-CYTOSOL[c]
1.000000
GLY-tRNAs[c]
0.412078
ALA-tRNAs[c]
0.433604
VAL-tRNAs[c]
0.329047
LEU-tRNAs[c]
0.375175
ILE-tRNAs[c]
0.293682
SER-tRNAs[c]
0.182975
THR-tRNAs[c]
0.239866
PHE-tRNAs[c]
0.162986
TYR-tRNAs[c]
0.132234
TRP-tRNAs[c]
0.007688
CYS-tRNAs[c]
0.010763
MET-tRNAs[c]
0.083031
LYS-tRNAs[c]
0.264468
ARG-tRNAs[c]
0.184512
HIS-tRNAs[c]
0.087643
ASP-tRNAs[c]
0.209114
ASN-tRNAs[c]
0.209114
GLN-tRNAs[c]
0.266005
GLT-tRNAs[c]
0.266005
PRO-tRNAs[c]
0.155298
apo-ACP[c]
0.000273109
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A8.9. Additional constraints
Table S26. List of biomass’s products for B. anthracis model under iron-rich
conditions Phase II. The name, reaction, as well as lower and upper boundaries are
provides.
Reaction name

CATAL-RXN

RXN-12121

RXN-12120

lower
boundary

0

0

0

upper
boundary

rationale

0

repressed by
aerobic
conditions

0

repressed by
aerobic
conditions

0

RXNI-3MAL_CPD9718__OXALACE
TIC_ACID_CPD12125.40.

0

0

LLACTDEHYDRO
GFMN-RXN

0

0

RXNCWI-17

0

0

URA-PHOSPHRXN

0

0

0

0

0

0

DEOXYADENPH
OSPHOR-RXN
DEOXYINOPHOS
PHOR-RXN

repressed by
aerobic
conditions
Doubt about
presence in the
bacteria,
additionally was
causing futile
cycle.
induction when
lactate present
in the media or
H2O2
represed in
presence of
glucose
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo

440

model
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,

Ref.

[270]

[270]

[270]

[271]
[5,164,16
5]

[272]

[273]

[273]
[273]

Reaction name

lower
boundary

upper
boundary

RXN-11743

0

0

XANTHOSINEPH
OSPHORY-RXN

0

0

DEOXYGUANPH
OSPHOR-RXN

0

0

RXN0-5199

0

0

INOPHOSPHORRXN

0

0

ADENPHOSPHOR
-RXN

0

0

RXN0-366

0

0

RXNCWI-82

0

0

RXNCWI-105

TRANS-RXNCWI7

0

0

0.000472

0.000964

441

rationale
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
on only when
deoxyribonucleo
sides are in the
media
experimentally
measured
boundary for the
ferricsiderophore
transport
experimentally
measured
boundary for the
ferricsiderophore

model
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2
IRDM1,
IRM1,
IRDM2,
IRM2

Ref.

[273]

[273]

[273]

[273]

[273]

[273]

[273]

[273]

IRDM1,
IRM1,
IRDM2,
IRM2

[187]

IRDM1,
IRM1,
IRDM2,
IRM2

[187]

Reaction name

lower
boundary

upper
boundary

TRANS-RXNCWI8

0

0.00119

RXNCWI-53

0

0

L-LACTATEDEHYDROGENA
SE-RXN

-1000

0

442

rationale
transport
experimentally
measured
boundary for the
ferricsiderophore
transport
not ATPase
transport for
iron, based on
the observation
that iron
concentration
were very low
lactate
dehydrogenase
only for lactate
production in
phase II

model

Ref.

IRDM1,
IRM1,
IRDM2,
IRM2

[187]

IRDM2

IRDM2,
IRM2

[164]
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